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ABSTRACT 
The purpose of this analysis was to determine whether following a higher protein 
(HP) diet for 10-weeks promotes a reduction of MetS and the individual NCEP ATP III 
MetS risk factors better than a higher carbohydrate (HC) diet, when combined with an 
exercise program.  633 women (age 46.2±11.4 yrs, height 163±7 cm, weight 92.7±18 kg, 
BMI 34.8±6 kg/m2) were assigned either a HP or HC diet in conjunction with 30 
minutes of circuit-style exercise 3x/wk for 10-weeks.  Participants consumed 1,425±355 
kcal/day while the HP group (N=371) consumed 1.14±0.5, 1.41±0.7, and 0.63±0.3 
g/kg/d CHO, PRO, fat and the HC group (N=292) consumed 0.78±0.3, 2.20±0.7, and 
0.60±0.2 g/kg/d.  Participants were retrospectively categorized as apparently healthy 
(N=377) or metabolic syndrome (≥3 MetS risk factors, N=286).  Body composition, 
anthropometrics, resting energy expenditure, lipid profiles, markers of glucose 
homeostasis, and fitness parameters were assessed at 0 and 10 weeks.  Data were 
analyzed using ANOVA or MANOVA for repeated measures.  The HP group 
experienced a greater decrease in scanned mass (HP -3.9±3.5, HC -3.0±3.5 kg, p=0.002), 
fat mass (HP-3.1±2.7, HC -2.4±2.8 kg, p=0.003), weight (HP -4.3±3.6, HC -3.2±3.4 kg, 
p<0.001), and body mass index (HP -1.6±1.3, HC -1.2±1.3 kg/m2, p<0.001), and tended 
to experience a greater decrease in waist circumference (HP -4.0±5.7, HC -3.2±5.7 cm, 
p=0.07).  Individuals with MetS experienced greater decreases in weight (AH -3.6±3.4, 
MS -4.2±3.6 kg, p=0.054), body mass index (AH -1.3±1.3, MS -1.6±1.3 kg/m2, 
p=0.046), systolic blood pressure (AH -0.5±13.3, MS -5.9±16.0 mmHg, p<0.001), 
diastolic blood pressure (AH -0.4±8.9, MS -4.1±10.5 mmHg, p<0.001), triglycerides 
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(AH -0.00±0.47, -0.23±0.73 mmol/L, p<0.001), and glucose (AH +0.01±0.73, MS  
-0.24±1.19 mmol/L, p=0.001) and a trend towards a greater decrease in scanned mass 
(AH -3.3±3.5, MS -3.8±3.5 kg, p=0.07) and lean mass (AH -0.56±2.0, MS -0.89±2.0 kg, 
p=0.07).  Results indicate that participants following the HP diet experienced more 
favorable changes in body composition and triglyceride levels, and that participants with 
MetS have greater room for improving markers of health on a diet and exercise protocol. 
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CHAPTER I  
INTRODUCTION 
BACKGROUND 
Metabolic Syndrome is a combination of health markers that has a direct effect on 
atherosclerotic disease.  While there are multiple definitions, the general trend embraces 
risk factors such as abdominal obesity, insulin resistance, atherogenic dyslipidemia, 
elevated blood pressure, and elevated plasma glucose [1].  These markers have an 
additive effect on disease risk, increasing the risk for cardiovascular disease two-to-four 
times and elevating the risk of type 2 diabetes five-to-nine times [2-7].  The National 
Cholesterol Education Program – Adult Treatment Panel III created a definition for 
metabolic syndrome in 2001 that has been widely accepted and validated [2, 8-11].  The 
modified ATP III criteria, published in 2004 states that for a woman to be diagnosed 
with metabolic syndrome, she must have at least three of the following: central obesity 
(waist circumference >88 cm), hypertriglyceridemia (fasting triglycerides ≥1.7 mmol/L), 
low levels of high density lipoprotein cholesterol (<1.3 mmol/L), hypertension (blood 
pressure ≥135/85 mmHg or taking medication), and/or fasting plasma glucose ≥5.6 
mmol/L) [8, 12]. 
In the United States, it is estimated that one-quarter of the adult population has 
metabolic syndrome [13], which was predicted to include 47 million Americans in 2000 
[14], and may be as high as 50-75 million now [15].  Obesity may be to blame for this 
rise, as prevalence of metabolic syndrome increases in a graded fashion with body mass 
index [16, 17].  Obesity affects over 35% of US adults [18], and approximately one-third 
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of individuals who are overweight or obese manifest the metabolic syndrome condition 
[1, 17, 19, 20].  This becomes a larger concern for women, as two million more women 
than men are categorized as obese [21, 22] and the leading cause of death for women is 
cardiovascular disease [23, 24].  Unfortunately, it does not appear that this prevalence 
will diminish any time soon, as younger generations are already experiencing these 
health deficits.  Nearly one million children in the US express the metabolic syndrome 
condition [25, 26], and more than 17% of adolescents are obese [27].   
Most individuals with metabolic syndrome could benefit greatly from therapeutic 
lifestyle modification [3, 8, 17].  A combination of proper nutrition with physical 
activity is likely the best prescription for preventing and reversing the markers of 
metabolic syndrome.  However, regarding the treatment of this condition, the most 
beneficial nutrition protocol is still heavily debated. 
The National Cholesterol Education Program – Adult Treatment Panel III 
promotes a ratio of 15% protein, 50-60% carbohydrate, and 25-30% of caloric intake 
from fat for individuals with metabolic syndrome [17].  However, many other 
recommendations on the specific proportions of protein, carbohydrate, and fat to 
consume are touted by various researchers and organizations [28-30].  A review of 
current research suggests that reducing carbohydrate consumption can positively benefit 
triglyceride levels [31-40].  While there can be health benefits achieved by substituting 
some carbohydrate with either fat or protein, the addition of protein especially during a 
weight loss and exercise program will better preserve fat free mass and promote more 
optimal changes in body composition [41-43].  However that is not to say that higher 
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carbohydrate diets do not possess some health benefits; it may be that dietary guidelines 
should be individualized based on the patient’s specific metabolic phenotype [43].   
A dose-response relationship exists between low physical activity levels and 
increased cardiovascular disease risk and the individual components of metabolic 
syndrome [5, 44, 45].  Only 11-46% of the US adult population engages in the 
recommended amount of physical activity [46], and women are not as likely to reach the 
recommendations as men [47].  Therapeutic lifestyle change should focus on reversing 
the sedentary lifestyle, the atherogenic diet, and the overweight / obese status [33].  This 
is most effectively achieved with physical activity accompanied by weight reduction in 
order to target each element of metabolic syndrome individually [1, 7, 17, 48]. 
Moderate physical activity can improve the risk factors and/or reduce the likelihood 
of developing metabolic syndrome [8, 49].  Cardiorespiratory fitness is inversely 
correlated with the metabolic abnormalities of metabolic syndrome, cardiovascular 
disease, and type 2 diabetes mellitus.  This is found to be true regardless of age, gender, 
ethnicity, or body weight [3, 6, 14, 24, 29, 50-53], and these health benefits have been 
noted at various durations and intensities [51, 53, 54].  Resistance exercise appears to 
produce preventative benefits as well, due to gains in muscle mass and strength, 
reduction in body fat, and improvement of insulin sensitivity [21, 42, 47]. 
Weight loss appears to be an integral component in the treatment of metabolic 
syndrome and corresponding diseases [8, 33, 55, 56].  A linear relationship exists 
between weight and waist circumference, blood pressure, lipid levels, and fasting 
glucose [50, 57, 58].  A decrease of seven-to-ten percent body weight over six-twelve 
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months is advised for patients with metabolic syndrome [27, 58-60].  Additional benefits 
may be obtained by placing focus on the loss of fat mass specifically [55].   
A combination of dietary intervention with physical activity will best achieve the 
desired weight loss and reversal of metabolic syndrome risk factors.  Specifically for 
women, a program that offers both higher carbohydrate and higher protein dietary 
options and also includes a 30-minute circuit-style resistance-training protocol three 
days a week may prove advantageous.  Previous research from the Exercise and Sport 
Nutrition Lab has shown great success with weight and fat loss, maintenance or gain of 
fat free mass, maintenance of resting energy expenditure, and improvements in markers 
of fitness with this combined diet and exercise intervention [61, 62].  More recent 
research from the Exercise and Sport Nutrition Lab suggests that the higher protein diet 
may provide a more beneficial effect on insulin sensitivity as well as the aforementioned 
variables [63].  
STATEMENT OF THE PROBLEM 
When combined with an exercise and weight loss program, does a higher protein 
hypoenergetic diet promote a reduction in the prevalence of metabolic syndrome and 
each of the individual risk factors better than a higher carbohydrate hypoenergetic diet in 
overweight and sedentary women between the ages of 18-75?  
PURPOSE 
The purpose of this analysis was to determine whether following the higher 
protein diet intervention for ten-weeks promotes a reduction of metabolic syndrome and 
the individual NCEP ATP III metabolic syndrome risk factors better than the higher 
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carbohydrate diet for the same time period, when both diets are combined with a circuit-
style resistance-based exercise program.  
GENERAL STUDY OVERVIEW 
This study is a retrospective analysis of eight ten-week weight loss studies that 
evaluated the effects of adherence to two dietary interventions while participating in a 
circuit-training based exercise program in women aged 18-75 years old.  Female 
applicants who met the physician-approved criteria completed the ten-week diet and 
exercise protocol.  Based on their responses on a carbohydrate tolerance questionnaire, 
participants were assigned to a hypocaloric diet either higher in protein or in 
carbohydrate and partook in a circuit-based resistance-training program.  After study 
completion, participants were retrospectively categorized based on their baseline risk 
level for metabolic syndrome (apparently healthy versus metabolic syndrome; < or ≥ 
three ATP III risk factors respectively) to determine whether the macronutrient content 
of the diet combined with the exercise program differentially effected women designated 
as having metabolic syndrome.  Additionally, further analysis was performed 
categorizing participants based on each metabolic syndrome risk factor independently 
(low versus high waist circumference, low versus high triglycerides, high versus low 
HDL cholesterol, low versus high blood pressure, and low versus high fasting glucose), 
in order to ascertain how the different dietary protocols affect each risk factor 
individually.  
Dietary intake, anthropometric measurements, resting energy expenditure, body 
composition, and serum clinical chemistry samples were assessed at 0 and 10 weeks.  
  
 
6 
Participants also performed a maximal cardiopulmonary exercise stress test as well as 
lower and upper body muscular strength and endurance tests during each assessment.  
Questionnaires related to quality of life and body image were also completed at each 
session. 
Hypotheses 
Diet 
H1: There will be a statistically significant difference in macronutrient intakes between 
the two diet groups. 
Metabolic Syndrome 
H2: There will be statistically significant differences in the markers of metabolic 
syndrome in participants with and without the presence of three or more metabolic 
syndrome risk factors.  
Metabolic Syndrome Risk Factor Group 
H3: There will be statistically significant differences observed in changes in body 
composition as a result of diet intervention and/or the presence of three or more 
metabolic syndrome risk factors.  
H4: There will be no statistically significant differences observed in resting energy 
expenditure as a result of diet intervention and/or the presence of three or more 
metabolic syndrome risk factors.  
H5: There will be no statistically significant differences observed in resting 
hemodynamic parameters as a result of diet intervention and/or the presence of three or 
more metabolic syndrome risk factors. 
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H6: There will be statistically significant differences observed in blood lipids as a result 
of diet intervention and/or the presence of three or more metabolic syndrome risk 
factors.  
H7: There will be statistically significant differences observed in markers of glucose 
homeostasis as a result of diet intervention and/or the presence of three or more 
metabolic syndrome risk factors.  
H8: There will be no statistically significant differences observed in fitness parameters 
as a result of diet intervention and/or the presence of three or more metabolic syndrome 
risk factors. 
H9: There will be no statistically significant differences observed in psychometric 
parameters (as measured via questionnaires regarding quality of life and body image) as 
a result of diet intervention and/or the presence of three or more metabolic syndrome 
risk factors. 
Waist Circumference Metabolic Syndrome Risk Factor 
H10: There will be statistically significant differences observed in changes in body 
composition as a result of diet intervention and/or the presence of the waist 
circumference metabolic syndrome risk factor. 
H11: There will be no statistically significant differences observed in resting energy 
expenditure as a result of diet intervention and/or the presence of the waist 
circumference metabolic syndrome risk factor.  
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H12: There will be no statistically significant differences observed in resting 
hemodynamic parameters as a result of diet intervention and/or the presence of the waist 
circumference metabolic syndrome risk factor.  
H13: There will be statistically significant differences observed in blood lipids as a result 
of diet intervention. 
H14: There will be no statistically significant differences observed in blood lipids as a 
result of the presence of the waist circumference metabolic syndrome risk factor.  
H15: There will be statistically significant differences observed in markers of glucose 
homeostasis as a result of diet intervention and/or the presence of the waist 
circumference metabolic syndrome risk factor.  
H16: There will be no statistically significant differences observed in fitness parameters 
as a result of diet intervention and/or the presence of the waist circumference metabolic 
syndrome risk factor. 
H17: There will be no statistically significant differences observed in psychometric 
parameters (as measured via questionnaires regarding quality of life and body image) as 
a result of diet intervention and/or the presence of the waist circumference metabolic 
syndrome risk factor. 
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Triglyceride Metabolic Syndrome Risk Factor 
H18: There will be statistically significant differences observed in body composition as a 
result of diet intervention. 
H19: There will be no statistically significant differences observed in body composition 
as a result of the presence of the triglyceride metabolic syndrome risk factor. 
H20: There will be no statistically significant differences observed in resting energy 
expenditure parameters as a result of diet intervention and/or the presence of the 
triglyceride metabolic syndrome risk factor. 
H21: There will be no statistically significant differences observed in resting 
hemodynamic parameters as a result of diet intervention and/or the presence of the 
triglyceride metabolic syndrome risk factor. 
H22: There will be statistically significant differences observed in blood lipids as a result 
of diet intervention and/or the presence of the triglyceride metabolic syndrome risk 
factor. 
H23: There will be statistically significant differences observed in markers of glucose 
homeostasis as a result of diet intervention and/or the presence of the triglyceride 
metabolic syndrome risk factor.  
H24: There will be no statistically significant differences observed in fitness parameters 
as a result of diet intervention and/or the presence of the triglyceride metabolic 
syndrome risk factor. 
H25: There will be no statistically significant differences observed in psychometric 
parameters (as measured via questionnaires regarding quality of life and body image) as 
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a result of diet intervention and/or the presence of the triglyceride metabolic syndrome 
risk factor. 
HDL Cholesterol Metabolic Syndrome Risk Factor 
H26: There will be statistically significant differences observed in body composition as a 
result of diet intervention. 
H27: There will be no statistically significant differences observed in body composition 
as a result of the presence of the HDL metabolic syndrome risk factor. 
H28: There will be no statistically significant differences observed in resting energy 
expenditure parameters as a result of diet intervention and/or the presence of the HDL 
metabolic syndrome risk factor. 
H29: There will be no statistically significant differences observed in resting 
hemodynamic parameters as a result of diet intervention and/or the presence of the HDL 
metabolic syndrome risk factor. 
H30: There will be statistically significant differences observed in blood lipids as a result 
of diet intervention and/or the presence of the HDL metabolic syndrome risk factor. 
H31: There will be statistically significant differences observed in markers of glucose 
homeostasis as a result of diet intervention. 
H32: There will be no statistically significant differences observed in markers of glucose 
homeostasis as a result of the presence of the HDL metabolic syndrome risk factor. 
H33: There will be no statistically significant differences observed in fitness parameters 
as a result of diet intervention and/or the presence of the HDL metabolic syndrome risk 
factor. 
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H34: There will be no statistically significant differences observed in psychometric 
parameters (as measured via questionnaires regarding quality of life and body image) as 
a result of diet intervention and/or the presence of the HDL metabolic syndrome risk 
factor. 
Blood Pressure Metabolic Syndrome Risk Factor 
H35: There will be statistically significant differences observed in body composition as a 
result of diet intervention. 
H36: There will be no statistically significant differences observed in body composition 
as a result of the presence of the blood pressure metabolic syndrome risk factor. 
H37: There will be no statistically significant differences in resting energy expenditure as 
a result of diet intervention and/or the presence of the blood pressure metabolic 
syndrome risk factor. 
H38: There will be no statistically significant differences observed in resting 
hemodynamic parameters as a result of diet intervention. 
H39: There will be statistically significant differences observed in resting hemodynamic 
parameters as a result of the presence of the blood pressure metabolic syndrome risk 
factor. 
H40: There will be statistically significant differences observed in blood lipids as a result 
of diet intervention. 
H41: There will be no statistically significant differences observed in blood lipids as a 
result of the presence of the blood pressure metabolic syndrome risk factor. 
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H42: There will be statistically significant differences observed in markers of glucose 
homeostasis as a result of diet intervention. 
H43: There will be no statistically significant differences observed in markers of glucose 
homeostasis as a result of the presence of the blood pressure metabolic syndrome risk 
factor. 
H44: There will be no statistically significant differences observed in fitness parameters 
as a result of diet intervention and/or the presence of the blood pressure metabolic 
syndrome risk factor. 
H45: There will be no statistically significant differences observed in psychometric 
parameters (as measured via questionnaires regarding quality of life and body image) as 
a result of diet intervention and/or the presence of the blood pressure metabolic 
syndrome risk factor. 
Glucose Metabolic Syndrome Risk Factor 
H46: There will be statistically significant differences observed in body composition as a 
result of diet intervention. 
H47: There will be no statistically significant differences observed in body composition 
as a result of the presence of the glucose metabolic syndrome risk factor. 
H48: There will be no statistically significant differences observed in resting energy 
expenditure parameters as a result of diet intervention and/or the presence of the glucose 
metabolic syndrome risk factor. 
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H49: There will be no statistically significant differences observed in resting 
hemodynamic parameters as a result of diet intervention and/or the presence of the 
glucose metabolic syndrome risk factor. 
H50: There will be statistically significant differences observed in blood lipids as a result 
of diet intervention and/or the presence of the glucose metabolic syndrome risk factor. 
H51: There will be statistically significant differences observed in markers of glucose 
homeostasis as a result of diet intervention and/or the presence of the glucose metabolic 
syndrome risk factor. 
H52: There will be no statistically significant differences observed in fitness parameters 
as a result of diet intervention and/or the presence of the glucose metabolic syndrome 
risk factor. 
H53: There will be no statistically significant differences observed in psychometric 
parameters (as measured via questionnaires regarding quality of life and body image) as 
a result of diet intervention and/or the presence of the glucose metabolic syndrome risk 
factor. 
Delimitations 
The parameters of this study were as follows:  
1. Sedentary, overweight women (body mass index >27 kg/m2) between the ages of 18-
75 were recruited for the studies in this analysis. 
2. Recruitment was based on flyers distributed at physicians’ offices, in local 
newspapers and television channels, on the Internet, and through campus mail. 
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3. Familiarization sessions as well as all testing was performed in the Exercise and Sport 
Nutrition Lab at Baylor University or Texas A&M University.  
4. Assignment to the higher protein or higher carbohydrate diet groups was based on 
participant response on a Carbohydrate Tolerance Questionnaire. 
5. Subjects had been sedentary for at least three months prior to the start of the study. 
6. Participants had not utilized nutritional supplements that would affect muscle mass, 
anabolic/catabolic hormone levels, or weight loss for at least three months prior to the 
start of each study. 
7. Subjects were required to obtain consent from their physician if they had any 
diagnosed controlled metabolic disorders. 
Limitations 
1. Recruitment was limited to Baylor University, Texas A&M University and the 
surrounding Waco and College Station communities, specifically to those who 
responded to the advertisements.  Due to the non-random nature, this may affect the 
application on the general population.  
2. Participation was limited to those who were self-motivated to respond to the 
advertisement, and additional incentives were given for completing the program.  This 
may also affect the application on the general population. 
3. Participants were required to follow the assigned nutrition plan in addition to 
completing the exercise circuit three times a week. 
4. Participants were required to follow the nutrition and exercise program within a free-
living environment. 
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5. The exercise protocol utilized (Curves®) has an associated cost, which may limit 
application to those who can afford to participate. 
6. Participant information regarding tobacco use was not available within the database.  
Cigarette smoking is a large risk factor for cardiovascular disease and could also affect 
many of the metabolic syndrome variables. 
7. Ethnicity data was not available in the database utilized.  The prevalence (and 
potentially the causes) of metabolic syndrome varies by ethnicity, and analysis related to 
this topic was unable to be performed due to unavailable information.  However, the 
population was a diverse representation of Central Texas including Caucasian, Hispanic, 
and African American individuals.   
8. The NCEP ATP III definition of metabolic syndrome is not specific as to whether the 
blood pressure indicator is systolic ≥ 130 mmHg and diastolic ≥85 or whether it is 
either/or.  For this study, we identified individuals with either elevated systolic or 
diastolic as having the blood pressure risk factor for metabolic syndrome. 
9. Inherent limitations exist in the laboratory equipment utilized for collection and 
analysis of the data. 
Assumptions 
1. Participants were honest when answering the screening questions for entrance into the 
study, as well as questionnaires and food logs throughout the study. 
2. Participants followed the assigned dietary protocol as specified. 
3. Participants fasted for 12 hours prior to each testing session. 
4. Participants abstained from exercise for 24 hours prior to each testing session. 
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5. Participants exerted maximal effort on the maximal treadmill and strength tests. 
6. Participants notified the staff in the case of any adverse events. 
7. Laboratory equipment was properly calibrated and functional for all testing sessions. 
8. The population sample was normally distributed. 
9. There was equal variability between the groups. 
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CHAPTER II  
REVIEW OF THE LITERATURE 
INTRODUCTION 
As!a health concern for close to a century, metabolic syndrome (MetS) has carried 
numerous aliases to include the deadly quartet, plurimetabolic syndrome, insulin 
resistance syndrome, dysmetabolic syndrome, and syndrome X [14, 51, 64].  While 
several organizations have unique criteria for MetS, the general trend includes risk 
factors that have a direct effect on atherosclerotic disease, including abdominal obesity, 
insulin resistance, atherogenic dyslipidemia, elevated blood pressure, and elevated 
plasma glucose [1].  Some individuals argue that MetS is imprecisely defined, and doubt 
the value of MetS as a cardiovascular disease (CVD) risk factor and its designation as a 
syndrome [48].  However, various definitions and numerous combinations in the 
expression of risk factors truly portray a “syndrome,” in which the risk factor clustering 
occurs in greater likelihood than could be expected by chance [1, 7, 65].  This is not just 
a “disease” or a discrete entity with a uniform pathology or treatment [1, 7].  
A timely diagnosis of metabolic syndrome is critical, as early intervention may help 
prevent the future development of type 2 diabetes mellitus (T2DM), CVD, and other 
chronic diseases [48, 66, 67].  The individual risk factors of MetS have an additive effect 
on disease risk, leading to an increase in risk for CVD by two-to-four fold and elevate 
the risk of T2DM by as much as five-to-nine fold [2-7].  Additionally, a diagnosis of 
T2DM along with MetS increases the CVD risk more than either condition 
independently [17, 68].  
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Three of the more prevalent definitions of MetS are outlined by the World Health 
Organization, the National Cholesterol Education Program – Adult Treatment Panel III 
(NCEP ATP III), and the International Diabetes Foundation, and are defined in Table 
2.1.  Each definition embraces precise criteria that must be present in specified 
combinations of risk factors in order to create the metabolic syndrome profile for that 
organization.   
 
 
Table 2.1: Criteria for the Diagnosis of Metabolic Syndrome in Women, by 
Organization 
 
Clinical Measure WHO                  
(1998) 
ATP III                
(2004 modified) 
IDF                     
(2005) 
Insulin Resistance 
IGT, IFG, or T2DM 
plus any 2 of the 
following: 
N/A 
any 3 of the following: N/A 
Body Weight 
WHR >0.85 
or  
BMI >30 kg/m2 
WC ≥88 cm 
WC ≥80 cm 
plus any 2 of the 
following: 
Lipid 
TG ≥1.7 mmol/L 
and/or  
HDL <1.0 mmol/L 
TG ≥1.7 mmol/L 
and/or 
HDL <1.3 mmol/L 
TG ≥1.7 mmol/L† 
HDL 1.3 mmol/L† 
 
Blood Pressure ≥140/90 mm Hg ≥135/85 mm Hg† ≥130 mm Hg systolic ≥85 mm Hg diastolic† 
Glucose IGT, IFG, or T2DM ≥5.6 mmol/L (includes diabetes) 
≥5.6 mmol/L 
(includes diabetes) 
Other Microalbuminuria   
Table adapted from Diagnosis and Management of the Metabolic Syndrome, Grundy et al [1]. 
Values listed are specific to women. 
BMI, body mass index; HDL-C, high density lipoprotein cholesterol; IFG, impaired fasting glucose; IGT indicates impaired glucose tolerance; T2DM, 
type 2 diabetes mellitus; WHR, waist-to-hip ratio; TG, triglycerides.  
†Criteria includes a Rx for that clinical measure. 
 
 
For the World Health Organization (WHO) definition (identified in 1998), insulin 
resistance (or glucose intolerance or diagnosed diabetes) is a requirement for metabolic 
syndrome, plus the addition of at least two other risk factors: obesity (body mass index 
(BMI)  >30 kg/m2 or waist-to-hip ratio >0.85), dyslipidemia (fasting triglycerides ≥1.7 
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mmol/L or HDL cholesterol <1.0 mmol/L), hypertension (blood pressure >140/90 
mmHg), and/or microalbuminuria (albumin excretion >20 µg/min) [8].  The values listed 
in this report focus specifically on diagnosis for women.   
The NCEP ATP III identifies six components of MetS that relate to CVD; abdominal 
obesity, atherogenic dyslipidemia (to include elevated triglycerides (TG), small low-
density lipoprotein (LDL) particles, and/or low levels of high-density lipoprotein (HDL) 
cholesterol), elevated blood pressure (BP), insulin resistance (with or without glucose 
intolerance), a proinflammatory state, and a prothrombotic state [14, 19].  While the 
NCEP ATP III definition (created in 2001 and modified in 2004) does not embrace any 
particular risk factor as a mandatory prerequisite, a female must have at least three of the 
following to meet their diagnosis of MetS: central obesity (waist circumference (WC) 
>88 cm), hypertriglyceridemia (TG ≥1.7 mmol/L), low HDL cholesterol (<1.3 mmol/L), 
hypertension (BP ≥135/85 mmHg or taking medication), and/or fasting plasma glucose 
(≥5.6 mmol/L or diagnosed diabetes) [8].  This “grab bag” definition, as it has been 
described, allows for ten possible phenotypes of MetS, nine of which include a lipid 
abnormality [3, 4].   
The International Diabetes Foundation (IDF) offers a newer definition (created in 
2005) in which central obesity is a mandatory prerequisite (WC ≥80 cm for women) and 
two additional factors are required for diagnosis: glucose >5.6 mmol/L (or diagnosed 
diabetes), HDL cholesterol <1.29 mmol/L (or drug treatment for low HDL), TG ≥ 1.7 
mmol/L (or drug treatment for high TG), and/or BP ≥ 130/85 mmHg (elevated systolic 
and/or diastolic blood pressure, or drug treatment for hypertension) [3, 7].  IDF and 
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NCEP ATP III differ in the lower waist circumference and blood pressure criteria in 
IDF, which explains why previous statements claim that if the IDF definition were 
utilized more frequently, it would substantially increase the prevalence of MetS [17, 69, 
70].  Yet, the NCEP ATP III criterion appears to be utilized most commonly.  
In addition to abdominal obesity and insulin resistance, a variety of other 
conditions may influence MetS to include physical inactivity, aging, hormone 
imbalance, inflammation, impaired endothelial function, increased sympathetic nervous 
system activity, genetic abnormalities, fetal malnutrition, and environmental factors [1, 
14, 20, 51, 71].  Furthermore, MetS is associated with numerous ailments including 
polycystic ovarian syndrome, non-alcoholic fatty liver disease, gallstones, sleep 
disturbances, sexual impotence, and some forms of cancer [15, 17].  In some cases, MetS 
may be the result of commonly prescribed medications such as corticosteroids, 
antidepressants, antihistamines and antipsychotics, likely due to their side effect of 
weight gain [17, 60, 72, 73]. 
Previous comparative research studies have considered whether a diagnosis of MetS 
is more beneficial than a diagnosis of each risk factor independently [48, 71, 74], and 
also whether one definition has more predictive capabilities over another [2, 8-11].   
Kahn [48] has found the MetS definitions to be imprecise, and raises doubt in the 
predictive power of a metabolic syndrome diagnosis in forecasting diabetes.  He further 
describes MetS as merely a multivariate risk factor for CVD and states that based on 
current definitions, MetS does not warrant designation as a syndrome.  Stern et al [71, 
74] and others [71, 74], also believe that independent of insulin resistance (and treatment 
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of diabetes if necessary), MetS may not have additional predictive capabilities for CVD 
risk.  Yet many other researchers have found a diagnosis of MetS (using various 
organization’s definitions) to be beneficial in predicting future disease risk.  A 
comparison between the WHO and the NCEP ATP III definitions found that while the 
two definitions identified similar proportions of the population with MetS (25.1% and 
23.9% respectively), the actual individuals that were identified varied by as much as 15-
20% depending on the definition utilized (mainly by differences found within 
ethnicities), although both criteria were similar in their prediction of CVD risk [8, 9].  
Another review of three analyses found the NCEP ATP III definition to be a slightly 
better predictor of CVD and all-cause mortality in two out of the three studies evaluated 
[2, 10, 11].  It has been stated that while the WHO definition may be the most useful for 
research purposes, the NCEP ATP III may be more applicable for clinical practice [8].  
PREVALENCE 
Metabolic syndrome is quite common, and prevalence increases with both age and 
BMI.  In the United States alone, approximately one-quarter of the adult population 
(~24% of men and ~23.4% of women) is diagnosed with MetS [13, 20].  In the year 
2000, 47 million Americans had MetS [14], and this number was projected to reach 50-
75 million by 2010 [15].  While only ~6.7% of twenty-year-olds have MetS, greater than 
40% of individuals over 60 may have this disease [14, 17, 19].  The third report by the 
National Health and Nutrition Examination Survey found that MetS increases with BMI 
in a graded fashion; where only 1-3% of individuals with a BMI between 18.5-20.9 
kg/m2, but 9.6-22.5% of individuals with a BMI of 25-26.9 kg/m2 have the syndrome 
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[16, 17].  Likewise, data from this survey has also found that as BMI increases, the 
prevalence for each individual risk factor also increases [19].   
Obesity 
Obesity is a major risk factor for MetS and may be to blame for the rise in the 
syndrome’s prevalence. Approximately one-third of individuals who are overweight or 
obese manifest the MetS condition [1, 17, 19, 20].  Due to this potential correlation, it is 
important to note that obesity affects more than one-third (35.7%) of US adults [18].  
Additionally, obesity prevalence is on the rise.  Two separate analyses have been 
performed to predict the prevalence of obesity in the US by 2030.  Finkelstein et al [18] 
utilized a non-linear trend and data from the 1990-2008 Behavioral Risk Factor 
Surveillance System to predict obesity rising as high as 42% of the population.  
Meanwhile, Wang et al [18, 75] used a linear trend with data from the 1970’s-2004 
National Health and Nutrition Examination Survey reports, and estimate obesity 
affecting 51% of the US population by 2030!  This continual rise in obesity, whatever 
the estimated percentage, causes concern for a continued increase in the prevalence of 
MetS as well.   
Global and Adolescence 
Metabolic syndrome and the related illnesses are not only a concern in the US, nor 
exclusive to adults. On a global scale, WHO reported that 60% (35 of 58 million) of 
deaths in 2005 were a result of chronic diseases such as CVD and T2DM, and predict a 
17% increase over the next decade [76, 77].  Additionally, obesity is estimated to affect 
312 million people worldwide [13].   
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In regards to adolescents, it is suspected that nearly one million children have MetS 
in the US alone [25, 26].  Obesity affects over 17% of US children and adolescents [27], 
and the number of children who are overweight or obese has doubled over the last few 
decades [78].  This suggests that the prevalence of childhood MetS is also likely to rise.  
Lawson [79] has estimated that greater than four million US adolescents and young 
adults have a risk level for MetS equivalent to individuals greater than 60 years old, 
based on their level of obesity.  
CONCERNS FOR WOMEN 
There are also specific concerns regarding women and the metabolic syndrome. 
While the prevalence of MetS is similar in both genders, women are reported as having a 
higher morbidity related to the disease [80, 81].  According to the 2003-2006 National 
Health and Nutrition Examination Survey report [19], abdominal obesity, hypertension, 
and hyperglycemia are the MetS risk factors of highest prevalence in women at 53%, 
40%, and 39% respectively.  This report additionally mentions that the prevalence of 
many of the risk factors (abdominal obesity, hypertriglyceridemia, hypertension, and 
hyperglycemia) increase with each successive age bracket, and also found overweight 
and obese females to be five and 17 times as likely, respectively, to meet the criteria for 
MetS as normal weight females.  In the US, two million more women than men are 
categorized as obese [21, 22], the leading cause of death for women is CVD [23, 24], 
and annual CVD mortality exceeds the mortality rate from breast cancer in women 
younger than 50 [81, 82].  These health issues may be either the cause or effect of MetS.   
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Two additional concerns for women are heredity and menopause.  A comparison of 
National Health and Nutrition Examination Survey data between 1988-2004 states that 
daughters of mothers diagnosed with diabetes were almost twice as likely as other 
women to either express the MetS phenotype (adjusted odds ratio 1.96), be obese 
(adjusted odds ratio 1.7-2.1), have elevated plasma glucose levels (adjusted odds ratio 
1.9), and/or have low levels of HDL (adjusted odds ratio 1.6) [81].  Additionally, 
menopause relates to an increase in abdominal obesity, a shift to a more atherogenic 
lipid profile (higher total cholesterol (TC), LDL, and TG, and lower HDL), and a four-
fold increase in CVD risk [50].  This data suggests that the high prevalence of MetS and 
related illnesses found today will have a detrimental impact on future generations of 
women as well. 
PREVIOUS RESEARCH ON THE TREATMENT OF METABOLIC 
SYNDROME 
Individuals with high short-term risk for CVD may need drug therapy for distinct 
MetS risk factors, however most individuals with MetS could benefit greatly from 
therapeutic lifestyle modification (TLC) [3, 8, 17].  While the primary focus for reducing 
CVD risk is LDL cholesterol reduction (which is not a MetS risk factor) and smoking 
cessation, the treatment of MetS and accompanying risk factors is the secondary aim [1].  
Modification of hypertension and dyslipidemia can decrease the risk of CVD, while 
glucose regulation can reduce the risk of T2DM [51].  TLC should focus on reversing 
the sedentary lifestyle, the atherogenic diet, and the overweight / obese status [33].  This 
is most effectively achieved with physical activity accompanied by weight reduction (a 
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reasonable goal is ~10% in one year), which will aid insulin resistance modification and 
target each element of MetS individually [1, 7, 17, 48].  Even when weight loss is not 
achieved, physical activity may be beneficial in decreasing abdominal fat and improving 
insulin sensitivity [51].  Furthermore, research from the Exercise and Sport Nutrition 
Lab (ESNL) [62, 83], as well as others [51], proves for exercise to effectively reverse 
MetS variables, it should be combined with appropriate dietary modification.  Likewise, 
adding exercise to a nutritional intervention may be more successful than dieting alone 
[52].  The specific effects of various dietary modifications with and without physical 
activity are discussed in further detail below.  
Nutrition 
Until Ornish’s published findings in 1998 [26, 84], stating that proper nutrition 
may be related to disease reversal and prevention, clinicians thought heart disease could 
only be reversed through surgery.  In regards to nutrition advice for the treatment or 
prevention of MetS, there is agreement among clinicians and researchers concerning 
general health guidelines, but disagreement on the specific dietary treatment. The 
consensus includes a recommendation for reduced consumption of simple sugars with an 
increased intake of fruits, vegetables, complex carbohydrates, whole grains and fiber [1, 
7, 17, 21, 60, 85], a low intake of saturated fat, trans-fat, and cholesterol [1, 7, 17, 21, 
33, 60], and the inclusion of fish, nuts, and low-fat dairy products [1, 17, 85].  Many also 
recommend reducing sodium intake specifically for hypertensive individuals [1, 7, 17].  
The NCEP ATP III specifically promotes caloric balance (for weight maintenance) and a 
ratio of 15% protein (PRO), 50-60% carbohydrate (CHO), and 25-30% of caloric intake 
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from fat for individuals with MetS [17].  Additionally the NCEP ATP III recommends 
consuming 20-30 g/day of fiber, less than 200 mg/day of cholesterol, less than 7% 
kcal/day from saturated fat, and fat consumption made up of 10% polyunsaturated fat 
and 20% monounsaturated fat [17].  
Specific dietary recommendations may be confusing to MetS patients, as all ends 
of the spectrum have been advised.  Numerous research studies have attempted to define 
the most beneficial macronutrient composition to regulate/prevent MetS and/or the 
individual health components.  For this review, a search was performed through EBSCO 
and Google Scholar, using queries with combinations of the following words or phrases: 
“metabolic syndrome” + “diet” + “protein” + “carbohydrate” + “weight” + “blood 
pressure” + “lipids” + “obesity”.  The search took place between February 1-25, 2013 
and excluded studies prior to the year 2000 as well as studies that did not report at least 
three of the risk factors for MetS.  The review is divided into four categories: 1) research 
on carbohydrate restriction alone, 2) the adjustment of carbohydrate and fat consumption 
percentages, 3) the elevation of protein consumption, and 4) elevated protein 
consumption with specific exercise prescriptions.   
Carbohydrate Restriction 
There has been inconsistency in study findings regarding the relationship 
between MetS and carbohydrate (CHO) consumption [29].  Many researchers suggest 
that a high intake of CHO should be avoided [60], since high CHO diets (>60%) may 
elevate glucose, insulin, and TG levels [21, 29, 86, 87], and lower CHO consumption 
can more greatly decrease weight and TG levels and lead to an improvement in insulin 
  
 
27 
sensitivity [31-33].  Yet other studies have found an inverse correlation between high 
CHO consumption and prevalence of CVD [28, 88], or generally no significant 
relationship between CHO consumption and the prevalence of MetS and/or insulin 
resistance [29]. 
Table 2.2 identifies nine carbohydrate restriction studies with varying reductions 
in CHO allotment, from 20-70 grams a day.  Seven of the nine studies found a 
significant decrease in TG [34-40], while the other two reported no significant difference 
[89, 90].  Of additional benefit to combatting MetS, all of the studies lead to a significant 
decrease in weight [34-39, 89, 90], five of the studies measured a reduction in blood 
pressure [34, 35, 39, 40, 89] , two studies [35, 36]  (and a third only in men [90]) found a 
significant increase in HDL, and one (severely low CHO) study also showed a 
significant decrease in fasting glucose [38] (with another study showing significance 
only in men [90]).  Furthermore, many studies also measured a decrease in other health 
markers such as TC and LDL, two of the studies lead to a significant decrease in body 
fat percentage [34, 35], and one study specifically calculated a decrease in prevalence of 
MetS by 50% when consuming only 10-25% daily calories from CHO [89].  The 
benefits of reducing CHO consumption are evident, yet the question still remains as to 
which macronutrient most appropriately fills the necessary caloric requirement.   
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Table 2.2: Carbohydrate Restriction for Treatment of Metabolic Syndrome Risk Factors 
 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Exercise Wt BP TG HDL Glu Other 
Meckling, 
Gauthier, 
Grubb, Sanford  
(2002) 
[34] 
8 weeks 
reduced 
carb and 
calorie 
~70g/day 
CHO 
~5740 kJ/day                                   
(deficit of 
~2644 kJ/day) 
maintain 
normal 
activity 
levels 
-6.1%* 
SBP -
7.5%*               
DBP -8%* 
 ! NS NS 
TC !           
LDL!      
Body fat % !  
20 women;  
~34.4 y/o, BMI~30.7 
Westman  
et al  
(2002) 
[35] 
6 months 
very low 
carb 
<25 g/d 
CHO until 
achieved 
40% target 
weight loss; 
then 50 g/d  
no limit on 
caloric intake 
encouraged 
to exercise 
≥20 min 
3x/wk 
-10.3%* SBP!   DBP!  -43.1%* 
+19.2%
* --- 
TC -5.1%*                      
LDL -7.4%*                    
body fat % !  
41 overwt/ 
obese healthy 
(31 fem); ~43.7 y/o,  
BMI~31.4 
Hickey  
et al  
(2003) 
[36] 
~30-40 weeks              
(retrospect follow-up) 
carb 
restricted 
(CRD) 
<20 g/day 
CHO 
CHO gradually 
added back in 
once weight 
loss or risk 
reduction 
achieved. 
--- -1.1% --- -38%* +13%* --- TC -13%*                        LDL -16%* 
80 patients with 
atherogenic 
dyslipidemia  
(27% women);  
~66 y/o, BMI~28.1 
Boden et al 
(2005) 
[37] 
2 weeks (inpatient)    
after normal diet for one 
week 
low carb 
only 21 g/d CHO                                                                              
no limits to fat and protein 
consumption 
maintain 
normal 
activity 
levels 
-1.8% --- -35%* NS --- 
TC -10%* 
 
insulin sensitivity 
improved ~75% 
10 obese 
(7 fem) T2DM; 
 ~51 y/o, BMI~40.3 
Yancy et al 
(2005) 
[38] 
16 weeks low-carb 
ketogenic 
diet 
(LCKD) 
<20 g/d CHO 
unlimited 
meat, poultry, 
etc.             
Fats and oils 
not restrict. 
encouraged 
to exercise 
aerobically 
30 min 
3x/wk 
Wt -6.6%*                        
WC -5.2%* NS -42%* NS -16.6%* HbA1c -16% 
21#overwt#(1#fem)#
T2DM;#~56#y/o,#
BMI~42.2#
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Table 2.2: Continued 
Authors(
(Date)#
Study(Length((((((((((((((((
Study(
Population#
Groups# Dietary(Protocol((%PRO:CHO:FAT)# Exercise# Wt# BP# TG( HDL# Glu# Other(
Hayes et al 
(2006) 
[39] 
12 weeks                                     
(2 phases; 
2 and 10 weeks) 
Phase I 28:10:62 
similar to 
South Beach 
Diet 
--- 
Wt -3.3%                
WC -1.2% 
SBP -6.2%               
DBP -8.6% 
-43.4%* 
NS NS --- 
20 overwt/obese  
(16 fem) MetS; 
~47.5 y/o, BMI~33.9 
Phase II 30:27:43 Wt -5.6%*                WC -4.5%* -16.5% 
Miller et al 
(2007) 
[89] 
3 months                               
(2 phases: 
2 and 10-11 wks) 
Phase 1 (2 
weeks) 28:10:62 
No specific 
caloric 
restrictions 
given 
--- Wt -5.4%*                           WC -5.0%* 
SBP -
5.9%*            
DBP -
9.0%* 
NS NS NS prevalence of MetS                               -50% 
21 adults (81% fem) 
MetS (ATP III); 
~47 y/o, BMI~33.8 
Phase 2 
(10-11 
weeks) 
30:27:43 
Muzio et al 
(2007) 
[40] 
5 months low carb 19:48:33 ~500 kcal/day defecit from 
estimated 
expenditure 
encouraged 
to increase 
PA 
NS ! ! 
NS decrease 
--- 
100 (73 fem); ~52.4 y/o, 
BMI~37.2 high carb 13:65:22 NS decrease dec LDL: ! 
Sasakabe, 
Haimoto, 
Umegaki, 
Wakai 
(2011) 
[90] 
6 months 
moderate 
low-carb 
diet (LCD) 
HbA1c 
<9%, cut 
CHO from 
dinner; 
HbA1c 
≥9%, cut 
CHO from 
bfast and 
dinner 
no specific 
ratio 
prescribed; 
free 
consumption 
of PRO and 
FAT 
maintain 
normal 
activity 
levels 
Men -2.8%                 
Women -3% NS NS 
Men 
+10.6%
*             
Women 
NS 
Men  
-13.4%*                 
Women 
NS 
LDL:                       
Women -15.3%*                  
Men NS 
52 with T2DM 
(24 fem); 
~60.0 y/o, BMI~24.5 
BMI, (body mass index) values are listed in kg/m2.  BP, blood pressure; CHO, carbohydrate; DBP, diastolic blood pressure; Fem, females; Glu, glucose; HbA1c, hemoglobin A1c; LDL, low density lipoprotein 
cholesterol; PA, physical activity; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; WC, waist circumference; Wt, weight; y/o, years old.    
Values are calculated percent change from baseline.  Listed values are significantly different from baseline, representing a time effect.  Bold and * indicate p<0.05 for group/diet effect.  Within a study, values 
that do not share a common superscript are significantly different.  ---, value not reported or measured; NS, no significant change from baseline; NDE, no diet effect; "! significant change, yet specific value 
not reported.     
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Carbohydrate Versus Fat Consumption 
Similar to carbohydrates, the recommended percentage of daily fat consumption 
also varies greatly.  As previously mentioned, the NCEP ATP III suggests no more than 
30% fat [17], yet others recommend a fat intake of 35% or even as high as 40% can be 
beneficial [1, 28].  While some argue that the percentage of fat intake is unrelated to the 
markers of MetS [29, 30], others contend that humans are largely sensitive to fat 
consumption and that there is a delicate window (25-35%) of fat consumption for 
optimal lipid level regulation [1].  Certainly the content of fat must be considered.  
Consumption of saturated fats has been proven to promote dyslipidemia and lead to 
atherogenesis [85], while unsaturated fatty acid consumption, specifically 
monounsaturated fat, can reduce the prevalence of CVD [28].   
More than just considering each macronutrient individually, Grundy and colleagues 
[28] raise the question of whether the specific ratio of fat-to-CHO affects MetS risk 
factors.  Interestingly, Brunner et al [29, 30] found no relationship between any of the 
macronutrients (PRO, CHO, or fat) to the prevalence of MetS.  However, this review 
aims to dig deeper. 
The literature search returned 24 studies on CHO vs. fat consumption that met the 
criteria for this review.  Of these studies, two focus on the comparison of simple vs. 
complex carbohydrates [91, 92], one compares a low-fat diet group to a control [93], two 
compare popular dietary programs (such as Atkins and the American Diabetes 
Association) [94, 95], and 19 specifically measure the effects of various carbohydrate 
versus fat ratios [31, 96-113].  These 24 studies are summarized in Table 2.3.
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Table 2.3: Carbohydrate versus Fat Restriction for Treatment of Metabolic Syndrome Risk Factors 
 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Exercise Wt BP TG HDL Glu Other 
Rodriguez-
Villar et al  
(2000) 
[96] 
6 weeks;                                 
crossover design  
(no wash out) 
high-carb 
(CHO) 15:55:30     
isocaloric diets, 
prescribed 
based on est. 
energy req. 
maintain normal 
activity levels NDE --- NDE NDE NDE --- 22 with T2DM;  
~61 y/o, BMI~28.3 
high MUFA 
(MUFA) 
15:40:45     
25% MUFA 
Noakes  
and Clifton  
(2000) 
[97] 
12 weeks very low fat (VLF) 19:71:10 
~6500 kJ/day maintain normal activity levels 
Wt -9.7%                                              
WC -8% 
!a -8% 
NS --- 
TC -14.8%b                       
LDL -19%b 
62 subjects;  
~45.7 y/o, BMI~31.2 
high sat fat 
(HSF) 
18:50:32                                
17% from sat fat !
b -23.1% TC -8%
a                       
LDL -6.5%a 
high unsat 
fat (HUF) 
20:48:32                    
6% from sat fat !
b -21.9% TC -17%
b                       
LDL -19.8%*b 
Saris et al  
(2000) 
[91] 
6 months control dietary intervention typical of the average national intake 
--- 
+0.9%a 
--- NS NS NS 
FM +1.8%a 
398 moderately obese 
(51% fem); ~39 y/o, 
BMI~30.4 
high carb 
simple 
low-fat food with simple:complex carb 
ratio of 1.5:0.5 -1%
b FM -3.8%b 
high carb 
complex  
low-fat food with simple:complex carb 
ratio of 0.5:1.5 -2%
b FM -5.3%b 
Poppitt et al  
(2001) 
[92] 
 
6 months control maintain fat intake ~35-40% 
encouraged to 
not reduce 
caloric intake 
--- 
NS 
NS 
NS 
! --- 
TC NS 
39 (27 fem)  
with MetS;  
~46 y/o, BMI~32 
low-fat, 
complex 
carb  
(LF-CC) 
10% ! fat 
 1:2 carbs 
simple:complex  
-4.7%* TC -11.1%* 
low-fat, 
simple carb  
(LF-SC) 
10% ! fat 
and consume  2:1 
carbs 
simple:complex 
NS " TC NS 
Tuomilehto  
et al 
(2001) 
[93] 
~3.2 years                            
follow-up control general nutrition/exercise advice --- 
Wt -0.9%                   
WC -1.3% 
SBP -0.7%              
DBP -3.5% -0.6% +2.1% -0.9% 
--- 522 overwt (350 fem) 
with IGT; 
~55 y/o, BMI~31 
low fat 
fat consumption <30% 
<10% saturated fat, 
≥15 g/1000 kcal fiber 
moderate ex for 
30 min/d 
Wt -
4.7%*                  
WC -4%* 
SBP -3.6%*               
DBP -5.8%* -11.7%* 
+4.3% 
(p=.06) -3.7%* 
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Table 2.3: Continued 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Exercise Wt BP TG HDL Glu Other 
Landry et al  
(2003) 
[98] 
7 weeks high carb 13:60:27          
ad lib maintain normal activity levels 
-2.9% 
--- 
NS 
--- 
-3.8% 
--- 37 healthy males;  
~34 y/o, BMI~28  low carb 13:46:41          -2% -24% NS 
Colette et al  
(2003) 
[99] 
8 weeks high CHO 20:55:25  10% from MUFA 30% ! initial 
energy intake 
no exercise 
prescribed 
-7.2% 
--- 
NS NS NS TC -7.5%                            LDL NS 
32 overwt  
(23 fem);  
~49 y/o, BMI~35  
high MUFA 20:40:40                25% from MUFA -6.9% -21.9% -8.5% -11.5% 
TC -9.8%                           
LDL -8.2% 
Brehm, Seeley, 
Daniels, 
D'Alessio  
(2003) 
[100] 
6 months very low carb 
20 g/day CHO for 
2 weeks, increase 
to 40-60 g/day 
ad libitim maintain normal 
activity levels 
-9.3%* SBP -1.7%        DBP -6.3% -23.4%* +13.4% -9.1% 
body fat -
12.8%* 
53 healthy, obese fem; 
~44 y/o, BMI~33.6 low fat 15:55:30     
-500 kcal/day 
baseline -4.2% 
SBP -1.7%        
DBP -1.3% +1.6% +8.4% -4.0% body fat -5.2% 
Samaha et al  
(2003) 
[31] 
6 month low-carb ≤30 g CHO/day no fat restrictions 
--- 
-4.5%* 
NS 
-20%* 
NS 
all:  
-8.6%*                  
T2DM: 
-15%* --- 
132 severely obese 
(23 fem); ~53.5 y/o, 
BMI ~43 
low-fat 30% kcal/day from fat 
-500 kcal/day 
deficit -1.4% -4% 
all:  
-1.6%                  
T2DM: 
-3.2%* 
Volek et al 
(2004) 
[101] 
4 week period;  
cross-over design 
very low 
carb 30:10:60 hypocaloric  
(-500 
kcal/day) 
maintain normal 
activity levels --- --- 
-22.5% +1.9% -3.5% 
TC:+1%                          
LDL: +5.3%                        
HOMA: -
14%* 
13 overwt/obese fem;  
~34 y/o, BMI~29 low-fat 20:55:25 -11.2% -7.7%* 
+2.3%
* 
TC:-7%*                          
LDL: -5.3%*                        
HOMA: 
+27.3% 
Miyashita 
et al 
(2004) 
[102] 
4 weeks low carb 25:40:35 low calorie: 
1000 
kcal/day 
walking 2x/d for 
30 min ea 
-12.3% 
--- -40-50% 
" -49.8% 
TC: -20% 22 obese (6 fem) 
T2DM; ~52.4 y/o, 
BMI~27 
high carb 25:65:10 -9.9% NS -49% 
Gerhard et al 
(2004) 
[103] 
6 weeks;                           
crossover 
(6-12 week wash) 
low fat 15:65:20 10% energy refined sugar; 
diets 25%+ 
est energy 
req. 
maintain normal 
activity levels 
-1.5%* 
--- NS 
-7.1% 
NS --- 11 subjects (8 fem) 
T2DM; ~50.4 y/o, 
BMI~37.2 
high-
MUFA 
15:45:40 
26% MUFA -0.5% -4.5% 
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Table 2.3: Continued 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Exercise Wt BP TG HDL Glu Other 
Meckling, 
O'Sullivan, 
Saari 
(2004) 
[104] 
10 weeks low-fat (LF) <20% fat -2540 kJ/day maintain normal 
activity levels 
-7.4% SBP -9.2%        DBP -6.4% -25.4% -15.4% -10.2% LBM: -1.7%* 
31 overwt/obese; 
~42 y/o, BMI~32.2 
low-carb 
(LC) 
50-70 g/day of 
CHO 
-3195 
kJ/day -9.9% 
SBP -8.2%        
DBP -7.9% -29.4% +12.2%* -8.0% LBM: -3.3% 
Yancy et al 
(2004) 
[105] 
6 months low-carb 20g/day CHO, gradually increased 
high-pro, 
high-fat                     
Atkins encouraged to exercise 30 min 
3x/wk 
-12.9%* 
NDE 
-42%* +9.8%* 
--- 
TC: -3.3%                          
LDL: +1% 
120 overwt, 
hyperlipidemic;  
~44-45 y/o, BMI~34.5 
low-fat <30% fat, with <10% saturated fat 
500-1000 
kcal/day less 
than maint. 
-6.7% -14.4% -2.9% TC: -5.6%                          LDL: -5% 
Shai et al 
(2008) 
[106] 
2 years;                                                
6 months wt loss                                           
18 months maint 
low-fat / 
restrict cal 
<30% fat, 
<10% sat fat 
1500 
kcal/day 
women               
1800 
kcal/day men --- 
-3.2%a SBP -3.3%        DBP -1.1% -1.7% +16.3% NS TC/HDL -12% 
322 moderately obese 
(14% fem); ~52 y/o, 
BMI 31 
med / 
restrict cal 
no more than 
 35% fat -4.8%
b SBP -4.1%        DBP -2.7% NS NS -35%* NS 
low-carb / 
no-restrict 
cal 
20 g/day CHO for 
2 months, increase 
to 120 g/day 
cal, pro, and 
fat not 
limited 
-5.1%b SBP -3.0%        DBP -1.0% -13%* +22.4%* NS 
TC/HDL -
20%* 
Davis et al 
(2009) 
[107] 
1 year low-carb 20-25 g/day CHO, gradually increased 
modified 
Atkins diet rec 150 min/wk 
physical activity 
-3.3% SBP +1.6%        DBP -4.0% -10.7% +12.3%* 
--- --- 105 overwt adults 
with T2DM; 
~54 y/o, BMI~36 
low-fat 25% fat modeled after DPP -3.1% 
SBP -6.0%        
DBP -2.9% -0.7% +5% 
Brehm et al 
(2009) 
[108] 
1 year high MUFA 15:55:30 20% MUFA -200-300 
kcal/day from 
calc expend. 
encouraged to 
walk 30 min/d 
several d/wk 
-3.9% SBP -1.5%           DBP -6.4% 
NS 
+11.9% -5.3% 
--- 124 overwt/obese  
(61 fem) T2DM, 
 ~56.5 y/o, BMI ~35.9 
high CHO 15:60:25 -3.7% SBP -0.8%               DBP -5.2% +11.6% -5.9% 
Iqbal et al  
(2009) 
[113] 
24 months low-carb 
<30g/day CHO;  
no restrictions on 
fat/cal intake 
weekly 
nutrition 
sessions for 
one month; 
monthly 
thereafter 
encouraged to 
exercise 30 min 
5x/wk 
-1.3% SBP -8.0%                 DBP -4.8% -16.5% +1.7% -1.1% 
--- 144 obese, diabetic 
(15 fem); ~60 y/o, 
BMI~37/5 
low-fat ≤30% cal fat with  -500 kcal / day -0.2% 
SBP -3.2%                 
DBP -5.4% -7.8% +2.0% -3.0% 
Mueller et al  
(2010) 
[109] 
140 days total;                                  
70 days fed,  
70 days own 
carb-
controlled 20:30:50   
-500-700 
kcal/d, 
adjusted from 
indirect 
calorimetry 
--- 
-10% 
--- 
-23.3% -0.5% -3.1% 
--- 16 (15 fem,  
mostly non-white), 
~46-49 y/o, BMI~39.5 
fat-
controlled 20:50:30     -8.2% +1.3% +2.8% -3.8% 
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Table 2.3: Continued 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Exercise Wt BP TG HDL Glu Other 
Foster et al  
(2010) 
[110] 
2 years low carb 
20 g/day CHO for 
3 months, 
gradually increased 
No pro or fat 
limit 
walking 4 
x/week, 
progressing from 
20-min to 50-
min/session by 
19 wks 
-6.1% SBP -2.2%                  DBP -2.6%                          
24 mo: -
10.8% +16.8%* 
--- 
LDL -4.0% 
307 subjects;  
~45.5 y/o, BMI ~36.1 low-fat 15:55:30  
1200-1800 
kcal/day  -0.7% 
SBP -2.1%                  
DBP -0.7%                          
24 mo: -
11.8% +10.22% LDL -6.5% 
Goldstein  
et al  
(2011) 
[94] 
12 months;                                 
1 month DASH,                        
3 months supervision,             
8 months follow up 
modified 
Atkins 
(ATK) 
25 g/CHO daily 
increasing to 
40g/day after 6 
weeks 
cal, pro, and 
fat not 
limited advised aerobic 
activity for 30 
min, 3 x/week 
-3.7% SBP -9.9%        DBP -10.5% -19.5% +10% +71.7% 
--- 
52 T2DM;  
~56 y/o, BMI~33.2 
ADA cal-
restrict 
(ADA) 
20:40-45:35-40   
Men 1500 
kcal/day                     
women 1200 
kcal/day 
-5.9% SBP -3.7%        DBP -4.7% -2.0% +12.3* +20.2% 
Rajaie, 
Azadbakht, 
Khazaei, 
Esmaillzadeh  
(2012) 
[111] 
6 weeks;                           
crossover  
2 week washout 
high carb 
(HC) 20:60:20    Crossover 
between 
groups 
maintain normal 
activity levels 
WC -2.5% SBP -2.4%           DBP -2.2% +0.1% 
NS NS 
MetS 
prevalence:                    
NS 
30 overwt/obese  
fem w MetS (ATP 
III); BMI>25 
moderate 
restricted 
carb (MRC) 
21:43:36     WC -3.7% SBP -7.1%           DBP -16%* -18.1% 
MetS 
prevalence:                   
-35.8%* 
Metkus, 
Dobrosielski, 
Stewart (2012) 
[112] 
6 months low carb not specified 
isocaloric supervised exercise training 
Wt: -13.3%*                
WC: 11.8%* SBP -8%                
DBP -11.6% 
-42%* +15.3%* 
-6.1% --- 77 overwt/obese 
healthy; ~48.5 y/o low fat not specified 
Wt: -8.3%                
WC: -5.9% -6.3% +1.5% 
Hussain et al 
(2012) 
[95] 
 
24 week Low cal diet (LCD) 
reduced fat, 
lean meats 
Diets were 
self-selected --- 
D: Wt-7%                     
WC-3.5%                   
ND: Wt -
5.1%                                  
WC -2.8% --- 
NS NS ! TC NS LDL NS 
363 overwt/obese             
76.3% fem 
(27% diabetic (D)); 
~37.2 y/o, BMI~37.3 
Low carb 
ketogenic 
diet 
(LCKD) 
~20g/d CHO, 
gradually 
increasing 5/g/d in 
later weeks 
D: Wt -12%*                      
WC-7.3%*                  
ND: Wt -
12%*                                     
WC -6.1%* 
! " !* TC !                         LDL ! 
BMI (body mass index) values are listed in kg/m2.  BP, blood pressure; CHO, carbohydrate; DASH, dietary approaches to stop hypertension; DBP, diastolic blood pressure; DPP, diabetes prevention program; Fem, 
females; FM, fat mass; Glu, glucose; HDL, high density lipoprotein cholesterol; HOMA, homeostasis model assessment; IGT, impaired glucose tolerance; LBM, lean body mass; LDL, low density lipoprotein 
cholesterol; MetS, metabolic syndrome; MUFA, monounsaturated fatty acids; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglycerides; WC, waist circumference; Wt, 
weight; y/o, years old.    
Values are calculated percent change from baseline.  Listed values are significantly different from baseline, representing a time effect.  Bold and * indicate p<0.05 for group/diet effect.  Within a study, values that do 
not share a common superscript are significantly different.  ---, value not reported or measured; NS, no significant change from baseline; NDE, no diet effect; "! significant change, yet specific value not reported.     
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Modifying the simple:complex CHO ratio without altering the fat ratio (or caloric 
intake) appears to have minimal effect on the markers of MetS and led to a decrease in 
HDL in all groups [92], while adding a low-fat diet component to the simple:complex 
CHO ratio also did not lead to an improvement in the markers of metabolic health [93].  
Focusing on low fat consumption (<30% kcal/day) proved to significantly benefit almost 
all markers of MetS; weight, WC, BP, TG, and glucose, and led to a trend in improved 
HDL with a p-value of 0.06 [93].  In the diet comparisons, no statistically significant 
advantage was found between the Atkins (restricted carbohydrate) and American 
Diabetes Association (restricted calorie) diets for MetS markers [94], but Hussain et al 
[95] did find a significant improvement in all MetS markers measured (weight, WC, TG, 
HDL, and glucose) as well as TC and LDL for both diabetic and non-diabetic subjects 
using a low CHO ketogenic diet when compared to a low calorie reduced fat diet [95].  
By keeping the PRO consumption ratio constant and altering the fat and CHO 
percentages, the lower CHO consumption did lead to reduced TG in seven of the 19 
studies reviewed [31, 98-100, 105, 106, 112].  Additionally, eight of the studies reported 
a significant increase in HDL for the low-CHO (high-fat) group [99, 102, 104-107, 110, 
112] (with an additional study reporting a significant decrease in HDL in the higher 
CHO group [101]), four lead to a significant decrease in weight [31, 100, 105, 112], two 
studies found a decrease in BP with lower CHO consumption [97, 111], and two showed 
a decrease in fasting glucose [31, 99] (with an additional study reporting a significant  
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increase in glucose in the higher CHO group [101]), while five studies found no 
significant differences between the diets [96, 103, 108, 109, 113] .  These studies further 
promote CHO restriction for improving the markers of MetS, yet the lower fat diet also 
proved beneficial.  This leads to the consideration of focusing on PRO consumption 
instead.  
Increased Protein Consumption 
A vast amount of research has proven higher protein (carbohydrate-restricted) 
intake to be beneficial for weight loss and markers of health [41, 42].  While the current 
recommended daily allowance of PRO is 0.8 g/kg/day [114, 115], most Americans 
consume more than 15% of their total energy intake from protein, which amounts to 
approximately 1.2-1.5 g/kg of body weight [115-118].  Greater quantities of PRO 
consumption have proven advantageous in retaining fat free mass (FFM) during weight 
loss [43], with higher quartiles of PRO intake resulting in greater FFM retention [42, 
119].  Additionally, PRO intake >1.4g/kg/day may result in greater weight loss and body 
fat loss, as well as improved blood lipid profiles and glycemic control [43, 63, 120].  
Placing focus on higher protein consumption (25-30% of energy, ≥1.2 g/kg/day) may be 
beneficial in the treatment of MetS based on the aforementioned factors as well as the 
reputation for protein to enhance satiety [43, 55], prevent a decrease in resting energy 
expenditure while dieting [62], improve muscle function and strength [118], and improve 
blood pressure [55].  
Some researchers have expressed concern regarding potential health risks of high 
protein consumption (>2-3 times the RDA), in such that an increased acid load may lead 
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to increased calcium excretion with an increased osteoclast / decreased osteoblast 
activity and an overall negative calcium balance [115].  Meanwhile, the current 
recommended daily allowance has been based on epidemiological studies without an end 
goal of increasing muscle mass or function [118].  Elevated protein consumption, ≥2.0 
g/kg/d has not been proven to be harmful [117, 118], and previous research from the 
ESNL has reported no significant changes in bone mineral -content, -area, or -density, or 
in blood markers such as calcium, alkaline phosphatase, uric acid, total protein, or 
creatinine when consuming a higher protein diet for 10-weeks (accompanied with 
resistance training), specifically in women [121].  
The aforementioned literature search returned 51 studies on increased protein 
consumption that met the criteria for this review.  Sixteen of these studies incorporated a 
prescribed exercise program, and will be discussed separately.  Of the 35 studies not 
including physical activity guidelines, each study included a “higher protein 
consumption” group that assigned a protein intake ranging from 25-35% of daily caloric 
intake.  Collectively, these studies demonstrate that replacing some CHO with additional 
PRO, can significantly decrease TG [122-139], BP [133, 138, 140-143], fasting glucose 
[127, 128, 134], weight [131, 134, 135, 139, 142, 144, 145] and body fat [122, 125, 131, 
142, 146, 147] and increase HDL [123, 126, 131, 132, 134-136, 139], as well as decrease 
TC [123, 129, 133, 145, 146] and LDL [123, 129, 133, 145, 146].  Two studies even 
demonstrated a proven decrease in MetS prevalence [139, 148].  Replacing some CHO 
with an increase in the percentage of PRO seems to be a prevalent and effective 
treatment for all markers of MetS.  These studies are summarized in Table 2.4.  
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Table 2.4: Increased Protein Consumption for Treatment of Metabolic Syndrome Risk Factors 
 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Wt BP TG HDL 
 
Glu 
 
Other 
Layman et al  
(2002) 
[122] 
 
10 weeks CHO 
CHO/PRO ratio: 
3.5         
(68 g pro/d) isoenergetic; 1700kcal/d with ~50 
g/d fat (<30%) 
-8.1% 
--- 
NS 
NS --- 
Body Fat 
 -12.2%              
24 overwt fem;  
50.1 y/o, BMI~30.3 Protein 
CHO/PRO ratio: 
1.4  
(125 g pro/d) 
-8.9% -21.5%* Body Fat  -14.4%*        
Parker et al  
(2002) 
[146] 
12 weeks total;                         
8 wk restriction             
4 wk balance 
LP 16:55:26     
8 weeks 1600 kcal;  
4 weeks energy balance 
-5.3% 
NDE 
-10.6% 
NE 
-5.5% 
Men lost > fat            
TC: -0.2%                             
LDL +2.8% 
54 obese (35 fem) 
with T2DM;  
~61.2 y/o, BMI~34 
HP 28:42:28      -5.6% -16.8% -8.8% 
women lost > fat             
TC -6.8%*                     
LDL -5.7%*          
Volek et al  
(2003) 
[123] 
4 week period;                          
cross-over design  
4 week wash out 
low fat 20:55:25  Energy levels assigned 
to nearest 200 kcal 
increment based on 
REE from indirect 
calorimetry 
NDE --- 
NS NS 
--- 
NS 
10 healthy 
normolipidemic 
women;  
~26.3 y/o, BMI~22 
very low carb 30:10:60  -30.2%* +32%*   TC +15.8%                   LDL +14.6%                 
Gannon et al  
(2003) 
[124] 
5 weeks; 
 cross-over design         
2-week wash out 
high-protein 30:40:30 ~2200 kcal/day with 
similar fat and fiber 
consumption 
NS NS 
! 
NS NS --- 12 (2 fem) with 
untreated T2DM; 
~61 y/o, BMI ~31 
control 15:55:30 ---  
Johnston, Tjonn, 
Swan  
(2003) 
[149] 
6 weeks high carb low fat (HCLF) 15:66:19        <30% fat, low refined sugar (<10% total 
energy), high in fiber 
(>20 g/d) 
-5.9% 
--- NS 
NS 
NS 
TC -12.2% 
16 healthy;  
bw 19-54 y/o; 
BMI~29 
high pro low 
fat (HPLF) 32:41:27        -5.7% -13.5% 
TC -9.5%        
>satisfaction        
<hunger 
Farnsworth et al 
(2003) 
[125] 
16 weeks total                              
12 wk restriction                  
4 wk balance 
high protein 
(HP) 27:44:29 12 week energy restriction 
(6-6.3 MJ/d) 
4 week energy balance 
(~8.2 MJ/d) 
men: -
9.7%      
women: 
7.9% 
NS 
-23%* 
+5% NS  
women 
maintained 
LBM* 
57 overwt/obese 
(43 fem) fasting 
insulin > 12 mU/L; 
~50 y/o, BMI~33 
standard 
protein (SP) 16:57:27 -10% LBM -3.5%  
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Table 2.4: Continued 
Authors 
(Date) 
Study 
Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Wt BP TG HDL 
 
Glu 
 
Other 
Foster et al  
(2003) 
[126] 
1 year low-carb / high-pro 
20g/day CHO initially, 
gradually increased 
high-pro, high-fat                     
Atkins program -4.4% 
NS 
-17%* +11%* 
NS                       TC NS LDL NS 63 obese subjects 
(43 fem);  
~44 y/o, BMI~34 
conventional 15:60:25    
1200-1500 kcal/day 
for women 1500-1800 
kcal/day for men 
-2.5% +.0.7% +1.6% 
Gannon, Nuttall  
(2004) 
[127] 
5 weeks;  
cross-over design         
5-week wash out 
control 15:55:30     
2,825 kcal/day  
NS 
--- 
-14.4% 
NS 
NS 
--- 
8 men with 
untreated T2DM higher protein 30:20:50 NS -39.4%* -29%* 
Sharman, Gomez, 
Kraemer, Volek  
(2004) 
[128] 
6 weeks;                                  
crossover design  
no wash out 
very low carb 30:10:60  
hypoenergetic  
(-2.1 MJ/d) --- --- 
-44%* 
NS 
-6%* TC -10.8%                                 LDL NS 
15 men;  
~33.2 y/o, 
BMI~34.3 
low fat 
20:55:25  
<10% sat fat and  
<300 mg chol 
NS NS TC -14.7%                                    LDL -18%* 
Brinkworth et al 
(2004) 
[150] 
12 weeks 
intervention low protein 15:55:30 8 weeks energy restriction               
(~6.7 mJ/day)                                        
4 weeks energy 
balance 
-5.9% 
SBP -4.5%        
DBP -
2.9% 
-9.2% 
NS 
-8% 
--- 38 obese patients 
(23 fem) T2DM; 
~61.8 y/o, 
BMI~33.5 
high protein 30:40:30 -5.5% 
SBP -4.4%        
DBP -
4.6% 
-20.3% -7% 
Brinkworth et al 
(2004) 
[151] 
68 weeks total;                          
12 wk restriction                 
4 wk balance               
52 wk min support 
standard 
protein (SP) 15:55:30 
energy restriction  
~6.5 MJ/day     
energy balance  
~8.3 MJ/day 
-2.9% SBP NS        DBP+1.3% 
NS 
+15.4% 
NS 
HOMA -
13.8% 
58 (45 fem) obese 
nondiabetic with 
hyperinsulinemia 
(fasting insulin 
~17.8 mU/l);  
~50.2 y/o, BMI 34 
high protein 
(HP) 30:40:30 -4.1% 
SBP NS        
DBP -
1.4% 
+16.1% HOMA -19.3% 
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Table 2.4: Continued 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Wt BP TG HDL 
 
Glu 
 
Other 
Due, Toubro, Skov, 
Astrup  
(2004) 
[144] 
6 months strict 
intervention 
high protein 
(HP) 25:45:30   energy intake was ad 
libitum 
Wt: -10.8%*                      
WC: -10.3%* 
--- NS NS NS --- 50 overwt/obese (38 
fem); ~39.6 y/o, 
BMI~30.4 
medium protein 
(MP) 12:58:30           
Wt: -6.7%                         
WC: -4.2% 
Appel et al 
(2005) 
[129] 
6 weeks; 
crossover design 
2 week wash 
carbohydrate 15:58:27 
Caloric intakes were 
assigned based on 
expenditure in order 
to keep body weight 
stable. 
--- 
SBP -6.7%               
DBP -5.3% NS -2.3 
--- 
TC -6.1%                         
LDL -9% 
164 adults (73 fem) 
pre- or HT;  
~53.6 y/o, BMI~30.2 
protein 25:48:27 SBP -7.2%
a               
DBP -6.8%a -16.2%
a.b -5.2a TC -9.8%
a,b                         
LDL -11%a 
MUFA 15:48:37 SBP -7.1%
a               
DBP -6.2%a -9.2%
a NS TC -7.6%
a                         
LDL -10.1% 
Sargrad, Homko, 
Mozzoli, Boden 
(2005) 
[140] 
8 weeks high-pro 30:40:30 
~1300 kcal/day 
-2.6% SBP -8.1%               DBP -23.4% NS 
NS NS LDL -14.3% 
12 (9 fem) T2DM; 
~47.5 y/o, BMI~34.5 high-carb 15:55:30 -2.3% NS -5.1% -18.2% LDL NS 
Luscombe-Marsh  
et al 
(2005) 
[152] 
16 weeks total;                         
12 wk restriction             
4 wk balance 
low-fat,  
high pro  
(LF-HP) 
34:37:29 
energy restriction 
~6000 kJ/day  
(30% restriction of 
total energy)                                                                                                                                      
energy balance 
maintained same 
macro comp. 
-9.5% 
 
SBP -5.4%               
DBP: NS -15.9% +10.1% NS
HOMA -34%                     
TC -2.9%                            
LDL -0.7% 
57 overwt/obese 
(32 fem) 
insulin >12mU/L; 
~50.2 y/o, BMI~33.8 
high-fat, 
standard pro 
(HF-SP) 
18:37:45 
Hodgson, Burke, 
Beilin, Puddey 
(2006) 
[141] 
8 weeks control maintain usual diet 
NS 
SBP +1.2%       
DBP NS 
NS NS 
-4.1%* 
--- 60 HT (22 fem); 
~58.6 y/o, BMI~27.7 protein 
partially replace 
CHO-rich foods 
with lean red meat 
qty of lean red meat 
substituted: 
if <8500 kJ/day, 
given 36 g/day         
if >8500 kJ/day, 
given 50 g/day 
SBP -1.4%*         
DBP NS +2.0% 
McAuley et al 
(2006) 
[130] 
12 months total;                         
4 mo supervised                             
8 mo follow-up 
high-fat (HF) no more than 20 g/day CHO for 2 wk, increasing to 50 g/day by 8 wk -5.6% 
NS 
-25.1% +10.5%* 
NS --- 
93 overwt  
insulin-resistant fem 
high-pro (HP) 30:40:30    consuming low-glycemic carbs -8.5% -36.3%* +4.1% 
high-carb (HC) 15:55:30 aim for 25-30 g/d fiber -4.5% -16.5% -1.7% 
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Table 2.4: Continued 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Wt BP TG HDL 
 
Glu 
 
Other 
Leidy, Carnell, 
Mattes, Campbell  
(2007) 
[153] 
12 weeks normal protein (NP) 
.8 g/kg/d PRO          
18:57:25      
-750 kcal/day 
-10.7% SBP -3.5%               DBP -11.1% -9.8% -9.5% -7.3%* 
TC -14.6%                  
LDL -18.6%                                 
LBM -5.8%* 
46 women;  
~50 y/o, BMI~30.6 
high protein 
(HP) 
1.4 g/kg/d PRO      
30:45:25 -21.3% 
SBP -4.6%               
DBP -4.4% -21.3% -13.8% +1.2% 
TC -16.8%              
LDL -17.5%                  
LBM -3.5% 
Clifton, Keogh, 
Noakes  
(2007) 
[154] 
64 weeks total;                              
12 wk weight loss                 
52 wk follow up 
high pro (HP) 34:46:20    ~5600 kJ/day  
with <10% sat fat -5.2% --- 
-24.3% -26.6% 
-11.5% --- 
79 healthy fem;  
~49 y/o, BMI~32.8 high carb (HC) 17:64:20   -9.3% -25.6% 
Keogh et al  
(2008) 
[131] 
8 weeks 
very low-carb 
high-sat fat 
(LC) 
35:4:61        
20% as sat fat 
~30% energy 
restriction          
~6000 kJ/day  
for women          
~7000 kJ/day  
for men 
-7.4%* SBP -8.3%        DBP +9.5% -31.3%* +7.1%* -3.5% 
abd fat -
19%*                     
TC -5.6%                           
LDL -3.1% 
99 overwt/obese  
+ one add'l MetS  
risk factor (IDF),  
~50 y/o, BMI~33.7 
high-carb  
low-sat fat 
(HC) 
24:46:30     
<8% as sat fat -6.5% 
SBP -9.6%        
DBP -9.1% -16.7% NS -3.6% 
abd fat -13%             
TC -9.4%*                    
LDL -9.4%* 
Tay et al  
(2008) 
[132] 
24 weeks 
very low carb, 
high fat 
(VLCHF) 
35:4:61        
20% as sat fat energy restricted  
~6-7 MJ/day       
30% deficit 
-12.3% SBP -9.2%        DBP -6.2% -40%* +17.6%* -3.2% 
TC NS                                 
LDL NS 
88 (57 fem) obese 
+1 add'l MetS  
risk factor;  
~50.5 y/o, BMI~33.7 
high carb, low 
fat (HCLF) 
24:46:30           
<8% as sat fat -10.5% 
SBP -7.9%        
DBP -7.1% -19.7% +6% -3.8% 
TC -10%*                                              
LDL -
14.1%*                   
Jenkins et al 
(2009) 
[133] 
4 weeks low-carb,       high pro 
CHO=130g/day      
31:26:43 
high vegetable 
protein and 
vegetable oil 
-4.7% SBP -1.9%*        DBP -2.4%* -40.2%* -4.2% 
--- 
TC -20.2%*          
LDL -
20.9%* 
44 (26 fem postmen) 
LDL>131 mg/dL, 
TG <442 mg/dL, 
and BMI>27 
high-carb, 
control 16:58:25 
lacto-ovo vegetarian 
diet -5% --- -21.4% -6% 
TC -12.6%,                   
LDL -13.1% 
Volek et al 
(2009) 
[134] 
12 weeks carb restrict (CRD) 28:12:59 
~1,500 kcal/day 
-10.4%* 
--- 
-50.7%* +11%* -12%* HOMA -55.2%* 
40 atherogenic 
dyslipidemia;  
~32.6-37 y/o, 
BMI ~32-33.5 
low-fat (LFD) 20:56:24 -3.3% -19.3% -2.6% -2.1% HOMA -17.6% 
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Table 2.4: Continued 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Wt BP TG HDL 
 
Glu 
 
Other 
Lee et al  
(2009) 
[147] 
12 week high protein (HP) 30:50:20  
1500 kcal/day men                         
1200 kcal/day 
women                 
25g/day fiber                                   
meal replacement 
2x/day 
Wt: -6.6%                 
WC: -6.6% 
--- 
-29.4% +11.2% NS 
>70% 
compliance:                
-15.9% FM* 
75 subjects;  
~48 y/o, BMI~28.5  
conventional 
(C) 15:65:20  
Wt: -6.4%                      
WC: -7.5% -24.9% +17.2% -4.3% 
>70% 
compliance:             
-8.7% FM 
Claessens, van 
Baak, Monsheimer, 
Saris  
(2009) 
[135] 
18 weeks total;                             
5-6 wk restriction     
12 wk maintain 
high-carb (HC) 
weight 
maintenance >55% 
CHO 
5-6 wk restriction, -
500 kcal/day liquid 
VLCD + 
unrestricted low-
carb vegetables 
~30% fat on wt 
maintenance 
Wt: -8.2%        
WC: -9.2% 
SBP -6.0%        
DBP -4.2% +23.8 NS -2.6% --- 
48  (31 fem);  
~45.5 y/o, BMI~33 
high-pro casein 
(HPC) weight maintenance   
>25% PRO 
Wt: -11.0%*        
WC: -10.6%* 
SBP -6.5%        
DBP -8.1% -22.9* +10.9% +2.9%* no diff bw protein 
groups high-pro whey 
(HPW) 
Wt: -11.2%*        
WC: -11.5%* 
SBP -9.6%        
DBP -9.7% -28.2%* +9.1% -1.8%* 
Brinkworth et al  
(2009) 
[136] 
12 months 
very low carb, 
high sat fat 
(LC) 
35:4:61        energy restricted  ~6-7 MJ/day -15.4% 
SBP -10.4%        
DBP -8.7% -34.7%* +20.7%* -5.3% 
FFM -6%                             
TC +13.0%                                    
LDL +19%* 
69 obesity  
+ 1 MetS risk factor; 
~51.4 y/o, 
BMI~33.4  
high carb, low 
fat (LF) 24:46:30   isocaloric -12.2% 
SBP -10.8%        
DBP -10.2% -12.2% +5.1% -5.4% 
FFM -4.1%                    
TC +1.8%                                           
LDL +2.9% 
Lim, Noakes, 
Keogh, Clifton 
(2009) 
[137] 
3 months  
intensive support 
very low carb 
(VLC) 
35:4:61 
20% as sat fat 
energy content = 
6500 kJ 
-9.1% SBP -8.1%                      DBP -4.9% -38.9%
a 0%a -1.9% 
--- 113; ~47 y/o, 
BMI 32, + one add'l 
CVD risk 
very low fat 
(VLF) 
20:70:10 
3% as sat fat -7.5% 
SBP -5.5%                      
DBP -2.7% -6.3%
b -7.1%b +1.9% 
high unsat fat 
(HUF) 20:50:30 -6.8% 
SBP -2.4%                      
DBP -2.5% -12.5%
b -7.7%b -3.7% 
Papakonstantinou           
et al 
(2010) 
[138] 
4 weeks                                       
crossover design 
3 week washout 
high pro, low 
fat (HPLF) 30:50:20 crossover between 
groups 
Wt: -3.3%                           
WC: -31.9% 
SBP -9.0%*        
DBP -9.3%* -29.4%* -8.3% -11.3% 
TC -12.5%                         
LDL -13.5% 
17 obese (12 fem) 
T2DM; 
~46 y/o, BMI 31-45 
low pro, high 
fat (LPHF) 15:50:35 
Wt: -3.2%                           
WC: -3.7% 
SBP -3%                
DBP NS -21.1% NS -13.3% 
TC -10.9%                      
LDL NS 
 Morenga, Williams, 
Brown, Mann  
(2010) 
[145] 
10 weeks standard low-fat, high-carb 20:50:30    advice regarding strict adherence to 
energy intake goals 
was not given. 
Wt: NS                          
WC: NS 
NS NS NS 
NS TC: -3.3%                   LDL: +2% 
89 overwt/obese 
fem; ~42 y/o, 
BMI~32.7 
high pro, high 
fiber (HPHF) 
30:50:20  
>35 g/d fiber 
Wt: -1.8%*                  
WC: -2.3% -2.1% 
TC: -4.6%*                        
LDL: -5%* 
Lopez-Jimenez,  
Xu, Edens  
(2010) 
[148] 
6 months experimental  lower CHO, relatively high protein MUFA and PUFA enriched -6.4% 
--- 
-24.4% +3.8 -1.4% -32%* MetS Prevalence 
55 MetS patients 
(ATP III)  
BMI ~34-35 
control <30% fat standard rec for diabetics -4.7% -21.1% -0.4% -1.5% 
-15% MetS 
Prevalence  
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Table 2.4: Continued 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Wt BP TG HDL 
 
Glu 
 
Other 
Flechtner-Mors  
et al  
(2010) 
[139] 
12 months conventional protein (C)  
15:55:30 
.8g/kg body wt 500 kcal/d less than 
estimated RMR 
Wt: -6.62%                      
WC: -7.2 
--- 
-5.4% 0% -10.2% 
34.8% no 
longer met 
MetS criteria 
110 (88 fem) with 
MetS; ~49.75 y/o, 
BMI~36.25 
high pro (P) 30:40:30    1.34 g/kg 
Wt: -9.12%*                             
WC: -10.9* -34.7%* +4.6%* -9.1% 
64.5% no 
longer met 
MetS criteria 
Toscani et al  
(2011) 
[155] 
8 weeks high protein (HP) 30:40:30   Energy content 
estimated to 20-25 
kcal/kg current 
weight per day 
P: Wt: -4.3%              
WC: -2.0%                                       
C: Wt: -1.8%                   
WC: -2.5% NS NS NS NS --- 30 (18 with PCOS 
[P]) ~22.7 y/o,  
22 controls [C]  
~29.3 y/o) BMI >25 
normal protein 
(NP) 15:55:30    
P: Wt: -3.7%              
WC: -3.5%                                       
C: Wt: -4.1%                   
WC: -2.8% 
Morenga et al  
(2011) 
[142] 
8 weeks mod-high pro (HP) 30:40:30 -2000-4000 kJ/day                             
for a 0.5-1 kg/wk 
weight loss 
Wt: -4.9%*                     
WC: -5.8 
SBP -4.3%        
DBP -5.9%* -20.7% NS -38% 
body fat -
6.1%* 
83 overwt/obese 
fem; ~41.9 y/o, 
BMI~33.9 
high-fiber high-
carb (Hfib)  
20:50:30                           
>35 g/d fiber 
Wt: -3.6%                  
WC: -4.8% 
SBP -1.4%               
DBP -1.1% -12.9% NS -53.1% 
body fat -
3.3% 
Pearce, Clifton, 
Noakes  
(2011) 
[156] 
12 weeks 
high-pro  
low-chol 
(HPLchol) 
213 mg cholesterol 
hypoenergetic  
(6-7 mJ)  
30:40:30  
-6% 
SBP -3.5%        
DBP -4% -23% -5.6% -9.3% TC -5.8% 
65 T2DM or IGT; 
~54.4 y/o,  
BMI 34.1,  
LDL 2.67 mmol/l 
high-pro high-
chol (HPHchol) 590 mg cholesterol 
SBP -7.7%        
DBP -8.5% -25% +1.5%* -4.4% TC -1.5% 
Larsen, Mann, 
Maclean, Shaw  
(2011) 
[143] 
3 month energy 
restriction  high protein 30:40:30    3 month energy 
restriction ~6400 
kJ/day or 30% 
energy reduction 
Wt: -2.9%                
WC: -2.8%                   
SBP -2.3%*                        
DBP NS                    -20.9% 
12 mo: 
+6.7% 
--- 
TC -4.9% 
99 overwt/obese  (51 
fem) T2DM; ~59.3 
y/o,  
BMI 27-40 
high carb 15:55:30     Wt: -3.2%                WC: -2.3%           
SBP 0%                        
DBP NS                    -19%          
12 mo: 
+6.7% TC -6.6% 
BMI (body mass index) values are listed in kg/m2.  Abd, abdominal; ATP III, National Cholesterol Education Program - Adult Treatment Panel III; BP, blood pressure; CHO, carbohydrate; DBP, diastolic blood 
pressure; Fem, female; FFM, fat free mass; FM, fat mass; Glu, glucose; HDL, high density lipoprotein cholesterol; HOMA, homeostatic model assessment; HT, hypertension; IDF, International Diabetes 
Foundation; LBM, lean body mass; LDL, low density lipoprotein cholesterol; MetS, metabolic syndrome; MUFA, monounsaturated fatty acids; PCOS, polycystic ovarian syndrome; PRO, protein; PUFA, 
polyunsaturated fatty acids; RMR, resting metabolic rate; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglycerides; VLCD, very low calorie diet; WC, waist 
circumference; Wt, weight; y/o, years old.    
Values are calculated percent change from baseline.  Listed values are significantly different from baseline, representing a time effect.  Bold and * indicate p<0.05 for group/diet effect.  Within a study, values that 
do not share a common superscript are significantly different.  ---, value not reported or measured; NS, no significant change from baseline; NDE, no diet effect; "! significant change, yet specific value not 
reported.     
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While there is agreement that total energy intake is the primary focus of weight 
loss and management, the dispute regarding the proper macronutrient balance is still a 
concern.  Research by Campbell and Meckling [67] has shown that while the amount of 
weight loss may be similar regardless of the macronutrient composition, a higher protein 
diet may result in more fat loss and lower fasting insulin concentrations.  Additionally, a 
review on the differential effects of dietary treatments on blood lipids has suggested that 
there may be benefit in tailoring treatments to specific individuals in such that a CHO-
based, low-fat diet may work better for persons needing to lower total cholesterol (TC) 
and LDL, while a PRO-based diet could positively benefit individuals who have elevated 
TG and low HDL [43].  Perhaps the same dietary prescription will not work for all 
health profiles.   
Physical Activity 
Physical activity may be a key player in the cause and treatment of MetS.  Mokdad 
et al [157] suggest that the combination of poor diet and inactivity could become the 
leading cause of preventable death in the US, overtaking tobacco use.  Bassuk et al [46] 
have estimated that only 11-46% of the US adult population engages in the 
recommended amount of physical activity regularly.  It is projected that as much as 70% 
of the US population is classified as sedentary (defined as less than three 20-minute 
sessions of demanding physical activity a week) [33, 60, 71].  Additionally, women may 
not be as likely to reach these recommendations as men (47.9% and 50.7% respectively) 
[47]. 
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Low activity levels are related to the individual components of MetS [5], so much 
so that a dose-response relationship is identified between low physical activity levels and 
increased CVD risk [44, 45].  Physical inactivity can lead to CVD risk in a similar 
manner as obesity, by increasing inflammatory markers and fasting plasma glucose 
levels, as well as elevating blood pressure [158].  Additionally, a sedentary state can lead 
to obesity, modified insulin sensitivity in the muscle, and an increased risk of diabetes 
[77, 159].  Conversely, being physically active could possibly reduce the risk of 
developing diabetes (by as much as 34% for every one hour of brisk walking per day) 
[77, 159]. 
General Physical Activity 
Moderate physical activity can improve the risk factors and/or reduce the 
likelihood of developing MetS [8, 49].  Over time, increased activity could lead to lower 
body weight and higher cardiorespiratory fitness levels, both of which would modulate 
insulin action and other components of MetS [17, 45, 51, 60].  Specifically, physical 
activity is associated with reductions in resting BP, abdominal fat, TG, and fasting 
glucose, as well as an increase in HDL cholesterol [24].  While the current guidelines 
recommend participating in moderate-intensity exercise for ≥30 minutes on most days of 
the week [1, 47], specific studies have found higher fitness levels and more vigorous 
activity (5-9 metabolic equivalents) to be the most strongly correlated with MetS risk 
reduction [13, 45, 160, 161].  Others have found both the amount of physical activity 
(expenditure) and fitness level (measured by peak oxygen consumption, VO2 max) to 
have independent affects on MetS components [45, 162, 163], while some question the 
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significance of the correlation with VO2 max [163].  Additional findings have proven 
that even in the absence of enhanced fitness, physical activity is still beneficial in 
creating a more desirable metabolic profile [52, 164]. 
Aerobic Activity 
Extensive research has proven cardiorespiratory fitness to be inversely correlated 
with the metabolic abnormalities of MetS, CVD, and T2DM regardless of age, gender, 
ethnicity, or body weight [3, 6, 14, 24, 29, 50-53].  Specifically, the Cross-Cultural 
Activity Participation Study by Irwin et al [56] found the odds of having MetS to be 
82% lower among the most active women, 86% lower among women reporting any 
amount of vigorous activity, and 93% lower among women in the highest quartile of 
maximum treadmill duration compared to their lowest level counterparts.  Similarly, 
individuals in the lowest fitness category may be ten times as likely as those in the 
highest fitness category to develop MetS [24].  In regards to specific cardiovascular 
measurements, Okura et al [52] found each one-ml/kg/min increase in VO2 max to 
translate to ~7% reduced risk of MetS.  LaMonte et al [165] computed a one-metabolic 
equivalent increase in maximal treadmill testing to equate to a ~17% reduced risk level, 
specifically in women.  More precisely, it has been calculated that a woman in her 40’s 
would need to achieve a VO2 of ~28 ml/kg/min in order to reduce her MetS risk by 
moving out of the lowest fitness category [24]. 
The ability to drastically increase cardiorespiratory fitness is questionable based on 
genetic and environmental limitations [24].  The appropriate exercise prescription and 
intensity is also heavily debated [6].  Some researchers believe that lower intensity (40-
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60% VO2 max) exercise that can be maintained for a longer duration (≥60 minutes), 
more frequently (up to five days a week) will lead to the greatest improvement in 
cardiorespiratory fitness [51].  Moderate and moderate-vigorous (>60% VO2max) 
intensities have also been purported to be most effective [166].  Previous reviews [51, 
53, 54] have found that while both moderate and vigorous activity may equally affect 
body fat, systolic blood pressure (SBP), and lipid profile (lowering TG and raising 
HDL), vigorous intensity may be superior for further affecting diastolic blood pressure 
(DBP) and glucose metabolism.  Although benefits may be achieved with either 
intensity, shorter time periods with more vigorous activity could be utilized [166].  A 
review by Laaksonen et al [167] stated that 180 minutes/week of moderate intensity 
aerobic training, but only 60 minutes of moderate-vigorous activity, is necessary to 
decrease the risk of MetS by 50% [167].  It is promising to note that even a single bout 
of activity, either moderate or vigorous intensity, can promote short-term benefits to 
include lower TG, SBP and DBP, and greater insulin sensitivity [168].  
Resistance Training 
Resistance exercise appears to produce risk-reducing benefits as well.  It is 
postulated that resistance training may provide protective effects through the achieved 
strength gains, reduction in body fat, and improvement of insulin sensitivity [21, 42, 47].  
Muscular strength has been suggested to be inversely associated with all-cause mortality 
[47] and reduced risk of developing MetS (by 34%) [169, 170].  Previous reviews have 
found routine resistance training (2-3 times/week) to lead to decreased resting BP, 
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abdominal fat, and improved insulin resistance [53, 170], but limited to no benefit has 
been reported on fasting lipid levels [170].    
When combined with a hypocaloric diet, resistance training can aid in the 
maintenance and/or increase of both lean body mass and resting metabolic rate, which 
may otherwise be at risk of decrement with diet alone [62, 170].  There is a progressive 
reduction in strength and muscle mass associated with aging, which may explain the 
increasing risk of conditions such as MetS over the life span.  Since RT has proven to be 
more effective in the prevention rather than the restoration of muscle mass [118], 
performing this type of activity at an early age, and throughout life, may offset the 
deleterious effects.  Finally, further benefit may be achieved by the combination of 
aerobic and resistance training exercises, with aerobic exercise incorporating the 
improvements to the lipid profile as well [47, 171]. 
Protein Modification with Exercise 
As the independent benefits of both higher protein consumption and exercise 
have each been previously discussed, the combination of the two may lead to even 
greater prevention and/or reversal of MetS.  It is known that the combination of exercise 
with a higher protein diet can enhance weight loss, fat loss, and aid in fat free mass 
retention [43], which is certainly beneficial for an individual with MetS.   
Sixteen studies that incorporate higher PRO consumption with physical activity 
met the criteria for this literature review, and are summarized in Table 2.5.  These 
studies utilize PRO percentages ranging from 22-34% of daily caloric intake.  
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Table 2.5: Increased Protein Consumption with Exercise for Treatment of Metabolic Syndrome Risk Factors 
 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Exercise Wt BP TG HDL 
 
Glu 
 
Other 
Suh and Lee  
(2005) 
[172] 
8 weeks 
high-pro + 
exercise 
(HPE) 
25% caloric intake was soy protein 
aerobic activity 
3x/week for >30 
min @  
50-65 max 
capacity 
-4.1%* 
--- 
NS +5.8%* -9.8%* TC: -7.8%* 
30 fem; ~24.5 y/o, 
BMI~21.9 
exercise only 
(EXO) maintain usual diet -3.3% NS NS NS TC: NS 
control (CON) --- NS NS NS NS TC: NS 
Noakes, Keogh, 
Foster, Clifton  
(2005) 
[173] 
12 weeks high-pro (HP) 34:46:20  
Isocaloric  
5600 kJ 
increase activity 
to ≥30 min 
3x/week 
-8.75% --- -21.9%* -6.8% -3.4% --- 
100 fem; ~49 y/o, 
BMI~32 
high-carb 
(HC) 17:64:20  -8.05% -8.05% -7.5% -6.8% -4.1% -4.1% 
Layman et al 
(2005) 
[43] 
4 month CHO .8 PRO: >3.5 
CHO g/kg/day  
both diets 7.1 
MJ/d and 30% 
fat 
voluntary, 
walking 30 min 
5d/wk 
-8.3% 
--- 
NS -7.7% 
--- 
TC: -10.1%                               
LDL: -13%*                         
> FFM loss 
48 fem, 
 ~46 y/o,  
BMI~33  
CHO + EX mandatory  
5 d walk       
2 d RT/wk 
-8.4% NS NS TC: -9.0%                          LDL: -10%* 
HP + Ex 
1.6 PRO: <1.5 
CHO g/kg/day  
-11.4%* -25.2%* NS TC: NS                              LDL: NS 
HP 
voluntary, 
walking 30 min 
5d/wk 
-9.5%* -21.1%* NS TC: NS                                      LDL: NS 
McAuley et al 
(2005) 
[174] 
24 weeks total;                                 
8 wk weight loss                            
8 wk maintenance               
8 wk no supervision 
high-carb, 
high-fiber 
(HC) 
focused on 
number of 
servings of each 
food group 
recommendations 
involved food 
choices, did not 
prescribe a total 
energy amount 
for consumption 
encouraged to 
exercise 30 min 
5x/wk 
Wt: -4.8%a         
WC: -6.3%a 
SBP -1.6%        
DBP -1.3% -18.1%
a -3.4%a -6% 
--- 
96 normoglycemic, 
insulin resistant fem, 
30-70 y/o, BMI >27 
(HF) high-fat / 
Atkins Diet  
20g/day CHO 
gradually 
increased 
Wt: -7.4%b         
WC: -9.0%b 
SBP -3.1%        
DBP -2.4%* -39.9%
b +7.7%b -5.9% 
high-pro / 
Zone Diet 
(HP) 
30:40:30    Wt: -7.4%
b         
WC: -8.1%b 
SBP -2.4%        
DBP -1.3% -31.2%
b +0.8%a,b -3.9% 
Dansinger et al  
(2005) 
[175] 
2 months strict 
intervention Atkins 
<20g/d CHO with a  
gradual increase to 50 g/d CHO 
encouraged to 
perform 60 min 
weekly  
Wt: -3.6%                   
WC: -3%                 
SBP: -3.3%                          
DBP: -5.5%                         -15.1%*                          +6.7%*                  -7.7%            
TC: NS                           
LDL: NS 
160 overwt/obese 
known HT, 
dyslipidemia, or 
hyperglycemia; 
BMI~35  
Zone 30:40:30   Wt: -3.8%                   WC: -2.8%                      
SBP: NS                         
DBP: -6.2%                    -24.4%*                        NS             NS 
TC: -8.3%*                                 
LDL: -7%*                               
Weight 
Watchers 
24-32 points daily;  
~1,200-1,600 kcal/day 
Wt: -3.6%                   
WC: -3.2%                     
SBP: -3.6%                          
DBP: -4.2%                             NS NS 
TC: -
7%*                                 
LDL: -
9%*                           
TC: -6.7%*                                 
LDL: -9%*                           
Ornish vegetarian diet with  <10% energy from fat 
Wt: -3.5%                   
WC: -2.4%                      
SBP: NS                          
DBP: -3.3%        NS -8% 
 TC: -
9%*                                
LDL-
12%*                             
TC: -8.9%*                                 
LDL: -12%*                             
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Table 2.5: Continued 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Exercise Wt BP TG HDL 
 
Glu 
 
Other 
Ferrara et al  
(2006) 
[176] 
6 months high pro (HP) 22:50:28                   1.9 g/kg PRO performing  90+ min  
an-/aerobic 
training 3x/wk 
-2.8% 
NS NS NS NS 
TC -25% 
15 healthy men; 
~26.4 y/o, BMI~23.5 
normal protein 
(NP) 15:60:25    1.3 g/kg PRO NS TC -15.3% 
Meckling and 
Sherfey  
(2007) 
[120] 
12 Weeks CON 1:1 PRO:CHO        
≤30% fat 
500 kcal/d less than 
analyzed intake 
--- -2.7% SBP -7.1%        DBP -7.4% NS 
NS NS 
TC NS                          
LDL NS 
 44 overwt/obese 
fem; ~42.5 y/o, 
BMI~30 
CONEx 3x/week,  
36 min circuit,  
65-80% MHR 
-5% SBP -5.4%        DBP NE 
TC -17.5%                       
LDL NS 
HPEx 3:1 PRO:CHO   
(~.75g/kg PRO; 
~1371 kcal/d) 
-8.1% SBP -5.2%        DBP -4.9% -29.9%* 
TC NS                          
LDL NS 
HP --- -5.5% SBP -7%                 DBP -8.9% 
NS 
 
TC -32%                                 
LDL -41.5% 
Bowden et al  
(2007) 
[177] 
12 weeks same kcal (Diet 1) 
same caloric 
consumption as 
baseline High-pro / low-carb,  
25:45:30  
recommended  
30 min/day  
4-6 x/wk  
@ 60-85% MHR 
NS --- NS 
NS 
--- 
DEXA BF  
-6.86%* 
48 young, 
normolipidemic, 
normoglycemic, 
sedentary 
-500 kcal  
(Diet 2) 
-500 kcal/day from 
baseline ! NS 
Gardner et al 
(2007) 
[178] 
12 months total:                            
2 mo weekly 
instruction             
10 mo follow up 
Atkins 
20 g/day CHO 
gradual increase to 
50 g/day 
no focus on energy 
restriction 
some 
encouragement to 
increase activity 
-5.2%a SBP -6.4%
a               
DBP -6%a -23.4%
a +9.2%a NS 
--- 
 
Zone 30:40:30 incorporated 
specific goals for 
energy restriction 
-1.7%b SBP -2.9%
b               
DBP -3%a,b -3.4%
b +4.2%a,b NS 
311 overwt/obese, 
nondiabetic, 
premenopausal;  
~41 y/o, BMI~32 
LEARN 55-60% CHO,              <10% sat fat -3.0%
a,b SBP -2.7%
b               
DBP -3%a,b -12.3%
a,b +5.5%a,b NS 
Ornish 10% fat no focus on energy restriction -2.4%
a,b SBP -1.6%
b               
DBP -1%b -12.6%
a,b 0%b NS 
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Table 2.5: Continued 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Exercise Wt BP TG HDL 
 
Glu 
 
Other 
Lasker, Evans, 
Layman  
(2008) 
[179] 
4 month PRO ~1700 kcal/day 30:40:30 
1.6 g/kg/d Pro       
<170 g/d CHO      
~90 min/week 
-9.1%                    
(p=0.07) 
--- 
-34%* +5%* 
NS 
FM: -8.7%*                         
LDL: +2.5% 
50 subjects; 
 ~47 y/o, BMI ~33.6 CHO 
~1700 kcal/day 
15:55:30 
0.8 g/kg/d PRO        
>220 g/d CHO          -7.3% -14% -3% 
FM: -5.7%                             
LDL: -7%* 
Layman et al  
(2009) 
[180] 
4 month wt loss    moderate pro (PRO) 
1.6g/kg/d PRO          
<170 g/d CHO           
(30:40:30) 
1700 kcal/day 
females; 1900kcal/d 
males; 30% fat; 17 g 
fiber 
voluntary, 
walking 30 min 
5d/wk 
-8.7%,     
--- 
" ! 
--- 
FM -22%                 
130 subjects;  
~45.4 y/o,  
BMI ~32.6 
conventional 
high-carb 
(CHO) 
0.8 g/kg/d PRO        
>220 g/d CHO         
(15:55:30) 
 -7.6%,       --- --- TC "   LDL "  
Sacks et al 
(2009) 
[181] 
2 years low-fat,  ave-pro 15:65:20 -750 kcal/day deficit 
from baseline intake 
with 20 g/day 
dietary fiber,  
<150 mg/cholesterol 
per 1000 kcal,  
<8% saturated fat 
90 min/wk of 
moderate activity NS 
SBP -0.8%               
DBP -0.8% -11.5% +5.6% +1.1 
LDL:  
-5.9%* 
811 overwt;  
~51 y/o, BMI ~33 
low-fat,  
high-pro 25:55:20 
SBP -1.7%               
DBP -1.3% -16.6% +6.5% +1.0 
LDL:  
-3.9%* 
high-fat,  
ave-pro 15:45:40 
SBP -1.3%               
DBP -1.5% -12.4% +6.3% +1.6 LDL: -0.2% 
high-fat,  
high pro 25:35:40 
SBP -0.7%               
DBP -0.3% -16.7% +8.8%* +2.8 LDL: -1.3%* 
Wycherley et al  
(2010) 
[42] 
16 weeks                                                                                                                        Con 
19:53:26  
Females 6 MJ/day                     
Males 7 MJ/day 
--- Wt: -8.9%                 WC: -7.4% 
SBP -9.5%        
DBP -8.9% -26.1% 0 -23.9% 
--- 83 with T2DM,  
~56.1 y/o,  
BMI~35.4 
Con + RT RT 3x/week, 2 
sets, 8-12 reps @ 
70-85% 1RM 
Wt: -10%                 
WC: -9.9% 
SBP -12%        
DBP -9.9% -18.8% -9.1% -21.8% 
HP + RT 
 33:43:22  
Wt: -13%*                 
WC: -12%* 
SBP -10%        
DBP -8.9% -27.8% -9.1% -23.2% 
HP --- Wt: -8.8%                 WC: -7.8% 
SBP -11%        
DBP -12% -20% -8.3% -26.3% 
Josse et al  
(2011) 
[182] 
16 weeks high pro, high dairy (HPHD) 30:40:30    
30% total pro, 15% 
from dairy 7 d/wk aerobic 
exercise  
for 250 cal. 
expenditure;  
2 d/wk RT 
Wt -5%                                  
WC -4.9% --- 
" 
--- --- 
FFM +1.4%*                       
TC: "                         
LDL:" 
90 overwt/obese 
premeno fem;  
~28 y/o, BMI ~31 
adeq pro, med 
dairy (APMD) 15:55:30    
15% total pro, 7.5% 
from dairy --- FFM -0.4% 
adeq pro, low 
dairy (APLD) 15:55:30   
15% total pro, <2% 
from dairy " 
FFM -1.4%                
TC: "                         
LDL: " 
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Table 2.5: Continued 
Authors 
(Date) 
Study Length                
Study 
Population 
Groups Dietary Protocol (%PRO:CHO:FAT) Exercise Wt BP TG HDL 
 
Glu 
 
Other 
Campbell and 
Meckling (2012) 
[67] 
12 weeks LP 1g PRO: 4 g CHO 
low fat, 
hypo- and 
iso-energetic 
60 minutes, 
circuit, 3x/week 
@ 65-80% MHR 
Wt: -6.3%                        
WC: -7.6%a 
SBP -6.7%                 
DBP -6.7% -15.1% -13.7% 
NS 
lean mass +4.2% 
54 overweight/obese 
women with MetS 
risk factors; (~40.2 
y/o, BMI~35.5 kg/m2 
NP 1g PRO: 2g CHO Wt: -9.1%                  WC: -11%ab* 
SBP -6.3%                 
DBP -7.2% -26.6% -16.3% lean mass +10.0%* 
HP 1g PRO: 1g CHO Wt: -7.2%         WC: -8.1%b 
SBP -7.9%                 
DBP -6.3% -18.0% -12.6% lean mass +7.3% 
Dutheil et al 
(2012) 
[183] 
26 weeks total;                              
3 weeks residential                     
6 months follow up 
Normal
protein 
intake (NPI) 
1.0 g/kg/day 
-500 kcal/day 
2-3 hrs/day      
(2 hr walking,  
1 hr lt aerobics)   
40-60% HRR  
Wt: -5.4%                    
WC: -5.9% 
NS NS NS NS TC NS                          LDL NS 28 (9 fem)  
with MetS (IDF);  
61.8 y/o, BMI~33.4 
high protein 
intake (HPI) 1.2 g/kg/day 
Wt: -8.2%                 
WC: -8.2% 
BMI (body mass index) values are listed in kg/m2.  BF, body fat; BP, blood pressure; CHO, carbohydrate; DBP, diastolic blood pressure; FFM, fat free mass; FM, fat mass; Glu, glucose; HDL, high density lipoprotein 
cholesterol; HRR, heart rate reserve; HT, hypertension; LDL, low density lipoprotein cholesterol; MetS, metabolic syndrome; MHR, maximum heart rate; PRO, protein; RT, resistance training; SBP, systolic blood pressure; 
T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglycerides; WC, waist circumference; Wt, weight; y/o, years old. 
Values are calculated percent change from baseline.  Listed values are significantly different from baseline, representing a time effect.  Bold and * indicate p<0.05 for group/diet effect.  Within a study, values that do not share a 
common superscript are significantly different.  ---, value not reported or measured; NS no significant change from baseline; NDE, no diet effect; éê significant change, yet specific value not reported.   
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While most studies are comparisons with a higher carbohydrate consumption group, 
some studies compared popular diet programs (such as Atkins, Zone, and Weight 
Watchers) and others compared different protein allotments.  Most of the studies focused 
on increasing aerobic exercise, while a few utilized resistance exercises as well.  While 
the studies that integrated resistance training may have further aided in weight loss [42, 
43] and lean mass gain [182], both aerobic and resistance training (combined with a 
higher protein diet) lead to similar benefits regarding MetS: decreased TG [43, 120, 173, 
174, 178-180, 182] and weight [42, 43, 172, 174, 178], increased HDL [172, 175, 178-
181], and a few studies also found decreases in glucose [172], and blood pressure [178], 
as well as fat mass [179, 180] and TC [172].  Perhaps more differences between the 
types of exercise would have been noted if looking at fitness variables (such as strength, 
muscular endurance, and cardiorespiratory fitness) however this review focused 
specifically on the markers of MetS.        
Weight Loss 
Based on the research reviewed above, weight loss appears to be an integral 
component in the treatment of MetS [33, 55, 56].  More drastically stated, a linear 
relationship has been found to exist between weight and WC, SBP, DBP, TG, HDL, and 
fasting glucose [50, 57].  In a study by Hillier et al [57], each kilogram gained resulted in 
a 22% increase in risk of developing MetS.  A decrease in body weight has been found 
to lower TC, TG, and glucose levels, decrease BP, and reduce insulin resistance [58].  
Weight reduction will not only improve each of the MetS risk factors, it will also 
specifically reduce the risk for T2DM [8].  Surprisingly, it only takes a small reduction 
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to achieve health benefits.  The National Institutes of Health has shown that losing as 
little as five-to-ten pounds can decrease elevated glucose levels [21, 184].  A decrease of 
seven-to-ten percent body weight over 6-12 months is advised for the treatment of MetS 
[27, 58-60].  It is promising that ideal body weight need not be achieved in order to 
begin the reversal of the diseased state.   
The benefits of a TLC program with diet and exercise collectively, versus either 
component individually, have been repeatedly proven.  Ross et al [33, 185] have shown 
that while both diet-induced and exercise-induced weight loss may lead to similar 
decrements in abdominal obesity and insulin resistance, cardiovascular exercise is 
beneficial in improving fitness and reducing abdominal fat specifically.  Layman et al 
[43] have found the effects of diet and exercise combined to be independent and additive 
in their improvement of both absolute and percent change in body fat.  Cardiovascular 
exercise is beneficial in maximizing caloric expenditure, while resistance training is key 
to maintaining or increasing lean body mass particularly in conjunction with a deficit in 
caloric consumption [67].  
With various compositions of the MetS profile, perhaps the same protocol for 
weight loss will not be advantageous for each patient [26].  Depending on the exact 
health concerns requiring attention, general body weight loss can be beneficial for 
insulin sensitivity and lipid metabolism, while loss of fat mass specifically, may be 
necessary for blood pressure reduction [55].   
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INDIVIDUAL RISK FACTORS 
A review of each NCEP ATP III MetS risk factor independently is beneficial 
toward the development of individualized TLC programs. These risk factors will be 
discussed in the order of their prevalence in women according to the 2003-2006 
NHANES report: abdominal obesity (53%), hypertension (40%), hyperglycemia (39%), 
hypertriglyceridemia (31%) and low HDL cholesterol (25%) [19].   
Obesity 
According to the NCEP ATP III definition, a waist circumference (WC) >88 cm 
is a risk factor for MetS in women [8].  Central obesity is heavily interrelated with 
additional risk factors of MetS, CVD, and T2DM, and according to some may be the 
driving force behind the increased MetS prevalence [1, 5].  Past research has shown WC 
alone to be an independent predictor for CVD [42, 83, 186, 187].  Abdominal obesity is 
linked to metabolic abnormalities such as elevated fasting glucose, blood pressure, and 
inflammatory markers [158].  It is closely associated with insulin resistance (which is a 
powerful risk factor in the development of T2DM and CVD) [17], and has the potential 
to cause an atherogenic lipoprotein profile (to include hypertriglyceridemia and reduced 
HDL, among other lipoprotein abnormalities) [85].  Health conditions related to obesity 
are to blame for over 300,000 US deaths and $117 billion in health care expenses each 
year [21, 22]. 
Obesity Treatment  
Weight reduction is essential for reversing MetS, and should be achieved through 
a combination of reduced caloric intake and increased physical activity [67].  Due to the 
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thought that excess dietary fat may be to blame for obesity, the American Heart 
Association among other organizations advise a low-fat diet [67].  Interestingly, others 
have pointed out that the prevalence of MetS has increased even in conjunction with a 
decrease in dietary fat consumption in the US [67, 188].  The vague guidelines for 
reducing a large WC in MetS have included weight reduction, consumption of a 
hypocaloric diet, increased physical activity, and utilization of drugs if necessary [17].  
While Buchholz and Scheoller [189] firmly believe that “a calorie is a calorie” in regards 
to weight loss, research from the ESNL has shown that greater PRO consumption, when 
in combination with a resistance-based circuit training program, may be more effective 
than higher CHO ingestion for WC reduction [62, 63, 83].  Additional studies have 
professed the benefits of utilizing both aerobic training for reducing body mass and fat 
mass and resistance training for increase lean mass and potentially decrease fat mass as 
well [171]. 
Blood Pressure 
Blood pressure higher than 135/80 mmHg (in addition to taking blood pressure 
medication) is a risk factor for MetS according to the NCEP ATP III [8].  According to 
the Center of Disease Control [190], one-in-three US adults (68 million people) have 
high blood pressure.  Additionally the American Heart Association stated in 2012 that 
30% of Americans have prehypertension [191].  A pre-hypertensive diagnosis increases 
the risk of developing hypertension (HT), and hypertension increases risk for CVD 
[192].  The good news is that TLC works well for mild hypertension [5], and a focus on 
weight loss is also beneficial towards blood pressure reduction [193].  This relationship 
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is achieved primarily through increases in blood volume and cardiac output as well as 
other physiological changes in the renin-angiotensin system [58, 194, 195].  Ramsey et 
al [58, 194, 195] anticipate that every one-kilogram reduction in weight loss may result 
in a 1.5-2.5 mmHg drop in blood pressure.  Additionally, a large meta-analysis has 
found that lowering systolic (SBP) and diastolic (DBP) blood pressure by ten and six 
mmHg respectively, can lead to a 40% and 30% reduction in the risk of cardiovascular-
related premature death [13, 196]. 
Blood Pressure Treatment  
In addition to the general recommendation of weight reduction [17], the following 
recommendations have been suggested for the treatment of elevated blood pressure with 
MetS: dietary salt restriction [17, 58], increased potassium intake [58], and medication 
as needed.  The Joint National Committee on Prevention, Detection, Evaluation and 
Treatment of High Blood Pressure states in their guidelines that drug therapy is required 
in patients with BP >140/90 mmHg [17, 197].  However, utilization of particular 
hypertensive medications (such as TZDs and beta blockers) may exacerbate other risk 
factors of the metabolic syndrome [17, 73, 198].  
In regards to diet and exercise, there is not conclusive evidence on the efficacy of 
ingesting any particular macronutrient for BP reduction [115].  A review by Eriksson et 
al [5] reported the following regarding exercise: it can provide a moderate 
antihypertensive effect, it is most beneficial in cases of mild hypertension or prevention, 
it can prevent age-associated elevations in BP, and that these benefits of exercise may be 
greater in women than in men. Additionally, the antihypertensive effects of exercise may 
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be due to the accumulation of single exercise bouts rather than chronic changes, 
although long-term resistance training can favorably lower resting BP.  One meta-
analysis has even estimated that exercise can be utilized to decrease SBP and DBP by 
eleven and eight mmHg respectively [199]. 
Hyperglycemia 
As an easy and effective tool for measuring hyperglycemia, the NCEP ATP III 
recommends a fasting plasma glucose test, where a value ≥5.6 mmol/L is an indicator 
for MetS [8].  The Center of Disease Control estimated that as of 2003, 14.4% of US 
adults (29 million people) have diabetes or impaired fasting glucose [200].  
Hyperglycemia alone is not responsible for the increased CVD risk; rather it is the 
combination with the metabolic abnormalities that accompany it [85, 201].  Elevated 
glucose suggests a prediabetic state, and may be a predictor of insulin resistance.  Lipid 
overload specifically in the liver and muscle tissues may be to blame, which could lead 
to a suppressed insulin regulation of hepatic glucose output and impaired insulin-
mediated glucose disposal respective to each tissue [28, 51].  Grundy et al [28] define 
the three major causes of insulin resistance to be genetics, abdominal obesity, and lack 
of exercise.  Additionally, obesity, hypertension, dyslipidemia, and a sedentary lifestyle 
are all factors related to MetS that can also predispose an individual to insulin resistance, 
reducing the target tissue’s ability to respond to normal concentrations of insulin [21].   
There are many mechanisms that could be responsible for linking insulin 
resistance to CVD; to include increased free fatty acid levels, increased sympathetic 
nervous system activity, vascular smooth muscle cell proliferation, impaired endothelial 
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function, and inflammation, although the specific cause(s) of insulin resistance are not 
well understood [71, 202, 203].  Obesity causes grave concern towards the development 
of insulin resistance (as well as T2DM and CVD) as the accumulation of fat mass has 
been found to drive insulin resistance, and insulin sensitivity decreases as body fat 
percentage increases [28, 42, 85].  Abdominal fat in particular leads to higher levels of 
free fatty acids than lower body fat accumulation, which may explain the linkage 
between insulin resistance and abdominal obesity [28]. 
Hyperglycemia Treatment  
Body weight and physical fitness both have the ability to regulate insulin 
resistance and reverse hyperglycemia [45, 48, 204].  The National Institutes of Health 
has found that losing as little as five-to-ten pounds may lower elevated glucose levels 
into a healthy range [21, 205].  Exercising regularly will lead to an increase in insulin 
sensitivity in the skeletal muscles [118, 206].  Some short-term benefits of physical 
activity include an increase in the number of muscular glucose transporters and 
improved insulin-mediated glucose disposal.  Recurrent exercise can lead to reduced free 
fatty acid levels and increased insulin sensitivity [5, 28, 56, 170, 207].  Additionally, 
fitness level (VO2max) has been correlated with the prevention of T2DM, with low 
fitness levels leading to an increased risk [208].   
Generally stated, “dietary modification and enhanced physical activity” could 
prevent the evolution of prediabetes to T2DM [20, 60], however specifics for either 
treatment have not been identified.  Some suggestions include to: reduce overall fat 
consumption, increase monounsaturated fat intake, increase fiber, and exercise regularly 
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[17, 193, 209].  While there are numerous drug options for the treatment of T2DM, no 
medications have been licensed for the treatment of hyperglycemia in conjunction with 
MetS [17].  Conversely, a variety of studies comparing TLC versus medication for 
insulin resistance have proven lifestyle intervention to be more successful in greater 
weight loss, and reducing the incidence of T2DM [17, 33, 210, 211], with further benefit 
achieved with greater amounts of exercise [93].  
Specific dietary protocols for hyperglycemia have been controversial.  Grundy et 
al [28] have found high-monounsaturated fat diets to be more advantageous than high-
CHO intakes in regards to insulin resistance, which coincides with the Nurses’ Health 
Study [77] that has found an increased diabetes risk with high glycemic load and trans-
fat consumption.  Conversely, the San Luis Valley study [29, 212] found no association 
between CHO intake and hyperinsulinemia.  Higher PRO diets have proven beneficial 
for improving glycemic control [63, 118, 213].  Wycherley et al [42] prefer a 
combination of high protein and resistance training to reduce insulin concentrations in 
overweight, type-2 diabetics.  Kreider et al [63] have also reported a greater reduction in 
fasting glucose when performing resistance-based circuit exercise combined with 
replacing a portion of dietary CHO with PRO.  While higher concentrations of protein in 
the diet may be beneficial, a review of the literature by Dr. Eisenstein et al [115], has 
found mixed results regarding the effects of a high protein diet (and its effects on 
glycemic index) on glucose response and insulin sensitivity, and specifically states 
concern for the use of these diets in patients diagnosed with diabetes.  
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Aerobic exercise can be beneficial for glycemic control in both single bouts and 
with persistent training [5], and a range of volumes and intensities will prove efficacious 
[51].  Chronic exercise may be necessary to sustain the improvements in insulin 
sensitivity and glucose tolerance, and these benefits may be experienced regardless of 
age, body weight, and diabetes status [5].  Resistance training is also valuable for 
increasing the glycogen storage capacity of muscles and thus for long-term glycemic 
control [5]. 
Dyslipidemia 
Evaluation of the full lipid profile offers two MetS risk factors based on the NCEP 
ATP III definition of MetS: hypertriglyceridemia (TG ≥1.7 mmol/L) and low HDL (<1.3 
mmol/L) [8].  However, if a patient with MetS has an LDL cholesterol above 100 mg/dL 
(or 2.6 mmol/L), then LDL becomes the primary target for treatment, prior to focusing 
on reduction of the MetS risk factors specifically [1, 17, 193, 214].  Additionally if a 
patient with MetS has established CVD or T2DM, the optimal goal for LDL becomes 
<70mg/dL (or 1.8 mmol/L) [17, 214]. 
Poor diet may be to blame for the majority of a dyslipidemic state.  Fat consumption, 
specifically trans- and saturated- fatty acids, is known to increase the concentration of 
LDL cholesterol and total cholesterol levels [28, 33].  Excessive intake of CHO leads to 
increased TG concentration, which may play a role in the formation of small LDL 
particles, and typically also lowers HDL concentrations [28].  Furthermore, the type of 
CHO consumed may alter the affect on TG; for example, Jenkins [28, 215] found that 
high-fiber cereal grains did not increase TG. 
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The state of obesity can further exacerbate dyslipidemia.  Excess body weight is 
significantly related to the rate of daily cholesterol production, causing an increase in TG 
and an impaired removal of LDL cholesterol [58, 216].  Weight loss has been proven to 
have a substantial effect on the lipid profile.  A meta-analysis has revealed that a one-
kilogram decrease in body weight can lead to a decrease in each of the following lipid 
values: TG (-0.05 mmol/L), LDL cholesterol (-0.02 mmol/L), TG (-0.015 mmol/L), and 
HDL cholesterol (-0.007 mmol/L) [43, 58].  Additionally, the decrease in HDL 
cholesterol during weight loss mentioned above has further been shown to increase once 
weight loss stabilizes [58].  Exercise not only assists with weight reduction, it may 
independently aid in the normalization of TG and HDL cholesterol levels [33], although 
other researchers have found that exercise may not impact HDL cholesterol if it is not 
paired with hypertriglyceridemia at baseline [217]. 
Dyslipidemia treatment 
Similar to each of the other risk factors, a combination of diet and exercise will be 
most beneficial for reducing the dyslipidemic state.  If LDL cholesterol is a primary 
concern, specific nutritional suggestions include the reduction of cholesterol, saturated- 
and trans-fat, yet most commonly medication may be prescribed [17].  Once LDL 
cholesterol is properly managed, the general TLC treatment for atherogenic dyslipidemia 
may include: weight reduction, caloric restriction with a fat intake between 25-35%, 
reduced saturated fat and cholesterol consumption, greater intake of omega-3 fatty acids, 
and a focus on complex CHO and fiber [1, 17, 193].  However, based on the individual’s 
specific lipid profile, specialized treatment may be more beneficial.  A higher CHO, 
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lower fat diet can lead to greater changes in LDL and total cholesterol, while a higher 
PRO diet may better assist in the lowering of TG and elevation of HDL cholesterol [43].  
Yet, other studies have found no effect of protein consumption on blood lipids [115], 
and the ESNL has found that replacing dietary carbohydrate with a greater proportion of 
dietary protein can reduce total and LDL cholesterol by 2.5% and 2.8% respectively 
[83].  Various medications (and combinations) are also prescribed to dyslipidemic 
individuals [17], with nicotinic acid proving to be quite effective [184], though it is 
recommended to first attempt TLC for three to six months unless the patient is 
considered high risk [17]. 
Additionally, at least 30 minutes of exercise five days a week is advised for 
individuals with dyslipidemia [193].  Physically active individuals have proven to have 
lower levels of TG and LDL cholesterol, and higher levels of HDL cholesterol than their 
sedentary counterparts [5].  A review by Carroll and Dudfield [51] found that even in the 
absence of weight loss, regular exercise training at a moderate intensity can raise HDL 
cholesterol and lower TG.  
CONCLUSION 
 MetS is a condition of great concern.  Having a combination of three or more risk 
factors creates an additive effect on disease risk, increasing the risk of both CVD and 
T2DM.  The NCEP ATP III criteria have been proven to be beneficial in identifying 
MetS and predicting future disease risk.  In the US alone, approximately one-quarter of 
the adult population is diagnosed with MetS.  While the prevalence is similar in both 
men and women, women are reported as having a higher morbidity related to the 
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disease.  Additionally, a large proportion of the US population is sedentary.  A TLC 
program of diet and exercise is the best treatment for preventing and reversing the 
markers of MetS.    
 Research from the ESNL has proven that for exercise to effectively improve 
MetS variables, it should be combined with appropriate dietary modification.  However 
the question remains as to what is “appropriate” dietary modification.  The NCEP ATP 
III promotes a ratio of 15% protein PRO, 50-60% CHO, and 25-30% fat.  Conversely, 
this literature review demonstrated the benefits of reducing CHO consumption, and 
specifically replacing CHO with higher quantities of PRO, and further benefit with the 
addition of exercise.  Yet, certain health benefits, specifically regarding the markers of 
MetS, were noted with various macronutrient combinations.  Perhaps different dietary 
recommendations should be prescribed for individuals based on their specific metabolic 
profile.   
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CHAPTER III  
METHODS 
EXPERIMENTAL APPROACH 
This study is a retrospective analysis of previous research performed in the Exercise 
and Sport Nutrition Laboratory (ESNL) that evaluated the effects of higher protein (HP) 
or higher carbohydrate (HC) diet interventions while participating in a circuit-style 
resistance-based exercise program.  Eight studies were utilized, that recruited overweight 
and sedentary participants with individual study focuses pertaining to generally healthy, 
post-menopausal, osteoarthritic, and/or special populations.  The demographics of each 
study are depicted in Table 3.1.  Each of these studies initially measured the 
effectiveness of the Curves® exercise and weight loss program (Curves International, 
Waco, TX) on health outcomes and weight loss in sedentary obese females.  This diet 
and exercise protocol is specifically designed to improve fitness and promote weight loss 
[218].  For the purposes of this analysis, participants were retrospectively categorized as 
having < or ≥ three risk factors for metabolic syndrome (MetS) utilizing the National 
Cholesterol Education Program – Adult Treatment Panel III (NCEP ATP III) criteria.  
Additionally, further analysis was performed categorizing participants based on each 
metabolic syndrome risk factor independently (high/low waist circumference, high/low 
triglycerides, low/high HDL cholesterol, high/low blood pressure, and high/low fasting 
glucose), in order to ascertain how the different dietary protocols affect each risk factor 
individually.  
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Table 3.1: Baseline Demographics per Study 
 
Study N Age Height Weight BMI Fat % 
1 130 39.1±8.0 164.7±6.6 96.7±19.3 35.6±6.6 44.3±3.2 
2 129 38.5±8.1 163.3±6.7 92.6±15.5 34.8±5.7 44.7±4.4 
3 135 54.2±4.8 162.8±6.6 91.0±16.9 34.3±6.0 46.4±4.4 
4 30 54.3±8.7 163.1±6.9 88.5±13.3 33.3±4.7 46.1±3.1 
5 125 49.3±9.7 162.4±6.4 95.6±20.5 36.2±7.1 45.8±4.9 
6 46 41.0±11.5 163.8±7.2 88.8±12.2 33.1±4.3 43.9±4.6 
7 31 38.3±7.6 162.7±8.2 96.3±19.5 36.2±5.7 45.2±4.3 
8 37 65.7±4.9 161.6±5.8 80.2±11.0 30.7±4.0 43.6±3.9 
Overall 663 46.2±11.4 163.2±6.7 92.7±17.7 34.8±6.2 45.2±4.3 
Height in cm, weight in kg, fat percentage measured via DEXA. 
 
 
Participants were prescribed either a HP or HC diet for ten weeks and participated in 
a supervised circuit-style resistance-training program.  Primary outcome measures 
included the NCEP ATP III risk factors for MetS, which comprise: waist circumference 
(WC), blood pressure (BP), and fasting levels of triglycerides (TG), HDL cholesterol, 
and glucose [184].  Secondary outcome measures included body weight, body 
composition, resting energy expenditure (REE), LDL cholesterol, and total cholesterol.  
Tertiary outcome measures included markers of cardiovascular and muscular fitness, as 
well as qualitative measures of psychosocial status.  After study completion, participants 
were retrospectively categorized into two groups, Apparently Healthy (AH) and 
Metabolic Syndrome (MS), according to their baseline risk level for MetS (using a value 
of < or ≥ three ATP III risk factors respectively).  The purpose of this analysis was to 
determine whether the AH and MS groups were differentially affected by the 
macronutrient content of the diet (HP vs. HC) combined with the exercise program in 
regards to the aforementioned outcome measures.  Additionally, the effect of the 
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different diets (HP vs. HC) on each ATP III MetS risk factor was analyzed using the 
entire study population. 
PARTICIPANTS 
The research protocols for the studies utilized in this database were reviewed and 
approved by the Institutional Review Boards at Baylor University and/or Texas A&M 
University prior to study initiation.  The targeted population was sedentary, overweight 
(BMI >27) females between the ages of 18-75 with no recent participation in a diet or 
exercise program.  Recruitment included referrals from area physicians as well as 
advertisements posted in local newspapers and television channels, on the Internet, and 
through campus mail.  Interested participants were first pre-screened on the phone to 
determine eligibility.  The following were considered contraindications for participation: 
1) presence or diagnosis of any metabolic or cardiovascular disorder including known 
electrolyte abnormalities (such as heart disease, arrhythmias, diabetes, thyroid disease, 
or hypogonadism), 2) history of hypertension, hepatorenal, musculoskeletal, 
autoimmune, or neurological disease, 3) currently taking or prescribed medications for 
thyroid, hyperlipidemia, hypoglycemia, hypertension, or androgenic medications, 4) 
having taken ergogenic levels of nutritional supplements that may affect muscle mass 
(e.g. creatine or HMB), anabolic/catabolic hormone levels (e.g. androstenedione or 
dehydroepiandrosterone), or weight loss (e.g. ephedra or thermogenics) within three 
months prior to the start of the study, and/or 5) being pregnant, having been pregnant 
within the past year, or an interest in becoming pregnant within the next three months.  
Prior to enrollment in the study, participants with controlled metabolic disorders were 
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required to obtain medical clearance from their personal physician, affirming that their 
condition was medically controlled and that it would not influence study results.     
Upon passing the telephone pre-screening, eligible participants were then invited 
to attend a familiarization session to learn more about the study details and complete the 
necessary paperwork.  The familiarization session included the completion of personal 
and medical history forms, a verbal and written explanation of the study details, and a 
description of potential risks of participation.  Participants were given an opportunity to 
practice testing procedures and were familiarized with the exercise training equipment.  
Those participants who still met the eligibility criteria and agreed to the terms of the 
study were required to sign human subject informed consent statements in compliance 
with the Human Subjects Guidelines of Baylor University and/or Texas A&M 
University and the American College of Sports Medicine.  A total of 663 women were 
used in the analysis.  Participants were 46±11 years old, 163±7 cm in height, 93±18 kg 
in weight, and had a BMI of 34.8±6 kg/m2 (mean ± standard deviation).     
TESTING SEQUENCE 
Table 3.2 shows the general research design and time course for assessments.  
Participants were tested at baseline (0 weeks), and after ten weeks of performing their 
assigned exercise and diet intervention.  For each testing session, subjects were required 
to refrain from vigorous physical activity, alcohol intake, and ingestion of over-the-
counter medications for 48-hours, as well as maintain a fasted state for 12-hours prior to 
the appointment.  Participants were also required to record all food and fluid intake on 
dietary record forms for four days (including three week days and one week-end day) 
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before each testing session.  All testing was conducted in the early morning hours, at 
approximately the same time each day starting at 5:00 am. 
 
Table 3.2: Overview of Research Design and Testing Schedule 
 
 Familiarization Baseline (0 weeks) 10 weeks 
Complete Paperwork 
Review Medical History 
Sign Informed Consent 
Dietary Assignment 
Diet Record Review  
Body Weight 
Waist and Hip Measurements 
Resting Energy Expenditure 
BIAa 
DEXAb Scan 
Resting BPc and HRd 
Fasting Blood 
Maximal Cardiopulmonary 
Exercise Test 
1RMe and 80% 1RM Isotonic 
Leg Press and Bench Press 
Measures 
Survey Completionf 
Diet Record Review  
Body Weight 
Waist and Hip Measurements 
Resting Energy Expenditure 
BIAa 
DEXAb Scan 
Resting BPc and HRd 
Fasting Blood 
Maximal Cardiopulmonary 
Exercise Test 
1RMe and 80% 1RM Isotonic 
Leg Press and Bench Press 
Measures 
Survey Completionf 
aBioelectrical Impedance Analysis 
bDual Energy X-ray Absorptiometry 
cBlood Pressure 
dHeart Rate 
eRepetition Maximum 
fStandardized Quality of Life (SF-36) and Eating Satisfaction Inventory 
 
 
During all testing sessions, participants were weighed and had waist- and hip- 
circumference measured.  Resting energy expenditure (REE) was tested using the 
ParvoMedics TrueMax 2400 Metabolic Measurement System, and body composition 
was measured using dual-energy x-ray absorptiometry (DEXA).  While in a supine 
rested state, blood pressure and heart rate were measured using standard procedures.  
Next, approximately 20 mL of fasting blood was then obtained using venipuncture 
techniques at an antecubital vein.  Participants then performed a maximal 
cardiopulmonary exercise stress test as well as lower and upper body muscular strength 
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and endurance tests.  Additionally, participants completed questionnaires regarding 
quality of life and body image at each testing session. Participants also completed a 
weekly medical safety / side effect report that was analyzed by the ESNL research nurse.  
Subjects were removed from the study if they reported any unusual adverse events in 
which the supervising nurse or physician recommended discontinuation. 
DIETARY INTERVENTION 
A carbohydrate/glycemic tolerance questionnaire developed by The Institute for 
Nutritional Science was used to determine dietary group assignments.  Individuals with a 
positive response on the questionnaire indicated carbohydrate (CHO) intolerance and 
were assigned to the HP group, whereas the participants with a negative response were 
assigned to the HC group.  The diets were isoenergenic, and low in fat.  In order to 
stimulate weight loss, both the HC and the HP groups were advised to consume 1,200 
kcal per day for one week (phase I).  Participants were then directed to increase their 
caloric intake to 1,600 kcal per day for nine weeks (phase II) in order to maintain a 
steady weight loss without negatively affecting metabolism [219].  Upon initiation of the 
study, participants were given menus and diet plans to assist with adherence.  
Participants also discussed their exercise and dietary compliance with a registered 
dietitian or exercise physiologist every two weeks throughout the ten-week protocol.  
Overall, participants consumed an average of 1,425 kcal/day.  Table 3.3 provides the 
macronutrient breakdown by percent caloric intake as well as grams per kilogram per 
day for each dietary group.     
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Table 3.3: Higher Protein Versus Higher Carbohydrate Dietary Intervention 
 
Diet Group 
% Caloric Intake grams / kg / day 
PRO CHO FAT PRO CHO FAT 
HP 29% 35% 36% 1.14 1.41 0.63 
HC 18% 51% 31% 0.78 2.20 0.60 
HC, higher carbohydrate group; HP, higher protein group; PRO, protein; CHO, carbohydrate 
 
 
EXERCISE INTERVENTION 
The exercise protocol consisted of three supervised 30-minute circuit-training 
sessions each week, for the ten-week period (30 workouts total).  A trained fitness 
instructor educated each participant on the proper use of the equipment.  Participants 
performed as many repetitions as possible within thirty seconds on each of the 13 bi-
directional machines, with 30-seconds of floor-based calisthenic exercise in between 
each.  Each machine contained calibrated pneumatic resistance pistons that allowed for 
opposing muscle groups to be trained in a concentric-only fashion.  The exercises and 
machines are listed in Table 3.4.  In an interval manner, the calisthenic exercises were 
utilized to maintain an elevated heart rate corresponding to 60-80% of maximal heart 
rate (MHR) throughout the workout [220].  Subjects completed two rotations of the 
circuit, corresponding to exercising for approximately 26 minutes.  Participants then 
cooled down with a standardized whole-body stretching routine.  A trained fitness 
instructor, who monitored exercise intensity and proper technique, supervised each 
workout.  Additionally, workout attendance was recorded to monitor compliance, which 
was set prior to initiation of the study at a minimum of 70% compliance (21/30 exercise 
sessions).  Although it was not quantified during this study, participants were 
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additionally encouraged to walk or engage in recreational activities for at least 30 
minutes a day on the days that they did not perform circuit training.    
 
 
Table 3.4: Machines and Exercises Used in Circuit-Style Program 
 
Calisthenic Exercises Exercise Machines 
running in place 
high knees 
arm circles 
boxing moves 
stepping 
leg kicks 
elbow flexion / extension 
knee flexion / extension 
shoulder press / lateral pull 
hip abductor / adductor 
chest press / seated row 
horizontal leg press 
squat 
abdominal crunch / back 
extension 
pec dec 
oblique twist 
shoulder shrug / dip 
hip extension 
side bends 
 
 
TESTING PROTOCOLS 
Dietary Inventories 
Subjects recorded four days (three weekdays and one weekend day) of food and 
fluid intake prior to each testing session.  A registered dietitian analyzed the caloric and 
macronutrient intakes using ESHA Food Processor (Version 8.6, 2006, ESHA Research 
Inc, Salem OR) Nutritional Analysis software.   
Anthropometric Measurements 
 Height and weight, along with waist and hip circumference measurements were 
taken at each testing session.  Both height and weight were determined utilizing standard 
procedures on a calibrated electronic scale (Cardinal Detecto Scale Model 8430, Webb 
City, Missouri) with a precision of ±0.02 kg.  Hip and waist circumference were 
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measured using a tension-controlled tape measure per measurement guidelines 
established by the American College of Sports Medicine [220].   
Resting Energy Expenditure 
 The ParvoMedics TrueMax 2400 Metabolic Measurement System (ParvoMedics, 
Inc., Sandy, UT) was utilized to assess resting energy expenditure (REE).  Fasted 
subjects rested on an exam table in a supine position with their legs propped up at a 90-
degree angle and remained motionless without falling asleep for approximately 20-
minutes.  A clear metabolic canopy was placed over their head and neck to determine 
resting oxygen uptake (VO2) and energy expenditure.  Metabolic measurements were 
taken after the first ten minutes in which the principle variables (such as VO2 L/min) 
changed less than 5% within a five-minute period [221].  The manufacturer reported 
coefficient of variation for this device in lean, healthy individuals is ±2%.  
Body Composition 
 Measurements of body composition included total body scanned mass, fat mass, 
fat free mass, and body fat percentage.  Body composition (excluding the cranium) was 
assessed with the Hologic Discovery W (Hologic Inc., Waltham, MA) dual energy x-ray 
absorptiometer (DEXA) with APEX Software (APEX Corporation Software, Pittsburg, 
PA).  Previous research has validated the accuracy of utilizing DEXA for body 
composition measurement [222, 223].  Test-retest reliability studies on total fat free / 
soft tissue mass performed on this DEXA machine have previously produced mean 
coefficients of variation for of 0.31-0.45% with a mean intra-class correlation of 0.985 
[224].  
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Resting Cardiovascular Parameters 
 Using standard clinical procedures, heart rate and blood pressure were 
determined in a supine position after resting quietly for five minutes.  Heart rate was 
measured by palpation of the radial artery.  A manual mercurial sphygmomanometer 
(American Diagnostic Corporation, model #AD-720, Hauppuage, NY) was utilized for 
blood pressure measurements, with stethoscope auscultation of the brachial artery [220].         
Blood Collection and Analysis 
Fasted serum samples were collected using standard phlebotomy techniques via a 
sterile venipuncture of an antecubital vein.  The tubes were immediately centrifuged at 
1100 x g for 15 minutes using a standard bench top centrifuge (Cole Palmer, Vernon 
Hills, IL, Model # 17250-10).  The serum was then removed with a pipette and placed 
into micro-centrifuge tubes, frozen at -20°C, and analyzed at a later time for clinical 
chemistry panels.  Serum samples were analyzed for a complete metabolic panel using a 
calibrated Dade Behring Dimension RXL (Siemens AG, Munich, Germany) automated 
clinical chemistry analyzer.  Coefficient of variation for the tests using this analyzer was 
similar to previously published data for these tests (range: 1.0-9.6%) [225].  In the event 
that the Dade was not available, serum samples were analyzed by Quest Diagnostics 
(Quest Diagnostics, 5850 Rogerdale Road, Houston TX, USA 77072) using an Olympus 
AAU 5400 Chemistry Immuno Analyzer (Olympus America Inc., Center Valley, PA, 
USA).  Additionally, fasting insulin was assayed in duplicate using a commercially 
available Enzyme Linked Immunosorbent Assay (ELISA) kit (NO. 80-INSHU-E10, 
ALPCO, Salem, NH).  The BioTek ELX-808 Ultramicroplate reader (BioTek 
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Instruments Inc, Winooski, VT) was utilized at an optical density of 450 nm against a 
known standard curve using standard procedures with BioTek Gen5 Analysis software 
(BioTek Instruments Inc, Winooski, VT). The intra-assay coefficient of variation has 
been shown to range from 2.9% to 6.2%, with an inter-assay coefficient of variation 
range of 5.4% to 8.6% (ALPCO, Salem, NH). The Homeostatic Model Assessment for 
Insulin Resistance (HOMA-IR) was calculated as the product of fasting insulin (µU/mL) 
and fasting glucose (mg/dL) divided by 405 [226].    
Fitness Assessments 
Maximal Cardiopulmonary Exercise Test 
 A symptom-limited, Bruce maximal treadmill exercise protocol was performed at 
each testing session in order to assess peak aerobic capacity (peak VO2) [220].  The 
Quinton 710 ECG (Quinton Instruments, Bothell, WA), Trackmaster TMX425C 
treadmill (JAS Fitness Systems, Newton, KS), and Parvo Medics 2400 TrueMax 
Metabolic Measurement System (ParvoMedics, Inc., Sandy, UT) were utilized.  The 
mean coefficient of variation for assessing peak VO2 with the Bruce protocol has been 
previously reported to be 6.5% (range of 2.0-14%) [227].  Every morning prior to 
testing, calibration of gas and flow sensors was completed and found to be within 3% of 
the previous calibration point.   
Throughout the test, HR, BP, and rate of perceived exertion were monitored and 
heart function was assessed using a standard 12-lead arrangement [220].  Experienced 
lab assistants conducted all cardiorespiratory treadmill tests.  The ECG was reviewed to 
ensure that no contraindications for exercise testing were present [220].  The Bruce 
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treadmill protocol was performed following the speeds and grades listed in the standard 
protocol [228].  An ECG printout, BP, and rate of perceived exertion were obtained near 
the end of each stage.  The participant was encouraged to exercise to their maximum 
potential unless clinic signs requiring termination of the test became evident [220].  
Once the exercise test was complete, the participant performed an active recovery for 
three minutes, followed by a three-minute seated recovery period.  
Isotonic Strength Tests 
 A standard isotonic Olympic bench press and 45° hip sled / leg press (both from 
Nebula Fitness, Versailles, OH) were utilized to determine upper and lower body 
maximal strength and muscular endurance.  Trained lab assistants experienced in 
performing exercise testing conducted all strength tests.  Hand positioning on the bench 
press, and seat and foot positioning on the leg press were consistent between testing 
sessions.  Test-retest reliability comparisons for these tests performed by resistance-
trained subjects in the ESNL have produced low mean coefficients of variation and high 
reliability (bench press 1.9%, intraclass r=0.94 and leg press: 0.7%, intraclass r=0.91) 
[229].     
 To assess both upper and lower body strength, participants performed a one rep 
maximum (1RM) protocol.  Each individual started with a warm-up (two sets of ten 
repetitions at approximately 50% of their anticipated 1RM).  Next participants 
experienced a progressive increase (five to ten lbs. on bench press, 10-25 lbs on leg 
press) where they attempted a single-repetition, and rested two minutes before 
attempting another increase, until 1RM on the bench press was achieved.  Following 
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determination of the participant’s 1RM, subjects rested for four minutes and then 
performed an upper body muscular endurance test by performing as many repetitions as 
possible without stopping, at a calculated weight of 80% of their 1RM [230].      
Psychosocial Assessments  
 In order to measure the psychosocial dimensions that may change due to the 
experience-of and results-gained throughout the study, participants completed the SF-36 
Health-Related Quality of Life and also the Body Image Questionnaire at each testing 
session (See Appendices G and H) [231, 232].  The SF-36 assessed various physical and 
mental components to include: physical functioning (the ability to perform most 
vigorous physical activities without limitation to health), role physical (the ability to 
work and perform daily activities), bodily pain (limitations due to pain), general health 
(assessment of personal health), vitality (perception of energy level), social functioning 
(ability to perform normal social activities), role emotion (problems with work or other 
daily activities), and mental health (state of feelings of peacefulness, happiness, and 
calmness).  The Body Image Questionnaire is a compilation of three questionnaires: the 
Rosenberg Self-Esteem Scale (RSE), which assesses unidimensional global self-esteem, 
the Social Physique Anxiety Scale (SPAS), and the Multidimensional Body-Self 
Relations Questionnaire (MBSRQ-AS), which assesses self-attitudinal disposition 
towards the physical construct including appearance evaluation, appearance orientation, 
overweight preoccupation, self-classified weight, and body areas satisfaction scale [233-
235]. 
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STATISTICAL ANALYSIS 
All subjects who completed the studies were included in the analysis.  The series 
mean method was used to replace any missing data points with the exception of waist 
circumference.  One study utilized in this analysis did not record waist circumference.  
Therefore, a one-way analysis of variance (ANOVA) was used to determine the average 
weight and body fat percentage for individuals that met the MetS criteria for elevated 
waist circumference.  All participants missing this data who met this criteria were coded 
with a “1” for having the MetS criteria.  The mean value of all of the participants coded 
“0” or “1” for not having or having the risk factor respectively was calculated, and used 
as a replacement value for the missing waist circumference measurements. 
The analysis was performed retrospectively on 663 women (n=663) from eight 
previous weight loss studies in the ESNL.  Participants were retrospectively categorized 
into two groups, Apparently Healthy (AH) or Metabolic Syndrome (MS), based on the 
presence of MetS as identified using the NCEP ATP III criteria (< or ≥ three risk factors, 
respectively).  A secondary analysis was conducted to determine the effect of HP and 
HC diets with each MetS risk factor independently stratified for the entire study 
population.   
The statistical analysis was performed using SPSS (Version 20, IBM 
Corporation, Armonk, NY).  Participant baseline demographic data were analyzed by 
ANOVA.  Related variables were grouped together and analyzed by multivariate 
analysis of variance (MANOVA) with repeated measures.  Overall MANOVA effects 
were examined using the Wilks’ Lambda time, time x diet, time x MS, and time x diet x 
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MS p-levels.  Greenhouse-Geisser univariate tests of within-subjects time, time x diet, 
time x MS, and time x diet x MS effects and between-subjects univariate group effects 
were reported for each variable analyzed within the MANOVA model.  Non-correlated 
variables were analyzed by repeated measures ANOVA with univariate diet, MS, time, 
time x diet, time x MS, and time x diet x MS interaction effects reported.  Delta values 
or percent difference were calculated and analyzed on select variables by ANOVA for 
repeated measures to assess the changes and normalize any differences in baseline 
values.  Delta values were calculated by subtracting the baseline testing session (T1) 
from ten-week testing session (T2-T1). Percent differences were calculated by 
subtracting T1 from T2, dividing by T1, then multiplying by 100 [(T2-T1)/T1·100].   
Data were considered statistically significant when the probability of type I error 
was ≤0.05, and statistical trends were considered when the probability of error ranged 
between p>0.05 to p≤0.10.  Tukey’s least significant difference post hoc analysis was 
performed to determine where significance between group-combinations was obtained.  
Unless otherwise stated, data are presented throughout the text as mean ± standard 
deviation (X ± SD).  The sample had sufficient power (HC: n=291; HP: n=370; need 
n=217 per group for a power of 0.8 at the 0.05 α-level) to assess statistically significant 
changes in outcome measures.     
  
  
 
80 
CHAPTER IV  
RESULTS 
BASELINE DEMOGRAPHICS 
Table 4.1 presents the baseline demographics for each of the diet and health 
status groups.  Data from a total of 663 participants were used in the analysis.  
Participants were 46.2±11.4 years old, 163±7 cm in height, 92.7±18 kg in weight, and 
categorized as obese with a BMI of 34.8±6 kg/m2 (mean ± standard deviation).  
Significant baseline differences were observed between the diet groups for weight (HP 
96±19, HC 89±15 kg, p<0.001), body mass index (HP 36±7, HC 33±5 kg/m2, p<0.001) 
and DEXA fat percentage (HP 46±4, HC 45±4%, p=0.023).  Additionally, significant 
baseline differences were observed between the health status groups for age (AH 45±12, 
MS 48±11 years, p=0.013), weight (AH 90±18, MS 96±18 kg, p<0.001), and body mass 
index (AH 34±6, MS 36±6 kg/m2, p<0.001).  
The numerical and percent frequencies of each metabolic syndrome risk factor 
are listed in Table 4.2.  In order of prevalence, waist circumference (80%) was the most 
prevalent risk factor for this study population, which was to be expected due to 
recruitment of overweight participants.  Next, glucose (41%) and HDL cholesterol 
(40%) demonstrated similar levels of prevalence, then blood pressure (37%), and finally 
elevated triglycerides were the least frequent risk factor observed (33%).  Table 4.3 
represents the N-sizes for the number of risk factors per diet group.  Overall, 43% of the 
participants (N=286) had three or more risk factors and were characterized as having 
metabolic syndrome. 
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Table 4.1: Baseline Demographics for All Diet and Health Status Groups 
 
Variable Group Baseline P-level 
Age (Years) HP-AH 44.6 ± 11.3 D = 0.17 
 HP-MS 47.1 ± 10.6 M = 0.013 
 HC-AH 46.1 ± 12.3 D x M = 0.82 
 HC-MS 48.1 ± 11.0  
 HP 45.8 ± 11.0  
 HC 46.9 ± 11.8  
 AH 45.3 ± 11.8  
 MS 47.5‡ ± 10.7  
 All 46.2 ± 11.4  
Height (cm) HP-AH 163.5 ± 6.6 D = 0.74 
 HP-MS 162.7 ± 6.8 M = 0.69 
 HC-AH 163.1 ± 6.5 D x M = 0.24 
 HC-MS 163.5 ± 7.1 
 
 HP 163.2 ± 6.7 
 HC 163.3 ± 6.7 
 AH 163.3 ± 6.6 
 MS 163.0 ± 6.9 
 All 163.2 ± 6.7 
Weight (kg) HP-AH 93.7 ± 19.0 D = 0.001 
 HP-MS 98.1 ± 18.9 M = 0.001 
 HC-AH 86.5 ± 14.8 D x M = 0.60 
 HC-MS 92.3 ± 14.4 
 
 HP 95.8† ± 19.1 
 HC 88.8 ± 14.9 
 AH 90.3 ± 17.5 
 MS 95.8‡ ± 17.5 
 All 92.7 ± 17.7 
Body Mass Index HP-AH 35.0 ± 6.6 D = 0.001 
(kg/m2) HP-MS 37.0 ± 6.4 M = 0.001 
 HC-AH 32.5 ± 5.3 D x M = 0.99 
 HC-MS 34.5 ± 4.9 
 
 HP 35.9† ± 6.6 
 HC 33.3 ± 5.2 
 AH 33.8 ± 6.1 
 MS 36.0‡ ± 6.0 
 All 34.8 ± 6.2 
DEXA Body Fat HP-AH 45.5 ± 4.3 D = 0.023 
(%) HP-MS 45.5 ± 4.5 M = 0.80 
 HC-AH 44.7 ± 4.4 D x M = 0.85 
 HC-MS 44.8 ± 3.8 
 
 HP 45.5† ± 4.4 
 HC 44.7 ± 4.2 
 AH 45.1 ± 4.4 
 MS 45.2 ± 4.3 
 All 45.2 ± 4.3 
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = 
metabolic syndrome risk factor, D = diet effect, M = metabolic syndrome risk factor 
effect, D x M = diet by metabolic syndrome risk factor effect. 
Values are means ± standard deviations from 198 participants in the HP-AH group, 173 
in the HP-MS group, 179 in the HC-AH group, 113 in the HC-MS group, 371 in the HP 
group, 292 in the HC group, 377 in the AH group, 286 in the MS group, and 663 
participants total.   
† Significant diet effect, p < 0.05.  ‡ Significant metabolic syndrome effect, p < 0.05.  
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Overall, 43% of the participants (N=286) had three or more risk factors and were 
characterized as having metabolic syndrome. 
 
Table 4.2: Baseline Frequencies per Metabolic Syndrome Risk Factor 
 
Risk Factor Baseline HP HC TTL 
Waist Circumference 316 (85%) 215 (74%) 531 (80%) 
Glucose 157 (42%) 116 (40%) 273 (41%) 
HDL Cholesterol 151 (41%) 112 (38%) 263 (40%) 
Blood Pressure 148 (40%) 96 (33%) 244 (37%) 
Triglycerides 124 (33%) 96 (33%) 220 (33%) 
HP, higher protein; HC, higher carbohydrate; TTL, total N-size.  Percentages are 
based on the N-size for HP (N=371), HC (N=292), and total (N=663) 
 
 
 
Table 4.3: Number of Risk Factors per Diet Group 
 
Number of Risk 
Factors 
Baseline 
HP HC Total 
0 18 26 44 Apparently 
Healthy 
57% 
1 69 61 130 
2 111 92 203 
3 105 68 173 Metabolic 
Syndrome 
43% 
4 50 39 89 
5 18 6 24 
HP, higher protein (N=371); HC, higher carbohydrate (N=292), Total 
(N=663).   
 
 
 
ANALYSIS OF ENERGY INTAKE 
An analysis utilizing one-way ANOVA on the baseline values for each of the 
nutrition variables (expressed in grams/day, grams/kg/day, and percent intake) revealed 
no significant  
differences between the diet groups (see baseline values on tables 4.4-4.6), with the 
exception of protein reported in g/d (p<0.001).  However, when expressed relative to 
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body weight (g/kg/d), the baseline values for protein were not significantly different 
between the HP and HC diet groups (p=0.07).  Table 4.4 depicts the time x diet 
MANOVA for total energy intake in kcals/day as well as macronutrient intake in g/day.  
The MANOVA revealed an overall time (Wilks’ Lambda p<0.001) and time x diet 
(Wilks’ Lambda p<0.001) effect.  Dieting reduced energy intake in both groups (-
452±616 kcal/day), with a significantly greater decrease reported in the HP group (HP -
507±624, HC -383±599 kcal/day, p=0.01).  Throughout the study, protein intake 
significantly increased in the HP group (+22.1±42 g/day) and decreased in the HC group 
(-6.4±24.7 g/day, p<0.001).  While carbohydrate intake decreased in both groups during 
the study protocol, a significantly greater decrease was reported for the higher protein 
group (HP -99.3±90.5, HC -36.1±79.9 g/day, p<0.001).  Post-hoc analysis revealed that 
participants in the HP group consumed more protein (HP 100±36, HC 66±20 g/day, 
p<0.001) and less carbohydrate (HP 125±55, HC 184±48 g/day, p<0.001) than those in 
the HC group.  Fat intake decreased in similar amounts for each group throughout the 
study protocol (-22.7±32.1 g/day), while the higher protein group consumed 
significantly more fat (in grams/day) throughout the study (HP 66.7±0.9, HC 62.4±1.0 
g/day, mean (SEM), p=0.001).  
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Table 4.4: Dietary Intake Before and After Ten Weeks of Exercise and Dietary 
Intervention Expressed in Grams 
 
 
 
 
Table 4.5: Dietary Intake Before and After Ten Weeks of Exercise and Dietary 
Intervention Expressed in Grams per Kilogram 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Energy Intake HP 20.4 ± 5.8 15.9g ± 5.2 18.2† ± 0.2 T = 0.001 
(kcal/kg/day) HC 21.0 ± 6.6 17.4ag ± 4.7 19.2 ± 0.3 D = 0.003 
 Time 20.7 ± 6.1 16.6* ± 5.0    T x D = 0.09 
Protein Intake HP 0.83 ± 0.2 1.14g ± 0.5 0.99† ± 0.01 T = 0.001 
(g/kg/day) HC 0.83 ± 0.2 0.78a ± 0.3 0.81 ± 0.02 D = 0.001 
 Time 0.83 ± 0.2 0.98* ± 0.4    T x D = 0.001 
Carbohydrate  HP 2.40 ± 0.9 1.41g ± 0.7 1.91† ± 0.03 T = 0.001 
Intake (g/kg/day) HC 2.52 ± 0.9 2.20ag ± 0.7 2.36 ± 0.04 D = 0.001 
 Time 2.46 ± 0.9 1.76* ± 0.8    T x D = 0.001 
Fat Intake HP 0.83 ± 0.3 0.63g ± 0.3 0.73 ± 0.01 T = 0.001 
(g/kg/day) HC 0.85 ± 0.3 0.60g ± 0.2 0.73 ± 0.01 D = 0.79 
 Time 0.84 ± 0.3 0.62* ± 0.2    T x D = 0.10 
HP = higher protein, HC = higher carbohydrate, T = time effect, D = diet effect, T x D = time by diet effect.  
Values are means ± standard deviations (except group means are means ± standard error) from 371 in the HP group, 292 in the HC group, and 663 
participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).   
a Significantly different than HP group, P < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
 
 
 
  
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Energy Intake HP 1,908 ± 498 1,402g ± 377 1,655 ± 17 T = 0.001 
(kcal/day) HC 1,835 ± 575 1,452g ± 323 1,644 ± 19 D = 0.66 
 Time 1,876 ± 534 1,424* ± 355    T x D = 0.01 
Protein Intake HP 78.0 ± 20.7 100.1g ± 36.1 89.0† ± 0.9 T = 0.001 
(g/day) HC 72.2a ± 18.7 65.8ag ± 19.8 69.0 ± 1.1 D = 0.001 
 Time 75.4 ± 20.1 85.0* ± 34.5    T x D = 0.001 
Carbohydrate  HP 224.3 ± 76.8 125.0g ± 54.7 174.6† ± 2.6 T = 0.001 
Intake (g/day) HC 220.6 ± 78.8 183.5ag ± 48.4 201.5 ± 2.9 D = 0.001 
 Time 222.2 ± 77.6 150.7* ± 59.6    T x D = 0.001 
Fat Intake HP 77.7 ± 24.5 55.8g ± 20.9 66.7† ± 0.9 T = 0.001 
(g/day) HC 74.2 ± 30.8 50.6ag ± 16.3 62.4 ± 1.0 D = 0.001 
 Time 76.2 ± 27.5 53.5* ± 19.2    T x D = 0.51 
HP = higher protein, HC = higher carbohydrate, T = time effect, D = diet effect, T x D = time by diet effect.  
Values are means ± standard deviations (except group means are means ± standard error) from 371 in the HP group, 292 in the HC 
group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).   
a Significantly different than HP group, P < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table 4.6: Dietary Intake Before and After Ten Weeks of Exercise and Dietary 
Intervention Expressed in Percentages 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Energy Intake HP 1,908 ± 498 1,402g ± 377 1,655 ± 17 T = 0.001 
(kcal//day) HC 1,835 ± 575 1,452g ± 323 1,644 ± 19 D = 0.66 
 Time 1,876 ± 534 1,424* ± 355    T x D = 0.010 
Protein Intake HP 17.1 ± 6.2 29.2g ± 8.7 23.1† ± 0.3 T = 0.001 
(%) HC 16.3 ± 3.9 18.4ag ± 4.7 17.3 ± 0.3 D = 0.001 
 Time 16.7 ± 5.3 24.4* ± 9.0    T x D = 0.001 
Carbohydrate  HP 46.5 ± 8.1 35.3g ± 9.9 40.9† ± 0.3 T = 0.001 
Intake (%) HC 47.6 ± 7.6 50.5ag ± 7.1 49.1 ± 0.4 D = 0.001 
 Time 47.0 ± 7.9 42.0* ± 11.5    T x D = 0.001 
Fat Intake HP 36.4 ± 5.8 35.5g ± 7.3 36.0† ± 0.3 T = 0.001 
(%) HC 36.1 ± 6.4 31.2ag  ± 6.1 33.6 ± 0.3 D = 0.001 
 Time 36.3 ± 6.1 33.6* ± 7.1    T x D = 0.001 
HP = higher protein, HC = higher carbohydrate, T = time effect, D = diet effect, T x D = time by diet effect.  
Values are means ± standard deviations (except group means are means ± standard error) from 371 in the HP group, 292 in the HC group, and 663 
participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).   
a Significantly different than HP group, P < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
 
 
 
As Tables 4.5 and 4.6 present, similar findings were observed when energy 
intake data were expressed in kcals/kg/day and macronutrient percentage of daily energy 
intake.  Yet, Table 4.5 also demonstrates that relative to body weight, a group effect was 
observed for total energy intake, demonstrating the higher carbohydrate group consumed 
more calories throughout the study (HP 18.2±0.2, HC 19.2±0.3 kcal/kg/d, mean (SEM), 
p=0.003), and those in the HP group tended to experience greater decreases in total 
energy consumption (HP -4.5±6.7, HC -3.6±6.5 kcal/kg/d, p=0.09).  Additionally, when 
expressed as g/kg/day (Table 4.5), participants in the higher carbohydrate group tended 
to experience a greater decrease in fat intake (HP -0.20±0.33, HC -0.24±0.35 g/kg/d, 
p=0.10).  This relationship was found to be significant when expressed as percent of 
macronutrient consumption, with the HC group experiencing a significantly greater 
decrease in fat intake (HP -1.0±8.4, HC -4.9±8.1%, p<0.001).  Figures 4.1 and 4.2 depict 
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the relative macronutrient consumption (g/kg/d) for protein, carbohydrate, and fat at 
baseline and ten-weeks, and reveal the significantly greater protein consumption in the 
HP group and carbohydrate consumption in the HC group.  Hypothesis H1 was therefore 
accepted in that statistically significant difference were observed between the HP and 
HC groups regarding macronutrient intake.  
 
 
Figure 4.1: Comparison of Macronutrient Consumption at Baseline 
 
 
Figure 4.2: Comparison of Macronutrient Consumption at Ten Weeks 
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ANALYSIS OF METABOLIC SYNDROME STATUS 
Table 4.7 depicts the time x metabolic syndrome risk factor MANOVA for the 
metabolic syndrome risk factors.  A baseline ANOVA of the NCEP ATP III metabolic 
syndrome risk factor variables confirmed that each risk factor was significantly different 
between the groups (apparently healthy vs. metabolic syndrome) at baseline.  This was 
to be expected, considering the groups were stratified based on whether or not they 
expressed these metabolic syndrome risk factors.  As anticipated, the MANOVA 
revealed an overall time (Wilks’ Lambda p<0.001) and time x metabolic syndrome risk 
factor (Wilks’ Lambda p<0.001) effect for the metabolic syndrome variables.  In regards 
to health status, both groups (AH and MS) significantly reduced the mean values for 
each risk factor over the course of the study (time effect, p<0.001), with a significantly 
greater decrease found in the MS group for all variables (time x metabolic syndrome 
effect, p<0.001) except waist circumference (p=0.12) and HDL cholesterol (which 
experienced a significantly greater decrease in the AH group, p=0.011).   
 Analysis of MANOVA univariate tests revealed significant time x metabolic 
syndrome risk factor effects in which the MS group demonstrated a significantly greater 
decrease in systolic blood pressure (AH -0.47±13.3, MS -5.91±16.0 mmHg, p<0.001), 
diastolic blood pressure (AH -0.35±8.92, MS -4.08±10.5 mmHg, p<0.001), triglycerides 
(AH -0.00±0.47, MS -0.23±0.73 mmol/L, p<0.001), and glucose (AH +0.01±0.73, MS  
-0.24±1.19 mmol/L, p=0.001) than the AH group.   
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Table 4.7: Changes in Metabolic Syndrome Risk Factor Values After Ten Weeks of 
Exercise and Dietary Intervention 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Waist  AH 95.9 ± 12.5 92.5g ± 12.4 94.2 ± 0.6 T = 0.001 
Circumference MS 102.9b ± 12.6 98.8bg ± 11.9 100.8‡ ± 0.7 M = 0.001 
(cm) Time 98.9 ± 13.0 95.2* ± 12.6    T x M = 0.12 
Systolic Blood AH 120.9 ± 12.2 120.5 ± 13.2 120.7 ± 0.6 T = 0.001 
Pressure (mmHg) MS 130.4b ± 15.7 124.4bg ± 14.6 127.4‡ ± 0.7 M = 0.001 
 Time 125.0 ± 14.6 122.2* ± 13.9    T x M = 0.001 
Diastolic Blood AH 78.0 ± 8.4 77.6 ± 9.0 77.8 ± 0.4 T = 0.001 
Pressure (mmHg) MS 83.6b ± 9.6 79.5bg ± 9.0 81.6‡ ± 0.4 M = 0.001 
 Time 80.4 ± 9.4 78.4* ± 9.1    T x M = 0.001 
Triglycerides AH 1.22 ± 0.5 1.22 ± 0.6 1.22 ± 0.03 T = 0.001 
(mmol/L) MS 2.01b ± 0.9 1.78bg ± 0.9 1.89‡ ± 0.04 M = 0.001 
 Time 1.56 ± 0.8 1.46* ± 0.8    T x M = 0.001 
HDL Cholesterol AH 1.49 ± 0.3 1.41g ± 0.3 1.45 ± 0.01 T = 0.001 
(mmol/L) MS 1.24b ± 0.3 1.20bg ± 0.3 1.22‡ ± 0.02 M = 0.001 
 Time 1.39 ± 0.3 1.32* ± 0.3    T x M = 0.011 
Glucose AH 5.30 ± 0.8 5.30 ± 0.7 5.30 ± 0.05 T = 0.002 
(mmol/L) MS 6.15b ± 1.6 5.91bg ± 1.4 6.03‡ ± 0.06 M = 0.001 
 Time 5.66 ± 1.3 5.57* ± 1.1  T x M = 0.001 
AH = apparently healthy, MS = metabolic syndrome risk factor group, T = time effect, M = metabolic syndrome risk factor effect, T x M = time by 
metabolic syndrome risk factor effect. 
Values are means ± standard deviations (except group means are means ± standard error) from 377 in the AH group, 286 in the MS group, and 663 
participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  ‡ Significant metabolic syndrome effect, p < 0.05 (univariate). 
b Significantly different than AH group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
 
 
 
However, the AH group experienced a significantly greater reduction in HDL 
cholesterol (AH -0.09±0.25, MS -0.04±0.21 mmol/L, p=0.011).  While overall waist 
circumference significantly decreased over time (-3.65±5.7 cm), no significant 
differences were seen between the AH and MS groups in centimeters lost throughout the 
study (p=0.12).  Comparison of the delta change from baseline for each metabolic 
syndrome risk factor can be seen in Figures 4.3 and 4.4.  Hypothesis H2 was therefore 
accepted in that statistically significant differences were observed between the AH and 
MS groups in the markers of metabolic syndrome.   
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Figure 4.3: Delta Change in Metabolic Syndrome Risk Factors Over the Ten Week 
Study; Waist Circumference and Blood Pressure 
 
 
Figure 4.4: Delta Change in Metabolic Syndrome Risk Factors Over the Ten Week 
Study; Triglycerides, HDL, and Glucose 
 
 
ANALYSIS OF METABOLIC SYNDROME AS A RISK FACTOR 
 Three-way MANOVAs and/or ANOVAs have been utilized to analyze all 
variables measured on participants regarding time x diet x metabolic syndrome risk 
factor status.  The next 11 tables represent the mean values and p-levels for each analysis 
regarding the metabolic syndrome risk factor. 
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Energy Intake 
 Table 4.8 depicts the time x diet x metabolic syndrome risk factor MANOVA for 
total energy intake in kcals/kg/day as well as macronutrient intake in g/kg/day.  The 
MANOVA revealed an overall time (Wilks’ Lambda p<0.001) and time x diet (Wilks’ 
Lambda p<0.001) effect, but no significant time x metabolic syndrome risk factor 
(Wilks’ Lambda p=0.24) or time x diet x metabolic syndrome risk factor (Wilks’ 
Lambda p=0.20) interactions.  Post hoc analysis on the ten-week values was utilized to 
determine the following: Participants in the HC group and the AH group consumed 
significantly more calories relative to body weight (HP 15.9±5.2, HC 17.4±4.7 
kcal/kg/d, p<0.001) (AH 17.0±5.4, MS 16.0±4.4 kcal/kg/d, p=0.007).  Further review of 
the individual group-combinations revealed that total energy consumption was 
significantly different in each group, with the HC-AH group consuming significantly 
more energy than the other groups (17.9±5.1 kcal/kg/d, p=0.033).  Participants in the HP 
group and the AH group consumed significantly more protein relative to body weight 
(HP 1.14±0.5, HC 0.78±0.3 g/kg/d, p<0.001) (AH 1.01±0.5, MS 0.96±0.4 g/kg/d, 
p=0.013).  Specifically, the HP-AH group consumed significantly more protein than HC-
AH (p<0.001), and HP-MS consumed significantly more protein than HC-MS 
(p<0.001).  The HC group consumed significantly more carbohydrate relative to body 
weight (HP 1.41±0.7, HC 2.20±0.7 g/kg/d, p<0.001), with no significant difference 
observed between the risk factor groups (p=0.09).      
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Table 4.8: Dietary Intake Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Metabolic Syndrome Risk Factor Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Energy Intake  HP-AH 20.52 ± 5.64 16.29g ± 5.62     T = 0.001 
(kcal/kg/day) HP-MS 20.28 ± 5.92 15.45g ± 4.55     D = 0.007 
 HC-AH 21.35 ± 6.80 17.89c,g ± 5.05     M = 0.028 
 
HC-MS 20.55 ± 6.21 
16.62d,f
,g ± 4.03       D x M = 0.49 
 HP 20.41 ± 5.76 15.90g ± 5.16 18.14† ± 0.23 T x D = 0.11 
 HC 21.04 ± 6.58 17.39ag ± 4.71 19.10 ± 0.27 T x M = 0.31 
 AH 20.91 ± 6.22 17.05g ± 5.41 19.01 ± 0.23 T x D x M = 0.90 
 MS 20.39 ± 6.03 15.91bg ± 4.38 18.23‡ ± 0.27  
 Time 20.69 ± 6.14 16.56* ± 5.02        
Protein Intake HP-AH 0.85 ± 0.25 1.18g ± 0.55     T = 0.001 
(g/kg/day) HP-MS 0.82 ± 0.21 1.10g ± 0.40     D = 0.001 
 HC-AH 0.84 ± 0.23 0.82c ± 0.28     M = 0.006 
 HC-MS 0.80 ± 0.22 0.73d ± 0.20       D x M = 0.74 
 HP 0.83 ± 0.23 1.14g ± 0.49 0.99† ± 0.01 T x D = 0.001 
 HC 0.83 ± 0.23 0.78a ± 0.26 0.80 ± 0.02 T x M = 0.15 
 AH 0.84 ± 0.24 1.01g ± 0.48 0.92 ± 0.01 T x D x M = 0.93 
 MS 0.81 ± 0.22 0.96bg ± 0.38 0.87‡ ± 0.02  
 Time 0.83 ± 0.23 0.98* ± 0.44        
Carbohydrate HP-AH 2.40 ± 0.86 1.42g ± 0.69     T = 0.001 
Intake  HP-MS 2.40 ± 0.87 1.41g ± 0.62     D = 0.001 
(g/kg/day) HC-AH 2.54 ± 0.95 2.27c,g ± 0.76     M = 0.28 
 HC-MS 2.50 ± 0.91 2.10d,f,g ± 0.61       D x M = 0.32 
 HP 2.40 ± 0.87 1.41g ± 0.66 1.91† ± 0.03 T x D = 0.001 
 HC 2.52 ± 0.93 2.20ag ± 0.71 2.35 ± 0.04 T x M = 0.31 
 AH 2.47 ± 0.91 1.82g ± 0.84 2.16 ± 0.03 T x D x M = 0.42 
 MS 2.44 ± 0.89 1.68g ± 0.70 2.10 ± 0.04  
 Time 2.46 ± 0.90 1.76* ± 0.79        
Fat Intake HP-AH 0.84 ± 0.28 0.66g ± 0.29     T = 0.001 
(g/kg/day) HP-MS 0.82c ± 0.27 0.60g ± 0.22     D = 0.65 
 HC-AH 0.87 ± 0.34 0.61g ± 0.23     M = 0.022 
 HC-MS 0.81 ± 0.31 0.59g ± 0.19       D x M = 0.93 
 HP 0.83 ± 0.27 0.63g ± 0.26 0.73 ± 0.01 T x D = 0.15 
 HC 0.85 ± 0.33 0.60g ± 0.21 0.72 ± 0.01 T x M = 0.86  
 AH 0.85 ± 0.31 0.64g ± 0.26 0.75 ± 0.01 T x D x M = 0.23 
 MS 0.82 ± 0.28 0.60bg ± 0.21 0.71‡ ± 0.01  
 Time 0.84 ± 0.30 0.62* ± 0.24        
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = metabolic syndrome risk factor, T = time effect, D = diet effect, 
M = metabolic syndrome risk factor effect, D x M = diet by metabolic syndrome risk factor effect, T x D = time by diet effect, T x M = time by 
metabolic syndrome risk factor effect, T x D x M = time by diet by metabolic syndrome risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 198 participants in the HP-AH group, 173 in the 
HP-MS group, 179 in the HC-AH group, 113 in the HC-MS group, 371 in the HP total group, 292 in the HC total group, 377 in the AH group, 
286 in the MS group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant metabolic syndrome 
effect, p < 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than AH group, p < 0.05 
(post hoc LSD).  c Significantly different than HP-AH group, p < 0.05 (post hoc LSD).  d Significantly different than HP-MS group, p < 0.05 
(post hoc LSD).  f Significantly different than HC-AH group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc 
LSD). 
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The HC-AH group consumed significantly more carbohydrate than HP-AH (p<0.001) 
and HC-MS (p=0.033), and HC-MS consumed significantly more carbohydrate than HP-
MS (p<0.001).  Finally, participants categorized as apparently healthy consumed 
significantly more fat (AH 0.64±0.3, MS 0.60±0.2 g/kg/d, p=0.034), with the HP-AH 
group consuming a significantly greater amount than HP-MS (p=0.027).    
Body Composition  
The variables related to body composition are broken down into two tables of 
analysis: DEXA scan measurements and anthropometric measurements.  All of the 
variables within the DEXA measurements were analyzed using a three-way MANOVA, 
while the anthropometric variables were each analyzed using individual three-way 
ANOVAs.   
 Table 4.9 depicts the time x diet x metabolic syndrome risk factor MANOVA for 
DEXA scan measurements.  The three-way MANOVA revealed an overall time (Wilks’ 
Lambda p<0.001) and time x diet (Wilks’ Lambda p=0.036) effect for the DEXA 
variables, but no significant time x metabolic syndrome risk factor (Wilks’ Lambda 
p=0.35) or time x diet x metabolic syndrome risk factor (Wilks’ Lambda p=0.52) effect.  
However, there was a significant time x metabolic syndrome risk factor interaction 
(Wilks’ Lambda p=0.010) when run as a two-way MANOVA.  Analysis of MANOVA 
univariate tests revealed significant time effects (p<0.001) in changes in total scanned 
mass (-3.5±3.5 kg), fat mass (-2.8±2.8 kg), lean mass (-0.7±2.0 kg), and fat percentage (-
1.5±1.9%).  
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Table 4.9: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Metabolic Syndrome Status and Measured Via DEXA Scan 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Scanned Mass  HP-AH 87.3 ± 18.0 83.6g ± 17.6     T = 0.001 
(kg) HP-MS 91.5c ± 17.9 87.3c,g ± 17.1     D = 0.001 
 HC-AH 80.3c ± 14.3 77.5c,g ± 13.6     M = 0.001 
 HC-MS 85.8d,f ± 13.8 82.5d,f,g ± 13.2       D x M = 0.60 
 HP 89.2 ± 18.1 85.3g ± 17.5 87.4 ± 0.83 T x D = 0.002 
 HC 82.5a ± 14.3 79.5a,g ± 13.7 81.6 ± 0.96 T x M = 0.070 
 AH 84.0 ± 16.7 80.7g ± 16.1 82.2 ± 0.83 T x D x M = 0.94 
 MS 89.2b ± 16.6 85.4b,g ± 15.9 86.8 ± 0.97  
 Time 86.2 ± 16.9 82.7* ± 16.2        
Fat Mass (kg) HP-AH 40.2 ± 11.3 37.1g ± 11.2     T = 0.001 
 HP-MS 42.2 ± 11.6 39.0g ± 11.2     D = 0.001 
 HC-AH 36.1c ± 9.2 33.8c,g ± 8.8     M = 0.001 
 HC-MS 38.7d,f ± 8.7 36.0d,g ± 8.3       D x M = 0.79 
 HP 41.1 ± 11.4 38.0g ± 11.2 39.6 ± 0.53 T x D = 0.003 
 HC 37.1a ± 9.1 34.7a,g ± 8.7 36.2 ± 0.61 T x M = 0.36 
 AH 38.2 ± 10.5 35.5g ± 10.2 36.8 ± 0.53 T x D x M = 0.44  
 MS 40.8b ± 10.7 37.9b,g ± 10.2 39.0 ± 0.62  
 Time 39.3 ± 10.7 36.5* ± 10.3        
Lean Mass (kg) HP-AH 45.3 ± 7.9 44.7g ± 7.6     T = 0.001 
 HP-MS 47.5c ± 7.4 46.4c,g ± 7.0     D = 0.001 
 HC-AH 42.5c ± 6.3 41.9c,g ± 6.1     M = 0.001 
 HC-MS 45.4d,f ± 6.2 44.7d,f,g ± 6.1       D x M = 0.40 
 HP 46.3 ± 7.7 45.5g ± 7.4 46.0 ± 0.36 T x D = 0.18 
 HC 43.6a ± 6.4 43.0a,g ± 6.2 43.6 ± 0.41 T x M = 0.07 
 AH 44.0 ± 7.3 43.4g ± 7.1 43.6 ± 0.36 T x D x M = 0.27  
 MS 46.6b ± 7.0 45.7b,g ± 6.7 46.0 ± 0.42  
 Time 45.1 ± 7.3 44.4* ± 7.0        
Body Fat (%) HP-AH 45.5 ± 4.3 43.8g ± 4.7     T = 0.001 
 HP-MS 45.5 ± 4.5 44.1g ± 4.7     D = 0.048 
 HC-AH 44.7 ± 4.4 43.3g ± 4.4     M = 0.75 
 HC-MS 44.8 ± 3.8 43.4g ± 4.0       D x M = 0.94 
 HP 45.5 ± 4.4 43.9g ± 4.7 44.7 ± 0.23 T x D = 0.20 
 HC 44.7a ± 4.2 43.4g ± 4.3 44.0 ± 0.26 T x M = 0.78 
 AH 45.1 ± 4.4 43.6g ± 4.6 44.3 ± 0.22 T x D x M =0.24  
 MS 45.2 ± 4.3 43.8g ± 4.5 44.4 ± 0.26  
 Time 45.2 ± 4.3 43.7* ± 4.5        
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = metabolic syndrome risk factor, T = time effect, D = diet effect, 
M = metabolic syndrome risk factor effect, D x M = diet by metabolic syndrome risk factor effect, T x D = time by diet effect, T x M = time by 
metabolic syndrome risk factor effect, T x D x M = time by diet by metabolic syndrome risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 198 participants in the HP-AH group, 173 in the 
HP-MS group, 179 in the HC-AH group, 113 in the HC-MS group, 371 in the HP total group, 292 in the HC total group, 377 in the AH group, 286 
in the MS group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant metabolic syndrome 
effect, p < 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than AH group, p < 0.05 
(post hoc LSD).  c Significantly different than HP-AH group, p < 0.05 (post hoc LSD).  d Significantly different than HP-MS group, p < 0.05 (post 
hoc LSD).  f Significantly different than HC-AH group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Changes in total scanned mass (HP -3.9±3.5, HC -3.0±3.5 kg, p=0.002) and fat mass 
(HP-3.1±2.7, HC -2.4±2.8 kg, p=0.003) were significantly greater in the HP group.  
When analyzed based on metabolic syndrome risk, those with MS tended to experience 
greater decreases in scanned mass (AH -3.9±3.5, MS -3.0±3.5 kg, p=0.07) and lean mass 
(AH -0.55±2.0, MS -0.88±2.0 kg, p=0.07).  No significant group differences were 
observed for body fat percentage, and no significant time x diet x metabolic syndrome 
risk factor interactions were seen in any body composition variables measured via 
DEXA.  Post hoc analysis of body composition data expressed in delta changes from 
baseline revealed a significantly greater decrease in scanned mass for HP-AH (-3.7±3.5) 
than HC-AH (-2.8±3.5, p=0.019) and for HP-MS (-4.2±3.5 kg) than HC-MS 
 (-3.3±3.5, p=0.036).  A significantly greater decrease in fat mass was observed for HP-
AH (-3.1±2.7 kg) than HC-AH (-2.3±2.6 kg, p=0.004), as well as a significantly greater 
decrease in lean mass for HP-MS (-1.0±2.1 kg) than HP-AH (-0.6±1.9 kg, p=0.025).  
Figures 4.5 and 4.6 depict the delta change from baseline for each DEXA body 
composition variable for both the individual group comparisons and the group-
combinations.     
 
  
 
95 
 
Figure 4.5: Delta Changes in DEXA Body Composition Variables, by Diet and 
Metabolic Syndrome Status 
 
 
Figure 4.6: Delta Changes in DEXA Body Composition Variables, by Group-
Combination 
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Anthropometric Measurements 
 Table 4.10 depicts the individual time x diet x metabolic syndrome risk factor 
ANOVAs for each of the anthropometric body composition variables.  The variables 
included are weight (kg), body mass index (kg/m2), and waist- and hip- circumference 
(cm), and are each discussed individually below.   
In regards to weight, the three-way ANOVA revealed an overall time (p<0.001), 
time x diet (p<0.001) and time x metabolic syndrome risk factor (p=0.054) effect, with 
no significant time x diet x metabolic syndrome risk factor effect (p=0.69).  Analysis of 
the ANOVA univariate test revealed a significant time effect (-3.8±3.5 kg, p<0.001), 
with a significantly greater decrease in the HP group (HP -4.3±3.6, HC -3.2±3.4 kg, 
p=0.001), and the MS group (AH -3.6±3.4, MS -4.2±3.6 kg, p=0.054).  Post hoc delta 
analysis of weight data expressed in delta changes from baseline revealed the HP-AH 
group lost significantly more weight (-4.1±3.5 kg) than HC-AH (-3.0±3.2 kg, p=0.003), 
and the HP-MS group lost significantly more weight (-4.5±3.6 kg) than HC-MS (-
3.6±3.6 kg, p=0.043).  
 For body mass index, the three-way ANOVA revealed an overall time 
(p<0.001), time x diet (p<0.001) and time x metabolic syndrome risk factor (p=0.046) 
effect for BMI with no significant time x diet x metabolic syndrome risk factor effect 
(p=0.74).  Analysis of the ANOVA univariate test revealed a significant time effect (-
1.4±1.3 kg/m2, p<0.001), with a significantly greater decrease in the HP group (HP -
1.6±1.3, HC -1.2±1.3 kg/m2, p<0.001), and the MS group (AH -1.3±1.3, MS -1.6±1.3 
kg/m2, p=0.046).     
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Table 4.10: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Metabolic Syndrome Status and Measured via Anthropometric 
Measurements 
 
Variable Grou
p 
Baseline 10 Weeks Group 
(SEM) 
P-level 
Weight (kg) HP-AH 93.7 ± 19.0 89.7g ± 18.5     T = 0.001 
 HP-MS 98.1c ± 18.9 93.6c,g ± 18.0     D = 0.001 
 HC-AH 86.5c ± 14.8 83.5c,g ± 14.1     M = 0.001 
 HC-MS 92.3d,f ± 14.4 88.7d,f,g ± 13.9       D x M = 0.62 
 HP 95.8 ± 19.1 91.5g ± 18.3 93.8† ± 0.9 T x D = 0.001 
 HC 88.8a ± 14.9 85.5a,g ± 14.2 87.8 ± 1.0 T x M = 0.054 
 AH 90.3 ± 17.5 86.7g ± 16.8 88.3 ± 0.9 T x D x M = 0.69 
 MS 95.8b ± 17.5 91.7b,g ± 16.6 93.2‡ ± 1.0  
 Time 92.7 ± 17.7 88.9* ± 16.9        
Body Mass Index HP-AH 35.0 ± 6.6 33.5g ± 6.4     T = 0.001 
(kg/m2) HP-MS 37.0c ± 6.4 35.3c,g ± 6.2     D = 0.001 
 HC-AH 32.5c ± 5.3 31.4c,g ± 5.0     M = 0.001 
 HC-MS 34.5d,f ± 4.9 33.2d,f,g ± 4.7       D x M = 0.98 
 HP 35.9 ± 6.6 34.3g ± 6.4 35.2† ± 0.3 T x D = 0.001 
 HC 33.3a ± 5.2 32.1a,g ± 5.0 32.9 ± 0.3 T x M = 0.046 
 AH 33.8 ± 6.1 32.5g ± 5.9 33.1 ± 0.3 T x D x M = 0.74 
 MS 36.0b ± 6.0 34.5b,g ± 5.7 35.0‡ ± 0.4  
 Time 34.8 ± 6.2 33.3* ± 5.9        
Waist HP-AH 98.4 ± 13.2 94.8g ± 13.6     T = 0.001 
Circumference HP-MS 104.7c ± 13.0 100.2c,g ± 12.1     D = 0.001 
(cm) HC-AH 93.1c ± 11.0 90.0c,g ± 10.4     M = 0.001 
 HC-MS 100.0d,f ± 11.4 96.7d,f,g ± 11.3       D x M = 0.61 
 HP 101.3 ± 13.5 97.3g ± 13.2 99.5† ± 0.6 T x D = 0.07 
 HC 95.8a ± 11.7 92.6a,g ± 11.2 95.0 ± 0.7 T x M = 0.19 
 AH 95.9 ± 12.5 92.5g ± 12.4 94.1 ± 0.6 T x D x M = 0.48  
 MS 102.9b ± 12.6 98.8b,g ± 11.9 100.4‡ ± 0.7  
 Time 98.9 ± 13.0 95.2* ± 12.6        
Hip HP-AH 121.8 ± 13.5 118.4 ± 13.5     T = 0.001 
Circumference HP-MS 123.8 ± 14.3 120.8 ± 13.7     D = 0.001 
(cm) HC-AH 116.7 ± 11.8 114.6 ± 11.0     M = 0.005 
 HC-MS 120.9 ± 10.6 117.3 ± 10.5       D x M = 0.53 
 HP 122.7 ± 13.9 119.5g ± 13.6 121.2† ± 0.6 T x D = 0.40 
 HC 118.3a ± 11.5 115.6a,g ± 10.9 117.4 ± 0.7 T x M = 0.19 
 AH 119.4 ± 13.0 116.6g ± 12.5 117.9 ± 0.6 T x D x M = 0.022 
 MS 122.6b ± 13.0 119.4b,g ± 12.6 120.7‡ ± 0.7  
 Time 120.8 ± 13.1 117.8* ± 12.6        
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = metabolic syndrome risk factor, T = time effect, D = diet effect, 
M = metabolic syndrome risk factor effect, D x M = diet by metabolic syndrome risk factor effect, T x D = time by diet effect, T x M = time by 
metabolic syndrome risk factor effect, T x D x M = time by diet by metabolic syndrome risk factor effect.    
Values are means ± standard deviations (except group means are means ± standard error) from 198 participants in the HP-AH group, 173 in the 
HP-MS group, 179 in the HC-AH group, 113 in the HC-MS group, 371 in the HP total group, 292 in the HC total group, 377 in the AH group, 
286 in the MS group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant metabolic syndrome 
effect, p < 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than AH group, p < 0.05 
(post hoc LSD).  c Significantly different than HP-AH group, p < 0.05 (post hoc LSD).  d Significantly different than HP-MS group, p < 0.05 
(post hoc LSD).  f Significantly different than HC-AH group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc 
LSD). 
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Post hoc delta analysis of body mass index data expressed in delta changes from baseline 
revealed a significantly greater decrease in BMI for HP-AH (-1.5±1.3 kg/m2) than HC-
AH (-1.1±1.2 kg/m2, p=0.003), and a significantly greater decrease in BMI for HP-MS (-
1.7±1.3 kg/m2) than HC-MS (-1.4±1.3 kg/m2, p=0.036).  
In regards to waist circumference, the three-way ANOVA revealed an overall 
time effect (p<0.001) and a trend towards significance for time x diet (p=0.07).  No 
significant time x metabolic syndrome risk factor (p=0.19) or time x diet x metabolic 
syndrome risk factor (p=0.48) interactions were observed.  Overall, participants lost an 
average of 3.7±5.7 cm in waist circumference throughout the ten-week protocol.  When 
analyzed based on time x diet, those consuming the higher protein diet tended to 
experience a greater decrease in waist circumference (HP -4.0±5.7, HC -3.2±5.7 cm, 
p=0.07).  Post hoc analysis of waist circumference data expressed in delta changes from 
baseline revealed a significant difference from baseline for each of the group-
combinations, but no other significant differences among groups.  
For hip circumference, the three-way ANOVA revealed an overall time 
(p<0.001) and time x diet x metabolic syndrome risk factor (p=0.022) effect for hip 
circumference.  Overall, participants lost an average of 3.0±5.1 cm in hip circumference 
throughout the ten-week protocol, yet no significant time x diet (p=0.40) or time x 
metabolic syndrome risk factor (p=0.19) interactions were observed.  Post hoc analysis 
of hip circumference data expressed in delta changes from baseline revealed that HC-AH 
lost significantly less centimeters (-2.1±5.0) than both HP-AH (-3.4±5.2, p=0.016) and 
HC-MS (-3.6±4.8, p=0.017).   
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Figures 4.7 and 4.8 depict the delta change from baseline for each 
anthropometric body composition variable for both the individual group comparisons 
and the group-combinations.  Based on these findings, hypothesis H3, which indicated 
there would be statistically significant differences in the changes of body composition as 
a result of diet intervention and/or the presence of metabolic syndrome risk status was 
accepted.           
 
 
Figure 4.7: Delta Changes in Anthropometric Body Composition Variables, by Diet and 
Metabolic Syndrome Status 
 
 
Figure 4.8: Delta Changes in Anthropometric Body Composition Variables, by Group-
Combination 
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Resting Energy Expenditure  
Table 4.11 depicts the time x diet x metabolic syndrome risk factor ANOVA for 
resting energy expenditure (REE), which was measured on a subset of 633 participants.  
The three-way ANOVA revealed an overall time (p<0.001) effect for resting energy 
expenditure.  No significant time x diet (p=0.30), time x metabolic syndrome risk factor 
(p=0.88), or time x diet x metabolic syndrome risk factor (p=0.98) interactions were 
observed.  Overall, participants lost an average of 55.6±212 kcal/day in resting energy 
expenditure throughout the ten-week protocol, yet no significant differences were 
observed over-time based on diet protocol or health status.  Post hoc analysis of resting 
energy expenditure data on delta calculations between testing sessions shows a 
significant change from baseline for all four group-combinations, but no significant 
differences between the groups. Therefore, hypothesis H4 is accepted, which indicated 
there would not be statistically significant differences in resting energy expenditure 
parameters as a result of diet intervention and/or the presence of metabolic syndrome 
risk status. 
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Table 4.11: Resting Energy Expenditure After Ten Weeks of Exercise and Dietary 
Intervention Based on Metabolic Syndrome Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Resting Energy HP-AH 1639.8 ± 272.6 1577.2g ± 269.9     T = 0.001 
Expenditure HP-MS 1761.4c ± 286.1 1696.7c,g ± 304.3     D = 0.001 
(kcal/day) HC-AH 1562.5c ± 239.4 1518.5c,g ± 246.4     M = 0.001 
 HC-MS 1661.8d,f ± 250.4 1614.7d,f,g ± 242.2       D x M = 0.57 
 HP 1697.4 ± 285.2 1633.8g ± 292.5 1668.8† ± 13.0 T x D = 0.30 
 HC 1600.7a ± 248.0 1555.5a,g ± 248.8 1589.4 ± 15.1 T x M = 0.88 
 AH 1603.1 ± 259.9 1549.4b ± 260.3 1574.5 ± 13.0 T x D x M =  
 MS 1723.0b ± 276.7 1665.1b,g ± 284.3 1683.7‡ ± 15.2 0.98 
 Time 1655.2 ± 273.7 1599.7* ± 276.8        
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = metabolic syndrome risk factor, T = time effect, D = diet effect, M = 
metabolic syndrome risk factor effect, D x M = diet by metabolic syndrome risk factor effect, T x D = time by diet effect, T x M = time by metabolic 
syndrome risk factor effect, T x D x M = time by diet by metabolic syndrome risk factor effect.                                                                                                                                     
Resting energy expenditure values are means ± standard deviations (except group means are means ± standard error) from 181 participants in the HP-
AH group, 176 in the HP-MS group, 163 in the HC-AH group, 113 in the HC-MS group, 357 in the HP total group, 276 in the HC total group, 344 in 
the AH group, 289 in the MS group, and 633 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant metabolic syndrome effect, 
p < 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than AH group, p < 0.05 (post hoc 
LSD).  c Significantly different than HP-AH group, p < 0.05 (post hoc LSD).  d Significantly different than HP-MS group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-AH group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
 
 
Hemodynamic Variables 
Table 4.12 depicts the time x diet x metabolic syndrome risk factor MANOVA 
for resting hemodynamic measurements including resting heart rate, systolic, and 
diastolic blood pressure.  The three-way MANOVA revealed an overall time (Wilks’ 
Lambda p<0.001) and time x metabolic syndrome risk factor (Wilks’ Lambda p<0.001) 
effect for resting hemodynamic parameters, but no significant time x diet (Wilks’ 
Lambda p=0.73) or time x diet x metabolic syndrome risk factor (Wilks’ Lambda 
p=0.83) interactions.  
Overall, resting heart rate decreased by 3.0±10.3 bpm (time effect p<0.001) 
throughout the ten-week study, however no significant changes were observed over time 
based on a specific dietary protocol or health status.  Additionally, post hoc delta 
analysis shows a significant change from baseline for each of the four group-
combinations, but no significant differences between the groups. 
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Table 4.12: Resting Hemodynamic Measurements After Ten Weeks of Exercise and 
Dietary Intervention Based on Metabolic Syndrome Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Resting Heart HP-AH 71.0 ± 9.8 68.6g ± 10.0     T = 0.001 
Rate (bpm) HP-MS 73.2c ± 10.8 69.3g ± 9.3     D = 0.44 
 HC-AH 70.0 ± 9.8 67.5g ± 10.1     M = 0.005 
 HC-MS 73.1f ± 11.3 69.4g ± 9.7       D x M = 0.46 
 HP 72.0 ± 10.3 68.9g ± 9.7 70.5 ± 0.5 T x D = 0.91 
 HC 71.2 ± 10.5 68.2g ± 9.9 70.0 ± 0.5 T x M = 0.10 
 AH 70.5 ± 9.8 68.1g ± 10.0 69.3 ± 0.4 T x D x M = 0.91  
 MS 73.1b ± 11.0 69.3g ± 9.4 71.2‡ ± 0.5  
 Time 71.6 ± 10.4 68.6* ± 9.8        
Resting Systolic HP-AH 121.3 ± 12.6 121.4 ± 13.3     T = 0.001 
Blood Pressure HP-MS 130.4c ± 15.5 124.8c,g ± 14.0     D = 0.33 
(mmHg) HC-AH 120.5 ± 11.9 119.4 ± 12.9     M = 0.001 
 HC-MS 130.3f ± 16.0 124.0f,g ± 15.5       D x M = 0.60 
 HP 125.6 ± 14.7 123.0g ± 13.7 124.5 ± 0.6 T x D = 0.43 
 HC 124.3 ± 14.4 121.2g ± 14.1 123.6 ± 0.7 T x M = 0.001 
 AH 120.9 ± 12.2 120.5 ± 13.2 120.7 ± 0.6 T x D x M = 0.87 
 MS 130.4b ± 15.7 124.4b,g ± 14.6 127.4‡ ± 0.7  
 Time 125.0 ± 14.6 122.2* ± 13.9        
Resting Diastolic HP-AH 78.6 ± 8.1 79.0 ± 8.9     T = 0.001 
Blood Pressure HP-MS 84.3c ± 9.6 80.2g ± 8.7     D = 0.001 
(mmHg) HC-AH 77.3 ± 8.6 76.1c ± 8.9     M = 0.001 
 HC-MS 82.6f ± 9.6 78.5f,g ± 9.5       D x M = 0.72 
 HP 81.3 ± 9.3 79.6g ± 8.8 80.5† ± 0.4 T x D = 0.28 
 HC 79.3a ± 9.4 77.0a,g ± 9.2 78.6 ± 0.5 T x M = 0.001 
 AH 78.0 ± 8.4 77.6 ± 9.0 77.7 ± 0.4 T x D x M = 0.38 
 MS 83.6b ± 9.6 79.5b,g ± 9.0 81.4‡ ± 0.5  
 Time 80.4 ± 9.4 78.4* ± 9.1        
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = metabolic syndrome risk factor, T = time effect, D = diet effect, M = 
metabolic syndrome risk factor effect, D x M = diet by metabolic syndrome risk factor effect, T x D = time by diet effect, T x M = time by metabolic 
syndrome risk factor effect, T x D x M = time by diet by metabolic syndrome risk factor effect.                                                                                                                                     
Resting hemodynamic values are means ± standard deviations (except group means are means ± standard error) from 198 participants in the HP-AH 
group, 173 in the HP-MS group, 179 in the HC-AH group, 113 in the HC-MS group, 371 in the HP total group, 292 in the HC total group, 377 in the 
AH group, 286 in the MS group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant metabolic syndrome effect, p 
< 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than AH group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-AH group, p < 0.05 (post hoc LSD).  d Significantly different than HP-MS group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-AH group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
 
 
In regards to blood pressure, over the course of the study, participants observed 
an average decrease in systolic blood pressure by 2.8±14.8 mmHg (time effect, p<0.001) 
and diastolic blood pressure by 2.0±9.8 mmHg (time effect, p<0.001).  While no 
significant differences were seen overtime based on diet, the MS group experienced a 
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significantly greater decrease in systolic blood pressure (AH -0.5±13.3, MS -5.9±16.0 
mmHg, p<0.001) and diastolic blood pressure (AH -0.4±8.9, MS -4.1±10.5 mmHg, 
p<0.001).  For both systolic and diastolic blood pressure, post hoc analysis on delta 
changes from baseline revealed that the HP-MS and HC-MS groups both demonstrated 
significant decreases from baseline (each with p<0.001).  
The HP-MS group experienced a significantly greater decrease in blood pressure 
than the HP-AH group (SBP: HP-AH +0.5±13.2, HP-MS -5.6±15.6 mmHg, p<0.001), 
(DBP: HP-AH +0.4±8.8, HP-MS -4.0±10.4 mmHg, p<0.001).  The HC-MS group 
experienced a significantly greater decrease in blood pressure than the HC-AH group 
(SBP: HC-AH -1.1±13.4, HC-MS -6.3±16.6 mmHg, p=0.003), (DBP: HC-AH -1.1±9.0, 
HC-MS -4.2±10.7 mmHg, p=0.009).    
Figures 4.9 and 4.10 depict the delta changes for the hemodynamic parameters 
over the ten week study.  Based on the time x metabolic syndrome risk factor effects for 
both SBP and DBP, hypothesis H5, which indicated there would not be statistically 
significant differences in resting hemodynamic parameters as a result of diet intervention 
and/or the presence of metabolic syndrome risk status, is rejected. 
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Figure 4.9: Delta Changes in Hemodynamic Variables, by Diet and Metabolic 
Syndrome Status 
 
 
 
Figure 4.10: Delta Changes in Hemodynamic Variables, by Group-Combination 
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Blood Lipids 
Table 4.13 depicts the time x diet x metabolic syndrome risk factor MANOVA 
for blood lipid values.  The variables reported that will each be discussed individually 
include total cholesterol (mmol/L), LDL cholesterol (mmol/L), HDL cholesterol 
(mmol/L), Triglycerides (mmol/L), and TC/HDL ratio.  The three-way MANOVA 
revealed a significant overall time (Wilks’ Lambda p<0.001) and time x metabolic 
syndrome risk factor (Wilks’ Lambda p<0.001) effect as well as a trend for a time x diet 
x metabolic syndrome risk factor (Wilks’ Lambda p=0.09) effect for blood lipids.  No 
significant time x diet (Wilks’ Lambda p=0.50) interaction was observed.     
In regards to total cholesterol, participants lost an average of 0.2±0.8 mmol/L 
(time effect, p<0.001) throughout the study protocol, however no significant diet or 
health status effects were reported over time.  Significant changes from baseline were 
observed through post hoc analysis on blood lipid data expressed in delta changes from 
baseline for the HP-AH (p=0.002), HP-MS (p<0.001), and HC-AH (p=0.005) groups.  
No significant differences were observed between the group-combinations in the post-
hoc analysis. 
For LDL cholesterol, participants lost an average of 0.14±0.6 mmol/L (time 
effect, p<0.001) throughout the study protocol, however no significant diet or health 
status effects were reported over time. Significant changes from baseline were observed 
through post hoc analysis on blood lipid data expressed in delta changes from baseline 
for the HP-AH (p=0.003), HP-MS (p<0.001), and HC-AH (p=0.001) groups.  
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Table 4.13: Fasting Blood Lipid Values After Ten Weeks of Exercise and Dietary 
Intervention Based on Metabolic Syndrome Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Total Cholesterol HP-AH 5.1 ± 0.9 5.0g ± 0.9     T = 0.001 
(mmol/L) HP-MS 5.3 ± 1.0 5.0g ± 1.0     D = 0.38 
 HC-AH 5.1 ± 1.0 4.9g ± 0.9     M = 0.001 
 HC-MS 5.4f ± 1.1 5.3d,f ± 1.0       D x M = 0.11 
 HP 5.2 ± 1.0 5.0g ± 1.0 5.1 ± 0.05 T x D = 0.40 
 HC 5.2 ± 1.0 5.0g ± 1.0 5.2 ± 0.05 T x M = 0.76 
 AH 5.1 ± 0.9 4.9g ± 0.9 5.0 ± 0.05 T x D x M = 0.48  
 MS 5.3b ± 1.1 5.1b,g ± 1.0 5.2‡ ± 0.05  
 Time 5.2 ± 1.0 5.0* ± 1.0        
LDL (mmol/L) HP-AH 3.0 ± 0.7 2.9g ± 0.7     T = 0.001 
 HP-MS 3.2c ± 0.8 3.0g ± 0.8     D = 0.19 
 HC-AH 3.0 ± 0.8 2.8g ± 0.8     M = 0.001 
 HC-MS 3.3f ± 0.9 3.3d,f ± 0.8       D x M = 0.047 
 HP 3.1 ± 0.8 3.0g ± 0.8 3.0 ± 0.04 T x D = 0.53 
 HC 3.1 ± 0.8 3.0g ± 0.8 3.1 ± 0.04 T x M = 0.64 
 AH 3.0 ± 0.8 2.9g ± 0.7 2.9 ± 0.04 T x D x M = 0.26  
 MS 3.3b ± 0.8 3.1b,g ± 0.8 3.2‡ ± 0.04  
 Time 3.1 ± 0.8 3.0* ± 0.8        
HDL (mmol/L) HP-AH 1.5 ± 0.3 1.4g ± 0.3     T = 0.001 
 HP-MS 1.2c ± 0.3 1.2c,g ± 0.3     D = 0.70 
 HC-AH 1.5 ± 0.3 1.4g ± 0.3     M = 0.001 
 HC-MS 1.2f ± 0.3 1.2f,g ± 0.3       D x M = 0.63 
 HP 1.4 ± 0.3 1.3g ± 0.3 1.3 ± 0.02 T x D = 0.71 
 HC 1.4 ± 0.3 1.3g ± 0.3 1.3 ± 0.02 T x M = 0.016 
 AH 1.5 ± 0.3 1.4g ± 0.3 1.5 ± 0.01 T x D x M = 0.40 
 MS 1.2b ± 0.3 1.2b,g ± 0.3 1.2‡ ± 0.02  
 Time 1.4 ± 0.3 1.3* ± 0.3        
Triglycerides  HP-AH 1.2 ± 0.5 1.2 ± 0.6     T = 0.001 
(mmol/L) HP-MS 2.0c ± 1.0 1.8c,g ± 0.9     D = 0.83 
 HC-AH 1.2 ± 0.5 1.3 ± 0.6     M = 0.001 
 HC-MS 2.0f ± 0.8 1.8f,g ± 0.8       D x M = 0.72 
 HP 1.6 ± 0.8 1.5g ± 0.8 1.6 ± 0.03 T x D = 0.13 
 HC 1.5 ± 0.7 1.5g ± 0.7 1.6 ± 0.04 T x M = 0.001 
 AH 1.2 ± 0.5 1.2 ± 0.6 1.2 ± 0.03 T x D x M = 0.001 
 MS 2.0b ± 0.9 1.8b,g ± 0.9 1.9‡ ± 0.04  
 Time 1.6 ± 0.8 1.5* ± 0.8        
TC/HDL ratio HP-AH 3.5 ± 0.7 3.6g ± 0.7     T = 0.026 
 HP-MS 4.4c ± 0.9 4.3c ± 1.0     D = 0.22 
 HC-AH 3.5 ± 0.8 3.6 ± 0.8     M = 0.001 
 HC-MS 4.4f ± 1.0 4.6d,f,g ± 1.1       D x M = 0.24 
 HP 3.9 ± 0.9 3.9 ± 0.9 4.0 ± 0.04 T x D = 0.42 
 HC 3.9 ± 1.0 4.0g ± 1.1 4.0 ± 0.05 T x M = 0.41 
 AH 3.5 ± 0.8 3.6g ± 0.8 3.6 ± 0.04 T x D x M = 0.027  
 MS 4.4b ± 0.9 4.4b ± 1.0 4.4‡ ± 0.05  
 Time 3.9 ± 0.9 4.0* ± 1.0        
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = metabolic syndrome risk factor, T = time effect, D = diet effect, 
M = metabolic syndrome risk factor effect, D x M = diet by metabolic syndrome risk factor effect, T x D = time by diet effect, T x M = time by 
metabolic syndrome risk factor effect, T x D x M = time by diet by metabolic syndrome risk factor effect.   
Values are means ± standard deviations (except group means are means ± standard error) from 198 participants in the HP-AH group, 173 in the 
HP-MS group, 179 in the HC-AH group, 113 in the HC-MS group, 371 in the HP total group, 292 in the HC total group, 377 in the AH group, 286 
in the MS group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  ‡ Significant metabolic syndrome effect, p < 0.05 (univariate).                                                                                                                                   
a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than AH group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-AH group, p < 0.05 (post hoc LSD).  d Significantly different than HP-MS group, p < 0.05 (post hoc LSD).  f 
Significantly different than HC-AH group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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No significant differences were observed between the group-combinations in the post-
hoc analysis. 
In regards to HDL cholesterol, participants lost an average of 0.07±0.2 mmol/L 
(time effect, p<0.001) throughout the study protocol.  While no effect was observed 
regarding dietary assignment over time, the AH group experienced a significantly 
greater decrease in HDL (AH -0.09±0.3, MS -0.04±0.2 mmol/L, p=0.016).  Post hoc 
analysis using delta change shows a significant decrease from baseline for all four of the 
group-combinations, and also that the HP-AH group lost significantly more HDL  
(-0.1±0.2 mmol/L) compared to HP-MS (-0.04±0.2 mmol/L, p=0.013). 
For triglycerides, participants lost an average of 0.10±0.6 mmol/L (time effect, 
p<0.001) throughout the study protocol.  No time x diet interaction was observed, 
however the MS group experienced a significantly greater decrease in triglycerides (AH 
-0.00±0.47, MS -0.22±0.73 mmol/L, delta p<0.001). Post hoc analyses based on delta 
change from baseline demonstrates a significant difference between HC-AH and all 
other group combinations, in that HC-AH was the only group that increased (+0.06±0.5 
mmol/L) in triglyceride value (delta p=0.052), however this value is not a significant 
increase from baseline.  Figures 4.11 and 4.12 depict the delta changes for the blood 
lipid parameters over the ten-week period.  
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Figure 4.11: Delta Changes in Blood Lipid Variables, by Diet and Metabolic Syndrome 
Status 
 
 
Figure 4.12: Delta Changes in Blood Lipid Variables, by Group-Combination 
 
 
In regards to TC/HDL ratio, participants gained an average of 0.05±0.7 in value 
(time effect, p=0.026), however no significant diet or health status effects were reported 
over time.  Time x diet x metabolic syndrome risk factor analysis revealed a significant 
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three-way interaction (p=0.027).  Analysis using delta changes from baseline revealed 
the HP-MS group to be significantly different from all other group combinations, in that 
all of the other groups increased in TC/HDL ratio over time, and HP-MS is the only 
group showing a decrease (-0.05±0.73, p=0.035), however this decrease was not a 
significant change in value from baseline.   
Upon observing the decrease in HDL cholesterol for all groups, and most 
significantly for the apparently healthy participants, a three-way ANOVA of TG/HDL 
ratio (using mmol/L values) was added in, as is depicted in Table 4.14.  A time x 
metabolic syndrome risk factor (p<0.001) effect, but only a trend in time (p=0.07), and 
no time x diet (0.38), or time x diet x metabolic syndrome risk factor (p=0.57) 
interactions were observed.  Participants in the MS group had significantly greater 
TG/HDL ratios both at baseline and at ten-weeks, however the MS group also 
experienced a significant decrease compared to an increase in the AH group (AH 
+0.05±0.42, MS -0.14±0.78, p<0.001).  Post hoc analysis using the delta change from 
baseline reveals that three of the groups-combinations experienced a significant change 
from baseline (HP-MS p=0.001; HC-AH p=0.052; and HC-MS p=0.019), with HP-MS 
(-0.14±0.8) experiencing a significantly greater decrease than HP-AH (+0.02±0.4, 
p=0.008) and HC-MS (-0.13±0.7) experiencing a significantly greater decrease than HC-
AH (+0.09±0.4, p=0.002). 
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Table 4.14: Calculated TG/HDL Ratio After Ten Weeks of Exercise and Dietary 
Intervention Based on Metabolic Syndrome Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
TG/HDL (mmol) HP-AH 0.9 ± 0.4 0.9 ± 0.5     T = 0.07 
 HP-MS 1.7c ± 0.9 1.6c,g ± 0.9     D = 0.88 
 HC-AH 0.9 ± 0.4 1.0g ± 0.5     M = 0.001 
 HC-MS 1.7f ± 0.8 1.6f,g ± 0.7       D x M = 0.51 
 HP 1.3 ± 0.8 1.2g ± 0.8 1.3 ± 0.03 T x D = 0.39 
 HC 1.2 ± 0.7 1.2 ± 0.7 1.3 ± 0.04 T x M = 0.001 
 AH 0.9 ± 0.4 0.9g ± 0.5 0.9 ± 0.03 T x D x M = 0.57 
 MS 1.7b ± 0.9 1.6b,g ± 0.9 1.6‡ ± 0.04  
 Time 1.2 ± 0.8 1.2 ± 0.8        
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = metabolic syndrome risk factor, T = time effect, D = diet effect, M = 
metabolic syndrome risk factor effect, D x M = diet by metabolic syndrome risk factor effect, T x D = time by diet effect, T x M = time by metabolic 
syndrome risk factor effect, T x D x M = time by diet by metabolic syndrome risk factor effect.                                                                                                                                     
Resting energy expenditure values are means ± standard deviations (except group means are means ± standard error) from 198 participants in the HP-
AH group, 173 in the HP-MS group, 179 in the HC-AH group, 113 in the HC-MS group, 371 in the HP total group, 292 in the HC total group, 377 in 
the AH group, 286 in the MS group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant metabolic syndrome effect, p 
< 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than AH group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-AH group, p < 0.05 (post hoc LSD).  d Significantly different than HP-MS group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-AH group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
 
 
Figures 4.13 and 4.14 depict the delta changes in the TC/HDL and TG/HDL 
ratios over the ten-week period.  Based on the findings from Table 4.13, hypothesis H6 is 
accepted.  This hypothesis indicated there would be statistically significant differences in 
the changes in blood lipids as a result of diet intervention and/or the presence of 
metabolic syndrome risk status.     
 
  
 
111 
 
Figure 4.13: Delta Changes in Blood Lipid Ratios, by Diet and Metabolic Syndrome 
Status 
 
 
Figure 4.14: Delta Changes in Blood Lipid Variables, by Group-Combination 
 
Glucose Homeostasis  
Table 4.15 depicts the individual time x diet x metabolic syndrome risk factor 
ANOVAs for markers of glucose homeostasis including glucose, insulin, and calculated 
HOMA (Homeostatic Model Assessment).  Each of these variables is discussed 
individually below.   
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Table 4.15: Fasting Glucose and Insulin Values After Ten Weeks of Exercise and 
Dietary Intervention Based on Metabolic Syndrome Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Glucose HP-AH 5.3 ± 0.8 5.3 ± 0.7     T = 0.003 
(mmol/L) HP-MS 6.2c ± 1.5 6.0c,g ± 1.5     D = 0.64 
 HC-AH 5.3 ± 0.8 5.4 ± 0.7     M = 0.001 
 HC-MS 6.1f ± 1.7 5.8f,g ± 1.3       D x M = 0.24 
 HP 5.7 ± 1.2 5.6g ± 1.2 5.7 ± 0.05 T x D = 0.64 
 HC 5.6 ± 1.3 5.5 ± 1.0 5.6 ± 0.06 T x M = 0.001 
 AH 5.3 ± 0.8 5.3 ± 0.7 5.3 ± 0.05 T x D x M = 0.48 
 MS 6.1b ± 1.6 5.9b,g ± 1.4 6.0‡ ± 0.06  
 Time 5.7 ± 1.3 5.6* ± 1.1        
Insulin HP-AH 3.3 ± 8.5 3.8 ± 9.4     T = 0.86 
(uIU/mL) HP-MS 4.9 ± 9.1 5.5 ± 10.9     D =0.001 
 HC-AH 5.8 ± 6.6 7.8c ± 11.5     M = 0.025 
 HC-MS 12.1d,f ± 18.4 9.5 ± 12.8       D x M = 0.36 
 HP 4.0 ± 8.8 4.5 ± 10.1 4.4† ± 0.80 T x D = 0.50 
 HC 8.3a ± 12.8 8.4a ± 12.0 8.8 ± 0.97 T x M = 0.07 
 AH 4.4 ± 7.8 5.5 ± 10.5 5.2 ± 0.80 T x D x M = 0.06  
 MS 7.7b ± 13.8 7.0 ± 11.8 8.0‡ ± 0.97  
 Time 5.7 ± 10.8 6.1 ± 11.1        
Calculated  HP-AH 0.8 ± 2.2 0.9 ± 2.3 
 
  
T = 0.85 
HOMA HP-MS 1.3 ± 2.5 1.6 ± 3.5 D = 0.001 
 HC-AH 1.4 ± 1.5 2.0c ± 3.5 M = 0.005 
 HC-MS 3.8d,f ± 6.9 2.6g ± 3.5 D x M = 0.23 
 HP 1.0 ± 2.3 1.2 ± 2.9 1.2† ± 0.23 T x D = 0.33 
 HC 2.3a ± 4.6 2.2a ± 3.5 2.4 ± 0.28 T x M = 0.06 
 AH 1.1 ± 2.0 1.4 ± 2.9 1.3 ± 0.23 T x D x M = 0.027  
 MS 2.3b ± 4.8 2.0 ± 3.5 2.3‡ ± 0.28  
 Time 1.6 ± 3.5 1.6 ± 3.2        
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = metabolic syndrome risk factor  
T = time effect, D = diet effect, M = metabolic syndrome risk factor effect, D x M = diet by metabolic syndrome risk factor effect, T x D = time by diet effect, T x M = time by 
metabolic syndrome risk factor effect, T x D x M = time by diet by metabolic syndrome risk factor effect.    
Glucose values are means ± standard deviations (except group means are means ± standard error) from 198 participants in the HP-AH group, 173 in the HP-MS group, 179 in the 
HC-AH group, 113 in the HC-MS group, 371 in the HP total group, 292 in the HC total group, 377 in the AH group, 286 in the MS group, and 663 participants total.  Insulin and 
HOMA values are means ± standard deviations (except group means are means ± standard error) from 80 participants in the HP-AH group, 69 in the HP-MS group, 58 in the HC-
AH group, 45 in the HC-MS group, 149 in the HP total group, 103 in the HC total group, 138 in the AH group, 114 in the MS group, and 252 participants total.    
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant metabolic syndrome effect, p < 0.05 (univariate).  a 
Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than AH group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-AH group, p < 0.05 (post hoc LSD).  d Significantly different than HP-MS group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-AH group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
 
 
For glucose, the three-way ANOVA revealed an overall time effect (p=0.003) 
and time x metabolic syndrome risk factor effect (p=0.001).  No significant time x diet 
(p=0.64) or time x diet x metabolic syndrome risk factor (p=0.48) interactions were 
observed.  Overall, participants lost an average of 0.10±1.0 mmol/L (time effect, 
p=0.003) in fasting glucose throughout the study protocol.  No significant effects were 
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observed overtime based on diet.  Based on analysis using delta change calculations 
from baseline, the MS group experienced a significant decrease in glucose whereas the 
AH group did not experience a significant change from baseline (AH +0.01±0.73 
mmol/L, MS -0.24±1.19 mmol/L, p=0.001).  Post hoc analysis on the delta change from 
baseline revealed that HP-MS and HC-MS were the only groups to significantly change 
from baseline (p=0.002 and p=0.006 respectively), and that HP-MS experienced 
significantly greater decreases than HP-AH (HP-AH -0.03±0.8, HP-MS -0.23±1.2, 
p=0.051) and HC-MS experienced a significantly greater decrease than HC-AH (HC-AH 
+0.06±0.7, HC-MS -0.24±1.19, p=0.009).    
Insulin was analyzed on a subset of 252 participants from which serum was 
measured within the study.  The three-way ANOVA revealed a trend for both time x 
metabolic syndrome risk factor (p=0.07) and time x diet x metabolic syndrome risk 
factor (p=0.06) effect for insulin.  No overall time effect (p=0.86) or a time x diet 
(p=0.50) interactions were observed.  Analysis on data calculated from delta change 
from baseline revealed a tendency for an increase in insulin for the AH group and a 
decrease in the MS group over time (AH +1.11±6.5 uIU/mL, MS -0.65±12.2 uIU/mL, 
p=0.07) however these values were not significantly different from baseline, nor were 
the ten-week values for each group significantly different from one another.  A trend was 
also observed in the time x diet x metabolic syndrome risk factor three-way interaction 
(p=0.06).  Post hoc analysis on insulin data expressed in delta changes from baseline 
revealed a significant increase in insulin for the HC-AH group (+1.9±9.4 uIU/mL) and a 
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decrease in the HC-MS group (-2.5±18.6 uIU/mL, p=0.017) though the decrease was not 
significantly different from baseline.   
Homeostatic Model Assessment was calculated and analyzed on the subset of 
252 participants for whom insulin measurements were obtained.  The three-way 
ANOVA revealed an overall time x diet x metabolic syndrome risk factor effect 
(p=0.027) and a trend for time x metabolic syndrome risk factor effect (p=0.06) for 
HOMA.  No overall time (p=0.85) or time x diet effect (p=0.33) was observed.  When 
analyzed by delta change from baseline, the MS group tended to experience a decrease 
in HOMA (-0.29±4.72) compared to an increase in the AH group (+0.33±2.0, p=0.06), 
however these values were not significantly different from baseline, nor were the ten-
week values significantly different from one another.  Post hoc analysis utilizing 
calculations on delta change from baseline demonstrate the HC-MS group was the only 
group to experience a significant change from baseline (-1.17±7.2, p=0.030), a 
significantly greater decrease in HOMA than HP-MS (+0.25±1.9, p=0.039) and HC-AH 
(+0.65±3.0, p=0.008).  Figures 4.15 and 4.16 depict the delta changes for the glucose 
homeostasis parameters over the ten-week period.  Based on these findings, hypothesis 
H7 is accepted, which indicated there would be statistically significant differences in the 
markers of glucose homeostasis as a result of diet intervention and/or the presence of 
metabolic syndrome risk status.     
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Figure 4.15: Delta Changes in Glucose Homeostasis Parameters, by Diet and Metabolic 
Syndrome Status 
 
 
Figure 4.16: Delta Changes in Glucose Homeostasis Parameters, by Group-
Combinations 
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Fitness Parameters  
Table 4.16 depicts the time x diet x metabolic syndrome risk factor analysis for 
fitness parameters including maximum strength and lift volume for both bench press and 
leg press, as well as peak VO2.  The bench press and leg press variables were analyzed 
together utilizing a three-way MANOVA using a subset of 596 participants, while peak 
VO2 was analyzed individually using a three-way ANOVA with the entire 663 
participants.  
The three-way MANOVA on strength and lift volume parameters revealed an 
overall time (Wilks’ Lambda p<0.001) effect.  No significant time x diet (Wilks’ 
Lambda p=0.39), time x metabolic syndrome risk factor (Wilks’ Lambda p=0.94), or 
time x diet x metabolic syndrome risk factor (Wilks’ Lambda p=0.26) interactions were 
observed.  Both bench press and leg press maximum strength demonstrated a significant 
time effect (p<0.001), with bench press demonstrating an overall increase of 2.15±4.99 
1RM/kg body weight (p<0.001), and leg press demonstrating an overall increase of 
15.2±28.6 1RM/kg body weight (p<0.001).  No strength or lift volume parameters 
experienced a diet or metabolic syndrome risk factor effect over time.  While none of the 
variables experienced a significant three-way interaction, bench press lift volume did 
reveal a trend towards a time x diet x metabolic syndrome risk factor effect (p=0.060).  
Review of the post hoc analysis based on calculated delta change from baseline revealed 
that both bench and leg press maximum strength experienced a significant change from 
baseline for all of the group-combinations, but no significant differences between group-
combinations. 
  
 
117 
Table 4.16: Fitness Parameters After Ten Weeks of Exercise and Dietary Intervention 
Based on Metabolic Syndrome Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Bench Press  HP-AH 31.0 ± 7.7 33.3g ± 7.7     T = 0.001 
Max Strength HP-MS 30.9 ± 7.5 32.5g ± 7.1     D = 0.28 
(1 RM / kg body HC-AH 29.2c ± 7.9 31.5c,g ± 8.1     M =  0.27 
weight) HC-MS 31.0 ± 7.6 33.3g ± 8.0       D x M = 0.07 
 HP 30.9 ± 7.6 32.9g ± 7.4 31.9 ± 0.4 T x D = 0.36 
 HC 29.9 ± 7.8 32.2g ± 8.1 31.3 ± 0.5 T x M = 0.48 
 AH 30.1 ± 7.9 32.5g ± 8.0 31.3 ± 0.4 T x D x M = 0.45  
 MS 30.9 ± 7.5 32.8g ± 7.4 31.9 ± 0.5  
 Time 30.5 ± 7.7 32.6* ± 7.7        
Bench Press HP-AH 174.7 ± 68.5 182.8 ± 74.4     T = 0.92 
Lift Volume HP-MS 186.5 ± 90.3 181.1 ± 87.3     D = 0.57 
(kg) HC-AH 177.8 ± 78.7 168.6 ± 77.0     M = 0.015 
 HC-MS 193.4 ± 92.6 198.4f ± 81.3       D x M = 0.12 
 HP 180.3 ± 79.7 182.0 ± 80.7 181.3 ± 3.7 T x D = 0.64 
 HC 183.8 ± 84.5 180.1 ± 79.9 184.5 ± 4.4 T x M = 0.97 
 AH 176.1 ± 73.3 176.1 ± 75.9 176.0 ± 3.7 T x D x M = 0.06  
 MS 189.1b ± 91.1 187.7b ± 85.3 189.9‡ ± 4.3  
 Time 181.8 ± 81.8 181.2 ± 80.3        
Leg Press  HP-AH 162.6 ± 46.2 177.9g ± 53.0     T = 0.001 
Max Strength HP-MS 165.8 ± 50.1 182.5g ± 51.6     D = 0.16 
(1 RM / kg body HC-AH 155.2 ± 54.3 169.9g ± 58.6     M = 0.17 
weight) HC-MS 163.4 ± 44.5 176.7g ± 49.3       D x M = 0.67 
 HP 164.1 ± 48.1 180.1g ± 52.3 172.2 ± 2.7 T x D = 0.42 
 HC 158.4 ± 50.8 172.5g ± 55.2 166.3 ± 3.2 T x M = 0.99 
 AH 159.1 ± 50.2 174.1g ± 55.7 166.4 ± 2.7 T x D x M = 0.59 
 MS 164.9 ± 48.0 180.3g ± 50.7 172.1 ± 3.2  
 Time 161.7 ± 49.3 176.8* ± 53.6        
Leg Press HP-AH 1782.7 ± 935.0 1889.6 ± 965.4     T = 0.19 
Lift Volume HP-MS 1864.7 ± 1004.8 1980.8 ± 1190.5     D = 0.004 
(kg) HC-AH 1639.6 ± 933.3 1593.7c ± 883.5     M = 0.18 
 HC-MS 1711.2 ± 744.2 1732.4d ± 928.0       D x M = 0.90 
 HP 1821.8 ± 968.3 1933.1g ± 1077.9 1879.5† ± 46.5 T x D = 0.10 
 HC 1667.3 ± 864.3 1647.4a ± 901.7 1669.2 ± 55.0 T x M = 0.61 
 AH 1715.6 ± 935.6 1751.0 ± 938.3 1726.4 ± 46.9 T x D x M = 0.70  
 MS 1806.5 ± 916.2 1886.6 ± 1103.1 1822.3 ± 54.7  
 Time 1755.4 ± 927.5 1810.3 ± 1015.1        
Peak VO2 HP-AH 20.7 ± 4.7 22.5g ± 4.7     T = 0.001 
(mL/kg/min) HP-MS 19.3c ± 4.2 21.3c,g ± 4.2     D = 0.024 
 HC-AH 20.8 ± 4.4 23.4g ± 4.8     M = 0.002 
 HC-MS 20.0 ± 3.8 22.6d,g ± 4.6       D x M = 0.49 
 HP 20.0 ± 4.5 21.9g ± 4.5 20.9† ± 0.22 T x D = 0.016 
 HC 20.5 ± 4.2 23.1a,g ± 4.7 21.7 ± 0.25 T x M = 0.80 
 AH 20.7 ± 4.6 22.9g ± 4.8 21.8 ± 0.21 T x D x M = 0.64  
 MS 19.6b ± 4.1 21.8b,g ± 4.4 20.8‡ ± 0.25  
 Time 20.2 ± 4.4 22.4* ± 4.6        
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = metabolic syndrome risk factor  
T = time effect, D = diet effect, M = metabolic syndrome risk factor effect, D x M = diet by metabolic syndrome risk factor effect, T x D = time by diet 
effect, T x M = time by metabolic syndrome risk factor effect, T x D x M = time by diet by metabolic syndrome risk factor effect.                                                                                                                                     
Strength values are means ± standard deviations (except group means are means ± standard error) from 189 participants in the HP-AH group, 182 in the 
HP-MS group, 169 in the HC-AH group, 123 in the HC-MS group, 371 in the HP total group, 292 in the HC total group, 358 in the AH group, 305 in 
the MS group, and 663 participants total.  Peak VO2 values are means ± standard deviations (except group means are means ± standard error) from 198 
participants in the HP-AH group, 173 in the HP-MS group, 179 in the HC-AH group, 113 in the HC-MS group, 371 in the HP total group, 292 in the 
HC total group, 377 in the AH group, 286 in the MS group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant metabolic syndrome effect, p 
< 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than AH group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-AH group, p < 0.05 (post hoc LSD).  d Significantly different than HP-MS group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-AH group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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The three-way ANOVA for peak VO2 revealed an overall time (p<0.001) and 
time x diet (p=0.016) effect.  No significant time x metabolic syndrome risk factor 
(p=0.80) or time x diet x metabolic syndrome risk factor (p=0.64) interactions were 
observed.  Overall, participants gained an average of 2.2±3.3 ml/kg/min (time effect, 
p<0.001) in aerobic capacity over the ten-week protocol.  The HC group experienced a 
significantly greater increase in peak aerobic capacity (HP +1.9±3.0, HC +2.6±3.7 
ml/kg/min, p=0.016).  No difference was seen overtime between the health status 
groups.  Post hoc analyses using calculated delta change from baseline revealed that the 
four group-combinations (HP-AH, HP-MS, HC-AH, and HC-MS) demonstrated 
significant increases from baseline (p<0.001 for each).  Additionally, the HC-AH group 
(+2.6±3.5 ml/kg/min) experienced a significantly greater increase in peak VO2 than the 
HP-AH group (+1.8±3.2 ml/kg/min, p=0.026).  Figures 4.17 and 4.18 depict the delta 
changes in peak VO2 over the ten-week period.  Due to the significant time x diet effect 
observed with peak aerobic capacity, hypothesis H8, which indicated there would not be 
statistically significant differences in fitness parameters as a result of diet intervention 
and/or the presence of metabolic syndrome risk status, must be rejected.    
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Figure 4.17: Delta Changes in Peak VO2, by Diet and Metabolic Syndrome Status 
 
 
Figure 4.18: Delta Changes in Peak VO2, by Group-Combination 
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Psychometric Analysis 
The variables related to quality of life are broken down into two tables of 
analysis, based on the questionnaire titles: SF36 - Quality of Life and Body Image.  The 
variables in each of these individual tables were collected in a questionnaire and run 
together in three-way MANOVAs. 
Table 4.17 depicts the time x diet x metabolic syndrome risk factor analysis for 
SF36 – Quality of Life.  The SF36 data was measured on a subset of 259 participants.  
The variables measured include physical function, role physical, bodily pain, general 
health, vital, social, role emotional, and mental health.  The three-way MANOVA 
revealed an overall time effect (Wilks’ Lambda p<0.001), but no overall significant time 
x diet (Wilks’ Lambda p=0.14), time x metabolic syndrome risk factor (Wilks’ Lambda 
p=0.35), or time x diet x metabolic syndrome risk factor (Wilks’ Lambda p=0.44) 
effects.    
Individual variables measured that experienced a time effect (including the 
overall effect and significance) include physical fitness (+6.0±22.6, p<0.001), bodily 
pain (+2.8±17.2, p=0.010), general health (+3.9±11.9, p<0.001), vital (+6.6±14.8, 
p<0.001), social (+2.7±17.3, p=0.017), and mental health (+8.0±15.0, p<0.001).  The 
higher protein group tended to experience a greater increase in the social aspect over 
time than the higher carbohydrate group (HP +4.4±15.5, HC +0.8±19.0, p=0.089).  The 
apparently healthy group tended to experience an increase in the role physical aspect 
while the MS group experienced a decrease, though neither group experienced a 
significantly change from baseline (AH +10.3±72.3, MS -4.3±62.9, p=0.09).     
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Table 4.17: Changes in SF36 - Quality of Life Inventory Values After Ten Weeks of 
Exercise and Dietary Intervention Based on Metabolic Syndrome Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Physical  HP-AH 79.0 ± 31.1 86.1g ± 27.4     T = 0.001 
Functioning HP-MS 71.5 ± 27.6 75.3c ± 19.6     D = 0.57 
 HC-AH 77.6 ± 23.8 82.9g ± 21.7     M = 0.036 
 HC-MS 74.6 ± 17.1 82.7g ± 18.1       D x M = 0.14 
 HP 75.7 ± 29.7 81.3g ± 24.7 78.0 ± 1.75 T x D = 0.64 
 HC 76.4 ± 21.2 82.8g ± 20.2 79.4 ± 1.86 T x M = 0.93 
 AH 78.3 ± 27.7 84.5g ± 24.8 81.4 ± 1.68 T x D x M = 0.24  
 MS 72.9 ± 23.3 78.7b,g ± 19.2 76.0‡ ± 1.93  
 Time 76.0 ± 26.0 82.0* ± 22.7        
Role Physical HP-AH 162.3 ± 140.9 176.7 ± 156.9     T = 0.44 
 HP-MS 117.3c ± 129.9 109.1c ± 127.7     D = 0.001 
 HC-AH 250.2c ± 144.1 256.2c ± 146.8     M = 0.06 
 HC-MS 246.4d ± 141.0 246.8d ± 148.6       D x M = 0.13 
 HP 142.2 ± 137.5 146.4 ± 148.0 141.3† ± 11.30 T x D = 0.99 
 HC 248.6a ± 142.3 252.3a ± 147.1 249.9 ± 12.01 T x M = 0.09 
 AH 205.2 ± 148.7 215.5 ± 156.8 211.4 ± 10.82 T x D x M = 0.30  
 MS 176.2 ± 149.2 171.9b ± 153.4 179.9 ± 12.44  
 Time 192.6 ± 149.4 196.6 ± 156.5        
Bodily Pain HP-AH 59.9 ± 19.1 63.8g ± 20.5     T = 0.010 
 HP-MS 58.1 ± 18.9 62.3g ± 21.1     D = 0.48 
 HC-AH 61.9 ± 21.8 63.7 ± 20.8     M = 0.65 
 HC-MS 62.1 ± 21.1 62.8 ± 22.9       D x M = 0.78 
 HP 59.1 ± 19.0 63.1g ± 20.7 61.0 ± 1.54 T x D = 0.16 
 HC 62.0 ± 21.4 63.3 ± 21.6 62.6 ± 1.64 T x M = 0.85 
 AH 60.9 ± 20.4 63.8g ± 20.6 62.3 ± 1.47 T x D x M = 0.76  
 MS 59.9 ± 19.9 62.5 ± 21.9 61.3 ± 1.69  
 Time 60.5 ± 20.2 63.2* ± 21.1        
General Health HP-AH 53.5 ± 28.0 59.1g ± 28.5     T = 0.001 
 HP-MS 46.5 ± 29.1 49.5c,g ± 28.1     D = 0.001 
 HC-AH 66.5c ± 21.8 69.7c,g ± 21.2     M = 0.054 
 HC-MS 63.2d ± 23.2 66.5d,g ± 23.5       D x M = 0.40 
 HP 50.4 ± 28.6 54.8g ± 28.6 52.1† ± 2.04 T x D = 0.48 
 HC 65.1a ± 22.3 68.4a,g ± 22.1 66.5 ± 2.17 T x M = 0.38 
 AH 59.8 ± 25.9 64.3g ± 25.7 62.2 ± 1.95 T x D x M = 0.35  
 MS 54.1 ± 27.7 57.3b,g ± 27.4 56.4‡ ± 2.24  
 Time 57.3 ± 26.8 61.2* ± 26.6        
Vital HP-AH 39.6 ± 21.8 48.7g ± 27.5     T = 0.001 
 HP-MS 43.3 ± 64.7 49.7g ± 64.4     D = 0.08 
 HC-AH 51.3 ± 17.7 55.5g ± 16.7     M = 0.89 
 HC-MS 49.0 ± 19.6 55.6g ± 21.0       D x M = 0.69 
 HP 41.3 ± 46.1 49.1g ± 47.5 45.3 ± 2.91 T x D = 0.18 
 HC 50.4a ± 18.5 55.5g ± 18.6 52.9 ± 3.09 T x M = 0.93 
 AH 45.3 ± 20.7 52.0g ± 23.1 48.8 ± 2.78 T x D x M = 0.15  
 MS 45.9 ± 49.4 52.4g ± 49.5 49.4 ± 3.20  
 Time 45.6 ± 36.0 52.2* ± 36.8        
 
 
 
 
  
 
122 
Table 4.17: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Social 
Functioning 
HP-AH 48.4 ± 26.0 54.8g ± 26.6 
 
  
T = 0.017 
HP-MS 43.6 ± 25.4 45.6c ± 26.2 D = 0.001 
HC-AH 58.4c ± 24.0 59.9 ± 22.7 M = 0.31 
HC-MS 60.4d ± 26.3 60.4d ± 27.0 D x M = 0.15 
HP 46.2 ± 25.7 50.7g ± 26.7 48.1† ± 1.95 T x D = 0.09 
HC 59.3a ± 24.9 60.1a ± 24.5 59.8 ± 2.08 T x M = 0.15 
AH 53.3 ± 25.5 57.3g ± 24.8 55.4 ± 1.87 T x D x M = 0.49  
MS 51.3 ± 27.0 52.3 ± 27.5 52.5 ± 2.15  
  Time 52.4 ± 26.1 55.2* ± 26.1   
Role Emotional HP-AH 227.9 ± 127.3 255.0 ± 143.5 
 
  
T = 0.44 
HP-MS 206.4 ± 130.4 218.3 ± 135.3 D = 0.001 
HC-AH 303.3c ± 227.6 281.8 ± 136.2 M = 0.42 
HC-MS 292.0d ± 121.8 300.0d ± 131.0 D x M = 0.31 
HP 218.3 ± 128.7 238.6 ± 140.6 226.9† ± 10.85 T x D = 0.11 
HC 298.6a ± 190.3 289.4a ± 133.9 294.3 ± 11.52 T x M = 0.66 
AH 264.7 ± 186.5 268.0 ± 140.2 267.0 ± 10.39 T x D x M = 0.17  
MS 245.4 ± 133.1 255.6 ± 138.9 254.2 ± 11.94  
  Time 256.3 ± 165.6 262.7 ± 139.6   
Mental Health 
 
HP-AH 57.9 ± 15.4 67.3g ± 15.3 
 
  
T = 0.001 
HP-MS 54.9 ± 15.6 62.4c,g ± 15.1 D = 0.86 
HC-AH 61.6 ± 14.6 66.5g ± 12.6 M = 0.38 
HC-MS 58.3 ± 13.9 69.2d,g ± 11.4 D x M = 0.99 
HP 56.5 ± 15.5 65.1g ± 15.3 60.6 ± 1.01 T x D = 0.86 
HC 60.3a ± 14.4 67.6g ± 12.1 63.9 ± 1.07 T x M =  0.49 
AH 59.7 ± 15.1 66.9g ± 14.0 63.3 ± 0.96 T x D x M = 0.70 
MS 56.4 ± 14.9 65.5g ± 13.9 61.2 ± 1.11  
  Time 58.3 ± 15.1 66.3* ± 13.9   
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = metabolic syndrome risk factor, T = time effect, D = diet effect, M = 
metabolic syndrome risk factor effect, D x M = diet by metabolic syndrome risk factor effect, T x D = time by diet effect, T x M = time by metabolic 
syndrome risk factor effect, T x D x M = time by diet by metabolic syndrome risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 83 participants in the HP-AH group, 69 in the HP-MS 
group, 77 in the HC-AH group, 60 in the HC-MS group, 152 in the HP total group, 137 in the HC total group, 160 in the AH group, 129 in the MS 
group, and 289 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant metabolic syndrome effect, 
p < 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than AH group, p < 0.05 (post hoc 
LSD).  c Significantly different than HP-AH group, p < 0.05 (post hoc LSD).  d Significantly different than HP-MS group, p < 0.05 (post hoc LSD).   
g Significantly different than baseline, p <0.05 (post hoc LSD). 
 
 
 
The mental health aspect was the only variable to experience a significant time x diet x 
metabolic syndrome risk factor effect (p=0.028).  Post hoc analysis on mental health data 
expressed in delta changes from baseline revealed the HC-AH group had the least 
significant increase (+4.9±12.5, p=0.051) compared to all of the other group-
combinations.  
Table 4.18 depicts the time x diet x metabolic syndrome risk factor analysis 
pertaining to the  Body Image Questionnaire.  Body Image data was collected on a 
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subset of 451 participants.  The variables measured include appearance evaluation, 
appearance orientation, body area satisfaction, overweight preoccupation, self-classified 
weight, Rosenberg self esteem, and social physique anxiety.  The three-way MANOVA 
revealed an overall time effect (Wilks’ Lambda p<0.001), but no overall significant time 
x diet (Wilks’ Lambda p=0.62), time x metabolic syndrome risk factor (Wilks’ Lambda 
p=0.40), or time x diet x metabolic syndrome risk factor (Wilks’ Lambda p=0.36) 
effects.    
Individual variables measured that experienced a time effect (including the 
overall effect and significance) include appearance evaluation (+0.4±0.6, p<0.001), body 
area satisfaction (+0.3±0.4, p<0.001), overweight preoccupation (+0.5±0.7, p<0.001), 
self-classified weight (-0.1±0.8, p=0.007), and Rosenberg self esteem (+0.4±3.3, 
p=0.005).  No Body Image variables experienced a diet effect over time.  The metabolic 
syndrome group experienced a tendency for a greater decrease for self-classified weight 
over the ten-week protocol (AH -0.03±0.8, MS -0.2±0.8, p=0.089).   The only variable 
to experience a significant time x diet x metabolic syndrome risk factor interaction was 
body area satisfaction (p=0.044).  Post hoc analysis using delta calculations revealed a 
significant increase from baseline in body area satisfaction for all four group-
combinations, and found HC-AH to have a significantly greater increase (+0.34±0.48) in 
body area satisfaction than all other group-combinations (p=0.037).  
 
 
  
  
 
124 
Table 4.18: Changes in Body Image Evaluation After Ten Weeks of Exercise and 
Dietary Intervention Based on Metabolic Syndrome Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Appearance 
Evaluation 
HP-AH 2.4 ± 0.7 2.8g ± 0.7 
 
  
T = 0.001 
HP-MS 2.4 ± 0.6 2.7g ± 0.6 D = 0.57 
HC-AH 2.5 ± 0.7 2.8g ± 0.7 M = 0.29 
HC-MS 2.4 ± 0.6 2.7g ± 0.7 D x M = 0.53 
HP 2.4 ± 0.6 2.7g ± 0.7 2.6 ± 0.04 T x D = 0.53 
HC 2.4 ± 0.6 2.8g ± 0.7 2.6 ± 0.04 T x M = 0.51 
AH 2.4 ± 0.7 2.8g ± 0.7 2.6 ± 0.04 T x D x M = 0.57 
MS 2.4 ± 0.6 2.7g ± 0.6 2.6 ± 0.04  
  Time 2.4 ± 0.6 2.8* ± 0.7   
Appearance 
Orientation 
HP-AH 4.1 ± 0.8 4.1 ± 0.9 
 
  
T = 0.32 
HP-MS 4.1 ± 0.9 4.1 ± 0.9 D = 0.008 
HC-AH 4.0 ± 0.8 3.9 ± 0.9 M = 0.58 
HC-MS 3.9d ± 0.8 3.8d ± 0.8 D x M = 0.34 
HP 4.1 ± 0.9 4.1 ± 0.9 4.1† ± 0.05 T x D = 0.53 
HC 3.9a ± 0.8 3.9a ± 0.9 3.9 ± 0.06 T x M = 0.48 
AH 4.1 ± 0.8 4.0 ± 0.9 4.0 ± 0.05 T x D x M = 0.53 
MS 4.0 ± 0.9 4.0 ± 0.9 4.0 ± 0.06  
  Time 4.1 ± 0.8 4.0 ± 0.9   
Body Area HP-AH 2.1 ± 0.7 2.3g ± 0.8     T = 0.001 
Satisfaction HP-MS 1.9c ± 0.8 2.2g ± 0.9     D = 0.002 
 HC-AH 2.3 ± 0.7 2.6c,g ± 0.8     M = 0.046 
 HC-MS 2.2d ± 0.7 2.5g ± 0.8       D x M = 0.73 
 HP 2.0 ± 0.8 2.3g ± 0.8 2.1† ± 0.05 T x D = 0.32 
 HC 2.2a ± 0.7 2.5a,g ± 0.8 2.4 ± 0.06 T x M = 0.49 
 AH 2.2 ± 0.7 2.5g ± 0.8 2.3 ± 0.05 T x D x M = 0.044 
 MS 2.0b ± 0.7 2.3g ± 0.9 2.2‡ ± 0.06  
 Time 2.1 ± 0.7 2.4* ± 0.8        
Overweight HP-AH 2.8 ± 0.8 3.4g ± 0.7     T = 0.001 
Preoccupation HP-MS 2.9 ± 0.6 3.4g ± 0.7     D = 0.16 
 HC-AH 2.9 ± 0.8 3.4g ± 0.7     M = 0.37 
 HC-MS 2.8 ± 0.7 3.2d,f,g ± 0.7       D x M = 0.047 
 HP 2.9 ± 0.7 3.4g ± 0.7 3.1 ± 0.04 T x D = 0.11 
 HC 2.9 ± 0.7 3.3a,g ± 0.7 3.1 ± 0.05 T x M = 0.77 
 AH 2.9 ± 0.8 3.4g ± 0.7 3.1 ± 0.04 T x D x M = 0.46  
 MS 2.8 ± 0.6 3.3g ± 0.7 3.1 ± 0.05  
 Time 2.9 ± 0.7 3.3* ± 0.7        
Self-Classified HP-AH 4.2 ± 0.8 4.2 ± 0.6     T = 0.007 
Weight HP-MS 4.3 ± 0.7 4.1g ± 0.7     D = 0.11 
 HC-AH 4.1 ± 0.7 4.0c ± 0.7     M = 0.16 
 HC-MS 4.3 ± 0.7 4.1 ± 0.8       D x M = 0.38 
 HP 4.2 ± 0.7 4.2 ± 0.7 4.2 ± 0.04 T x D = 0.62 
 HC 4.2 ± 0.7 4.0g ± 0.7 4.1 ± 0.04 T x M = 0.09 
 AH 4.1 ± 0.7 4.1 ± 0.6 4.1 ± 0.04 T x D x M = 0.30 
 MS 4.3b ± 0.7 4.1g ± 0.7 4.2 ± 0.04  
 Time 4.2 ± 0.7 4.1* ± 0.7        
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Table 4.18: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Rosenberg HP-AH 25.9 ± 3.9 26.3 ± 3.9     T = 0.005 
Self Esteem HP-MS 25.5 ± 4.0 26.3g ± 3.8     D = 0.55 
 HC-AH 25.8 ± 4.0 25.9 ± 3.8     M = 0.62 
 HC-MS 25.5 ± 3.9 26.0 ± 4.3       D x M = 0.93 
 HP 25.7 ± 3.9 26.3g ± 3.8 26.0 ± 0.22 T x D = 0.26 
 HC 25.7 ± 3.9 25.9 ± 4.0 25.8 ± 0.26 T x M = 0.22 
 AH 25.9 ± 4.0 26.1 ± 3.9 26.0 ± 0.22 T x D x M = 0.90  
 MS 25.5 ± 3.9 26.2g ± 4.0 25.8 ± 0.27  
 Time 25.7 ± 3.9 26.2* ± 3.9        
Social Physique HP-AH 31.1 ± 6.4 31.1 ± 6.6     T = 0.60 
Anxiety HP-MS 31.4 ± 6.1 31.7 ± 5.8     D = 0.86 
 HC-AH 31.1 ± 6.2 31.0 ± 5.1     M = 0.38 
 HC-MS 31.2 ± 5.6 31.8 ± 7.5       D x M = 0.99 
 HP 31.3 ± 6.3 31.4 ± 6.2 31.3 ± 0.32 T x D = 0.86 
 HC 31.1 ± 6.0 31.3 ± 6.1 31.2 ± 0.38 T x M = 0.49 
 AH 31.1 ± 6.3 31.0 ± 6.0 31.1 ± 0.32 T x D x M = 0.70  
 MS 31.3 ± 5.9 31.7 ± 6.5 31.5 ± 0.38  
 Time 31.2 ± 6.1 31.3 ± 6.2        
HP = higher protein, HC = higher carbohydrate, AH = apparently healthy, MS = metabolic syndrome risk factor, T = time effect, D = diet 
effect, M = metabolic syndrome risk factor effect, D x M = diet by metabolic syndrome risk factor effect, T x D = time by diet effect, T x M = 
time by metabolic syndrome risk factor effect, T x D x M = time by diet by metabolic syndrome risk factor effect.      Values are means ± 
standard deviations (except group means are means ± standard error) from 139 participants in the HP-AH group, 117 in the HP-MS group, 117 
in the HC-AH group, 78 in the HC-MS group, 256 in the HP total group, 195 in the HC total group, 256 in the AH group, 195 in the MS group, 
and 451 participants total.    
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant metabolic syndrome 
effect, p < 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than AH group, p < 0.05 
(post hoc LSD).  c Significantly different than HP-AH group, p < 0.05 (post hoc LSD).  d Significantly different than HP-MS group, p < 0.05 
(post hoc LSD).  f Significantly different than HC-AH group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc 
LSD). 
 
 
 
Based on the MANOVA univariate tests, revealing a significant time x diet x 
metabolic syndrome risk factor interaction for mental health (SF36), and body area 
satisfaction (Body Image), hypothesis H9, which stated there would be no significant 
differences observed in psychometric parameters as a result of diet intervention and/or 
the presence of the metabolic syndrome health status, is rejected. 
CHANGES IN METABOLIC SYNDROME STATUS 
 Table 4.19 depicts the N-sizes and percentages of participants who were 
identified with each metabolic syndrome risk factor both at baseline and at the end of the 
ten-week protocol.  By the end of the study, the prevalence of each risk factor for the 
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entire study population changed as follows: waist circumference -13%, glucose -4.2%, 
HDL +8.9%, blood pressure -7%, and triglycerides -4.4%.   
Table 4.20 depicts the number of risk factors experienced by each participant 
both at baseline and the end of the ten-week protocol.  Overall, the prevalence of 
metabolic syndrome for the study population dropped from 43% to 38%, a decrease of 
5.6% of the population.   
 
Table 4.19: Baseline and Ten-Week Frequencies per Metabolic Syndrome Risk Factor 
 
Risk Factor Baseline 10 Weeks HP HC TTL HP HC TTL 
Waist Circumference 316 
(85%) 
215 
(74%) 
531 
(80%) 
269 
(73%) 
-12% 
176 
(60%) 
-14% 
445  
(67%) 
-13% 
Glucose 157 
(42%) 
116 
(40%) 
273 
(41%) 
140 
(38%) 
-4% 
105 
(36%) 
-4% 
245 
(37%) 
-4% 
HDL Cholesterol 151 
(41%) 
112 
(38%) 
263 
(40%) 
188 
(51%) 
+10% 
134 
(46%) 
+8% 
322 
(49%) 
+9% 
Blood Pressure 148 
(40%) 
96 
(33%) 
244 
(37%) 
121 
(33%) 
-7% 
75 
(26%) 
-7% 
196 
(30%) 
-7% 
Triglycerides 124 
(33%) 
96 
(33%) 
220 
(33%) 
109 
(29%) 
-4% 
82 
(28%) 
-4% 
191 
(29%) 
-4% 
HP = higher protein; HC = higher carbohydrate; TTL = total n-size.  Percentages are based 
on the n-size for HP (n=371), HC (n=292), and total (n=663) 
 
 
Table 4.20: Ten-Week Changes in the Number of Risk Factors per Diet Group 
 
Number 
of Risk 
Factors 
Baseline 10 Weeks 
HP HC Total HP HC Total 
0 18 26 44 Apparently 
Healthy 
57% 
38 43 81 Apparently 
Healthy 
62% 
1 69 61 130 66 66 132 
2 111 92 203 119 82 201 
3 105 68 173 Metabolic 
Syndrome 
43% 
83 68 151 Metabolic 
Syndrome 
38% 
4 50 39 89 51 27 78 
5 18 6 24 14 6 20 
HC, higher carbohydrate; HP, higher protein, N-size for HP (n=371), HC (n=292), and total (n=663) 
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ANALYSIS OF INDIVIDUAL METABOLIC SYNDROME RISK FACTORS 
 In addition to the retrospective stratification of participants based on metabolic 
syndrome status, the study population was also retrospectively stratified based on each 
metabolic syndrome risk factor individually.  Groups classified as having the individual 
metabolic syndrome risk factor included high waist circumference, high triglycerides, 
low HDL cholesterol, high blood pressure, and high fasting glucose.  Each of the five 
risk factor stratifications were analyzed independently with diet composition (higher 
protein versus higher carbohydrate consumption) in order to differentiate the beneficial 
effects of diet on each risk factor individually.   
ANALYSIS OF WAIST CIRCUMFERENCE AS A RISK FACTOR 
 The metabolic syndrome waist circumference risk factor for women has been 
defined as a waist circumference value greater than 88 cm.  Participants have been 
identified as either low waist circumference (LWC; ≤88 cm, N=132), or high waist 
circumference (HWC; >88 cm, N=531).   
Energy Intake 
 Table 4.21 depicts the time x diet x waist circumference risk factor MANOVA 
for total energy intake in kcals/kg/day as well as macronutrient intake in g/kg/day.  The 
three-way MANOVA revealed overall time (Wilks’ Lambda p<0.001), time x diet 
(Wilks’ Lambda p<0.001), time x waist circumference risk factor (Wilks’ Lambda 
p=0.002), and time x diet x waist circumference risk factor (Wilks’ Lambda p=0.045) 
effects.  Post hoc analysis on the ten-week values was utilized to determine the 
following:  
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Table 4.21: Dietary Intake Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Waist Circumference Risk Factor Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Energy Intake  HP-LWC 22.6 ± 6.0 20.2g ± 5.2    T = 0.001 
(kcal/kg/day) HP-HWC 20.0c ± 5.6 15.2cg ± 4.8    D = 0.53 
 HC-LWC 22.0 ± 5.1 19.8g ± 5.1    WC = 0.001 
 HC-HWC 20.7 ± 7.0 16.5dfg ± 4.3    D x WC = 0.08 
 HP 20.4 ± 5.8 15.9g ± 5.2 19.5 ± 0.3 T x D = 0.47 
 HC 21.0 ± 6.6 17.4g ± 4.7 19.8 ± 0.3 T x WC = 0.001 
 LWC 22.3 ± 5.5 19.9g ± 5.1 21.2 ± 0.4 T x D x WC = 0.69 
 HWC 20.3b ± 6.2 15.7bg ± 4.6 18.1‡ ± 0.2  
 Time 20.7 ± 6.1 16.6* ± 5.0     
Protein Intake HP-LWC 0.95 ± 0.2 1.46g ± 0.6    T = 0.001 
(g/kg/day) HP-HWC 0.81c ± 0.2 1.09cg ± 0.5    D = 0.001 
 HC-LWC 0.88 ± 0.2 0.85c ± 0.2    WC = 0.001 
 HC-HWC 0.81f ± 0.2 0.76d ± 0.3    D x WC = 0.001 
 HP 0.83 ± 0.2 1.14g ± 0.5 1.08† ± 0.0 T x D = 0.001 
 HC 0.83 ± 0.2 0.78a ± 0.3 0.83 ± 0.0 T x WC = 0.003 
 LWC 0.91 ± 0.2 1.10g ± 0.5 1.04 ± 0.0 T x D x WC = 0.009 
 HWC 0.81b ± 0.2 0.95bg ± 0.4 0.87‡ ± 0.0  
 Time 0.83 ± 0.2 0.98* ± 0.4     
Carbohydrate HP-LWC 2.65 ± 0.9 1.80g ± 0.8    T = 0.001 
Intake (g/kg/day) HP-HWC 2.36c ± 0.9 1.35cg ± 0.6    D = 0.001 
 HC-LWC 2.66 ± 0.8 2.59c ± 0.8    WC = 0.001 
 HC-HWC 2.47 ± 1.0 2.07dfg ± 0.6    D x WC = 0.88 
 HP 2.40 ± 0.9 1.41g ± 0.7 2.04† ± 0.0 T x D = 0.001 
 HC 2.52 ± 0.9 2.20ag ± 0.7 2.45 ± 0.0 T x WC = 0.008 
 LWC 2.66 ± 0.8 2.26g ± 0.9 2.43 ± 0.1 T x D x WC = 0.35 
 HWC 2.40b ± 0.9 1.64bg ± 0.7 2.06‡ ± 0.0  
 Time 2.46 ± 0.9 1.76* ± 0.8     
Fat Intake HP-LWC 0.91 ± 0.3 0.79g ± 0.3    T = 0.001 
(g/kg/day) HP-HWC 0.82c ± 0.3 0.60cg ± 0.3    D = 0.048 
 HC-LWC 0.87 ± 0.2 0.67cg ± 0.2    WC = 0.001 
 HC-HWC 0.84 ± 0.4 0.58fg ± 0.2    D x WC = 0.044 
 HP 0.83 ± 0.3 0.63g ± 0.3 0.78† ± 0.0 T x D = 0.057 
 HC 0.85 ± 0.3 0.60ag ± 0.2 0.74 ± 0.0 T x WC = 0.028 
 LWC 0.89 ± 0.3 0.72g ± 0.3 0.81 ± 0.0 T x D x WC = 0.55 
 HWC 0.83b ± 0.3 0.59bg ± 0.2 0.71‡ ± 0.0  
 Time 0.84 ± 0.3 0.62* ± 0.2     
HP = higher protein, HC = higher carbohydrate, LWC = low waist circumference, HWC = high waist circumference, T = time effect, D = diet effect, 
WC = waist circumference risk factor effect, D x WC = diet by waist circumference risk factor effect, T x D = time by diet effect, T x WC = time by 
waist circumference risk factor effect, T x D x WC = time by diet by waist circumference risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 55 participants in the HP-LWC group, 316 in the HP-
HWC group, 77 in the HC-LWC group, 215 in the HC-HWC group, 371 in the HP total group, 292 in the HC total group, 132 in the LWC group, 531 
in the HWC group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant waist circumference effect, p 
< 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LWC group, p < 0.05 (post hoc 
LSD).  c Significantly different than HP-LWC group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HWC group, p < 0.05 (post hoc LSD).  
f Significantly different than HC-LWC group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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While there was no significant difference between the diet groups for energy intake, 
participants in the LWC group consumed significantly more calories relative to body 
weight (LWC 19.9±5.1, HWC 15.7±5.1 kcal/kg/d, p<0.001).  Further review of the 
individual group-combinations revealed HP-LWC consumed significantly more calories 
than HP-HWC (p=0.004), HC-LWC consumed significantly more calories than HC-
HWC (p<0.001), and HC-HWC consumed significantly more calories than HP-HWC 
(p=0.001).  Participants in the HP group and the LWC group consumed significantly 
more protein relative to body weight (HP 1.14±0.5, HC 0.78±0.3 g/kg/d, p<0.001) 
(LWC 1.10±0.5, HWC 0.95±0.4 g/kg/d, p<0.001).  Specifically, the HP-LWC group 
consumed significantly more protein than HP-HWC (p<0.001) and HC-LWC (p<0.001), 
and HP-HWC consumed significantly more protein than HC-HWC (p<0.001).  The HC 
group and the LWC group consumed significantly more carbohydrate relative to body 
weight (HP 1.41±0.7, HC 2.20±0.7 g/kg/d, p<0.001), (LWC 2.26±0.9, HWC 1.64±0.7 
g/kg/d, p<0.001).  All group-combinations were significantly different from one another, 
with the HC-LWC group consuming the greatest amount of carbohydrate (p<0.001).  
Finally, the HP group and the LWC group consumed significantly more fat relative to 
body weight (HP 0.63±0.3, HC 0.60±0.2 g/kg/d, p=0.002), (LWC 0.72±0.3, HWC 
0.59±0.2 g/kg/d, p<0.001), with the HP-LWC group consuming a significantly greater 
amount than HP-HWC (p<0.001) and HC-LWC (p=0.003), and HC-LWC consuming a 
significantly greater amount than HC-HWC (p=0.005).    
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Overall Analysis 
Table 4.22 represents the Greenhouse-Geisser univariate and (when applicable) 
Wilks’ Lambda multivariate p-levels for each of the variables and groups measured and 
analyzed by the combined diet and waist circumference risk factor interactions (time, 
diet, waist circumference risk factor, time x diet, time x waist circumference risk factor, 
diet x waist circumference risk factor, and time x diet x waist circumference risk factor).  
The significant findings per variable are discussed below.  When a significant three-way 
interaction was observed, the significant group differences revealed in the post hoc LSD 
pairwise comparisons analysis are also indicated.  Each corresponding hypothesis is also 
evaluated. 
Body Composition 
A three-way MANOVA on DEXA variables revealed an overall time (Wilks’ 
Lambda p<0.001) and a trend in time x diet effect (Wilks’ Lambda p=0.063).  Analysis 
of MANOVA univariate tests revealed a greater decrease with the higher protein diet for 
scanned mass (HP -3.9±3.5, HC -3.0±3.5 kg, p=0.032), fat mass (HP -3.1±2.7, HC -
2.4±2.8 kg, p=0.007), and body fat percentage (HP -1.6±1.9, HC -1.4±2.0%, p=0.010).  
A significant time x waist circumference risk factor interaction (Wilks’ Lambda 
p=0.006) showed a greater decrease in the high waist circumference group for both 
scanned mass (LWC -2.6±3.5, HWC -3.7±3.5 kg, p=0.003) and fat mass (LWC -
2.1±2.5, HWC -3.0±2.8 kg, p=0.006).  Additionally a time x diet x waist circumference 
risk factor trend (Wilks’ Lambda p=0.078) was observed, and the MANOVA univariate 
test for body fat showed significance (p=0.015).  
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Table 4.22: Significance Levels for Waist Circumference Risk Factor Analysis per Variable 
 
  Multivariate and Univariate P-Values Post Hoc Significance 
  T D T*D WC T*WC D*WC 
T*D*
WC 
HP-
LWC 
HP-
HWC 
HC-
LWC 
HC-
HWC HP HC LWC HWC 
Body Composition 0.001   0.063   0.006   0.078                 
Scanned Mass 0.001 0.105 0.032 0.001 0.003 0.018 0.82 g c,g g d,f,g g g b, g g 
Fat Mass 0.001 0.21 0.007 0.001 0.006 0.006 0.434 g c,g g d,f,g g g b, g g 
Lean Mass 0.001 0.035 0.98 0.001 0.16 0.19 0.14 
 
c,g g d,f,g g a,g b, g g 
Body Fat 0.001 0.43 0.010 0.001 0.78 0.007 0.015 g c,g c,g d,f,g g g b, g g 
Weight 0.001 0.12 0.004 0.001 0.001 0.020 0.60 g c,g g d,f,g g g b,g g 
Body Mass Index 0.001 0.042 0.004 0.001 0.001 0.034 0.61 g c,g g d,f,g g g b,g g 
Waist Circumference 0.001 0.045 0.27 0.001 0.001 0.053 0.62 
 
c,g 
 
f,g g a,g b,g g 
Hip Circumference 0.001 0.25 0.12 0.001 0.15 0.029 0.234 g c,g g d,f,g g g b,g g 
Resting Energy Expenditure 0.001 0.23 0.35 0.001 0.44 0.046 0.97 g c,g g d,f,g g g b,g g 
Hemodynamic  0.001   0.78   0.035   0.77                 
Resting Heart Rate 0.001 0.98 0.45 0.35 0.005 0.21 0.30 
 
g 
 
g g g 
 
g 
Systolic Blood Pressure 0.001 0.14 0.67 0.001 0.62 0.28 0.81 
 
g g f,g g g b,g g 
Diastolic Blood Pressure 0.001 0.011 0.46 0.001 0.55 0.88 0.80   c,g g d,f,g g a,g b,g g 
Blood Lipids 0.001   0.70   0.30   0.83                 
Total Cholesterol 0.001 0.27 0.35 0.62 0.25 0.021 0.77 g g g g g g g g 
LDL Cholesterol 0.001 0.33 0.45 0.57 0.14 0.009 0.69 g g g f,g g g g g 
HDL Cholesterol 0.001 0.76 0.88 0.001 0.98 0.88 0.87 g c,g g f,g g g b,g g 
Triglycerides 0.008 0.62 0.11 0.005 0.36 0.63 0.92  g  f g  b g 
TC/HDL Ratio 0.38 0.66 0.50 0.001 0.14 0.150 0.89       f,g     b g 
Glucose 0.09 0.36 0.18 0.022 0.51 0.46 0.20  g   g  b g 
Insulin 0.20 0.035 0.80 0.94 0.023 0.12 0.28   g d   g   
HOMA  0.36 0.055 0.71 0.95 0.031 0.08 0.23       d         
Maximum Strength 0.001   0.91   0.34   0.67                 
Bench Press Max Strength 0.001 0.17 0.74 0.06 0.91 0.46 0.61 g g g f,g g g g g 
Bench Press Lift Volume 0.51 0.91 0.58 0.040 0.18 0.78 0.86          
Leg Press Max Strength 0.001 0.78 0.72 0.001 0.32 0.52 0.22 g c,g g f,g g g b,g g 
Leg Press Lift Volume 0.96 0.102 0.46 0.001 0.23 0.63 0.50  c,g  d,f   b   
 Peak VO2 0.001 0.74 0.001 0.001 0.095 0.12 0.044 g c,g g d,f,g g g b,g g 
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Table 4.22: Continued 
  Multivariate and Univariate P-Values Post Hoc Significance 
  T D  T*D WC T*WC D*WC 
T*D*
WC 
HP-
LWC 
HP-
HWC 
HC-
LWC 
HC-
HWC HP HC LWC HWC 
SF36 Questionnaire 0.001   0.67   0.91   0.80                 
Physical Function 0.001 0.701 0.90 0.095 0.65 0.35 0.91 
 
g g g g g g g 
Role Physical 0.63 0.001 0.82 0.85 0.44 0.045 0.60 
   
d 
 
a 
 
  
Bodily Pain 0.006 0.76 0.22 0.31 0.28 0.82 0.93 
 
g 
  
g 
 
g   
General Health 0.001 0.010 0.48 0.020 0.92 0.044 0.96 g c,g 
 
d,g g a,g b,g g 
Vital 0.001 0.19 0.48 0.63 0.72 0.79 0.31 
 
g g g g g g g 
Social 0.102 0.08 0.23 0.24 0.37 0.009 0.81 
 
c,g 
 
d 
   
g 
Role Emotional 0.47 0.003 0.28 0.09 0.55 0.17 0.33 
   
d 
 
a 
 
  
Mental Health 0.001 0.20 0.94 0.025 0.83 0.78 0.30 g g g g g g b,g g 
Body Image Questionnaire 0.001   0.95   0.26   0.49                 
Appearance Evaluation 0.001 0.27 0.42 0.001 0.004 0.037 0.13 g c,g c,g g g g b,g g 
Appearance Orientation 0.16 0.24 0.90 0.20 0.56 0.25 0.43 
   
d 
   
  
Body Area Satisfaction Scale 0.001 0.23 0.68 0.001 0.29 0.09 0.38 g c,g g d,g g g b,g g 
Overweight Preoccupation 0.001 0.95 0.31 0.15 0.70 0.25 0.80 g g g g g g g g 
Self Classified Weight 0.045 0.97 0.87 0.001 0.86 0.18 0.55 
 
c 
 
g 
  
b g 
Rosenberg Self Esteem Scale 0.10 0.77 0.97 0.60 0.72 0.63 0.07 
 
g 
     
g 
Social Physique Anxiety Scale 0.79 0.40 0.87 0.047 0.83 0.19 0.65                 
T = time effect, D = diet effect, T x D = time by diet effect, WC = waist circumference risk factor effect, T x WC = time by waist circumference risk factor effect, D x WC = diet by waist circumference risk factor 
effect, T x D x WC = time by diet by waist circumference risk factor effect.  HP = higher protein, HC = higher carbohydrate, LWC = low waist circumference (≤88 cm), HWC = high waist circumference (>88 
cm). N=663 participants unless stated otherwise as follows: REE N=633, Insulin and HOMA N=252, Strength N=596, SF36 N=289, and Body Image N=451.   
Group breakdowns are as follows unless otherwise stated: 55 participants in the HP-LWC group, 316 in the HP-HWC group, 77 in the HC-LWC group, 215 in the HC-HWC group, 371 in the HP total group, 292 
in the HC total group, 132 in the LWC group, 531 in the HWC group, and 663 participants total; for REE: 47 participants in the HP-LWC group, 310 in the HP-HWC group, 67 in the HC-LWC group, 209 in the 
HC-HWC group, 357 in the HP total group, 276 in the HC total group, 114 in the LWC group, 519 in the HWC group, and 633 participants total; for insulin and HOMA: 25 participants in the HP-LWC group, 124 
in the HP-HWC group, 40 in the HC-LWC group, 63 in the HC-HWC group, 149 in the HP total group, 103 in the HC total group, 65 in the LWC group, 187 in the HWC group, and 252 participants total; for 
strength: 41 participants in the HP-LWC group, 299 in the HP-HWC group, 56 in the HC-LWC group, 200 in the HC-HWC group, 340 in the HP total group, 256 in the HC total group, 97 in the LWC group, 499 
in the HWC group, and 596 participants total; for SF36: 25 participants in the HP-LWC group, 127 in the HP-HWC group, 43 in the HC-LWC group, 94 in the HC-HWC group, 152 in the HP total group, 137 in 
the HC total group, 68 in the LWC group, 221 in the HWC group, and 289 participants total; and for Body Image: 37 participants in the HP-LWC group, 219 in the HP-HWC group, 60 in the HC-LWC group, 135 
in the HC-HWC group, 256 in the HP total group, 195 in the HC total group, 97 in the LWC group, 354 in the HWC group, and 451 participants total.    
Wilks’ Lambda Multivariate p-values for the group of variables are listed in bold. Greenhouse-Geisser Univariate p-values are listed for each variable included in the MANOVA (or ANOVA when indicated) 
analysis.  Superscripts indicate significant differences between groups using Post Hoc LSD Pairwise Comparisons. 
a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than HWC group, p < 0.05 (post hoc LSD).  c Significantly different than HP-LWC group, p < 0.05 (post hoc LSD).   
d Significantly different than HP-HWC group, p < 0.05 (post hoc LSD).  f Significantly different than HC-LWC group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Post hoc analysis of body composition data expressed in delta changes from baseline 
revealed the HP-LWC group demonstrated the greatest percent fat loss (-1.9±2.3%, 
p=0.044).   
Individual three-way ANOVAs were performed on weight, body mass index, 
waist circumference, and hip circumference.  A significant time x diet effect indicated a 
greater loss in the higher protein group for both weight (HP -4.3±3.6, HC –3.2±3.4 kg, 
p=0.004) and body mass index (HP -1.6±1.3, HC -1.2±1.3 kg/m2, p=0.004).  No 
significant time x diet effect was observed for waist circumference (p=0.272) or hip 
circumference (p=0.12).  Significant time x waist circumference risk factor effects were 
observed indicating a greater loss in the HWC group for weight (LWC -2.6±2.9, HWC  
-4.1±3.6 kg, p<0.001), body mass index (LWC -1.0±1.1, HWC -1.5±1.3 kg/m2, 
p<0.001), and waist circumference (LWC -0.9±4.2, HWC -4.3±5.9 cm, p<0.001).  The 
time x waist circumference risk factor interaction for hip circumference was not 
significant (p=0.15).  No significant time x diet x waist circumference risk factor 
interactions were observed for weight (p=0.60), body mass index (p=0.61), waist 
circumference (p=0.62), or hip circumference (p=0.24).  Based on these findings, 
hypothesis H10 is accepted, which indicated there would be statistically significant 
differences observed in changes in body composition as a result of diet intervention 
and/or the presence of the waist circumference metabolic syndrome risk factor. 
Resting Energy Expenditure 
The three-way ANOVA for resting energy expenditure and waist circumference 
risk factor revealed an overall time effect (p<0.001), but no significant interactions.  
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Therefore, hypothesis H11 is accepted, which stated there would be no statistically 
significant differences observed in resting energy expenditure as a result of diet 
intervention and/or the presence of the waist circumference metabolic syndrome risk 
factor.  
Resting Hemodynamic Parameters 
A three-way MANOVA on the resting hemodynamic parameters revealed an overall 
time (Wilks’ Lambda p<0.001) and time x waist circumference risk factor effect (Wilks’ 
Lambda p=0.035), with univariate significance observed specifically for resting heart 
rate (p=0.005).  This indicated a significantly greater decrease in heart rate for the HWC 
group over the ten-week protocol (LWC -0.82±9.6, HWC -3.6±10.4 bpm, p=0.005).  No 
significant time x diet (Wilks’ Lambda, p=0.78) or time x diet x waist circumference risk 
factor (Wilks’ Lambda p=0.77) interactions were observed.  Therefore, hypothesis H12 is 
rejected, which stated there would be no statistically significant differences observed in 
resting hemodynamic parameters as a result of diet intervention and/or the presence of 
the waist circumference metabolic syndrome risk factor.  
Blood Lipids 
While the three-way MANOVA for blood lipids revealed an overall time effect 
(Wilks’ Lambda p<0.001), no significant time x diet (Wilks’ Lambda p=0.70), time x 
waist circumference risk factor (Wilks’ Lambda p=0.30), or time x diet x waist 
circumference risk factor (Wilks’ Lambda p=0.83) interactions were observed.  Based on 
these findings hypothesis H13 is rejected, which stated there would be statistically 
significant differences observed in blood lipids as a result of diet intervention, and 
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hypothesis H14 is accepted, which stated there would be no statistically significant 
differences observed in blood lipids as a result of the presence of the waist 
circumference metabolic syndrome risk factor.  
Glucose Homeostasis 
No significant time effect or interactions were observed for the three-way 
ANOVA on glucose.   While both insulin and HOMA variables did not experience 
significant time (p=0.20 and p=0.36) or time x diet interactions (p=0.80 and p=0.71 
respectively), both variables demonstrated a significant time x waist circumference risk 
factor effect.  The LWC group demonstrated a significantly greater increases in 
comparison to mild decreases in the HWC group (that was not significantly different 
from baseline) for both insulin (LWC +2.59±9.7, HWC -0.4±9.0 uIU/mL, p=0.023) and 
HOMA (LWC +0.8±3.3, HWC -0.2±3.4, p=0.031). Based on the findings from this 
analysis hypothesis H15 is accepted, which stated there would be statistically significant 
differences observed in markers of glucose homeostasis as a result of diet intervention 
and/or the presence of the waist circumference metabolic syndrome risk factor.  
Fitness Parameters 
The three-way MANOVA on maximum strength revealed an overall time effect 
(Wilks’ Lambda p<0.001), but no significant interactions.  However, an ANOVA on 
cardiorespiratory fitness, measured by peak VO2, demonstrated significant effects with 
time, (p<0.001), time x diet (p=0.001) and time x diet x waist circumference risk factor 
(p=0.044), as well as a trend towards significance for time x waist circumference risk 
factor (p=0.095).  Analysis of the MANOVA univariate tests revealed the HC group 
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experienced a significantly greater increase in peak VO2 (HP +1.9±3.0, HC 2.6±3.7 
ml/kg/min, p=0.001), and the HWC group tended to experience a greater increase in 
peak VO2 (LWC +1.9±3.8, HWC +2.3±3.2 ml/kg/min, p=0.095).  Post hoc analysis on 
the time x diet x waist circumference risk factor using calculated delta change from 
baseline indicated that the HC-LWC group experienced the greatest gain in 
cardiorespiratory fitness (+2.66±4.0 ml/kg/min, p=0.013).  Due to the findings regarding 
cardiorespiratory fitness, hypothesis H16 is rejected.  This hypothesis stated there would 
be no statistically significant differences observed in fitness parameters as a result of diet 
intervention and/or the presence of the waist circumference metabolic syndrome risk 
factor. 
Psychometric Analysis 
While overall time effects (Wilks’ Lambda p<0.001) were observed for both the 
SF36-Quality of Life Questionnaire and the Body Image Questionnaires, the three-way 
MANOVAs did not reveal any significant interaction effects for the waist circumference 
risk factor analysis.  However review of the MANOVA univariate tests on the Body 
Image Questionnaire revealed a significant time x waist circumference risk factor 
interaction for appearance evaluation, indicating a significantly greater increase in the 
LWC group (LWC 0.50±0.6, HWC 0.31±0.6, p=0.004).  The univariate time x diet x 
waist circumference risk factor for the Rosenberg Self Esteem Scale revealed a trend 
(p=0.07), with post hoc analysis on the calculated delta changes from baseline revealed 
HP-HWC tended to experience a greater increase compared to HC-HWC (HP-HWC 
+0.74±3.3, HC-HWC +0.04±3.6, p=0.055).  Based on the time x waist circumference 
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risk factor interaction for appearance evaluation, hypothesis H17 is rejected, which stated 
there would be no statistically significant differences observed in psychometric 
parameters (as measured via questionnaires regarding quality of life and body image) as 
a result of diet intervention and/or the presence of the waist circumference metabolic 
syndrome risk factor. 
ANALYSIS OF HYPERTRIGLYCERIDEMIA AS A RISK FACTOR 
 The hypertriglyceridemia risk factor for metabolic syndrome in women has been 
defined as a triglyceride level greater than or equal to 1.7 mmol/L.  Participants have 
been identified as either low triglyceride (LTG; <1.7 mmol/L, N=443), or high 
triglyceride (HTG; ≥1.7 mmol/L, N=220).   
Energy Intake 
 Table 4.23 depicts the time x diet x triglyceride risk factor MANOVA for total energy 
intake in kcals/kg/day as well as macronutrient intake in g/kg/day.  The three-way MANOVA 
revealed overall time (Wilks’ Lambda p<0.001), time x diet (Wilks’ Lambda p<0.001), and 
time x diet x triglyceride risk factor (Wilks’ Lambda p=0.013) effects, but no significant 
time x triglyceride risk factor (Wilks’ Lambda p=0.16) interaction.  Post hoc analysis on 
the ten-week values was utilized to determine the following: Participants in the HC 
group and the HTG group consumed significantly more calories relative to body weight 
(HP 15.9±5.2, HC 17.4±4.7 kcal/kg/d, p<0.007) (LTG 16.2±5.1, HTG 17.2±4.8 
kcal/kg/d, p=0.042).  Further review of the individual group-combinations revealed that 
HP-LTG consumed significantly less energy than the other groups (15.2±4.9 kcal/kg/d, 
p<0.001).  
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Table 4.23: Dietary Intake Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on the Hypertriglyceridemia Risk Factor Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Energy Intake  HP-LTG 20.2 ± 5.7 15.2g ± 4.9    T = 0.001 
(kcal/kg/day) HP-HTG 20.9 ± 5.8 17.2cg ± 5.4    D = 0.042 
 HC-LTG 21.2 ± 7.0 17.5cg ± 5.0    TG = 0.22 
 HC-HTG 20.7 ± 5.6 17.2g ± 4.1    D x TG = 0.014 
 HP 20.4 ± 5.8 15.9g ± 5.2 18.4† ± 0.2 T x D = 0.20 
 HC 21.0 ± 6.6 17.4ag ± 4.7 19.1 ± 0.3 T x TG = 0.18 
 LTG 20.6 ± 6.3 16.2g ± 5.1 18.5 ± 0.2 T x D x TG = 0.35 
 HTG 20.8 ± 5.7 17.2bg ± 4.8 19.0 ± 0.3  
 Time 20.7 ± 6.1 16.6* ± 5.0     
Protein Intake HP-LTG 0.83 ± 0.2 1.09g ± 0.5    T = 0.001 
(g/kg/day) HP-HTG 0.85 ± 0.2 1.24cg ± 0.5    D = 0.001 
 HC-LTG 0.84 ± 0.2 0.81c ± 0.3    TG = 0.35 
 HC-HTG 0.81 ± 0.2 0.74d ± 0.2    D x TG = 0.002 
 HP 0.83 ± 0.2 1.14g ± 0.5 1.00† ± 0.0 T x D = 0.001  
 HC 0.83 ± 0.2 0.78a ± 0.3 0.80 ± 0.0 T x TG = 0.25 
 LTG 0.83 ± 0.2 0.97g ± 0.4 0.89 ± 0.0 T x D x TG = 0.030 
 HTG 0.83 ± 0.2 1.02g ± 0.5 0.91 ± 0.0  
 Time 0.83 ± 0.2 0.98* ± 0.4     
Carbohydrate HP-LTG 2.37 ± 0.9 1.35g ± 0.6    T = 0.001 
Intake (g/kg/day) HP-HTG 2.46 ± 0.8 1.54cg ± 0.8    D = 0.001 
 HC-LTG 2.51 ± 1.0 2.21cg ± 0.8    TG = 0.14 
 HC-HTG 2.56 ± 0.8 2.19dg ± 0.6    D x TG = 0.27 
 HP 2.40 ± 0.9 1.41g ± 0.7 1.93† ± 0.0 T x D = 0.001 
 HC 2.52 ± 0.9 2.20ag ± 0.7 2.34 ± 0.0 T x TG = 0.87 
 LTG 2.43 ± 0.9 1.73g ± 0.8 2.11 ± 0.0 T x D x TG = 0.30 
 HTG 2.50 ± 0.8 1.82g ± 0.8 2.19 ± 0.0  
 Time 2.46 ± 0.9 1.76* ± 0.8     
Fat Intake HP-LTG 0.82 ± 0.3 0.60g ± 0.3    T = 0.001 
(g/kg/day) HP-HTG 0.85 ± 0.3 0.68cg ± 0.3    D = 0.25 
 HC-LTG 0.87 ± 0.4 0.61g ± 0.2    TG = 0.65 
 HC-HTG 0.80 ± 0.3 0.60dfg ± 0.2    D x TG = 0.008 
 HP 0.83 ± 0.3 0.63g ± 0.3 0.74 ± 0.0 T x D = 0.17 
 HC 0.85 ± 0.3 0.60ag ± 0.2 0.72 ± 0.0 T x TG = 0.039 
 LTG 0.84 ± 0.3 0.61g ± 0.2 0.73 ± 0.0 T x D x TG = 0.67 
 HTG 0.83 ± 0.3 0.65g ± 0.2 0.73 ± 0.0  
 Time 0.84 ± 0.3 0.62* ± 0.2     
HP = higher protein, HC = higher carbohydrate, LTG = low triglyceride, HTG = high triglyceride risk factor, T = time effect, D = diet effect, TG = 
triglyceride risk factor effect, D x TG = diet by triglyceride risk factor effect, T x D = time by diet effect, T x TG = time by triglyceride risk factor 
effect, T x D x TG = time by diet by triglyceride risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 247 participants in the HP-LTG group, 124 in the HP-
HTG group, 196 in the HC-LTG group, 96 in the HC-HTG group, 371 in the HP total group, 292 in the HC total group, 443 in the LTG group, 220 in 
the HTG group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant triglyceride effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LTG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LTG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HTG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LTG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Participants in the HP group consumed significantly more protein relative to body 
weight (HP 1.14±0.5, HC 0.78±0.3 g/kg/d, p<0.001), with no significant differences 
between the triglyceride risk factor groups.  Specifically, the HP-HTG group consumed 
significantly more protein than all other group-combinations (1.24±0.5 g/kg/d, p=0.001).  
The HC group consumed significantly more carbohydrate relative to body weight (HP 
1.41±0.7, HC 2.20±0.7 g/kg/d, p<0.001), with no significant difference observed 
between the risk factor groups.  The HC-LTG group consumed significantly more 
carbohydrate than HP-LTG (p<0.001) and HC-HTG consumed significantly more 
carbohydrate than HP-HTG (p<0.001), which consumed significantly more carbohydrate 
than HP-LTG (p=0.014).  Finally, the HP group consumed significantly more fat (HP 
0.63±0.3, HC 0.60±0.2 g/kg/d, p=0.047) and the HTG tended to consume a greater 
amount of fat (LTG 0.61±0.2, HTG 0.65±0.2 g/kg/d, p=0.062), with the HP-HTG group 
consuming a significantly greater amount than any other group-combination (p=0.015).    
Overall Analysis  
Table 4.24 represents the Greenhouse-Geisser univariate and (when applicable) 
Wilks’ Lambda multivariate p-levels for each of the variables and groups measured and 
analyzed by the various diet and triglyceride risk factor interactions (time, diet, 
triglyceride risk factor, time x diet, time x triglyceride risk factor, diet x triglyceride risk 
factor, and time x diet x triglyceride risk factor).  The significant findings per variable 
are discussed below.  
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Table 4.24: Significance Levels for Triglyceride Risk Factor Analysis per Variable 
 
 Multivariate and Univariate P-Values Post Hoc Significance 
 T D T*D TG T*TG D*TG T*D*TG 
HP-
LTG 
HP-
HTG 
HC-
LTG 
HC-
HTG HP HC LTG HTG 
Body Composition 0.001   0.064   0.90   0.34                 
Scanned Mass 0.001 0.001 0.007 0.45 0.52 0.07 0.22 g g c.g g g a,g g g 
Fat Mass 0.001 0.001 0.004 0.35 0.58 0.35 0.61 g g c,g g g a,g g g 
Lean Mass 0.001 0.001 0.46 0.74 0.71 0.74 0.12 g g c,g g g a,g g g 
Body Fat 0.001 0.036 0.14 0.27 0.90 0.27 0.74 g g g g g g g g 
Weight 0.001 0.001 0.002 0.42 0.72 0.058 0.14 g c,g c,g g g a,g g g 
Body Mass Index 0.001 0.001 0.002 0.83 0.85 0.29 0.24 g g c,g d,g g a,g g g 
Waist Circumference 0.001 0.001 0.015 0.28 0.79 0.26 0.035 g g c,g g g a,g g g 
Hip Circumference 0.001 0.001 0.48 0.97 0.22 0.34 0.13 g g c,g g g a,g g g 
Resting Energy Expenditure 0.001 0.001 0.324 0.13 0.60 0.53 0.96 g g c,g g g a,g g g 
Hemodynamic 0.001   0.71   0.20   0.66                 
Resting Heart Rate 0.001 0.42 0.95 0.035 0.53 0.51 0.67 g g g d,g g g g g 
Systolic Blood Pressure 0.001 0.07 0.46 0.60 0.036 0.35 0.35 g g 
 
d,g g a,g g g 
Diastolic Blood Pressure 0.001 0.001 0.25 0.65 0.31 0.96 0.27 g   g d,g g a,g g g 
Blood Lipids 0.001   0.20   0.001   0.07                 
Total Cholesterol 0.001 0.61 0.24 0.001 0.45 0.76 0.19 g c,g g f g g b,g g 
LDL Cholesterol 0.001 0.33 0.31 0.001 0.68 0.33 0.08 g c,g g f g g b,g g 
HDL Cholesterol 0.001 0.83 0.60 0.001 0.094 0.81 0.52 g c,g g f g g b,g g 
Triglycerides 0.001 0.28 0.051 0.001 0.001 0.35 0.90  c,g g f,g g g b g 
TC/HDL Ratio 0.11 0.78 0.23 0.001 0.16 0.47 0.12 g c   f     b,g   
Glucose 0.006 0.29 0.50 0.001 0.21 0.63 0.92  c,g  f g  b g 
Insulin 0.66 0.002 0.67 0.031 0.62 0.98 0.53   c   a    
HOMA  0.98 0.003 0.42 0.010 0.40 0.91 0.22     c     a     
Maximum Strength 0.001   0.53   0.17   0.72                 
Bench Press Max Strength 0.001 0.76 0.41 0.69 0.18 0.004 0.96 g c,g c,g g g g g g 
Bench Press Lift Volume 0.89 0.46 0.86 0.84 0.78 0.102 0.17          
Leg Press Max Strength 0.001 0.45 0.51 0.43 0.17 0.045 0.95 g g c,g f,g g g g g 
Leg Press Lift Volume 0.40 0.016 0.15 0.13 0.40 0.23 0.58 g  c   a    
 Peak VO2 0.001 0.009 0.012 0.85 0.30 0.32 0.67 g g c,g d,g g a,g g g 
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Table 4.24: Continued 
  Multivariate and Univariate P-Values Post Hoc Significance 
  T D T*D TG T*TG D*TG 
T*D*
TG 
HP-
LTG 
HP-
HTG 
HC-
LTG 
HC-
HTG HP HC LTG HTG 
SF36 Questionnaire 0.001   0.076   0.096   0.60                 
Physical Function 0.001 0.43 0.67 0.23 0.22 0.24 0.79 g c g 
 
g g g   
Role Physical 0.52 0.001 0.91 0.08 0.31 0.93 0.60 
  
c d 
 
a 
 
  
Bodily Pain 0.039 0.42 0.13 0.31 0.047 0.47 0.29 g 
 
g 
 
g 
 
g   
General Health 0.001 0.001 0.72 0.66 0.21 0.55 0.18 g 
 
c,g d,g g a,g g g 
Vital 0.001 0.18 0.13 0.28 0.41 0.14 0.90 g g c,g g g g g g 
Social 0.009 0.001 0.07 0.52 0.66 0.23 0.77 g g c 
 
g a 
 
g 
Role Emotional 0.33 0.001 0.11 0.33 0.20 0.85 0.47 
  
c d 
 
a 
 
  
Mental Health 0.001 0.019 0.71 0.58 0.17 0.22 0.18 g g g d,f,g g g g g 
Body Image Questionnaire 0.001   0.72   0.70   0.34                 
Appearance Evaluation 0.001 0.55 0.58 0.26 0.71 0.62 0.96 g g g g g g g g 
Appearance Orientation 0.49 0.020 0.36 0.41 0.23 0.96 0.77 
  
c 
  
a 
 
  
Body Area Satisfaction Scale 0.001 0.002 0.64 0.74 0.20 0.88 0.033 g g c,g g g a,g g g 
Overweight Preoccupation 0.001 0.29 0.12 0.74 0.98 0.69 0.62 g g g g g g g g 
Self Classified Weight 0.024 0.14 0.43 0.66 0.87 0.39 0.48 
     
g g   
Rosenberg Self Esteem Scale 0.006 0.94 0.38 0.28 0.37 0.20 0.32 g 
   
g 
  
g 
Social Physique Anxiety Scale 0.56 0.74 0.83 0.44 0.46 0.85 0.59                 
T = time effect, D = diet effect, T x D = time by diet effect, TG = triglyceride risk factor effect, T x TG = time by triglyceride risk factor effect, D x TG = diet by triglyceride risk factor effect, T x D x TG = 
time by diet by triglyceride risk factor effect.  HP = higher protein, HC = higher carbohydrate, LTG = low triglyceride (<1.7 mmol/L), HWC = high triglyceride (≥1.7 mmol/L).  
N=663 participants unless stated otherwise as follows: REE N=633, Insulin and HOMA N=252, Strength N=596, SF36 N=289, and Body Image N=451.   
Group breakdowns are as follows unless otherwise stated: 247 in the HP-LTG group, 124 in the HP-HTG group, 196 in the HC-LTG group, 96 in the HC-HTG group, 371 in the HP total group, 292 in the HC 
total group, 443 in the LTG group, 220 in the HTG group, and 663 participants total; for REE: 239 in the HP-LTG group, 118 in the HP-HTG group, 188 in the HC-LTG group, 88 in the HC-HTG group, 357 
in the HP total group, 276 in the HC total group, 427 in the LTG group, 206 in the HTG group, and 633 participants total; for insulin and HOMA: 99 in the HP-LTG group, 50 in the HP-HTG group, 65 in the 
HC-LTG group, 38 in the HC-HTG group, 149 in the HP total group, 103 in the HC total group, 194 in the LTG group, 88 in the HTG group, and 252 participants total; for strength: 230 in the HP-LTG group, 
110 in the HP-HTG group, 177 in the HC-LTG group, 79 in the HC-HTG group, 340 in the HP total group, 256 in the HC total group, 407 in the LTG group, 189 in the HTG group, and 596 participants total; 
for SF36: 100 in the HP-LTG group, 52 in the HP-HTG group, 84 in the HC-LTG group, 53 in the HC-HTG group, 152 in the HP total group, 137 in the HC total group, 184 in the LTG group, 105 in the 
HTG group, and 289 participants total; and for Body Image: 177 in the HP-LTG group, 79 in the HP-HTG group, 127 in the HC-LTG group, 68 in the HC-HTG group, 256 in the HP total group, 195 in the 
HC total group, 304 in the LTG group, 147 in the HTG group, and 451 participants total.    
Wilks’ Lambda Multivariate p-values for the group of variables are listed in bold. Greenhouse-Geisser Univariate p-values are listed for each variable included in the MANOVA (or ANOVA when indicated) 
analysis.  Superscripts indicate significant differences between groups using Post Hoc LSD Pairwise Comparisons.  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different 
than HTG group, p < 0.05 (post hoc LSD).  c Significantly different than HP-LTG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HTG group, p < 0.05 (post hoc LSD).  f Significantly 
different than HC-LTG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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When a significant three-way interaction was observed, the significant group differences 
revealed in the post hoc LSD pairwise comparisons analysis are also indicated.  Each 
corresponding hypothesis is also evaluated. 
Body Composition 
 A three-way MANOVA on DEXA variables revealed an overall time 
effect (Wilks’ Lambda p<0.001) and a trend in time x diet (Wilks’ Lambda p=0.064), 
with univariate p-values revealing that participants in the higher protein group 
experienced a greater loss in both scanned mass (HP -3.9±3.5, HC -3.0±3.5 kg, p=0.007) 
and fat mass (HP -3.1±2.7, HC -2.4±2.8 kg, p=0.004).  No significant time x triglyceride 
risk factor (Wilks’ Lambda p=0.90) or time x diet x triglyceride risk factor (Wilks’ 
Lambda p=0.34) interactions were observed.  Individual three-way ANOVAs were 
performed on weight, body mass index, waist circumference, and hip circumference.  
Significant diet x time interactions were observed indicating a greater decrease in the 
higher protein group for weight (HP -4.3±3.6, HC -3.2±3.4 kg, p=0.002), body mass 
index (HP -1.6±1.3, HC -1.2±1.3 kg/m2, p=0.002), and waist circumference (HP  
-4.0±5.7, HC -3.2±5.7 cm, p=0.015).   No significant time x triglyceride risk factor 
interactions were observed for any of these variables.  A significant three-way 
interaction with time x diet x triglyceride risk factor was observed for waist 
circumference only (p=0.035), with post hoc analysis on the delta change from baseline 
indicating the HP-HTG group experienced a significantly greater decrease in waist 
circumference than HC-HTG (HP-HTG -4.6±5.5, HC-HTG -2.4±4.8 cm, p=0.005).  
Based on these findings, hypotheses H18 and H19 are accepted, which stated there would 
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be statistically significant differences observed in body composition as a result of diet 
intervention, and there would be no statistically significant differences observed in body 
composition as a result of the presence of the triglyceride metabolic syndrome risk 
factor, respectively. 
Resting Energy Expenditure 
The three-way ANOVA for resting energy expenditure and triglyceride risk 
factor revealed an overall time effect (p<0.001), but no significant interactions.  
Therefore, hypothesis H20 is accepted, which stated there would be no statistically 
significant differences observed in resting energy expenditure parameters as a result of 
diet intervention and/or the presence of the triglyceride metabolic syndrome risk factor. 
Resting Hemodynamic Parameters 
The three-way MANOVA for resting hemodynamic parameters and triglyceride 
risk factor revealed an overall time effect (Wilks’ Lambda p<0.001), but no significant 
interactions.  However, univariate MANOVA on systolic blood pressure revealed a 
significant time x triglyceride risk factor effect, revealing that the high triglyceride group 
experienced a significantly greater decrease in systolic blood pressure over the ten-week 
study (LTG -2.0±14.3, HTG -5.6±13.8 mmHg, p=0.036).  Based on this finding, 
hypothesis H21 is rejected.  This hypothesis stated there would be no statistically 
significant differences observed in resting hemodynamic parameters as a result of diet 
intervention and/or the presence of the triglyceride metabolic syndrome risk factor. 
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Blood Lipids 
A three-way MANOVA on blood lipids revealed an overall time effect (Wilks’ 
Lambda p<0.001).  While the overall time x diet interaction was not significant (Wilks’ 
Lambda p=0.20), analysis of MANOVA univariate tests revealed a significant time x 
diet effect for triglycerides, with the higher protein group experiencing a significantly 
greater decrease in triglyceride levels (HP -0.15±0.62, HC -0.05±0.61 mmol/L, 
p=0.051).  A significant time x triglyceride risk factor interaction (Wilks’ Lambda 
p<0.001) as well as a trend for a time x diet x triglyceride risk factor effect (Wilks’ 
Lambda p=0.075) were also observed.  Based on analysis of MANOVA univariate tests, 
participants identified as having high triglycerides experienced a significantly greater 
decrease in triglyceride levels (LTG +0.03±0.4, HTG -0.37±0.8 mmol/L, p<0.001).  
Additionally, the LTG group tended to experience a greater decrease in HDL levels than 
the HTG group (LTG -0.08±0.3, HTG -0.05±0.2 mmol/L, p=0.094.  Finally, post hoc 
analysis on the time x diet x triglyceride risk factor interaction revealed a trend towards 
significance for the LDL variable (univariate p=0.077), with the value for the HP-HTG 
group (3.1±0.8 mmol/L) significantly greater than the HP-LTG group (2.9±0.7 mmol/L, 
p=0.039), and the HC-HTG group (3.1±0.8 mmol/L) significantly greater than the HC-
LTG group (2.9±0.7, p<0.001) at time point 2.  Based on these findings, hypothesis H22 
is accepted, which stated there would be statistically significant differences observed in 
blood lipids as a result of diet intervention and/or the presence of the triglyceride 
metabolic syndrome risk factor. 
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Glucose Homeostasis 
The three-way ANOVA revealed a time effect for glucose (p=0.006), however no 
significant interactions were observed for glucose, insulin, or HOMA.  Therefore 
hypothesis H23 is rejected, which stated there would be statistically significant 
differences observed in markers of glucose homeostasis as a result of diet intervention 
and/or the presence of the triglyceride metabolic syndrome risk factor.  
Fitness Parameters 
The three-way MANOVA on maximum strength revealed an overall time effect 
(Wilks’ Lambda p<0.001), but no significant interactions.  However, an ANOVA on 
cardiorespiratory fitness, measured by peak VO2, demonstrated a significant time 
(p<0.001) and time x diet effect (p=0.012).  The HC group experienced a significantly 
greater increase in peak VO2 (HP +1.9±3.0, HC +2.6±3.7 ml/kg/min, p=0.012).  
Therefore hypothesis H24 is rejected, which stated there would be no statistically 
significant differences observed in fitness parameters as a result of diet intervention 
and/or the presence of the triglyceride metabolic syndrome risk factor. 
Psychometric Analysis 
The three-way MANOVA for SF36 demonstrated a time effect (Wilks’ Lambda 
p<0.001) and a trend towards significance for both time x diet (Wilks’ Lambda p=0.076) 
and time x triglyceride risk factor (Wilks’ Lambda p=0.096) effect.  Review of the 
MANOVA univariate tests reveals the higher protein group tended to have a greater 
increase in the social variable (HP +4.4±15.5, HC +0.8±19.0, p=0.073), and that the 
LTG group experienced a significantly greater increase in the bodily pain variable (LTG 
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+4.3±16.9,HTG +0.06±17.4, p=0.047).  No significant time x diet x triglyceride risk 
factor interactions were observed (Wilks’ Lambda p=0.60). 
For the Body Image analysis, a time effect (Wilks’ Lambda p<0.001), but no 
significant interactions were observed based on the MANOVA multivariate tests.  
However, review of the MANOVA univariate tests revealed a significant time x diet x 
triglyceride risk factor interaction for the body area satisfaction scale (p=0.033).  Post 
hoc analysis on the calculated delta changes from baseline revealed the HP-LTG 
(+0.2±0.4) group experienced significantly less of an increase in body area satisfaction 
than both HC-LTG (0.3±0.5, p=0.24) and HP-HTG (0.4±0.4, p=0.011).  Based on these 
findings, hypothesis H25 is rejected which stated there would be no statistically 
significant differences observed in psychometric parameters (as measured via 
questionnaires regarding quality of life and body image) as a result of diet intervention 
and/or the presence of the triglyceride metabolic syndrome risk factor. 
ANALYSIS OF HDL CHOLESTEROL AS A RISK FACTOR 
 The HDL cholesterol risk factor for metabolic syndrome in women has been 
defined as a HDL level less than 1.3 mmol/L.  Participants have been identified as either 
high HDL (HHDL; ≥1.3 mmol/L, N=400), or low HDL (LHDL; <1.3 mmol/L, N=263).   
Energy Intake 
 Table 4.25 depicts the time x diet x HDL risk factor MANOVA for total energy 
intake in kcals/kg/day as well as macronutrient intake in g/kg/day.  
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Table 4.25: Dietary Intake Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on HDL Cholesterol Risk Factor Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Energy Intake  HP-HHDL 20.1 ± 5.9 16.1g ± 5.6    T = 0.001 
(kcal/kg/day) HP-LHDL 20.8 ± 5.6 15.6g ± 4.4    D = 0.002 
 HC-HHDL 21.0 ± 6.3 17.2cg ± 4.7    HDL = 0.57 
 HC-LHDL 21.2 ± 7.0 17.7dg ± 4.7    D x HDL = 0.70 
 HP 20.4 ± 5.8 15.9g ± 5.2 18.2† ± 0.2 T x D = 0.055 
 HC 21.0 ± 6.6 17.4ag ± 4.7 19.3 ± 0.3 T x HDL = 0.39 
 HHDL 20.5 ± 6.1 16.6g ± 5.3 18.6 ± 0.2 T x D x HDL = 0.16 
 LHDL 21.0 ± 6.2 16.5g ± 4.6 18.8 ± 0.3  
 Time 20.7 ± 6.1 16.6* ± 5.0     
Protein Intake HP-HHDL 0.82 ± 0.2 1.17g ± 0.6    T = 0.001 
(g/kg/day) HP-LHDL 0.85 ± 0.2 1.10g ± 0.4    D = 0.001 
 HC-HHDL 0.84 ± 0.2 0.79c ± 0.3    HDL = 0.18 
 HC-LHDL 0.80 ± 0.2 0.78d ± 0.2    D x HDL = 0.93 
 HP 0.83 ± 0.2 1.14g ± 0.5 0.99† ± 0.0 T x D = 0.001 
 HC 0.83 ± 0.2 0.78a ± 0.3 0.80 ± 0.0 T x HDL = 0.25 
 HHDL 0.83 ± 0.2 1.00g ± 0.5 0.91 ± 0.0 T x D x HDL = 0.053 
 LHDL 0.83 ± 0.2 0.96g ± 0.4 0.88 ± 0.0  
 Time 0.83 ± 0.2 0.98* ± 0.4     
Carbohydrate HP-HHDL 2.37 ± 0.9 1.38g ± 0.7    T = 0.001 
Intake  HP-LHDL 2.45 ± 0.8 1.46g ± 0.6    D = 0.001 
(g/kg/day) HC-HHDL 2.48 ± 0.9 2.19cg ± 0.7    HDL = 0.12 
 HC-LHDL 2.60 ± 1.0 2.23dg ± 0.7    D x HDL = 1.0 
 HP 2.40 ± 0.9 1.41g ± 0.7 1.91† ± 0.0 T x D = 0.001 
 HC 2.52 ± 0.9 2.20ag ± 0.7 2.37 ± 0.0 T x HDL = 0.61 
 HHDL 2.42 ± 0.9 1.74g ± 0.8 2.10 ± 0.0 T x D x HDL = 0.69 
 LHDL 2.51 ± 0.9 1.79g ± 0.7 2.18 ± 0.0  
 Time 2.46 ± 0.9 1.76* ± 0.8     
Fat Intake HP-HHDL 0.82 ± 0.3 0.65g ± 0.3    T = 0.001 
(g/kg/day) HP-LHDL 0.85 ± 0.3 0.60cg ± 0.2    D = 0.95 
 HC-HHDL 0.85 ± 0.3 0.59cg ± 0.2    HDL = 0.98 
 HC-LHDL 0.84 ± 0.4 0.63g ± 0.2    D x HDL = 0.33 
 HP 0.83 ± 0.3 0.63g ± 0.3 0.73 ± 0.0 T x D = 0.27 
 HC 0.85 ± 0.3 0.60g ± 0.2 0.73 ± 0.0 T x HDL = 0.57 
 HHDL 0.83 ± 0.3 0.62g ± 0.3 0.73 ± 0.0 T x D x HDL = 0.013 
 LHDL 0.84 ± 0.3 0.61g ± 0.2 0.73 ± 0.0  
 Time 0.84 ± 0.3 0.62* ± 0.2     
HP = higher protein, HC = higher carbohydrate, HHDL = high HDL cholesterol, LHDL = low HDL cholesterol risk factor, T = time effect, D 
= diet effect, HDL = HDL cholesterol risk factor effect, D x HDL = diet by HDL cholesterol risk factor effect, T x D = time by diet effect, T x 
HDL = time by HDL cholesterol risk factor effect, T x D x HDL = time by diet by HDL cholesterol risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 220 participants in the HP-HHDL group, 151 
in the HP-LHDL group, 180 in the HC-HHDL group, 112 in the HC-LHDL group, 371 in the HP total group, 292 in the HC total group, 400 
in the HHDL group, 263 in the LHDL group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant HDL cholesterol 
effect, p < 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than HHDL group, p 
< 0.05 (post hoc LSD).  c Significantly different than HP-HHDL group, p < 0.05 (post hoc LSD).  d Significantly different than HP-LHDL 
group, p < 0.05 (post hoc LSD).  f Significantly different than HC-HHDL group, p < 0.05 (post hoc LSD).  g Significantly different than 
baseline, p <0.05 (post hoc LSD). 
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The three-way MANOVA revealed an overall time (Wilks’ Lambda p<0.001), time x 
diet (Wilks’ Lambda p<0.001), and time x diet x HDL risk factor (Wilks’ Lambda 
p=0.020) effect, but no significant time x HDL risk factor (Wilks’ Lambda p=0.68) 
interaction.  Post hoc analysis on the ten-week values was utilized to determine the 
following: Participants in the HC group consumed significantly more calories (HP 
15.9±5.2, HC 17.4±4.7 kcal/kg/d, p<0.001) and carbohydrate (HP 1.41±0.7, HC 
2.20±0.7 g/kg/d, p<0.001), while the HP group consumed significantly more protein (HP 
1.14±0.5, HC 0.78±0.3 g/kg/d, p<0.001) relative to body weight.  Regarding specific 
group-combinations, energy intake was significantly greater for HC-HHDL compared to 
HP-HHDL (p=0.029), and HC-LHDL was significantly greater than HP-LHDL 
(p=0.001).  For protein intake, HP-HHDL was significantly greater than HC-HHDL 
(p<0.001), and HP-LHDL was significantly greater than HC-LHDL (p<0.001).  For 
carbohydrate intake, HC-HHDL was significantly greater than HP-HHDL (p<0.001), 
and HC-LHDL was significantly greater than HP-LHDL (p<0.001).  Regarding fat 
intake, while there were no significant differences between the diet or HDL groups, the 
HP-HHDL group consumed significantly more fat than both HP-LHDL (p=0.021) and 
HC-HHDL (p=0.006).    
Overall Analysis 
Table 4.26 represents the Greenhouse-Geisser univariate and (when applicable) 
Wilks’ Lambda multivariate p-levels for each of the variables and groups measured and 
analyzed by the various diet and HDL risk factor interactions (time, diet, HDL risk 
factor, time x diet, time x HDL risk factor, diet x HDL risk factor, and time x diet x HDL 
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risk factor).  The significant findings per variable are discussed below.  When a 
significant three-way interaction was observed, the significant group differences 
revealed in the post hoc LSD pairwise comparisons analysis are also indicated.  Each 
corresponding hypothesis is also evaluated. 
Body Composition 
 The three-way MANOVA on DEXA variables revealed a significant time 
(Wilks’ Lambda p<0.001) and time x diet effect (Wilks’ Lambda p=0.033), but no 
significant time x HDL risk factor (Wilks’ Lambda p=0.68) or time x diet x HDL risk 
factor (Wilks’ Lambda p=0.42) interactions.  Review of the MANOVA univariate tests 
revealed the higher protein group resulted in a significantly greater decrease in scanned 
mass (HP -3.9±3.5, HC -3.0±3.5 kg, p=0.002) and fat mass (HP -3.1±2.7, HC -2.4±2.8 
kg, p=0.003).     
Individual three-way ANOVAs were used for weight, body mass index, and waist and 
hip circumference.  Significant univariate time x diet effects were observed for weight, 
body mass index, and a trend for waist circumference.  The higher protein group 
experienced a significantly greater decrease in weight (HP -4.3±3.6, HC -3.2±3.4 kg, 
p=0.001), body mass index (HP -1.6±1.3, HC -1.2±1.3 kg/m2, p=0.001), and tended to 
experience a greater decrease in waist circumference (HP -4.0±5.7, HC -3.2±5.7 cm, 
p=0.068).   
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Table 4.26: Significance Levels for HDL Cholesterol Risk Factor Analysis per Variable 
 
  Multivariate and Univariate P-Values Post Hoc Significance 
  T D T*D HDL T*HDL D*HDL 
T*D*
HDL 
HP-
HHDL 
HP-
LHDL 
HC-
HHDL 
HC-
LHDL HP HC HHDL LHDL 
Body Composition 0.001   0.033   0.68   0.42                 
Scanned Mass 0.001 0.001 0.002 0.14 0.35 0.37 0.84 
 
g c d g a,g g g 
Fat Mass 0.001 0.001 0.003 0.93 0.35 0.29 0.47 
 
g c 
 
g a,g b,g g 
Lean Mass 0.001 0.001 0.15 0.001 0.80 0.61 0.45 
 
c,g c d,f g a,g b,g g 
Body Fat 0.001 0.06 0.21 0.003 0.48 0.33 0.46   c,g     g g g g 
Weight 0.001 0.001 0.001 0.15 0.40 0.38 0.77 g g c,g d,g g a,g g g 
Body Mass Index 0.001 0.001 0.001 0.16 0.43 0.19 0.67 g g c,g d,g g a,g g g 
Waist Circumference 0.001 0.001 0.07 0.055 0.98 0.24 0.87 g g c,g d,f,g g a,g g g 
Hip Circumference 0.001 0.001 0.15 0.88 0.97 0.38 0.42 g g c,g g g a,g g g 
Resting Energy Expenditure 0.001 0.001 0.26 0.003 0.36 0.53 0.80 g c,g c,g d g a,g b,g g 
Hemodynamic 0.001   0.81   0.053   0.15                 
Resting Heart Rate 0.001 0.23 0.88 0.06 0.07 0.47 0.92 g g g g g g g g 
Systolic Blood Pressure 0.001 0.09 0.39 0.12 0.06 0.58 0.06 g g 
 
d,f,g g a,g b,g g 
Diastolic Blood Pressure 0.001 0.001 0.43 0.12 0.06 0.35 0.77   g c,g d,f,g g a,g b,g g 
Blood Lipids 0.001   0.34   0.001   0.48                 
Total Cholesterol 0.001 0.68 0.37 0.001 0.001 0.53 0.96 g c g  g g b,g   
LDL Cholesterol 0.001 0.42 0.67 0.77 0.001 0.39 0.66 g  g  g g g   
HDL Cholesterol 0.001 0.96 0.60 0.001 0.001 0.54 0.88 g c g f g g b,g g 
Triglycerides 0.001 0.52 0.047 0.001 0.09 0.72 0.94 g c,g  f g  b,g g 
TC/HDL Ratio 0.18 0.66 0.42 0.001 0.001 0.59 0.40 g c,g g f     b,g   
Glucose 0.032 0.23 0.50 0.18 0.16 0.14 0.39 g c   g  b,g   
Insulin 0.79 0.001 0.52 0.25 0.13 0.93 0.06   c   a    
HOMA  0.93 0.002 0.37 0.12 0.14 0.97 0.030     c g   a     
Maximum Strength 0.001   0.44   0.41   0.30                 
Bench Press Max Strength 0.001 0.39 0.25 0.001 0.38 0.031 0.20 g g c,g f,g g g b,g g 
Bench Press Lift Volume 0.94 0.48 0.68 0.001 0.44 0.031 0.17    f   b   
Leg Press Max Strength 0.001 0.31 0.61 0.001 0.17 0.016 0.36 g g c,g f,g g g b,g g 
Leg Press Lift Volume 0.13 0.016 0.14 0.14 0.16 0.004 0.28   c f g a    
 Peak VO2 0.002 0.015 0.012 0.30 0.024 0.80 0.98 g g c,g d,g g a,g g g 
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Table 4.26: Continued 
  Multivariate and Univariate P-Values Post Hoc Significance 
  T D T*D HDL T*HDL D*HDL 
T*D*
HDL 
HP-
HHDL 
HP-
LHDL 
HC-
HHDL 
HC-
LHDL HP HC HHDL LHDL 
SF36 Questionnaire 0.001   0.13   0.38   0.80                 
Physical Function 0.001 0.61 0.61 0.75 0.14 0.64 0.38 g g 
 
g g g g g 
Role Physical 0.42 0.001 0.92 0.06 0.36 0.53 0.30 
  
c d 
 
a b   
Bodily Pain 0.004 0.35 0.23 0.06 0.11 0.26 0.58 
 
g 
 
f g 
 
b g 
General Health 0.001 0.001 0.47 0.11 0.66 0.37 0.64 g g c,g d,g g a,g g g 
Vital 0.001 0.12 0.11 0.48 0.40 0.18 0.75 g g c,g g g g g g 
Social 0.024 0.001 0.09 0.018 0.11 0.39 0.69 g 
 
c f g a b,g   
Role Emotional 0.45 0.001 0.12 0.22 0.73 1.0 0.31 
  
c d 
 
a 
 
  
Mental Health 0.001 0.035 0.67 0.65 0.75 0.93 0.17 g g g g g g g g 
Body Image Questionnaire 0.001   0.51   0.72   0.84                 
Appearance Evaluation 0.001 0.58 0.46 1.0 0.78 0.30 0.42 g g g g g g g g 
Appearance Orientation 0.20 0.010 0.35 0.83 0.59 0.48 0.52 
   
d 
 
a 
 
  
Body Area Satisfaction Scale 0.001 0.001 0.20 0.55 0.75 0.62 0.94 g g c,g d,g g a,g g g 
Overweight Preoccupation 0.001 0.30 0.09 0.91 0.29 0.76 0.18 g g g g g g g g 
Self Classified Weight 0.007 0.105 0.57 0.53 0.21 0.33 0.92 
  
c 
  
g 
 
g 
Rosenberg Self Esteem Scale 0.008 0.55 0.29 0.16 0.81 0.77 0.42 g 
   
g 
 
g   
Social Physique Anxiety Scale 0.58 0.80 0.91 0.19 0.40 0.025 0.90       f         
T = time effect, D = diet effect, T x D = time by diet effect, HDL = HDL cholesterol risk factor effect, T x HDL = time by HDL cholesterol risk factor effect, D x HDL = diet by HDL cholesterol risk factor 
effect, T x D x HDL = time by diet by HDL cholesterol risk factor effect.  HP = higher protein, HC = higher carbohydrate, HHDL = high HDL cholesterol (≥1.3 mmol/L), LHDL = low HDL cholesterol (<1.3 
mmol/L). N=663 participants unless stated otherwise as follows: REE N=633, Insulin and HOMA N=252, Strength N=596, SF36 N=289, and Body Image N=451.   
Group breakdowns are as follows unless otherwise stated: 220 in the HP-HHDL group, 151 in the HP-LHDL group, 180 in the HC-HHDL group, 112 in the HC-LHDL group, 371 in the HP total group, 292 in 
the HC total group, 400 in the HHDL group, 263 in the LHDL group, and 663 participants total; for REE: 210 in the HP-HHDL group, 147 in the HP-LHDL group, 170 in the HC-HHDL group, 106 in the HC-
LHDL group, 357 in the HP total group, 276 in the HC total group, 380 in the HHDL group, 253 in the LHDL group, and 633 participants total; for insulin and HOMA: 83 in the HP-HHDL group, 66 in the HP-
LHDL group, 62 in the HC-HHDL group, 41 in the HC-LHDL group, 149 in the HP total group, 103 in the HC total group, 145 in the HHDL group, 107 in the LHDL group, and 252 participants total; for 
strength: 201 in the HP-HHDL group, 139 in the HP-LHDL group, 158 in the HC-HHDL group, 98 in the HC-LHDL group, 340 in the HP total group, 256 in the HC total group, 359 in the HHDL group, 237 in 
the LHDL group, and 596 participants total; for SF36: 89 in the HP-HHDL group, 63 in the HP-LHDL group, 83 in the HC-HHDL group, 54 in the HC-LHDL group, 152 in the HP total group, 137 in the HC 
total group, 172 in the HHDL group, 117 in the LHDL group, and 289 participants total; for Body Image: 150 in the HP-HHDL group, 106 in the HP-LHDL group, 120 in the HC-HHDL group, 75 in the HC-
LHDL group, 256 in the HP total group, 195 in the HC total group, 270 in the HHDL group, 181 in the LHDL group, and 451 participants total. 
Wilks’ Lambda Multivariate p-values for the group of variables are listed in bold. Greenhouse-Geisser Univariate p-values are listed for each variable included in the MANOVA (or ANOVA when indicated) 
analysis.  Superscripts indicate significant differences between groups using Post Hoc LSD Pairwise Comparisons.  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than 
LHDL group, p < 0.05 (post hoc LSD).  c Significantly different than HP-HHDL group, p < 0.05 (post hoc LSD).  d Significantly different than HP-LHDL group, p < 0.05 (post hoc LSD).  f Significantly different 
than HC-HHDL group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD).                
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No significant time x HDL risk factor or time x diet x HDL risk factor interactions were 
observed for any of these variables.  Based on these findings, hypotheses H26 and H27 are 
both accepted, which stated there would be statistically significant differences observed 
in body composition as a result of diet intervention, and there would be no statistically 
significant differences observed in body composition as a result of the presence of the 
HDL metabolic syndrome risk factor, respectively. 
Resting Energy Expenditure 
The three-way ANOVA for resting energy expenditure and HDL risk factor 
revealed an overall time effect (p<0.001), but no significant interactions.  Therefore, 
hypothesis H28 is accepted, which stated there would be no statistically significant 
differences observed in resting energy expenditure parameters as a result of diet 
intervention and/or the presence of the HDL metabolic syndrome risk factor. 
Resting Hemodynamic Parameters 
The three-way MANOVA on the resting hemodynamic parameters revealed a 
significant time (Wilks’ Lambda p<0.001) and time x HDL risk factor effect (Wilks’ 
Lambda p=0.053), but no significant time x diet (Wilks’ Lambda p=0.81) or time x diet 
x HDL risk factor (Wilks’ Lambda p=0.15) interactions.  Based on MANOVA 
univariate tests, there was a tendency for a greater decrease in the LHDL group for 
resting heart rate (HHDL -2.4±10.2, LHDL -3.9±10.5 bpm, p=0.070), systolic blood 
pressure (HHDL -2.1±14.9, LHDL -4.0±14.5 mmHg, p=0.061), and diastolic blood 
pressure (HHDL -1.4±9.8, LHDL -2.8±9.8 mmHg, p=0.063).  The univariate tests also 
revealed a trend towards significance for time x diet x HDL risk factor in systolic blood 
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pressure (p=0.06).  Post hoc analysis of the calculated delta change from baseline 
revealed the HC-LHDL group experienced a significantly greater decrease in systolic 
blood pressure than HC-HHDL (HC-HHDL -1.4±14.8, HC-LHDL -5.8±14.8 mmHg, 
p=0.013).  Based on these findings, hypothesis H29 is rejected, which stated there would 
be no statistically significant differences observed in resting hemodynamic parameters as 
a result of diet intervention and/or the presence of the HDL metabolic syndrome risk 
factor. 
Blood Lipids 
The three-way MANOVA on blood lipids revealed a significant time (Wilks’ 
Lambda p<0.001) and time x HDL risk factor (Wilks’ Lambda p<0.001), but no 
significant time x diet (Wilks’ Lambda p=0.34) or time x diet x HDL risk factor (Wilks’ 
Lambda p=0.48) interactions.  However, upon reviewing the MANOVA univariate tests, 
a significant time x diet effect was observed for triglycerides, with the higher protein 
group experiencing a significantly greater decrease (HP -0.15±0.62, HC -0.05±0.60 
mmol/L, p=0.047).  Participants with high HDL cholesterol experienced significantly 
greater reductions in total cholesterol (HHDL -0.33±0.8, LHDL -0.02±0.7 mmol/L, 
p<0.001) and LDL cholesterol (HHDL -0.22±0.6, LHDL -0.03±0.6 mmol/L, p<0.001), 
and a significantly greater increase in total cholesterol / HDL ratio (HHDL +0.14±0.6, 
LHDL -0.08±0.7, p<0.001).  Participants in the low HDL group experienced a 
significantly greater increase in HDL cholesterol (HHDL -0.14±0.2, LHDL +0.04±0.19 
mmol/L, p<0.001) and tended to have a greater decrease in triglycerides (HHDL  
-0.07±0.5, LHDL -0.15±0.7 mmol/L, p=0.092).  Based on these findings hypothesis H30 
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is accepted, which stated there would be statistically significant differences observed in 
blood lipids as a result of diet intervention and/or the presence of the HDL metabolic 
syndrome risk factor. 
Glucose Homeostasis 
The three-way ANOVA for glucose revealed a time effect (p=0.032), but no 
significant interaction effects.  Likewise, time x diet and time x HDL risk factor 
interactions were not significant for insulin and HOMA.  However, the time x diet x 
HDL risk factor interaction revealed a trend towards significance for insulin (p=0.057), 
and significance for HOMA (p=0.030).  Post hoc analysis on the calculated delta 
changes from baseline revealed a significant decrease in insulin for the HC-HHDL 
group compared to an increase for HC-LHDL (HC-HHDL +1.8±12.0, HC-LHDL  
-2.3±16.0 uIU/mL, p=0.028).  It also revealed the HC-LHDL group experienced a 
significant decrease in HOMA (-1.0±6.7) compared to significant increases for both HP-
LHDL (+0.3±1.9, p=0.044) and HC-HHDL (+0.6±3.6, p=0.019).  Based on these 
findings, hypothesis H31 which stated there would be statistically significant differences 
observed in markers of glucose homeostasis as a result of diet intervention is accepted, 
and hypothesis H32, which stated there would be no statistically significant differences 
observed in markers of glucose homeostasis as a result of the presence of the HDL 
metabolic syndrome risk factor, was rejected. 
Fitness Parameters 
The three-way MANOVA on muscular fitness variables revealed an overall time 
effect (Wilks’ Lambda p<0.001) but no significant interactions.  The three-way ANOVA 
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on cardiorespiratory fitness, measured by peak VO2, demonstrated a significant time 
(p<0.001), time x diet (p=0.012), and time x HDL risk factor (p=0.024) effect, but no 
significant time x diet x HDL risk factor effect (Greenhouse-Geisser p=0.98).  The HC 
and the HHDL groups both experienced a significantly greater increase in peak VO2 (HP 
+1.9±3.0, HC +2.6±3.7 ml/kg/min, p=0.012), (HHDL +2.6±3.4, LHDL ±2.2±3.3 
ml/kg/min, p=0.024).  However, these individual group findings did not prove 
significant when combined into a three-way interaction.  Based on the findings from the 
cardiorespiratory fitness analysis, hypothesis H33 is rejected.  This hypothesis stated that 
there would be no statistically significant differences observed in fitness parameters as a 
result of diet intervention and/or the presence of the HDL metabolic syndrome risk 
factor. 
Psychometric Analysis 
The three-way MANOVA analyses on the SF36 – Quality of Life and the Body 
Image Questionnaires both revealed a significant time effect (Wilks’ Lambda p<0.001), 
but no significant overall interactions.  However, review of the MANOVA univariate 
tests revealed a trend towards significance for the time x diet interaction for the social 
variable within the SF36, and the overweight preoccupation variable within the Body 
Image Questionnaire.  The higher protein group tended to have a greater increase in the 
social aspect (HP +4.4±15.5, HC +0.8±19.0, p=0.09) as well as in overweight 
preoccupation (HP +0.5±0.7, HC +0.4±0.7, p=0.09).  Since these values were only a 
trend towards significance, hypothesis H34 is still accepted.  This hypothesis stated there 
would be no statistically significant differences observed in psychometric parameters (as 
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measured via questionnaires regarding quality of life and body image) as a result of diet 
intervention and/or the presence of the HDL metabolic syndrome risk factor. 
ANALYSIS OF HYPERTENSION AS A RISK FACTOR 
 The hypertension risk factor for metabolic syndrome in women has been defined 
as a blood pressure value greater than or equal to 135 mmHg systolic and/or 85 mmHg 
diastolic.  Participants have been identified as either low blood pressure (LBP; <135/85 
mm/Hg, N=419), or high blood pressure (HBP; ≥135/85 mm/, N=244).   
Energy Intake 
 Table 4.27 depicts the time x diet x blood pressure risk factor MANOVA for 
total energy intake in kcals/kg/day as well as macronutrient intake in g/kg/day.  The 
three-way MANOVA revealed an overall time (Wilks’ Lambda p<0.001) and time x diet 
(Wilks’ Lambda p<0.001) effect, but no significant time x blood pressure risk factor 
(Wilks’ Lambda p=0.87) or time x diet x blood pressure risk factor (Wilks’ Lambda 
p=0.84) interactions.  Post hoc analysis on the ten-week values was utilized to determine 
the following: Participants in the HC group consumed significantly more calories (HP 
15.9±5.2, HC 17.4±4.7 kcal/kg/d, p=0.014) and carbohydrate (HP 1.41±0.7, HC 
2.20±0.7 g/kg/d, p<0.001), while the HP group consumed significantly more protein (HP 
1.14±0.5, HC 0.78±0.3 g/kg/d, p<0.001) relative to body weight.  Regarding specific 
group-combinations, energy intake was significantly greater for HC-LBP compared to 
HP-LBP (p=0.008), and HC-HBP was significantly greater than HP-HBP (p=0.009).  
For protein intake, HP-LBP was significantly greater than HC-LBP (p<0.001), and HP-
HBP was significantly greater than HC-HBP (p<0.001).   
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Table 4.27: Dietary Intake Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on the Hypertension Risk Factor Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Energy Intake  HP-LBP 20.86 ± 5.66 16.27g ± 5.30     T = 0.001 
(kcal/kg/day) HP-HBP 19.73 ± 5.87 15.33g ± 4.90     D = 0.003 
 HC-LBP 21.09 ± 6.59 17.57c,g ± 4.88     BP = 0.06 
 HC-HBP 20.94 ± 6.58 17.03d,g ± 4.36       D x BP = 0.35 
 HP 20.41 ± 5.76 15.90g ± 5.16 18.05† ± 0.24 T x D = 0.15 
 HC 21.04 ± 6.58 17.39a,g ± 4.71 19.16 ± 0.28 T x BP = 0.85 
 LBP 20.97 ± 6.11 16.88g ± 5.14 18.95 ± 0.22 T x D x BP = 0.60 
 HBP 20.21 ± 6.17 16.00g ± 4.76 18.26‡ ± 0.29   
 Time 20.69 ± 6.14 16.56* ± 5.02         
Protein Intake HP-LBP 0.86 ± 0.24 1.17g ± 0.52     T = 0.001 
(g/kg/day) HP-HBP 0.80c ± 0.22 1.10g ± 0.43     D = 0.001 
 HC-LBP 0.83 ± 0.23 0.80c ± 0.28     BP = 0.027 
 HC-HBP 0.82 ± 0.22 0.75d ± 0.21       D x BP = 0.41 
 HP 0.83 ± 0.23 1.14g ± 0.49 0.98† ± 0.01 T x D = 0.001 
 HC 0.83 ± 0.23 0.78a ± 0.26 0.80 ± 0.02 T x BP = 0.44 
 LBP 0.84 ± 0.24 1.00g ± 0.46 0.91 ± 0.01 T x D x BP = 0.82 
 HBP 0.81 ± 0.22 0.96g ± 0.40 0.87‡ ± 0.02   
 Time 0.83 ± 0.23 0.98* ± 0.44         
Carbohydrate HP-LBP 2.45 ± 0.85 1.44g ± 0.68     T = 0.001 
Intake (g/kg/day) HP-HBP 2.32 ± 0.88 1.37g ± 0.62     D = 0.001 
 HC-LBP 2.53 ± 0.92 2.23c,g ± 0.73     BP = 0.15 
 HC-HBP 2.51 ± 0.97 2.15d,g ± 0.66       D x BP = 0.57 
 HP 2.40 ± 0.87 1.41g ± 0.66 1.90† ± 0.03 T x D = 0.001 
 HC 2.52 ± 0.93 2.20a,g ± 0.71 2.36 ± 0.04 T x BP = 0.97 
 LBP 2.49 ± 0.88 1.81 ± 0.81 2.16 ± 0.03 T x D x BP = 0.45 
 HBP 2.40 ± 0.92 1.68 ± 0.74 2.09 ± 0.04   
 Time 2.46 ± 0.90 1.76* ± 0.79         
Fat Intake HP-LBP 0.85 ± 0.28 0.65g ± 0.28     T = 0.001 
(g/kg/day) HP-HBP 0.81 ± 0.27 0.61g ± 0.23     D = 0.95 
 HC-LBP 0.85 ± 0.33 0.61g ± 0.22     BP = 0.19 
 HC-HBP 0.85 ± 0.33 0.60g ± 0.20       D x BP = 0.30 
 HP 0.83 ± 0.27 0.63g ± 0.26 0.73 ± 0.01 T x D = 0.11 
 HC 0.85 ± 0.33 0.60g ± 0.21 0.73 ± 0.01 T x BP = 0.96 
 LBP 0.85 ± 0.30 0.63g ± 0.25 0.74 ± 0.01 T x D x BP = 0.95 
 HBP 0.82 ± 0.29 0.60g ± 0.22 0.71 ± 0.01   
 Time 0.84 ± 0.30 0.62* ± 0.24         
HP = higher protein, HC = higher carbohydrate, LBP = low blood pressure, HBP = high blood pressure risk factor, T = time effect, D = diet effect, BP 
= blood pressure risk factor effect, D x BP = diet by blood pressure risk factor effect, T x D = time by diet effect, T x BP = time by blood pressure risk 
factor effect, T x D x BP = time by diet by blood pressure risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 233 participants in the HP-LBP group, 148 in the HP-
HBP group, 196 in the HC-LBP group, 96 in the HC-HBP group, 371 in the HP total group, 292 in the HC total group, 419 in the LBP group, 244 in 
the HBP group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant blood pressure effect, p < 
0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LBP group, p < 0.05 (post hoc LSD).  
c Significantly different than HP-LBP group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HBP group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LBP group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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For carbohydrate intake, HC-LBP was significantly greater than HP-LBP (p<0.001), and 
HC-HBP was significantly greater than HP-HBP (p<0.001).  No significant differences 
were observed between group-combinations regarding fat intake.      
Overall Analysis 
 Table 4.28 represents the Greenhouse-Geisser univariate and (when applicable) 
Wilks’ Lambda multivariate p-levels for each of the variables and groups measured and 
analyzed by the various diet and blood pressure risk factor interactions (time, diet, blood 
pressure risk factor, time x diet, time x blood pressure risk factor, diet x blood pressure 
risk factor, and time x diet x blood pressure risk factor).  The significant findings per 
variable are discussed below.  When a significant three-way interaction was observed, 
the significant group differences revealed in the post hoc LSD pairwise comparisons 
analysis are also indicated.  Each corresponding hypothesis is also evaluated. 
Body Composition 
The three-way MANOVA on DEXA variables revealed an overall time (Wilks’ 
Lambda p<0.001) and time x diet (Wilks’ Lambda p=0.045) effect, but no significant 
time x blood pressure risk factor (Wilks’ Lambda p=0.52) or time x diet x blood pressure 
risk factor (Wilks’ Lambda p=0.32) interactions.  Review of the MANOVA univariate 
tests for DEXA variables demonstrated that for time x diet, the higher protein group 
experienced a significantly greater decrease in scanned mass (HP -3.9±3.5, HC -3.0±3.5 
kg, p=0.002) and fat mass (HP -3.1±2.7, HC -2.4±2.8 kg, p=0.007).  Additionally, 
regarding time x diet x blood pressure risk factor, body fat was significant at p=0.045.  
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Table 4.28: Significance Levels for Blood Pressure Risk Factor Analysis per Variable 
 
  Multivariate and Univariate P-Values Post Hoc Significance 
  T D T*D BP T*BP D*BP T*D*BP 
HP-
LBP 
HP-
HBP 
HC-
LBP 
HC-
HBP HP HC LBP HBP 
Body Composition 0.001   0.045   0.52   0.32                 
Scanned Mass 0.001 0.001 0.002 0.014 0.17 0.47 0.94 g c,g c,g d,g g a,g b,g g 
Fat Mass 0.001 0.001 0.007 0.018 0.13 0.75 0.32 g c,g c,g d,g g a,g b,g g 
Lean Mass 0.001 0.001 0.110 0.029 0.78 0.26 0.22 g c,g c,g d,g g a,g b,g g 
Body Fat 0.001 0.11 0.41 0.15 0.52 0.42 0.045 g g g g g g g g 
Weight 0.001 0.001 0.001 0.016 0.07 0.46 0.63 g c,g c,g d,g g a,g b,g g 
Body Mass Index 0.001 0.001 0.001 0.013 0.09 0.38 0.59 g c,g c,g d,g g a,g b,g g 
Waist Circumference 0.001 0.001 0.10 0.001 0.48 0.45 0.89 g c,g c,g d,g g a,g b,g g 
Hip Circumference 0.001 0.001 0.51 0.005 0.29 0.89 0.07 g c,g c,g d,g g a,g b,g g 
Resting Energy Expenditure 0.001 0.001 0.20 0.005 0.67 0.51 0.29 g c,g c,g d g a,g b,g g 
Hemodynamic 0.001   0.48   0.001   0.86                 
Resting Heart Rate 0.001 0.63 0.87 0.11 0.61 0.08 0.93 g g g g g g g g 
Systolic Blood Pressure 0.001 0.54 0.22 0.001 0.001 0.88 0.68 
 
c,g 
 
f,g g g b g 
Diastolic Blood Pressure 0.001 0.004 0.17 0.001 0.001 0.52 0.59 g c,g c f,g g a,g b g 
Blood Lipids 0.001   0.40   0.028   0.96                 
Total Cholesterol 0.001 0.38 0.53 0.003 0.09 0.28 0.99 g g g f,g g g b,g g 
LDL Cholesterol 0.001 0.32 0.66 0.015 0.38 0.44 0.76 g g g g g g g g 
HDL Cholesterol 0.001 0.61 0.85 0.27 0.045 0.67 0.90 g g g g g g g g 
Triglycerides 0.001 0.49 0.06 0.019 0.92 0.47 0.74 g c,g   g  b,g g 
TC/HDL Ratio 0.011 0.81 0.39 0.08 0.12 0.61 0.89       g   g b g 
Glucose 0.014 0.15 0.45 0.08 0.77 0.014 0.92  c  d g     
Insulin 0.47 0.037 0.87 0.019 0.52 0.001 0.68   c   a    
HOMA  0.68 0.034 0.72 0.015 0.43 0.001 0.60     c     a     
Maximum Strength 0.001   0.35   0.38   0.67                 
Bench Press Max Strength 0.001 0.07 0.67 0.22 0.10 0.19 0.27 g g g d,f,g g g g g 
Bench Press Lift Volume 0.96 0.60 0.64 0.39 0.30 0.024 0.57          
Leg Press Max Strength 0.001 0.047 0.30 0.46 0.26 0.16 0.40 g g g d,g g a,g    
Leg Press Lift Volume 0.30 0.001 0.054 0.98 0.74 0.07 0.44    d g a g g 
 Peak VO2 0.001 0.043 0.054 0.001 0.40 0.85 0.13 g c,g c,g f,g g a,g b,g g 
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Table 4.28: Continued 
  Multivariate and Univariate P-Values Post Hoc Significance 
  T D T*D BP T*BP D*BP T*D*BP 
HP-
LBP 
HP-
HBP 
HC-
LBP 
HC-
HBP HP HC LBP HBP 
SF36 Questionnaire 0.001   0.14   0.43   0.46                 
Physical Function 0.001 0.60 0.43 0.008 0.89 0.64 0.17 g c g g g g b,g g 
Role Physical 0.89 0.001 0.59 0.70 0.040 0.78 0.24 
  
c d 
 
a g   
Bodily Pain 0.014 0.94 0.20 0.001 0.98 0.18 0.93 g 
  
f g 
 
b,g   
General Health 0.001 0.001 0.57 0.50 0.73 0.76 0.62 g g c,g d,g g a,g g g 
Vital 0.001 0.10 0.41 0.94 0.21 0.81 0.07 g g g g g g g g 
Social 0.06 0.001 0.06 0.019 0.17 0.15 0.51 g 
 
c d,f g a g   
Role Emotional 0.630 0.001 0.07 0.79 0.70 0.96 0.69 
  
c 
  
a 
 
  
Mental Health 0.001 0.008 0.60 0.33 0.76 0.06 0.72 g c,g g d,g g a,g g g 
Body Image Questionnaire 0.001   0.54   0.88   0.77                 
Appearance Evaluation 0.001 0.58 0.48 0.80 0.57 0.49 0.50 g g g g g g g g 
Appearance Orientation 0.32 0.043 0.55 0.007 0.68 0.34 0.53 
  
c f 
 
a b   
Body Area Satisfaction Scale 0.001 0.007 0.31 0.001 0.52 0.23 0.25 g g c,g f,g g a,g b,g g 
Overweight Preoccupation 0.001 0.33 0.11 0.51 0.49 0.85 0.61 g g g g g g g g 
Self Classified Weight 0.013 0.12 0.66 0.57 0.69 0.29 0.61 
       
  
Rosenberg Self Esteem Scale 0.006 0.54 0.17 0.37 0.34 0.70 0.42 
 
g 
  
g 
  
g 
Social Physique Anxiety Scale 0.61 0.95 0.98 0.70 0.61 0.45 0.84                 
T = time effect, D = diet effect, T x D = time by diet effect, BP = blood pressure risk factor effect, T x BP = time by blood pressure risk factor effect, D x BP = diet by blood pressure risk factor effect, T 
x D x BP = time by diet by blood pressure risk factor effect.  HP = higher protein, HC = higher carbohydrate, LBP = low blood pressure (<135/85 mmHg), HBP = high blood pressure (≥135/85 mmHg).  
N=663 participants unless stated otherwise as follows: REE N=633, Insulin and HOMA N=252, Strength N=596, SF36 N=289, and Body Image N=451.   
Group breakdowns are as follows unless otherwise stated: 223 in the HP-LBP group, 148 in the HP-HBP group, 196 in the HC-LBP group, 96 in the HC-HBP group, 371 in the HP total group, 292 in the 
HC total group, 419 in the LBP group, 244 in the HBP group, and 663 participants total; for REE: 212 in the HP-LBP group, 145 in the HP-HBP group, 188 in the HC-LBP group, 88 in the HC-HBP 
group, 357 in the HP total group, 276 in the HC total group, 400 in the LBP group, 233 in the HBP group, and 633 participants total; for insulin and HOMA, 88 in the HP-LBP group, 61 in the HP-HBP 
group, 63 in the HC-LBP group, 40 in the HC-HBP group, 149 in the HP total group, 103 in the HC total group, 151 in the LBP group, 101 in the HBP group, and 252 participants total; for strength: 200 
in the HP-LBP group, 140 in the HP-HBP group, 172 in the HC-LBP group, 84 in the HC-HBP group, 340 in the HP total group, 256 in the HC total group, 372 in the LBP group, 224 in the HBP group, 
and 596 participants total;  for SF36: 102 in the HP-LBP group, 50 in the HP-HBP group, 95 in the HC-LBP group, 42 in the HC-HBP group, 152 in the HP total group, 137 in the HC total group, 197 in 
the LBP group, 92 in the HBP group, and 289 participants total; and for Body Image: 154 in the HP-LBP group, 102 in the HP-HBP group, 128 in the HC-LBP group, 67 in the HC-HBP group, 256 in 
the HP total group, 195 in the HC total group, 282 in the LBP group, 169 in the HBP group, and 451 participants total. 
Wilks’ Lambda Multivariate p-values for the group of variables are listed in bold. Greenhouse-Geisser Univariate p-values are listed for each variable included in the MANOVA (or ANOVA when 
indicated) analysis.  Superscripts indicate significant differences between groups using Post Hoc LSD Pairwise Comparisons.  a Significantly different than HP group, p < 0.05 (post hoc LSD).   
b Significantly different than HBP group, p < 0.05 (post hoc LSD).  c Significantly different than HP-LBP group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HBP group, p < 0.05 (post hoc 
LSD).  f Significantly different than HC-LBP group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD).                
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Post hoc analysis on the calculated delta change from baseline reveals that the HP-AH 
experienced a significantly greater decrease in fat percentage (-1.7±1.9%) compared to 
HC-AH (-1.2±2.0%, p=0.018).   
Individual three-way ANOVAs were used for weight, body mass index, and 
waist and hip circumference.  Significant univariate time x diet effects were observed for 
weight, body mass index, and a trend for waist circumference.  The higher protein group 
experienced a significantly greater decrease in weight (HP -4.2±3.6, HC -3.2±3.4 kg, 
p<0.001) and body mass index (HP -1.6±1.3, HC -1.2±1.3 kg/m2, p<0.001) as well as a 
tendency for a greater decrease in waist circumference (HP -4.0±5.7, HC -3.2±5.7 cm, 
p=0.095).  Both weight and body mass index experienced a trend towards a significant 
time x blood pressure risk factor effect.  The HBP group tended to have a greater 
decrease in weight (LBP -3.6±3.4, HBP -4.2±3.8 kg, p=0.07) and body mass index (LBP 
-1.36±1.3, HBP -1.56±1.4 kg/m2, p=0.09).  While no significant time x diet x blood 
pressure risk factor interactions were observed, hip circumference did reveal a trend 
towards significance with a p-value of 0.065.  Post hoc analysis on calculated delta 
change revealed HP-AH experienced a significantly greater decrease in hip 
circumference (-3.3±4.5%) compared to HC-AH (-2.3±5.0%, p=0.036).  Based on these 
findings, hypothesis H35, which stated there would be statistically significant differences 
observed in body composition as a result of diet intervention and hypothesis H36, which 
stated there would be no statistically significant differences observed in body 
composition as a result of the presence of the blood pressure metabolic syndrome risk 
factor are both accepted. 
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Resting Energy Expenditure 
The three-way ANOVA for resting energy expenditure and blood pressure risk 
factor revealed an overall time effect (p<0.001), but no significant interactions.  
Therefore, hypothesis H37 is accepted, which stated there would be no statistically 
significant differences in resting energy expenditure as a result of diet intervention 
and/or the presence of the blood pressure metabolic syndrome risk factor. 
Resting Hemodynamic Parameters 
The three-way MANOVA for resting hemodynamic parameters revealed a 
significant overall time (Wilks’ Lambda p<0.001) and time x blood pressure risk factor 
effect (Wilks’ Lambda p<0.001), but no significant time x diet (Wilks’ Lambda p=0.48) 
or time x diet x blood pressure risk factor (Wilks’ Lambda p=0.86) interactions.  Review 
of the MANOVA univariate tests revealed the HBP group experienced a significantly 
greater decrease compared to an increase in the LBP group for both systolic (LBP 
+1.1±12.3, HBP -9.5±16.1 mmHg, p<0.001) and diastolic pressure, (LBP +0.7±8.9, 
HBP -6.5±9.7 mmHg, p<0.001).  Based on these findings, hypotheses H38 and H39 are 
both accepted.  These hypotheses stated there would be no statistically significant 
differences observed in resting hemodynamic parameters as a result of diet intervention, 
and there would be statistically significant differences observed in resting hemodynamic 
parameters as a result of the presence of the blood pressure metabolic syndrome risk 
factor, respectively. 
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Blood Lipids 
  The three-way MANOVA on blood lipids revealed a significant time (Wilks’ 
Lambda p<0.001) and time x blood pressure risk factor effect (Wilks’ Lambda p=0.028), 
but no significant time x diet (Wilks’ Lambda p=0.40) or time x diet x blood pressure 
risk factor (Wilks’ Lambda p=0.96) interactions.  However, review of the MANOVA 
univariate tests does reveal a trend towards a time x diet interaction for triglycerides, 
which demonstrates the HP group tended to experience a greater decrease in triglyceride 
levels (HP -0.15±0.6, HC -0.05±0.6 mmol/L, p=0.06).  The HBP group experienced a 
significantly greater decrease in HDL cholesterol (LBP -0.05±0.23, HBP -0.09±0.23 
mmol/L, p=0.045) and tended to experience a greater decrease in total cholesterol (LBP  
-0.15±0.78, HBP -0.26±0.85 mmol/L, p=0.09).  Based on these findings, hypotheses H40 
is accepted and H41 is rejected.  These hypotheses stated there would be statistically 
significant differences observed in blood lipids as a result of diet intervention, and there 
would be no statistically significant differences observed in blood lipids as a result of the 
presence of the blood pressure metabolic syndrome risk factor, respectively. 
Glucose Homeostasis 
The three-way ANOVA for glucose revealed an overall time effect (p<0.014), 
but no significant interactions were observed for glucose, insulin, or HOMA.  Therefore 
hypothesis H42 is rejected, which stated there would be statistically significant 
differences observed in markers of glucose homeostasis as a result of diet intervention.  
However, hypothesis H43 is accepted, which stated there would be no statistically 
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significant differences observed in markers of glucose homeostasis as a result of the 
presence of the blood pressure metabolic syndrome risk factor. 
Fitness Parameters 
The three-way MANOVA on muscular fitness revealed an overall time effect 
(Wilks’ Lambda p<0.001), but no significant time x diet (Wilks’ Lambda p=0.35), time 
x blood pressure risk factor (Wilks’ Lambda p=0.38), or time x diet x blood pressure risk 
factor (Wilks’ Lambda p=0.67) interactions.  However, review of MANOVA univariate 
tests revealed a significant time x diet effect for leg press lift volume, where the higher 
protein group tended to have a significantly greater increase in leg press lift volume 
compared to a decrease in the higher carbohydrate group (HP +111.3±938, HC  
-19.9±829 kg, p=0.054). Additionally, a trend towards a time x blood pressure risk factor 
effect was observed for bench press maximum strength, in which the LBP group tended 
to experience a greater increase than HBP (LBP +2.40±5.0, HBP +1.74±4.9 kg, 
p=0.097).  The three-way ANOVA on cardiorespiratory fitness, measured by peak VO2, 
demonstrated a significant time (p<0.001) and time x diet effect (p=0.054).  The higher 
carbohydrate group experienced a significantly greater increase in peak VO2 (HP 
+1.9±3.0, HC +2.6±3.7 ml/kg/min, p=0.054).  Based on these finding, hypothesis H44 is 
rejected, which stated there would be no statistically significant differences observed in 
fitness parameters as a result of diet intervention and/or the presence of the blood 
pressure metabolic syndrome risk factor. 
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Psychometric Analysis 
The three-way MANOVA for SF36-Quality of Life demonstrated a significant 
time effect (Wilks’ Lambda p<0.001), but no significant time x diet (Wilks’ Lambda 
p=0.14), time x blood pressure risk factor (Wilks’ Lambda p=0.43) or time x diet x 
blood pressure risk factor (Wilks’ Lambda p=0.46) interactions.  Review of the 
MANOVA univariate tests reveals the higher protein group tended to experience greater 
improvement in the social variable (HP +4.4±15.5, HC +0.8±19.0, p=0.056) and the role 
emotional variable (HP +20.3±81.3, HC -9.2±180.4, p=0.07).  While no overall time x 
blood pressure risk factor effect was observed, MANOVA univariate tests revealed the 
LBP group experienced a significant increase compared to a decrease in the HBP group 
for the role physical variable (LBP +9.4±67.9, HBP -7.6±69.2, p=0.040).  A trend was 
also observed for time x diet x blood pressure risk factor for the vital variable (p=0.07), 
in which post hoc analysis on the calculated delta change from baseline revealed HP-AH 
experienced a significantly greater increase (+9.8±17.2) than both HC-AH (+4.9±13.1, 
p=0.019) and HP-MS (+4.0±13.1, p=0.024). 
The three-way MANOVA for Body Image demonstrated a significant time effect 
(Wilks’ Lambda p<0.001), but no significant time x diet (Wilks’ Lambda p=0.54), time 
x blood pressure risk factor (Wilks’ Lambda p=0.88) or time x diet x blood pressure risk 
factor (Wilks’ Lambda p=0.77) interactions.  Review of the MANOVA univariate tests 
also did not reveal any significant interactions.  Due to the significant univariate time x 
blood pressure interaction within the SF36 Questionnaire, hypothesis H45 is rejected, 
which stated there would be no statistically significant differences observed in 
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psychometric parameters (as measured via questionnaires regarding quality of life and 
body image) as a result of diet intervention and/or the presence of the blood pressure 
metabolic syndrome risk factor. 
ANALYSIS OF HYPERGLYCEMIA AS A RISK FACTOR 
 The hyperglycemia risk factor for metabolic syndrome in women has been 
defined as a fasting glucose level greater than or equal to 5.6 mmol/L.  Participants have 
been identified as having either low glucose (LG; <5.6 mmol/L, N=390), or high glucose 
(HG; ≥5.6 mmol/L, N=273).   
Energy Intake 
 Table 4.29 depicts the time x diet x glucose risk factor MANOVA for total 
energy intake in kcals/kg/day as well as macronutrient intake in g/kg/day.  The three-
way MANOVA revealed an overall time (Wilks’ Lambda p<0.001) and time x diet 
(Wilks’ Lambda p<0.001) effect, but no significant time x glucose risk factor (Wilks’ 
Lambda p=0.28) or time x diet x glucose risk factor (Wilks’ Lambda p=0.40) 
interactions.  Post hoc analysis on the ten-week values was utilized to determine the 
following: Participants in the HC group consumed significantly more calories (HP 
15.9±5.2, HC 17.4±4.7 kcal/kg/d, p<0.001) and carbohydrate (HP 1.41±0.7, HC 
2.20±0.7 g/kg/d, p<0.001) relative to body weight.  The HP group and the LG group 
consumed significantly more protein relative to body weight (HP 1.14±0.5, HC 0.78±0.3 
g/kg/d, p<0.001), (LG 1.01±0.5, HG 0.94±0.4 g/kg/d, p=0.014).  
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Table 4.29: Dietary Intake Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on the Hyperglycemia Risk Factor Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Energy Intake  HP-LG 20.7 ± 5.8 16.0g ± 5.4    T = 0.001 
(kcal/kg/day) HP-HG 20.0 ± 5.7 15.7g ± 4.7    D = 0.005 
 HC-LG 21.4 ± 6.7 17.7cg ± 4.9    G = 0.06 
 HC-HG 20.5 ± 6.3 16.9dg ± 4.3    D x G = 0.62 
 HP 20.4 ± 5.8 15.9g ± 5.2 18.1† ± 0.2 T x D = 0.11 
 HC 21.0 ± 6.6 17.4ag ± 4.7 19.1 ± 0.3 T x G = 0.72 
 LG 21.0 ± 6.3 16.8g ± 5.3 19.0 ± 0.2 T x D x G = 0.80 
 HG 20.2 ± 6.0 16.2g ± 4.6 18.3‡ ± 0.3  
 Time 20.7 ± 6.1 16.6* ± 5.0     
Protein Intake HP-LG 0.85 ± 0.2 1.19g ± 0.5    T = 0.001 
(g/kg/day) HP-HG 0.82 ± 0.2 1.08cg ± 0.4    D = 0.001 
 HC-LG 0.84 ± 0.2 0.80c ± 0.3    G = 0.007 
 HC-HG 0.81 ± 0.2 0.75d ± 0.2    D x G = 0.44 
 HP 0.83 ± 0.2 1.14g ± 0.5 0.98† ± 0.0 T x D = 0.001 
 HC 0.83 ± 0.2 0.78a ± 0.3 0.80 ± 0.0 T x G = 0.14 
 LG 0.84 ± 0.2 1.01g ± 0.5 0.92 ± 0.0 T x D x G = 0.42 
 HG 0.81 ± 0.2 0.94bg ± 0.4 0.87‡ ± 0.0  
 Time 0.83 ± 0.2 0.98* ± 0.4     
Carbohydrate HP-LG 2.44 ± 0.9 1.39g ± 0.7    T = 0.001 
Intake (g/kg/day) HP-HG 2.34 ± 0.9 1.45g ± 0.7    D = 0.001 
 HC-LG 2.56 ± 1.0 2.45cg ± 0.7    G = 0.24 
 HC-HG 2.47 ± 0.9 2.14dg ± 0.6    D x G = 0.41 
 HP 2.40 ± 0.9 1.41g ± 0.7 1.91† ± 0.0 T x D = 0.001 
 HC 2.52 ± 0.9 2.20ag ± 0.7 2.35 ± 0.0 T x G = 0.31 
 LG 2.50 ± 0.9 1.77g ± 0.8 2.16 ± 0.0 T x D x G = 0.24 
 HG 2.40 ± 0.9 1.74g ± 0.7 2.10 ± 0.0  
 Time 2.46 ± 0.9 1.76* ± 0.8     
Fat Intake HP-LG 0.84 ± 0.3 0.64g ± 0.3    T = 0.001 
(g/kg/day) HP-HG 0.82 ± 0.3 0.62g ± 0.2    D = 0.70 
 HC-LG 0.86 ± 0.3 0.61g ± 0.2    G = 0.17 
 HC-HG 0.82 ± 0.3 0.59g ± 0.2    D x G = 0.63 
 HP 0.83 ± 0.3 0.63g ± 0.3 0.73 ± 0.0 T x D = 0.13 
 HC 0.85 ± 0.3 0.60g ± 0.2 0.72 ± 0.0 T x G = 0.75 
 LG 0.85 ± 0.3 0.63g ± 0.3 0.74 ± 0.0 T x D x G = 0.64 
 HG 0.82 ± 0.3 0.61g ± 0.2 0.72 ± 0.0  
 Time 0.84 ± 0.3 0.62* ± 0.2     
HP = higher protein, HC = higher carbohydrate, LG = low glucose, MS = high glucose risk factor, T = time effect, D = diet effect, G = glucose risk 
factor effect, D x G = diet by glucose risk factor effect, T x D = time by diet effect, T x G = time by glucose risk factor effect, T x D x G = time by 
diet by glucose risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 214 participants in the HP-LG group, 157 in the 
HP-HG group, 176 in the HC-LG group, 116 in the HC-HG group, 371 in the HP total group, 292 in the HC total group, 390 in the LG group, 273 
in the HG group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant glucose effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Regarding specific group-combinations, energy intake was significantly greater for HC-
LG compared to HP-LG (p=0.001), and HC-HG was significantly greater than HP-HG 
(p=0.050).  For carbohydrate intake, HC-LG was significantly greater than HP-LG 
(p<0.001), and HC-HG was significantly greater than HP-HG (p<0.001).  For protein 
intake, HP-LG was significantly greater than both HP-HG (p=0.011) and HC-LG 
(p<0.001), and HP-HG was significantly greater than HC-HG (p<0.001). No significant 
differences were observed between group-combinations regarding fat intake.   
Overall Analysis 
Table 4.30 represents the Greenhouse-Geisser univariate and (when applicable) 
Wilks’ Lambda multivariate p-levels for each of the variables and groups measured and 
analyzed by the various diet and glucose risk factor interactions (time, diet, glucose risk 
factor, time x diet, time x glucose risk factor, diet x glucose risk factor, and time x diet x 
glucose risk factor).  The significant findings per variable are discussed below.  When a 
significant three-way interaction was observed, the significant group differences 
revealed in the post hoc LSD pairwise comparisons analysis are also indicated.  Each 
corresponding hypothesis is also evaluated. 
Body Composition 
Within the body composition analyses, a significant time (Wilks’ Lambda 
p<0.001) and time x diet effect (Wilks’ Lambda p=0.030) was observed for the DEXA 
variables, but no significant time x glucose risk factor (Wilks’ Lambda p=0.74) or time x 
diet x glucose risk factor (Wilks’ Lambda p=0.30) interactions were observed.  
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Table 4.30: Significance Levels for Glucose Risk Factor Analysis per Variable 
 
  Multivariate and Univariate P-Values Post Hoc Significance 
  T D T*D G T*G D*G T*D*G 
HP-
LG 
HP-
HG 
HC-
LG 
HC-
HG HP HC LG HG 
Body Composition 0.001   0.030   0.74   0.30                 
Scanned Mass 0.001 0.001 0.001 0.002 0.47 0.99 0.88 g c,g c,g d,f,g g a,g b,g g 
Fat Mass 0.001 0.001 0.004 0.006 0.23 0.99 0.27 g c,g c,g d,g g a,g b,g g 
Lean Mass 0.001 0.001 0.12 0.002 0.68 0.81 0.23 g c,g c,g d,f,g g a,g b,g g 
Body Fat 0.001 0.055 0.28 0.14 0.18 0.84 0.056 g g g g g g g g 
Weight 0.001 0.001 0.001 0.001 0.32 0.82 0.44 g c,g c,g d,f,g g a,g b,g g 
Body Mass Index 0.001 0.001 0.001 0.001 0.32 0.68 0.47 g c,g c,g d,f,g g a,g b,g g 
Waist Circumference 0.001 0.001 0.14 0.001 0.90 0.92 0.07 g c,g c,g d,f,g g a,g b,g g 
Hip Circumference 0.001 0.001 0.38 0.001 0.63 0.62 0.033 g c,g c,g d,f,g g a,g b,g g 
Resting Energy Expenditure 0.001 0.001 0.39 0.001 0.051 0.65 0.46 g c,g c d,g g a,g b,g g 
Hemodynamic 0.001   0.89   0.47   0.025                 
Resting Heart Rate 0.001 0.21 0.79 0.019 1.000 0.20 0.78 g c,g g g g g b,g g 
Systolic Blood Pressure 0.001 0.13 0.92 0.001 0.49 0.77 0.002 
 
g c,g f g g b,g g 
Diastolic Blood Pressure 0.001 0.001 0.55 0.001 0.11 0.74 0.15   g c,g f,g g a,g b,g g 
Blood Lipids 0.001   0.65   0.001   0.048                 
Total Cholesterol 0.001 0.72 0.47 0.001 0.001 0.54 0.77  g  g g g g g 
LDL Cholesterol 0.001 0.55 0.66 0.001 0.001 0.41 0.57  c,g  g g g b,g g 
HDL Cholesterol 0.001 0.72 0.96 0.001 0.011 0.48 0.27 g c,g g f,g g g b,g g 
Triglycerides 0.001 0.45 0.09 0.001 0.09 0.21 0.14 g c,g  f,g g  b,g g 
TC/HDL Ratio 0.025 0.93 0.42 0.001 0.70 0.20 0.68   c   f   g b   
Glucose 0.001 0.32 0.81 0.001 0.001 0.07 0.017  c,g g d,f,g g g b,g g 
Insulin 0.74 0.002 0.59 0.001 0.45 0.38 0.36  c  f  a b   
HOMA  0.94 0.002 0.38 0.001 0.28 0.19 0.19   c   f   a b   
Maximum Strength 0.001   0.40   0.54   0.48                 
Bench Press Max Strength 0.001 0.15 0.41 0.13 0.34 0.96 0.88 g g g g g g g g 
Bench Press Lift Volume 0.76 0.82 0.55 0.38 0.78 0.73 0.45          
Leg Press Max Strength 0.001 0.10 0.32 0.90 0.77 0.67 0.15 g g g g g g g g 
Leg Press Lift Volume 0.15 0.003 0.11 0.36 0.21 0.68 0.50   c  g a    
 Peak VO2 0.001 0.020 0.026 0.001 0.014 0.85 0.28 g c,g c,g f,g g a,g b,g g 
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Table 4.30: Continued 
  Multivariate and Univariate P-Values Post Hoc Significance 
  T D T*D G T*G D*G T*D*G 
HP-
LG 
HP-
HG 
HC-
LG 
HC-
HG HP HC LG HG 
SF36 Questionnaire 0.001   0.12   0.42   0.25                 
Physical Function 0.001 0.62 0.65 0.20 0.79 0.38 0.30 g c g g g g g g 
Role Physical 0.43 0.001 0.95 0.16 0.13 0.61 0.51 
  
c d 
 
a 
 
  
Bodily Pain 0.009 0.50 0.18 0.25 0.81 0.69 0.94 g g 
  
g 
  
  
General Health 0.001 0.001 0.53 0.03 0.19 0.79 0.10 g c c,g d,g g a,g b,g g 
Vital 0.001 0.09 0.24 0.97 0.37 0.33 0.020 g g 
 
g g g g g 
Social 0.018 0.001 0.08 0.27 0.10 0.24 0.51 g c 
 
d g a g   
Role Emotional 0.64 0.001 0.056 0.50 0.19 0.64 0.74 
  
c d 
 
a 
 
  
Mental Health 0.001 0.036 0.71 0.12 0.54 0.57 0.014 g c,g g d,g g g g g 
Body Image Questionnaire 0.001 
 
0.62   0.55   0.041                 
Appearance Evaluation 0.001 0.54 0.64 0.65 0.08 0.56 0.57 g g g g g g g g 
Appearance Orientation 0.31 0.032 0.66 0.002 0.52 0.28 0.15 
 
c c 
  
a b   
Body Area Satisfaction Scale 0.001 0.002 0.32 0.18 0.56 0.69 0.25 g g c,g g g a,g g g 
Overweight Preoccupation 0.001 0.22 0.26 0.31 0.72 0.29 0.18 g g g g g g g g 
Self Classified Weight 0.008 0.036 0.93 0.009 0.41 0.35 0.010 
 
g c,g 
 
g 
  
g 
Rosenberg Self Esteem Scale 0.006 0.67 0.10 0.055 0.53 0.62 0.11 
 
g 
  
g 
  
g 
Social Physique Anxiety Scale 0.74 0.82 0.70 0.72 0.95 0.99 0.18                 
T = time effect, D = diet effect, T x D = time by diet effect, G = glucose risk factor effect, T x G = time by glucose risk factor effect, D x G = diet by glucose risk factor effect, T x D x G = time by diet 
by glucose risk factor effect.  HP = higher protein, HC = higher carbohydrate, LG = low glucose (<5.6 mmol/L), HG = high glucose (≥5.6 mmol/L).  
N=663 participants unless stated otherwise as follows: REE N=633, Insulin and HOMA N=252, Strength N=596, SF36 N=289, and Body Image N=451.   
Group breakdowns are as follows unless otherwise stated: 214 in the HP-LG group, 157 in the HP-HG group, 176 in the HC-LG group, 116 in the HC-HG group, 371 in the HP total group, 292 in the 
HC total group, 390 in the LG group, 273 in the HG group, and 663 participants total; for REE: 209 in the HP-LG group, 148 in the HP-HG group, 169 in the HC-LG group, 107 in the HC-HG group, 
357 in the HP total group, 276 in the HC total group, 378 in the LG group, 255 in the HG group, and 633 participants total; for insulin and HOMA: 109 in the HP-LG group, 40 in the HP-HG group, 
67 in the HC-LG group, 36 in the HC-HG group, 149 in the HP total group, 103 in the HC total group, 176 in the LG group, 76 in the HG group, and 252 participants total; for strength: 196 in the HP-
LG group, 144 in the HP-HG group, 154 in the HC-LG group, 102 in the HC-HG group, 340 in the HP total group, 256 in the HC total group, 350 in the LG group, 246 in the HG group, and 596 
participants total; for SF36: 83 in the HP-LG group, 69 in the HP-HG group, 82 in the HC-LG group, 55 in the HC-HG group, 152 in the HP total group, 137 in the HC total group, 165 in the LG 
group, 124 in the HG group, and 289 participants total; and for Body Image: 161 in the HP-LG group, 95 in the HP-HG group, 120 in the HC-LG group, 75 in the HC-HG group, 256 in the HP total 
group, 195 in the HC total group, 281 in the LG group, 170 in the HG group, and 451 participants total. 
Wilks’ Lambda Multivariate p-values for the group of variables are listed in bold. Greenhouse-Geisser Univariate p-values are listed for each variable included in the MANOVA (or ANOVA when 
indicated) analysis.  Superscripts indicate significant differences between groups using Post Hoc LSD Pairwise Comparisons.  a Significantly different than HP group, p < 0.05 (post hoc LSD).   
b Significantly different than HG group, p < 0.05 (post hoc LSD).  c Significantly different than HP-LG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HG group, p < 0.05 (post hoc 
LSD).  f Significantly different than HC-LG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD).                
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Review of the MANOVA univariate tests revealed the higher protein group experienced 
a significantly greater decrease for both scanned mass (HP -3.9±3.5, HC -3.0±3.5 kg, 
p=0.001) and fat mass (HP -3.1±2.7, HC -2.4±2.8 kg, p=0.004).  Additionally, a trend 
was observed for body fat for the time x diet x glucose risk factor interaction (p=0.056).  
Post hoc analysis of body composition data expressed in delta changes from baseline 
revealed the HC-LG group experienced a significantly smaller decrease (-1.16±2.0%) in 
fat percentage than both HP-LG (-1.62±1.8%, p=0.020) and HC-HG (-1.66±1.9%, 
p=0.031).    
Individual three-way ANOVAs were used for weight, body mass index, and 
waist and hip circumference.  Significant time x diet effects were observed for both 
weight and body mass index.  The higher protein group experienced a significantly 
greater decrease in both weight (HP -4.3±3.6, HC -3.2±3.4 kg, p<0.001) and body mass 
index (HP -1.6±1.3, HC -1.2±1.3 kg/m2, p<0.001).  Additionally, a significant three-way 
interaction on time x diet x glucose risk factor was observed for hip circumference 
(p=0.033) and a trend was observed for waist circumference (p=0.073).  Post hoc 
analysis on waist and hip circumference as delta change from baseline revealed the HP-
LG experienced a significantly greater decrease than HC-LG in waist circumference 
(HP-LG -4.3±5.5, HC-LG -2.8±5.7 cm, p=0.010) and hip circumference (HP-LG  
-3.5±5.1, HC-LG -2.3±5.1 cm, p=0.019).  Based on these findings, hypothesis H46 which 
stated there would be statistically significant differences observed in body composition 
as a result of diet intervention, is accepted, and hypothesis H47 which stated there would 
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be no statistically significant differences observed in body composition as a result of the 
presence of the glucose metabolic syndrome risk factor, is rejected. 
Resting Energy Expenditure 
The three-way ANOVA on resting energy expenditure revealed a significant time 
(p<0.001) and time x glucose risk factor effect (p=0.051).  Participants in the high 
glucose group experienced a significantly greater decrease in resting energy expenditure 
(LG -42.4±202.7, HG -75.0±224 kcal/d, p=0.051).  Based on this finding, hypothesis H48 
is rejected, which stated there would be no statistically significant differences observed 
in resting energy expenditure parameters as a result of diet intervention and/or the 
presence of the glucose metabolic syndrome risk factor. 
Resting Hemodynamic Parameters 
No significant overall time x diet (Wilks’ Lambda p=0.89) or time x glucose risk 
factor (Wilks’ Lambda p=0.47) effects were observed within the MANOVA on resting 
hemodynamic parameters, however significant time (Wilks’ Lambda p<0.001) and time 
x diet x glucose risk factor (Wilks’ Lambda p=0.025) effects were observed.  Post hoc 
analysis using calculations of delta change from baseline revealed the HC-HG group 
experienced a significantly greater decrease in systolic blood pressure than all other 
group-combination (-5.1±14.9 mmHg, p=0.040).  Based on this finding, hypothesis H49 
is rejected, which stated there would be no statistically significant differences observed 
in resting hemodynamic parameters as a result of diet intervention and/or the presence of 
the glucose metabolic syndrome risk factor. 
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Blood Lipids 
The three-way MANOVA on blood lipid variables revealed a significant time 
(Wilks’ Lambda p<0.001), time x glucose risk factor (Wilks’ Lambda p<0.001), and 
time x diet x glucose risk factor (Wilks’ Lambda p=0.048) effect, but no significant time 
x diet (Wilks’ Lambda p=0.65) interaction.  While the overall MANOVA time x diet 
interaction was not significant, review of MANOVA univariate tests reveals that the 
higher protein group tended to experience a greater decrease in triglyceride levels (HP  
-0.15±0.62, HC -0.05±0.60 mmol/L, p=0.09).  Participants with high glucose 
experienced significantly greater decreases in total cholesterol (LG -0.09±0.8, HG  
-0.33±0.9 mmol/L, p<0.001), LDL cholesterol (LG -0.07±0.6, HG -0.25±0.7 mmol/L, 
p<0.001), and a tendency for a greater decrease in triglycerides (LG -0.07±0.5, HG  
-0.14±0.7 mmol/L, p=0.094). Participants in the high glucose group also experienced a 
significantly greater decrease in HDL cholesterol (LG -0.05±0.24, HG -0.09±0.2 
mmol/L, p=0.011).  While the three-way MANOVA on blood lipids demonstrated a 
trend towards significance for time x diet x glucose risk factor, when each of the lipid 
variables were analyzed independently, the interaction did not prove significant.  Based 
on these findings, hypothesis H50, which stated there would be statistically significant 
differences observed in blood lipids as a result of diet intervention and/or the presence of 
the glucose metabolic syndrome risk factor, is accepted. 
Glucose Homeostasis 
The three-way ANOVA on glucose revealed a significant time (p<0.001), time x 
glucose risk factor (p<0.001) as well as a time x diet x glucose risk factor (p=0.017) 
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effect.  Participants with high glucose levels experienced a significantly greater decrease 
in fasting glucose in comparison to a mild increase in the low glucose group (LG 
+0.12±0.6, HG -0.4±1.3 mmol/L, p<0.001).  Post hoc analysis on glucose data expressed 
in delta changes from baseline revealed the HP-HG group experienced a significantly 
greater decrease in fasting glucose (-0.34±1.3 mmol/L) compared to a slight increase in 
the HP-LG group (+0.03±0.6 mmol/L, p<0.001), and likewise the HC-HG group 
experienced a significantly greater decrease (-0.49±1.2 mmol/L) compared to a slight 
increase in the HC-LG group (+0.22±0.5 mmol/L, p<0.001).  No significant effects were 
observed within the insulin or HOMA analyses.  Based on these findings hypothesis H51 
is accepted, which stated there would be statistically significant differences observed in 
markers of glucose homeostasis as a result of diet intervention and/or the presence of the 
glucose metabolic syndrome risk factor. 
Fitness Parameters 
No significant interactions were observed in the three-way MANOVA on 
muscular fitness parameters, however there was a significant time effect (Wilks’ 
Lambda p<0.001).  The ANOVA on cardiorespiratory fitness, measured by peak VO2, 
demonstrated a significant time (Greenhouse-Geisser p<0.001), time x diet (Greenhouse-
Geisser p=0.026) and a time x glucose risk factor (Greenhouse-Geisser p=0.014) effect.  
The higher carbohydrate and low glucose groups both experienced a significantly greater 
increase in peak VO2 (HP +1.9±3.0, HC +2.6±3.7 ml/kg/min, p=0.026), (LG +2.5±3.6, 
HG +1.8±3.0 ml/kg/min, p=0.014).  Based on these results, hypothesis H52 which stated 
there would be no statistically significant differences observed in fitness parameters as a 
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result of diet intervention and/or the presence of the glucose metabolic syndrome risk 
factor, is rejected. 
Psychometric Analysis 
The three-way MANOVA on SF36-Quality of Life Questionnaire revealed a 
significant time (Wilks’ Lambda p<0.001), but no significant time x diet (Wilks’ 
Lambda p=0.12), time x glucose risk factor (Wilks’ Lambda p=0.42), or time x diet x 
glucose risk factor (Wilks’ Lambda p=0.25) interactions.  However, review of the 
MANOVA univariate tests revealed trends towards significance for both the social and 
role emotional variables for time x diet.  There was a tendency for a greater increase in 
the HP group for both the social aspect (HP +4.5±15.5, HC +0.9±19.2, p=0.08) and the 
role emotional aspect (HP +20.3±81.3, HC -9.2±180.4, p=0.056).  The social aspect also 
experienced a trend for time x glucose risk factor, where the LG group tended to 
experience a greater increase (LG +4.2±15.6, HG +0.9±19.0, p=0.10).  Finally, for the 
time x diet x glucose risk factor interaction, the general health aspect experienced a trend 
(p=0.10), and both the vital aspect (p=0.02) and the mental health aspect (p=0.014) were 
significant.  Post hoc analysis on the delta changes from baseline revealed that the HP-
LG group experienced a significantly greater increase in the general health aspect than 
HP-HG (HP-LG +6.3±13.0, HP-HG +2.1±10.6, p=0.030).  Regarding the vital aspect, 
the HC-LG group experienced significantly less of an increase (+2.9±12.7) compared to 
both HP-LG (+9.0±12.4, p=0.007) and HC-HG (+8.6±12.7, p=0.27).  For mental health, 
the HP-LG group experienced a significantly greater increase (+11.1±13.7) compared to 
both the HP-HG (+5.6±19.4, p=0.024) and HC-LG (+6.0±12.0, p=0.029) groups. 
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 The three-way MANOVA for the Body Image Questionnaire variables revealed a 
significant time (Wilks’ Lambda p<0.001) and time x diet x glucose risk factor (Wilks’ 
Lambda p=0.041) effect, but no significant time x diet (Wilks’ Lambda p=0.62) or time 
x glucose risk factor (Wilks’ Lambda p=0.55) interactions.  However, review of the 
MANOVA univariate tests revealed a trend towards significance for time x diet for the 
Rosenberg self esteem scale, where the HP group tended to experience a greater increase 
(HP +0.6±3.2, HC +0.2±3.4, p=0.10).  Additionally, a trend towards significance for 
time x glucose risk factor was observed for appearance evaluation, where the LG group 
tended to experience a greater increase (LG +0.39±0.6, HG +0.29±0.6, p=0.08).  
Regarding the significant overall three-way interaction, self-classified weight revealed 
the significant univariate interaction (p=0.010).  Post hoc analysis using the delta 
changes from baseline revealed that for the self-classified weight variable the HP-LG 
group experienced a significant increase (+0.02±0.8) compared to decreases in both HP-
HG (-0.24±0.6, p=0.010) and HC-LG (-0.17±0.7, p=0.044).  Based on these findings, 
hypothesis H53 is rejected, which stated there would be no statistically significant 
differences observed in psychometric assessments (as measured via questionnaires 
regarding quality of life and body image) as a result of diet intervention and/or the 
presence of the glucose metabolic syndrome risk factor. 
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CHAPTER V 
SUMMARY 
 
 This analysis sought to determine if following a higher protein diet intervention 
for ten-weeks promotes a reduction in metabolic syndrome and the individual NCEP 
ATP III risk factors more effectively than a higher carbohydrate diet for the same time 
period, when combined with a circuit-style resistance-based program.  Overall, 
participants in both dietary groups decreased body fat, resting heart rate and blood 
pressure, improved lipid profiles, and increased strength with no significant differences 
observed between groups.  Approximately 80% of weight lost for all participants was fat 
loss.  However, participants following the higher protein diet experienced a greater 
improvement in body composition (scanned mass, fat mass, and weight, with a trend for 
waist circumference).  Individuals classified as having metabolic syndrome benefited 
from greater reductions in body composition, blood pressure, triglycerides and glucose 
than participants categorized as apparently healthy, and participants with metabolic 
syndrome on the higher protein diet (HP-MS) experienced the greatest decrease in 
scanned mass overall.  Generally, participants with metabolic syndrome were more 
overweight, had higher blood pressure, and had less optimal lipid profiles at the 
beginning of the study, and therefore achieved greater benefits at the end of the ten-week 
diet and exercise protocol.  Similar results were found for each of the individual risk 
factor stratifications, in which the groups with elevated risk factors experienced greater 
benefits in that variable over the ten-week term.   
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This analysis generally concurs with earlier research on dietary interventions 
with, and without, exercise prescriptions.  Previous studies have demonstrated that a 
higher protein diet can lead to a greater reduction in weight [131, 134, 135, 139, 142, 
144, 145] and fat mass [43, 63, 120, 122, 125, 131, 142, 146, 147, 180, 203], when 
compared to a higher carbohydrate diet alone and also when combined with exercise [42, 
43, 172, 174, 178-180].  This analysis also agrees with other studies, specific to 
metabolic syndrome risk factors, that have shown no significant difference between 
higher carbohydrate and higher protein diets but observed an overall decrease in blood 
pressure [42, 67, 120, 131, 132, 135-137, 145, 152, 153, 156, 174, 175, 181, 236], HDL 
cholesterol [42, 67, 133, 153, 154, 173], and glucose [42, 131, 132, 136-139, 142, 147, 
148, 154, 156, 174, 236, 237].  
Many short-term studies comparing differing carbohydrate and protein 
allotments without an exercise component report findings similar to the present analysis.  
For example, Morenga et al[142] evaluated the effect of a moderate-high protein 
consumption (PRO:CHO:FAT 30:40:30) versus a high carbohydrate diet (20:50:30) on 
obese women for an eight-week period and reported that both groups lost weight, body 
fat, waist circumference, blood pressure, total cholesterol, LDL cholesterol, and glucose.  
Similar to the present analysis, the higher protein group lost significantly more weight 
and total body fat, yet Morenga’s participants also experienced a greater decrease in 
diastolic blood pressure.  Additionally, a twelve-week study by Noakes et al[173] 
compared obese females consuming either a higher protein (34:46:20) or a higher 
carbohydrate (17:64:20) diet and similarly revealed a decrease in weight, glucose, and 
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HDL cholesterol for both groups, yet also found a significantly greater decrease in 
triglycerides for the higher protein group.  This study also categorized participants based 
on triglyceride level (< or >1.5 mmol/L) and, similar to the present analysis, found that 
subjects with higher triglycerides lost a greater amount of fat mass on the higher protein 
diet. 
Furthermore, similar findings have been reported by many short-term studies 
with dietary assignments comparable to the present analysis that also include an exercise 
component.  In a four-month study by Layman et al[43], evaluating obese females 
consuming either a higher carbohydrate (0.8 g/kg/d PRO, 3.5 g/kg/d CHO) or a higher 
protein (1.6 g/kg/d PRO, <1.5 g/kg/d CHO) diet while participating in either voluntary 
walking or mandatory resistance training, the higher protein groups (regardless of 
exercise intervention) lost significantly more weight and fat mass, as observed in the 
present analysis, yet also experienced greater reductions in triglycerides.  Additionally, 
Layman et al also observed better maintenance of HDL cholesterol in their higher 
protein group and greater reductions in total and LDL cholesterol in their carbohydrate 
group, which were not reported in the present analysis.  Meckling and Sherfey[120] 
conducted a twelve-week study measuring the change in MetS risk factors in overweight 
females by utilizing a control group (CHO:PRO = 3.0) versus a higher protein 
(CHO:PRO = 1.0) diet with or without a 36-minute circuit training program three times a 
week.  Similar to the present analysis, exercising participants in the Meckling study 
improved cardiovascular fitness and lost weight (although this study found no 
differences based on diet), yet the higher protein diet combined with exercise lead to a 
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greater loss in triglycerides.  In a sixteen-week study by Wycherley et al[42], obese 
subjects with type 2 diabetes consumed either a higher carbohydrate (19:53:26) diet, or a 
higher protein diet (33:43:22), with or without the addition of resistance training three 
times a week.  While all groups improved body composition, blood pressure, lipid 
profile, and insulin sensitivity, the higher protein group with resistance training lost a 
significantly greater amount of weight, fat mass, and waist circumference, as was the 
case in the present analysis.  Finally, Layman et al[180] performed a four-month study 
on obese subjects comparing a higher carbohydrate (15:55:30; 0.8 g/kg/d PRO) and a 
higher protein (30:40:30; 1.6 g/kg/d PRO) diet with thirty-minutes of walking five times 
a week.  Similar to the present analysis, they found a greater decrease in fat mass in the 
HP group, however they also reported a greater decrease in triglycerides in the HP group 
and in total and LDL cholesterol in the HC group.  Interestingly, the beneficial affects of 
the HP diet on body composition and triglyceride levels were sustained during an eight-
month follow up, while the changes to the lipid profile based on the HC diet were not.  
This is promising for the results presented for the higher protein group in the present 
analysis. 
Many studies have shown diet and exercise protocols to be effective for subjects 
specifically with metabolic syndrome as well.  Miller et al[89] utilized a high protein and 
high fat diet (30:27:43) for three months in adults with MetS and observed a significant 
decrease in weight, waist circumference, blood pressure, and the prevalence of MetS.  In 
a six-week study on MetS subjects by Rajaie et al[111], a moderately-restricted 
carbohydrate diet lead to significantly greater reductions in diastolic blood pressure and 
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MetS prevalence.  Lopez-Jimenez et al [148] did not observe much difference between a 
low fat diet and a lower carbohydrate / higher protein diet in a six month protocol on 
metabolic syndrome, but observed an overall decrease in weight, triglycerides and 
glucose, with a greater decrease in MetS prevalence in the lower carbohydrate group.  In 
a twelve-month study on MetS subjects by Flechtner-Mors et al[139], the higher protein 
group (30:40:30) experienced significantly greater reductions in weight, waist 
circumference, triglycerides, and MetS prevalence.  Finally, similar to the present 
analysis, a study by Campbell and Meckling[67] that incorporated a 60-minute exercise 
circuit three times a week in addition to numerous protein:carbohydrate ratios observed 
few significant differences between the dietary protocols, but an overall decrease in 
weight, waist circumference, blood pressure, and triglycerides.  These studies support 
the present analysis in their findings that regardless of the specific dietary protocol, diet 
and exercise can lead to a reduction in prevalence of metabolic syndrome and its 
individual risk factors.   
Several studies, however, have reported findings that were not supported by the 
present analysis.  Numerous previous observations have reported that replacing some 
carbohydrate consumption with protein can lead to a greater decrease in triglyceride 
levels through diet alone [31-33, 122-139] and when combined with exercise [43, 120, 
173, 174, 178-180, 182], which was not observed in the present analysis.  Some studies 
have stated that higher protein intake more effectively leads to improved lipid profile 
and glycemic control [43, 63, 120], yet this observation was not apparent in the present 
analysis.  However, these studies suggest a protein intake >1.4 g/kg/day, and the present 
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analysis only utilized an intake of 1.14 g/kg/day protein for the HP group.  Other studies 
have indicated higher protein diets alone [123, 126, 131, 132, 134-136, 139] and 
combined with exercise [172, 175, 178-181] are more effective at increasing HDL 
cholesterol.  Conversely, the present analysis experienced a decrease in HDL throughout 
the study with no difference between diet groups, yet a larger decrease in the apparently 
healthy group than the metabolic syndrome group.  However, overall the AH group 
mean HDL was 1.4±0.3 mmol/L at the end of the study, well above the <1.3 mmol/L cut 
off point that defines HDL as a MetS risk factor.  Additionally, evidence suggests that 
lower fat diets may be responsible for the decrease in HDL cholesterol[97, 238], and/or 
that HDL particle size may shift during weight loss [238-240], but also that this decrease 
in HDL during weight loss may increase again once weight is stabilized [58].  The 
aforementioned shift is not taken into consideration within the HDL lipid measurement 
and therefore these results may not actually be indicative of an increase in risk, 
particularly considering total cholesterol, LDL cholesterol and triglycerides all decreased 
in the present analysis without a change in TC/HDL or TG/HDL ratios.    
CONCLUSION 
Overall, the present analysis has shown that diet and exercise are beneficial for 
improving markers of health.  This retrospective analysis was partially based on 
recommendations by Layman et al[43], suggesting that a CHO-based, low-fat diet may 
work better for persons needing to lower total cholesterol and LDL, while a PRO-based 
diet could positively benefit individuals who have elevated TG and low HDL.  
Unfortunately, the present analysis did not indicate a differential effect in blood lipid 
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values based on macronutrient ratios.  However, beneficial effects on body composition 
were seen with the higher protein diet regardless of whether individuals were stratified 
based on general metabolic syndrome status or by each MetS risk factor individually.  
The macronutrient ratios utilized for the higher carbohydrate group in this analysis 
correspond to the NCEP ATP III recommendations for individuals with MetS [17], and 
the protein intake in the HC group matches the current recommended daily allowance for 
protein [114, 115].  However the results from this analysis indicate that the current RDA 
for protein intake in the general population, as well as the dietary recommendations set 
forth by the NCEP ATP III for individuals with metabolic syndrome may not be the 
most effective, and should be replaced with a higher protein requirement in order to 
more effectively alter body composition in subjects with metabolic syndrome.   
Due to the nature of a retrospective analysis, this study experienced a few 
limitations and restrictions regarding the analysis and information available within the 
dataset.  One limitation regarding the analysis was that participants were assigned to a 
dietary protocol based on their response to the Carbohydrate Intolerance Questionnaire 
(Appendix F).  The fact that participants were initially labeled as carbohydrate tolerant 
or intolerant, and placed into higher carbohydrate or higher protein diets respectively, 
may produce a confounding variable within the analysis.  However, this questionnaire is 
an integral part of the Curves program that was utilized within the eight studies 
analyzed, and therefore unavoidable for the present analysis.  Moving forward, it would 
be beneficial to reproduce a similar analysis with participants randomly assigned to the 
dietary protocols and also for future research using these risk factor classifications to 
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include more specific dietary analysis (such as categorizing carbohydrate consumption 
as simple or complex, and fat consumption as saturated or unsaturated).  Additionally, 
the ability to analyze the population based on ethnic affiliation or menopause status may 
also reveal beneficial findings.     
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APPENDIX A 
WAIST CIRCUMFERENCE RISK FACTOR TABLES 
Table A.1: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Waist Circumference Status and Measured via DEXA Scan 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Scanned Mass  HP-LWC 71.6 ± 8.3 68.6g ± 8.1     T =0.001 
(kg) HP-HWC 92.3 ± 17.6 88.2c,g ± 17.1     D = 0.11 
 HC-LWC 72.3 ± 9.4 70.0g ± 9.1     WC = 0.001 
 HC-HWC 86.1 ± 14.1 82.8d,f,g ± 13.5       D x WC = 0.018 
 HP 89.2 ± 18.1 85.3g ± 17.5 80.2 ± 1.1 T x D = 0.032 
 HC 82.5 ± 14.3 79.5g ± 13.7 77.8 ± 1.0 T x WC = 0.003 
 LWC 72.0 ± 9.0 69.4b,g ± 8.7 70.6 ± 1.3 T x D x WC = 0.82 
 HWC 89.8 ± 16.5 86.0g ± 15.9 87.4‡ ± 0.7   
 Time 86.2 ± 16.9 82.7* ± 16.2         
Fat Mass (kg) HP-LWC 30.0 ± 4.9 27.3g ± 5.3     T = 0.001 
 HP-HWC 43.0 ± 11.1 39.9c,g ± 10.9     D = 0.21 
 HC-LWC 31.1 ± 5.6 29.4g ± 5.7     WC = 0.001  
 HC-HWC 39.2 ± 9.1 36.6d,f,g ± 8.8       D x WC = 0.006 
 HP 41.1 ± 11.4 38.0g ± 11.2 35.0 ± 0.7 T x D = 0.007 
 HC 37.1 ± 9.1 34.7g ± 8.7 34.1 ± 0.6 T x WC = 0.006 
 LWC 30.6 ± 5.3 28.5b,g ± 5.6 29.4 ± 0.8 T x D x WC = 0.43 
 HWC 41.5 ± 10.5 38.5g ± 10.2 39.7‡ ± 0.4   
 Time 39.3 ± 10.7 36.5* ± 10.3         
Lean Mass (kg) HP-LWC 39.9 ± 4.8 39.6 ± 4.3     T = 0.001 
 HP-HWC 47.4 ± 7.6 46.5c,g ± 7.3     D = 0.035 
 HC-LWC 39.5 ± 5.0 38.9g ± 4.7     WC = 0.001 
 HC-HWC 45.1 ± 6.3 44.5d,f,g ± 6.0       D x WC = 0.19 
 HP 46.3 ± 7.7 45.5g ± 7.4 43.4† ± 0.5 T x D = 0.98 
 HC 43.6 ± 6.4 43.0a,g ± 6.2 42.0 ± 0.4 T x WC = 0.16 
 LWC 39.7 ± 4.9 39.2b,g ± 4.5 39.5 ± 0.6 T x D x WC = 0.14 
 HWC 46.5 ± 7.2 45.7g ± 6.9 45.9‡ ± 0.3   
 Time 45.1 ± 7.3 44.4* ± 7.0         
Body Fat (%) HP-LWC 42.1 ± 4.0 40.2g ± 4.4     T = 0.001 
 HP-HWC 46.1 ± 4.2 44.6c,g ± 4.5     D = 0.43 
 HC-LWC 43.1 ± 3.9 42.1c,g ± 4.0     WC = 0.001 
 HC-HWC 45.3 ± 4.1 43.8d,f,g ± 4.3       D x WC = 0.007 
 HP 45.5 ± 4.4 43.9g ± 4.7 43.3 ± 0.3 T x D = 0.01 
 HC 44.7 ± 4.2 43.4g ± 4.3 43.6 ± 0.3 T x WC = 0.78 
 LWC 42.7 ± 4.0 41.3b,g ± 4.3 41.9 ± 0.4 T x D x WC = 0.015 
 HWC 45.8 ± 4.2 44.3g ± 4.4 44.9‡ ± 0.2   
 Time 45.2 ± 4.3 43.7* ± 4.5         
HP = higher protein, HC = higher carbohydrate, LWC = low waist circumference, HWC = high waist circumference, T = time effect, D = diet effect, 
WC = waist circumference risk factor effect, D x WC = diet by waist circumference risk factor effect, T x D = time by diet effect, T x WC = time by 
waist circumference risk factor effect, T x D x WC = time by diet by waist circumference risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 55 participants in the HP-LWC group, 316 in the HP-
HWC group, 77 in the HC-LWC group, 215 in the HC-HWC group, 371 in the HP total group, 292 in the HC total group, 131 in the LWC group, 531 
in the HWC group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant waist circumference effect, 
p < 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LWC group, p < 0.05 (post hoc 
LSD).  c Significantly different than HP-LWC group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HWC group, p < 0.05 (post hoc 
LSD).  f Significantly different than HC-LWC group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD).  
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Table A.2: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Waist Circumference Status and Measured via Anthropometric 
Measurements 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Weight (kg) HP-LWC 77.3 ± 8.6 74.0g ± 8.4     T = 0.001 
 HP-HWC 99.0 ± 18.5 94.5c,g ± 17.9     D = 0.12 
 HC-LWC 77.9 ± 9.3 75.8g ± 9.3     WC = 0.001 
 HC-HWC 92.7 ± 14.6 89.0d,f,g ± 14.0       D x WC = 0.020 
 HP 95.8 ± 19.1 91.5g ± 18.3 86.2 ± 1.1 T x D = 0.004 
 HC 88.8 ± 14.9 85.5g ± 14.2 83.8 ± 1.0 T x WC = 0.001 
 LWC 77.7 ± 9.0 75.0b,g ± 9.0 76.3 ± 1.4 T x D x WC =0.60  
 HWC 96.4 ± 17.3 92.3g ± 16.7 93.8‡ ± 0.7   
 Time 92.7 ± 17.7 88.9* ± 16.9         
Body Mass Index HP-LWC 29.5 ± 2.8 28.2g ± 3.0     T = 0.001 
(kg/m2) HP-HWC 37.1 ± 6.4 35.4c,g ± 6.2     D = 0.042 
 HC-LWC 29.3 ± 2.6 28.5g ± 2.7     WC = 0.001 
 HC-HWC 34.7 ± 5.2 33.4dfg ± 5.0       D x WC = 0.034 
 HP 35.9 ± 6.6 34.3g ± 6.4 32.5† ± 0.4 T x D =0.004 
 HC 33.3 ± 5.2 32.1g ± 5.0 31.5 ± 0.4 T x WC = 0.001 
 LWC 29.4 ± 2.7 28.4b.g ± 2.9 28.9 ± 0.5 T x D x WC = 0.61 
 HWC 36.1 ± 6.1 34.6g ± 5.8 35.1‡ ± 0.2   
 Time 34.8 ± 6.2 33.3 ± 5.9         
Waist HP-LWC 83.6 ± 3.0 82.1 ± 4.4     T = 0.001 
Circumference HP-HWC 104.4 ± 12.1 100.0c,g ± 12.4     D =0.045 
(cm) HC-LWC 83.1 ± 3.7 82.5 ± 5.3     WC = 0.001 
 HC-HWC 100.3 ± 10.1 96.2f,g ± 10.5       D x WC = 0.053 
 HP 101.3 ± 13.5 97.3g ± 13.2 92.5† ± 0.7 T x D = 0.27 
 HC 95.8 ± 11.7 92.6a,g ± 11.2 90.5 ± 0.7 T x WC = 0.001 
 LWC 83.3 ± 3.4 82.3b,g ± 4.9 82.8 ± 0.9 T x D x WC = 0.62 
 HWC 102.8 ± 11.5 98.4g ± 11.8 100.2‡ ± 0.5   
 Time 98.9 ± 13.0 95.2* ± 12.6         
Hip HP-LWC 110.4 ± 7.4 107.3g ± 7.2     T = 0.001 
Circumference HP-HWC 124.9 ± 13.6 121.7c,g ± 13.4     D = 0.25 
(cm) HC-LWC 110.9 ± 7.2 109.1g ± 7.2     WC = 0.001  
 HC-HWC 121.0 ± 11.6 118.0d,f,g ± 11.0       D x WC = 0.029 
 HP 122.7 ± 13.9 119.5g ± 13.6 116.0 ± 0.8 T x D = 0.12 
 HC 118.3 ± 11.5 115.6g ± 10.9 114.7 ± 0.8 T x WC = 0.15 
 LWC 110.6 ± 7.3 108.4b,g ± 7.2 109.4 ± 1.0 T x D x WC =0.23  
 HWC 123.3 ± 13.0 120.2g ± 12.6 121.4‡ ± 0.5   
 Time 120.8 ± 13.1 117.8* ± 12.6         
HP = higher protein, HC = higher carbohydrate, LWC = low waist circumference, HWC = high waist circumference, T = time effect, D = diet effect, WC 
= waist circumference risk factor effect, D x WC = diet by waist circumference risk factor effect, T x D = time by diet effect, T x WC = time by waist 
circumference risk factor effect, T x D x WC = time by diet by waist circumference risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 55 participants in the HP-LWC group, 316 in the HP-HWC 
group, 77 in the HC-LWC group, 215 in the HC-HWC group, 371 in the HP total group, 292 in the HC total group, 131 in the LWC group, 531 in the 
HWC group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant waist circumference effect, p < 
0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LWC group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LWC group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HWC group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LWC group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table A.3: Resting Energy Expenditure After Ten Weeks of Exercise and Dietary 
Intervention Based on Waist Circumference Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Resting Energy HP-LWC 1450.6 ± 182.5 1371.2g ± 158.9     T = 0.001 
Expenditure HP-HWC 1734.8 ± 279.5 1673.6c,g ± 287.6     D = 0.23 
(kcal/day) HC-LWC 1459.1 ± 207.9 1401.4g ± 214.1     WC = 0.001 
 HC-HWC 1646.0 ± 243.1 1604.9d,f,g ± 239.2       D x WC = 0.046 
 HP 1697.4 ± 285.2 1633.8g ± 292.5 1557.6 ± 18.2 T x D = 0.35 
 HC 1600.7 ± 248.0 1555.5g ± 248.8 1527.9 ± 16.4 T x WC = 0.44 
 LWC 1455.6 ± 197.0 1388.9b,g ± 193.1 1420.6 ± 22.2 T x D x WC = 0.97 
 HWC 1699.0 ± 268.7 1645.9g ± 271.0 1664.8‡ ± 10.4   
 Time 1655.2 ± 273.7 1599.7* ± 276.8         
HP = higher protein, HC = higher carbohydrate, LWC = low waist circumference, HWC = high waist circumference, T = time effect, D = diet effect, WC = 
waist circumference risk factor effect, D x WC = diet by waist circumference risk factor effect, T x D = time by diet effect, T x WC = time by waist 
circumference risk factor effect, T x D x WC = time by diet by waist circumference risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 47 participants in the HP-LWC group, 310 in the HP-HWC 
group, 67 in the HC-LWC group, 209 in the HC-HWC group, 357 in the HP total group, 276 in the HC total group, 114 in the LWC group, 519 in the HWC 
group, and 633 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant waist circumference effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LWC group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LWC group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HWC group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LWC group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table A.4: Resting Hemodynamic Measurements After Ten Weeks of Exercise and 
Dietary Intervention Based on Waist Circumference Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Resting Heart HP-LWC 68.7 ± 9.5 69.0 ± 8.5     T = 0.001 
Rate (bpm) HP-HWC 72.6 ± 10.4 68.9g ± 9.9     D = 0.98 
 HC-LWC 70.7 ± 11.0 69.1 ± 11.2     WC = 0.35 
 HC-HWC 71.3 ± 10.3 67.9g ± 9.5       D x WC = 0.21  
 HP 72.0 ± 10.3 68.9g ± 9.7 69.8 ± 0.6 T x D = 0.45 
 HC 71.2 ± 10.5 68.2g ± 9.9 69.8 ± 0.6 T x WC = 0.005 
 LWC 69.9 ± 10.4 69.1 ± 10.1 69.4 ± 0.8 T x D x WC = 0.30 
 HWC 72.1 ± 10.4 68.5g ± 9.7 70.2 ± 0.4   
 Time 71.6 ± 10.4 68.6* ± 9.8         
Resting Systolic HP-LWC 123.0 ± 14.2 120.1 ± 13.2     T = 0.001 
Blood Pressure HP-HWC 126.0 ± 14.8 123.5g ± 13.8     D = 0.14 
(mmHg) HC-LWC 120.4 ± 12.4 116.5g ± 13.6     WC = 0.001 
 HC-HWC 125.7 ± 14.9 122.9f,g ± 14.0       D x WC = 0.28 
 HP 125.6 ± 14.7 123.0g ± 13.7 123.1 ± 0.9 T x D = 0.67 
 HC 124.3 ± 14.4 121.2g ± 14.1 121.4 ± 0.8 T x WC = 0.62 
 LWC 121.5 ± 13.2 118.0b,g ± 13.5 120.0 ± 1.1 T x D x WC = 0.81  
 HWC 125.9 ± 14.8 123.2g ± 13.8 124.5‡ ± 0.5   
 Time 125.0 ± 14.6 122.2* ± 13.9         
Resting Diastolic HP-LWC 78.6 ± 8.7 76.6 ± 8.7     T = 0.001 
Blood Pressure HP-HWC 81.7 ± 9.3 80.1c,g ± 8.7     D = 0.011 
(mmHg) HC-LWC 77.1 ± 8.9 74.1g ± 7.7     WC = 0.001 
 HC-HWC 80.2 ± 9.5 78.1d,f,g ± 9.4       D x WC = 0.88 
 HP 81.3 ± 9.3 79.6g ± 8.8 79.3† ± 0.6 T x D = 0.46 
 HC 79.3 ± 9.4 77.0a,g ± 9.2 77.3 ± 0.5 T x WC = 0.55 
 LWC 77.7 ± 8.8 75.2b,g ± 8.2 76.6 ± 0.7 T x D x WC = 0.80  
 HWC 81.1 ± 9.4 79.3g ± 9.1 80.0‡ ± 0.3   
 Time 80.4 ± 9.4 78.4* ± 9.1         
HP = higher protein, HC = higher carbohydrate, LWC = low waist circumference, HWC = high waist circumference, T = time effect, D = diet effect, 
WC = waist circumference risk factor effect, D x WC = diet by waist circumference risk factor effect, T x D = time by diet effect, T x WC = time by 
waist circumference risk factor effect, T x D x WC = time by diet by waist circumference risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 55 participants in the HP-LWC group, 316 in the HP-
HWC group, 77 in the HC-LWC group, 215 in the HC-HWC group, 371 in the HP total group, 292 in the HC total group, 131 in the LWC group, 531 
in the HWC group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant waist circumference effect, p 
< 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LWC group, p < 0.05 (post hoc 
LSD).  c Significantly different than HP-LWC group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HWC group, p < 0.05 (post hoc LSD).  
f Significantly different than HC-LWC group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table A.5: Fasting Blood Lipid Values After Ten Weeks of Exercise  
and Dietary Intervention Based on Waist Circumference Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Total Cholesterol HP-LWC 5.5 ± 1.2 5.2g ± 1.1     T = 0.001 
(mmol/L) HP-HWC 5.2 ± 0.9 5.0g ± 0.9     D = 0.27 
 HC-LWC 5.1 ± 1.0 4.9g ± 0.9     WC = 0.62 
 HC-HWC 5.2 ± 1.1 5.1g ± 1.0       D x WC = 0.021 
 HP 5.2 ± 1.0 5.0g ± 1.0 5.2 ± 0.07 T x D = 0.35 
 HC 5.2 ± 1.0 5.0g ± 1.0 5.1 ± 0.06 T x WC = 0.25 
 LWC 5.3 ± 1.1 5.0g ± 1.0 5.2 ± 0.08 T x D x WC = 0.77  
 HWC 5.2 ± 1.0 5.0g ± 1.0 5.1 ± 0.04   
 Time 5.2 ± 1.0 5.0* ± 1.0         
LDL (mmol/L) HP-LWC 3.3 ± 0.9 3.0g ± 0.8     T = 0.001 
 HP-HWC 3.1 ± 0.7 2.9g ± 0.7     D = 0.33 
 HC-LWC 3.0 ± 0.7 2.8g ± 0.7     WC = 0.57 
 HC-HWC 3.2 ± 0.9 3.1f,g ± 0.8       D x WC = 0.009  
 HP 3.1 ± 0.8 3.0g ± 0.8 3.1 ± 0.05 T x D = 0.45 
 HC 3.1 ± 0.8 3.0g ± 0.8 3.0 ± 0.05 T x WC = 0.14 
 LWC 3.1 ± 0.8 2.9g ± 0.8 3.0 ± 0.06 T x D x WC = 0.69 
 HWC 3.1 ± 0.8 3.0g ± 0.8 3.1 ± 0.03   
 Time 3.1 ± 0.8 3.0* ± 0.8         
HDL (mmol/L) HP-LWC 1.5 ± 0.3 1.4g ± 0.3     T = 0.001 
 HP-HWC 1.4 ± 0.3 1.3c,g ± 0.3     D = 0.76 
 HC-LWC 1.5 ± 0.4 1.4g ± 0.3     WC = 0.001 
 HC-HWC 1.4 ± 0.3 1.3f,g ± 0.3       D x WC = 0.88 
 HP 1.4 ± 0.3 1.3g ± 0.3 1.4 ± 0.02 T x D = 0.88 
 HC 1.4 ± 0.3 1.3g ± 0.3 1.4 ± 0.02 T x WC = 0.98 
 LWC 1.5 ± 0.4 1.4b,g ± 0.3 1.5 ± 0.03 T x D x WC = 0.87 
 HWC 1.4 ± 0.3 1.3g ± 0.3 1.3‡ ± 0.01   
 Time 1.4 ± 0.3 1.3* ± 0.3         
Triglycerides  HP-LWC 1.4 ± 0.7 1.3 ± 0.9     T = 0.008 
(mmol/L) HP-HWC 1.6 ± 0.9 1.5g ± 0.8     D = 0.62 
 HC-LWC 1.3 ± 0.7 1.3 ± 0.8     WC = 0.005 
 HC-HWC 1.6 ± 0.8 1.5f ± 0.7       D x WC = 0.63 
 HP 1.6 ± 0.8 1.5g ± 0.8 1.5 ± 0.05 T x D = 0.11 
 HC 1.5 ± 0.7 1.5 ± 0.7 1.4 ± 0.05 T x WC = 0.36 
 LWC 1.4 ± 0.7 1.3b ± 0.8 1.4 ± 0.06 T x D x WC = 0.92 
 HWC 1.6 ± 0.8 1.5g ± 0.8 1.6‡ ± 0.03   
 Time 1.6 ± 0.8 1.5* ± 0.8         
TC/HDL ratio HP-LWC 3.8 ± 0.9 3.7 ± 1.0     T = 0.38 
 HP-HWC 3.9 ± 0.9 4.0 ± 0.9     D = 0.66 
 HC-LWC 3.6 ± 0.9 3.6 ± 0.9     WC = 0.001 
 HC-HWC 4.0 ± 1.0 4.1f,g ± 1.1       D x WC = 0.15 
 HP 3.9 ± 0.9 3.9 ± 0.9 3.9 ± 0.07 T x D = 0.50 
 HC 3.9 ± 1.0 4.0 ± 1.1 3.8 ± 0.06 T x WC = 0.14 
 LWC 3.7 ± 0.9 3.7b ± 0.9 3.7 ± 0.08 T x D x WC = 0.89 
 HWC 4.0 ± 1.0 4.0g ± 1.0 4.0‡ ± 0.04   
 Time 3.9 ± 0.9 4.0 ± 1.0         
HP = higher protein, HC = higher carbohydrate, LWC = low waist circumference, HWC = high waist circumference, T = time effect, D = diet effect, WC 
= waist circumference risk factor effect, D x WC = diet by waist circumference risk factor effect, T x D = time by diet effect, T x WC = time by waist 
circumference risk factor effect, T x D x WC = time by diet by waist circumference risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 55 participants in the HP-LWC group, 316 in the HP-
HWC group, 77 in the HC-LWC group, 215 in the HC-HWC group, 371 in the HP total group, 292 in the HC total group, 131 in the LWC group, 531 in 
the HWC group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant waist circumference effect, p < 
0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LWC group, p < 0.05 (post hoc LSD).  c 
Significantly different than HP-LWC group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HWC group, p < 0.05 (post hoc LSD).  f 
Significantly different than HC-LWC group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table A.6: Fasting Glucose and Insulin Values After Ten Weeks of Exercise  
and Dietary Intervention Based on Waist Circumference Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Glucose HP-LWC 5.6 ± 1.0 5.4 ± 1.1     T = 0.09 
(mmol/L) HP-HWC 5.7 ± 1.3 5.6g ± 1.2     D = 0.36 
 HC-LWC 5.3 ± 0.5 5.4 ± 0.6     WC = 0.022 
 HC-HWC 5.7 ± 1.5 5.6 ± 1.1       D x WC = 0.46 
 HP 5.7 ± 1.2 5.6g ± 1.2 5.6 ± 0.08 T x D = 0.18 
 HC 5.6 ± 1.3 5.5 ± 1.0 5.5 ± 0.07 T x WC = 0.51 
 LWC 5.4 ± 0.7 5.4b ± 0.8 5.4 ± 0.10 T x D x WC = 0.20 
 HWC 5.7 ± 1.4 5.6g ± 1.2 5.7‡ ± 0.05   
 Time 5.7 ± 1.3 5.6 ± 1.1         
Insulin HP-LWC 5.3 ± 6.3 7.2 ± 10.0     T = 0.20 
(uIU/mL) HP-HWC 3.7 ± 9.2 4.0 ± 10.1     D = 0.035 
 HC-LWC 5.5 ± 4.8 8.5g ± 12.5     WC = 0.94 
 HC-HWC 10.0 ± 15.8 8.4d ± 11.7       D x WC = 0.12 
 HP 4.0 ± 8.8 4.5 ± 10.1 5.0† ± 1.06 T x D = 0.80 
 HC 8.3 ± 12.8 8.4 ± 12.0 8.1 ± 0.98 T x WC = 0.023 
 LWC 5.4 ± 5.4 8.0g ± 11.6 6.6 ± 1.24 T x D x WC = 0.28 
 HWC 5.8 ± 12.2 5.5 ± 10.8 6.5 ± 0.75   
 Time 5.7 ± 10.8 6.1 ± 11.1         
Calculated  HP-LWC 1.5 ± 1.9 2.0 ± 3.7 
 
  
T = 0.36 
HOMA HP-HWC 1.0 ± 2.4 1.0 ± 2.7 D = 0.055 
 HC-LWC 1.3 ± 1.2 2.3 ± 4.1 WC = 0.95 
 HC-HWC 2.9 ± 5.7 2.2d ± 3.1 D x WC = 0.08 
 HP 1.0 ± 2.3 1.2 ± 2.9 1.4 ± 0.31 T x D = 0.71 
 HC 2.3 ± 4.6 2.2 ± 3.5 2.2 ± 0.28 T x WC = 0.031 
 LWC 1.4 ± 1.5 2.2 ± 3.9 1.8 ± 0.36 T x D x WC = 0.23 
 HWC 1.6 ± 3.9 1.4 ± 2.9 1.8 ± 0.22   
 Time 1.6 ± 3.5 1.6 ± 3.2         
HP = higher protein, HC = higher carbohydrate, LWC = low waist circumference, HWC = high waist circumference, T = time effect, D = diet effect, WC = 
waist circumference risk factor effect, D x WC = diet by waist circumference risk factor effect, T x D = time by diet effect, T x WC = time by waist 
circumference risk factor effect, T x D x WC = time by diet by waist circumference risk factor effect.                                                                                                                                    
Glucose values are means ± standard deviations (except group means are means ± standard error) from 55 participants in the HP-LWC group, 316 in the 
HP-HWC group, 77 in the HC-LWC group, 215 in the HC-HWC group, 371 in the HP total group, 292 in the HC total group, 131 in the LWC group, 531 in 
the HWC group, and 663 participants total.  Insulin and HOMA values are means ± standard deviations (except group means are means ± standard error) 
from 25 participants in the HP-LWC group, 124 in the HP-HWC group, 40 in the HC-LWC group, 63 in the HC-HWC group, 149 in the HP total group, 
103 in the HC total group, 65 in the LWC group, 187 in the HWC group, and 252 participants total. 
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant waist circumference effect, p < 
0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LWC group, p < 0.05 (post hoc LSD).  c 
Significantly different than HP-LWC group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HWC group, p < 0.05 (post hoc LSD).  f 
Significantly different than HC-LWC group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table A.7: Fitness Parameters After Ten Weeks of Exercise and Dietary Intervention 
Based on Waist Circumference Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Bench Press  HP-LWC 30.0 ± 8.3 32.2g ± 8.5     T = 0.001 
Max Strength HP-HWC 31.1 ± 7.5 33.0g ± 7.3     D = 0.17 
(1 RM / kg body HC-LWC 28.3 ± 6.7 30.4g ± 7.0     WC = 0.06 
weight) HC-HWC 30.3 ± 8.1 32.7f,g ± 8.3       D x WC = 0.46 
 HP 30.9 ± 7.6 32.9g ± 7.4 31.6 ± 0.6 T x D = 0.74 
 HC 29.9 ± 7.8 32.2g ± 8.1 30.5 ± 0.6 T x WC = 0.91 
 LWC 29.1 ± 7.4 31.2g ± 7.7 30.3 ± 0.7 T x D x WC = 0.61 
 HWC 30.8 ± 7.7 32.9g ± 7.7 31.8‡ ± 0.3   
 Time 30.5 ± 7.7 32.6* ± 7.7         
Bench Press HP-LWC 163.3 ± 65.6 175.1 ± 69.0     T = 0.51 
Lift Volume HP-HWC 182.6 ± 81.3 182.9 ± 82.2     D = 0.91 
(kg) HC-LWC 163.9 ± 65.9 172.0 ± 93.8     WC = 0.040 
 HC-HWC 189.4 ± 88.3 182.4 ± 75.7       D x WC = 0.78 
 HP 180.3 ± 79.7 182.0 ± 80.7 176.0 ± 5.7 T x D = 0.58 
 HC 183.8 ± 84.5 180.1 ± 79.9 176.9 ± 5.1 T x WC = 0.18 
 LWC 163.7 ± 65.5 173.3 ± 83.8 168.6 ± 7.0 T x D x WC = 0.86 
 HWC 185.3 ± 84.2 182.7 ± 79.6 184.3‡ ± 3.1   
 Time 181.8 ± 81.8 181.2 ± 80.3         
Leg Press  HP-LWC 139.0 ± 32.0 148.6g ± 35.8     T = 0.001 
Max Strength HP-HWC 167.6 ± 48.9 184.4c,g ± 52.7     D = 0.78 
(1 RM / kg body HC-LWC 138.4 ± 41.5 153.2g ± 44.9     WC = 0.001 
weight) HC-HWC 164.0 ± 51.9 178.0f,g ± 56.7       D x WC = 0.52 
 HP 164.1 ± 48.1 180.1g ± 52.3 159.9 ± 4.0 T x D = 0.72 
 HC 158.4 ± 50.8 172.5g ± 55.2 158.4 ± 3.7 T x WC = 0.32 
 LWC 138.6 ± 37.6 151.3b,g ± 41.2 144.8 ± 5.0 T x D x WC = 0.22 
 HWC 166.1 ± 50.1 181.8g ± 54.4 173.5‡ ± 2.2   
 Time 161.7 ± 49.3 176.8* ± 53.6         
Leg Press HP-LWC 1568.3 ± 798.9 1514.1 ± 695.5     T = 0.96 
Lift Volume HP-HWC 1856.5 ± 985.4 1990.5c,g ± 1108.8     D = 0.10 
(kg) HC-LWC 1461.2 ± 836.5 1401.3 ± 742.6     WC = 0.001 
 HC-HWC 1725.0 ± 865.2 1716.3d,f ± 931.5       D x WC = 0.63 
 HP 1821.8 ± 968.3 1933.1 ± 1077.9 1732.4 ± 70.8 T x D = 0.46 
 HC 1667.3 ± 864.3 1647.4 ± 901.7 1575.9 ± 64.2 T x WC = 0.23 
 LWC 1506.5 ± 818.3 1449.0b ± 721.5 1486.2 ± 87.3 T x D x WC = 0.50 
 HWC 1803.8 ± 940.4 1880.6 ± 1049.0 1822.1‡ ± 38.8   
 Time 1755.4 ± 927.5 1810.3 ± 1015.1         
Peak VO2 HP-LWC 23.2 ± 4.7 24.1g ± 5.0     T = 0.001 
(mL/kg/min) HP-HWC 19.5 ± 4.3 21.6c,g ± 4.3     D = 0.74 
 HC-LWC 21.8 ± 4.5 24.5g ± 4.8     WC = 0.001 
 HC-HWC 20.0 ± 4.0 22.6d,f,g ± 4.6       D x WC = 0.12 
 HP 20.0 ± 4.5 21.9g ± 4.5 22.1 ± 0.3 T x D = 0.001 
 HC 20.5 ± 4.2 23.1g ± 4.7 22.2 ± 0.3 T x WC = 0.10 
 LWC 22.4 ± 4.6 24.3b,g ± 4.9 23.4 ± 0.4 T x D x WC = 0.044 
 HWC 19.7 ± 4.2 22.0g ± 4.5 20.9‡ ± 0.2   
 Time 20.2 ± 4.4 22.4* ± 4.6         
HP = higher protein, HC = higher carbohydrate, LWC = low waist circumference, HWC = high waist circumference, T = time effect, D = diet effect, WC = waist 
circumference risk factor effect, D x WC = diet by waist circumference risk factor effect, T x D = time by diet effect, T x WC = time by waist circumference risk 
factor effect, T x D x WC = time by diet by waist circumference risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 55 participants in the HP-LWC group, 316 in the HP-HWC 
group, 77 in the HC-LWC group, 215 in the HC-HWC group, 371 in the HP total group, 292 in the HC total group, 131 in the LWC group, 531 in the HWC 
group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant waist circumference effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LWC group, p < 0.05 (post hoc LSD).  c 
Significantly different than HP-LWC group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HWC group, p < 0.05 (post hoc LSD).  f Significantly 
different than HC-LWC group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table A.8: Changes in SF36 - Quality of Life Inventory Values After Ten Weeks of 
Exercise and Dietary Intervention Based on Waist Circumference Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Physical  HP-LWC 81.6 ± 32.6 88.8 ± 26.4     T = 0.001 
Functioning HP-HWC 74.5 ± 29.1 79.8g ± 24.2     D = 0.70 
 HC-LWC 77.6 ± 15.9 84.8g ± 23.7     WC = 0.10 
 HC-HWC 75.8 ± 23.3 81.9g ± 18.5       D x WC = 0.35  
 HP 75.7 ± 29.7 81.3g ± 24.7 81.2 ± 2.4 T x D = 0.90 
 HC 76.4 ± 21.2 82.8g ± 20.2 80.0 ± 2.0 T x WC = 0.65 
 LWC 79.0 ± 23.3 86.2g ± 24.6 83.2 ± 2.7 T x D x WC = 0.91 
 HWC 75.1 ± 26.8 80.7g ± 21.9 78.0 ± 1.5   
 Time 76.0 ± 26.0 82.0* ± 22.7         
Role Physical HP-LWC 179.8 ± 143.7 182.1 ± 153.3     T = 0.63 
 HP-HWC 134.8 ± 135.6 139.4 ± 146.5     D = 0.001 
 HC-LWC 228.2 ± 137.3 223.1 ± 151.1     WC = 0.85 
 HC-HWC 258.0 ± 144.3 265.7d ± 144.1       D x WC = 0.045 
 HP 142.2 ± 137.5 146.4 ± 148.0 159.0† ± 15.2 T x D = 0.82 
 HC 248.6 ± 142.3 252.3a ± 147.1 243.7 ± 12.8 T x WC = 0.44 
 LWC 210.4 ± 140.6 208.0 ± 152.1 203.3 ± 17.5 T x D x WC = 0.60 
 HWC 187.2 ± 151.9 193.1 ± 158.1 199.5 ± 9.5   
 Time 192.6 ± 149.4 196.6 ± 156.5         
Bodily Pain HP-LWC 60.8 ± 20.6 67.0 ± 21.8     T = 0.006 
 HP-HWC 58.7 ± 18.7 62.4g ± 20.5     D = 0.76 
 HC-LWC 62.5 ± 21.0 65.8 ± 20.8     WC = 0.31 
 HC-HWC 61.8 ± 21.8 62.2 ± 22.0       D x WC = 0.82 
 HP 59.1 ± 19.0 63.1g ± 20.7 62.2 ± 2.1 T x D = 0.22 
 HC 62.0 ± 21.4 63.3 ± 21.6 63.0 ± 1.7 T x WC = 0.28 
 LWC 61.9 ± 20.7 66.2g ± 21.0 64.0 ± 2.4 T x D x WC = 0.93 
 HWC 60.0 ± 20.1 62.3 ± 21.1 61.3 ± 1.3   
 Time 60.5 ± 20.2 63.2* ± 21.1         
General Health HP-LWC 63.2 ± 25.9 67.8g ± 26.4     T = 0.001 
 HP-HWC 47.8 ± 28.5 52.2c,g ± 28.4     D = 0.01 
 HC-LWC 65.8 ± 21.8 69.2 ± 21.8     WC = 0.020 
 HC-HWC 64.8 ± 22.7 68.0d,g ± 22.4       D x WC = 0.044 
 HP 50.4 ± 28.6 54.8g ± 28.6 57.8† ± 2.7 T x D = 0.48 
 HC 65.1 ± 22.3 68.4a,g ± 22.1 66.9 ± 2.3 T x WC = 0.92 
 LWC 64.8 ± 23.2 68.7b,g ± 23.4 66.5 ± 3.1 T x D x WC = 0.96 
 HWC 55.0 ± 27.5 58.9g ± 27.2 58.2‡ ± 1.7   
 Time 57.3 ± 26.8 61.2* ± 26.6         
Vital HP-LWC 45.7 ± 22.0 51.1 ± 22.8     T = 0.001 
 HP-HWC 40.4 ± 49.5 48.7g ± 51.0     D =0.19 
 HC-LWC 50.7 ± 18.0 56.8g ± 18.2     WC = 0.63 
 HC-HWC 50.2 ± 18.8 55.0g ± 18.8       D x WC = 0.79 
 HP 41.3 ± 46.1 49.1g ± 47.5 46.5 ± 3.9 T x D = 0.48 
 HC 50.4 ± 18.5 55.5g ± 18.6 53.2 ± 3.3 T x WC = 0.72 
 LWC 48.8 ± 19.6 54.7g ± 20.0 51.0 ± 4.5 T x D x WC = 0.31 
 HWC 44.6 ± 39.7 51.4g ± 40.6 48.6 ± 2.4   
 Time 45.6 ± 36.0 52.2* ± 36.8         
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Table A.8: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Social 
Functioning 
HP-LWC 58.2 ± 28.3 60.3 ± 25.8 
 
  
T = 0.10 
HP-HWC 43.9 ± 24.7 48.8c,g ± 26.6 D =0.08 
HC-LWC 56.4 ± 20.5 56.2 ± 21.5 WC = 0.24  
HC-HWC 60.6 ± 26.7 61.9d ± 25.7 D x WC =0.009  
HP 46.2 ± 25.7 50.7 ± 26.7 52.8 ± 2.6 T x D = 0.23 
HC 59.3 ± 24.9 60.1 ± 24.5 58.8 ± 2.2 T x WC = 0.37 
LWC 57.1 ± 23.5 57.7 ± 23.1 57.8 ± 3.0 T x D x WC = 0.81 
HWC 51.0 ± 26.8 54.4g ± 26.9 53.8 ± 1.6   
  Time 52.4 ± 26.1 55.2 ± 26.1   
Role Emotional HP-LWC 216.7 ± 131.8 230.6 ± 138.8 
 
  
T = 0.47 
HP-HWC 218.6 ± 128.7 240.2 ± 141.4 D = 0.003 
HC-LWC 248.3 ± 130.6 260.5 ± 148.2 WC = 0.09 
HC-HWC 321.6 ± 208.8 302.6d ± 125.4 D x WC = 0.17  
HP 218.3 ± 128.7 238.6 ± 140.6 226.5† ± 14.5 T x D = 0.28 
HC 298.6 ± 190.3 289.4a ± 133.9 283.2 ± 12.2 T x WC = 0.55 
LWC 236.7 ± 131.0 249.5 ± 144.5 239.0 ± 16.6 T x D x WC = 0.33 
HWC 262.4 ± 174.7 266.7 ± 138.1 270.7 ± 9.0   
  Time 256.3 ± 165.6 262.7 ± 139.6   
Mental Health 
 
HP-LWC 61.0 ± 16.6 68.1g ± 13.3 
 
  
T = 0.001 
HP-HWC 55.7 ± 15.2 64.6g ± 15.7 D = 0.20 
HC-LWC 61.7 ± 17.1 70.9g ± 13.9 WC = 0.025 
HC-HWC 59.6 ± 13.0 66.1g ± 11.0 D x WC = 0.78 
HP 56.5 ± 15.5 65.1g ± 15.3 62.3 ± 1.4 T x D = 0.94 
HC 60.3 ± 14.4 67.6g ± 12.1 64.6 ± 1.1 T x WC = 0.83 
LWC 61.5 ± 16.8 69.9b,g ± 13.6 65.4 ± 1.6 T x D x WC = 0.30 
HWC 57.3 ± 14.4 65.2g ± 13.9 61.5‡ ± 0.8   
  Time 58.3 ± 15.1 66.3* ± 13.9   
HP = higher protein, HC = higher carbohydrate, LWC = low waist circumference, HWC = high waist circumference, T = time effect, D = diet effect, WC = 
waist circumference risk factor effect, D x WC = diet by waist circumference risk factor effect, T x D = time by diet effect, T x WC = time by waist 
circumference risk factor effect, T x D x WC = time by diet by waist circumference risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 25 participants in the HP-LWC group, 127 in the HP-HWC 
group, 43 in the HC-LWC group, 94 in the HC-HWC group, 152 in the HP total group, 137 in the HC total group, 68 in the LWC group, 221 in the HWC 
group, and 289 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant waist circumference effect, p < 
0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LWC group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LWC group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HWC group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LWC group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table A.9: Changes in Body Image Evaluation After Ten Weeks of Exercise  
and Dietary Intervention Based on Waist Circumference Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Appearance 
Evaluation 
HP-LWC 2.6 ± 0.6 3.2g ± 0.7 
 
  
T = 0.001 
HP-HWC 2.4 ± 0.6 2.7c,g ± 0.6 D = 0.27 
HC-LWC 2.5 ± 0.7 2.9c,g ± 0.7 WC = 0.001 
HC-HWC 2.4 ± 0.6 2.8g ± 0.7 D x WC = 0.037 
HP 2.4 ± 0.6 2.7g ± 0.7 2.7 ± 0.05 T x D = 0.42 
HC 2.4 ± 0.6 2.8g ± 0.7 2.6 ± 0.05 T x WC = 0.004 
LWC 2.5 ± 0.6 3.0b,g ± 0.7 2.8 ± 0.06 T x D x WC = 0.13 
HWC 2.4 ± 0.6 2.7g ± 0.7 2.6‡ ± 0.03   
  Time 2.4 ± 0.6 2.8* ± 0.7   
Appearance 
Orientation 
HP-LWC 4.0 ± 0.7 3.9 ± 0.7 
 
  
T = 0.16 
HP-HWC 4.2 ± 0.9 4.2 ± 0.9 D = 0.24 
HC-LWC 3.9 ± 0.8 3.9 ± 0.8 WC = 0.20 
HC-HWC 4.0 ± 0.8 3.9d ± 0.9 D x WC = 0.25 
HP 4.1 ± 0.9 4.1 ± 0.9 4.0 ± 0.07 T x D = 0.90 
HC 3.9 ± 0.8 3.9 ± 0.9 3.9 ± 0.07 T x WC = 0.56 
LWC 3.9 ± 0.8 3.9 ± 0.8 3.9 ± 0.09 T x D x WC = 0.43 
HWC 4.1 ± 0.8 4.1 ± 0.9 4.0 ± 0.05   
  Time 4.1 ± 0.8 4.0 ± 0.9   
Body Area HP-LWC 2.4 ± 0.7 2.7g ± 0.8     T = 0.001 
Satisfaction HP-HWC 2.0 ± 0.8 2.2c,g ± 0.8     D = 0.23 
 HC-LWC 2.3 ± 0.8 2.7g ± 0.8     WC = 0.001 
 HC-HWC 2.2 ± 0.7 2.5d,g ± 0.8       D x WC = 0.09 
 HP 2.0 ± 0.8 2.3g ± 0.8 2.3 ± 0.07 T x D = 0.68 
 HC 2.2 ± 0.7 2.5g ± 0.8 2.4 ± 0.06 T x WC = 0.29 
 LWC 2.3 ± 0.7 2.7b,g ± 0.8 2.5 ± 0.08 T x D x WC = 0.38 
 HWC 2.1 ± 0.7 2.3g ± 0.8 2.2‡ ± 0.04   
 Time 2.1 ± 0.7 2.4* ± 0.8         
Overweight HP-LWC 2.7 ± 0.8 3.2g ± 0.7     T = 0.001 
Preoccupation HP-HWC 2.9 ± 0.7 3.4g ± 0.7     D = 0.95 
 HC-LWC 2.9 ± 0.7 3.3g ± 0.7     WC = 0.15 
 HC-HWC 2.9 ± 0.7 3.3g ± 0.7       D x WC = 0.25 
 HP 2.9 ± 0.7 3.4g ± 0.7 3.1 ± 0.06 T x D = 0.31 
 HC 2.9 ± 0.7 3.3g ± 0.7 3.1 ± 0.05 T x WC = 0.70 
 LWC 2.8 ± 0.8 3.2g ± 0.7 3.0 ± 0.07 T x D x WC = 0.80 
 HWC 2.9 ± 0.7 3.4g ± 0.7 3.1 ± 0.03   
 Time 2.9 ± 0.7 3.3* ± 0.7         
Self-Classified HP-LWC 3.9 ± 0.7 3.8 ± 0.4     T = 0.045 
Weight HP-HWC 4.3 ± 0.7 4.2c ± 0.7     D =0.97 
 HC-LWC 4.0 ± 0.6 3.9 ± 0.5     WC = 0.001 
 HC-HWC 4.2 ± 0.7 4.1g ± 0.8       D x WC = 0.18 
 HP 4.2 ± 0.7 4.2 ± 0.7 4.1 ± 0.05 T x D = 0.87 
 HC 4.2 ± 0.7 4.0 ± 0.7 4.1 ± 0.04 T x WC = 0.86 
 LWC 4.0 ± 0.6 3.9b ± 0.5 3.9 ± 0.06 T x D x WC = 0.55 
 HWC 4.3 ± 0.7 4.2g ± 0.7 4.2‡ ± 0.03   
 Time 4.2 ± 0.7 4.1* ± 0.7         
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Table A.9: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Rosenberg HP-LWC 26.1 ± 3.8 26.0 ± 3.7     T = 0.10 
Self Esteem HP-HWC 25.6 ± 4.0 26.4g ± 3.9     D = 0.77 
 HC-LWC 25.8 ± 4.0 26.4 ± 4.2     WC = 0.60 
 HC-HWC 25.7 ± 3.9 25.7 ± 3.9       D x WC = 0.63 
 HP 25.7 ± 3.9 26.3 ± 3.8 26.0 ± 0.32 T x D = 0.97 
 HC 25.7 ± 3.9 25.9 ± 4.0 25.9 ± 0.28 T x WC = 0.72 
 LWC 25.9 ± 3.9 26.3 ± 4.0 26.1 ± 0.37 T x D x WC = 0.07 
 HWC 25.7 ± 3.9 26.1g ± 3.9 25.8 ± 0.20   
 Time 25.7 ± 3.9 26.2 ± 3.9         
Social Physique HP-LWC 29.5 ± 5.1 29.7 ± 4.7     T = 0.79 
Anxiety HP-HWC 31.6 ± 6.4 31.6 ± 6.4     D =0.40 
 HC-LWC 31.0 ± 5.5 30.8 ± 4.9     WC = 0.047 
 HC-HWC 31.2 ± 6.2 31.5 ± 6.6       D x WC = 0.19 
 HP 31.3 ± 6.3 31.4 ± 6.2 30.6 ± 0.45 T x D = 0.87 
 HC 31.1 ± 6.0 31.3 ± 6.1 31.1 ± 0.40 T x WC = 0.83 
 LWC 30.4 ± 5.4 30.4 ± 4.8 30.2 ± 0.53 T x D x WC = 0.65 
 HWC 31.4 ± 6.3 31.6 ± 6.5 31.4‡ ± 0.28   
 Time 31.2 ± 6.1 31.3 ± 6.2         
HP = higher protein, HC = higher carbohydrate, LWC = low waist circumference, HWC = high waist circumference, T = time effect, D = diet effect, WC 
= waist circumference risk factor effect, D x WC = diet by waist circumference risk factor effect, T x D = time by diet effect, T x WC = time by waist 
circumference risk factor effect, T x D x WC = time by diet by waist circumference risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 37 participants in the HP-LWC group, 219 in the HP-
HWC group, 60 in the HC-LWC group, 135 in the HC-HWC group, 256 in the HP total group, 195 in the HC total group, 97 in the LWC group, 354 in 
the HWC group, and 451 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant waist circumference effect, p < 
0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LWC group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LWC group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HWC group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LWC group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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APPENDIX B 
TRIGLYCERIDE RISK FACTOR TABLES 
Table B.1: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Triglyceride Status and Measured via DEXA Scan 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Scanned Mass  HP-LTG 90.5 ± 18.6 86.4g ± 18.0     T = 0.001 
(kg) HP-HTG 86.8 ± 16.7 83.2g ± 16.3     D = 0.001 
 HC-LTG 82.0 ± 14.8 79.0c,g ± 14.2     TG = 0.45 
 HC-HTG 83.5 ± 13.3 80.4g ± 12.6       D x TG = 0.07 
 HP 89.2 ± 18.1 85.3g ± 17.5 86.7† ± 0.9 T x D = 0.007 
 HC 82.5 ± 14.3 79.5a,g ± 13.7 81.2 ± 1.0 T x TG = 0.52 
 LTG 86.7 ± 17.6 83.1g ± 16.8 84.5 ± 0.8 T x D x TG =0.22  
 HTG 85.3 ± 15.4 82.0g ± 14.8 83.5 ± 1.1   
 Time 86.2 ± 16.9 82.7* ± 16.2         
Fat Mass (kg) HP-LTG 41.7 ± 11.7 38.6g ± 11.4     T = 0.001 
 HP-HTG 39.8 ± 10.9 36.9g ± 10.6     D = 0.001 
 HC-LTG 37.0 ± 9.6 34.6c,g ± 9.1     TG = 0.35 
 HC-HTG 37.2 ± 8.0 34.8g ± 7.7       D x TG = 0.35 
 HP 41.1 ± 11.4 38.0g ± 11.2 39.3† ± 0.6 T x D = 0.004 
 HC 37.1 ± 9.1 34.7a,g ± 8.7 35.9 ± 0.6 T x TG = 0.58 
 LTG 39.7 ± 11.0 36.8g ± 10.7 38.0 ± 0.5 T x D x TG = 0.61  
 HTG 38.7 ± 9.8 36.0g ± 9.5 37.2 ± 0.7   
 Time 39.3 ± 10.7 36.5* ± 10.3         
Lean Mass (kg) HP-LTG 46.9 ± 8.1 46.0g ± 7.7     T = 0.001 
 HP-HTG 45.1 ± 6.9 44.5g ± 6.7     D = 0.001 
 HC-LTG 43.2 ± 6.4 42.7c,g ± 6.2     TG = 0.74 
 HC-HTG 44.5 ± 6.4 43.8g ± 6.1       D x TG = 0.74 
 HP 46.3 ± 7.7 45.5g ± 7.4 45.6† ± 0.4 T x D = 0.46 
 HC 43.6 ± 6.4 43.0a,g ± 6.2 43.5 ± 0.4 T x TG = 0.71 
 LTG 45.2 ± 7.6 44.5g ± 7.2 44.7 ± 0.3 T x D x TG = 0.12  
 HTG 44.9 ± 6.7 44.2g ± 6.5 44.5 ± 0.5   
 Time 45.1 ± 7.3 44.4* ± 7.0         
Body Fat (%) HP-LTG 45.6 ± 4.4 44.0g ± 4.7     T = 0.001 
 HP-HTG 45.4 ± 4.5 43.8g ± 4.7     D = 0.036 
 HC-LTG 44.9 ± 4.3 43.5g ± 4.4     TG = 0.27 
 HC-HTG 44.3 ± 3.7 43.0g ± 4.0       D x TG = 0.27 
 HP 45.5 ± 4.4 43.9g ± 4.7 44.7† ± 0.2 T x D = 0.14 
 HC 44.7 ± 4.2 43.4g ± 4.3 43.9 ± 0.3 T x TG = 0.90 
 LTG 45.3 ± 4.4 43.8g ± 4.6 44.5 ± 0.2 T x D x TG = 0.74  
 HTG 44.9 ± 4.2 43.4g ± 4.4 44.1 ± 0.3   
 Time 45.2 ± 4.3 43.7* ± 4.5         
HP = higher protein, HC = higher carbohydrate, LTG = low triglyceride, HTG = high triglyceride, T = time effect, D = diet effect, TG = 
triglyceride risk factor effect, D x TG = diet by triglyceride risk factor effect, T x D = time by diet effect, T x TG = time by triglyceride risk factor 
effect, T x D x TG = time by diet by triglyceride risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 247 participants in the HP-LTG group, 124 in the 
HP-HTG group, 196 in the HC-LTG group, 96 in the HC-TG group, 371 in the HP total group, 292 in the HC total group, 443 in the LTG group, 
220 in the HTG group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant triglyceride effect, p < 
0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LTG group, p < 0.05 (post hoc 
LSD).  c Significantly different than HP-LTG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HTG group, p < 0.05 (post hoc 
LSD).  f Significantly different than HC-LTG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table B.2: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Triglyceride Status and Measured via Anthropometric 
Measurements 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Weight (kg) HP-LTG 97.1 ± 19.6 92.7g ± 18.8     T = 0.001 
 HP-HTG 93.1 ± 17.6 89.1c,g ± 17.2     D = 0.001 
 HC-LTG 88.2 ± 15.4 85.1c,g ± 14.7     TG = 0.42 
 HC-HTG 89.9 ± 13.8 86.4g ± 13.1       D x TG = 0.058 
 HP 95.8 ± 19.1 91.5g ± 18.3 93.0† ± 0.9 T x D = 0.002 
 HC 88.8 ± 14.9 85.5a,g ± 14.2 87.4 ± 1.1 T x TG = 0.72 
 LTG 93.2 ± 18.4 89.3g ± 17.5 90.8 ± 0.8 T x D x TG = 0.14  
 HTG 91.7 ± 16.1 88.0g ± 15.6 89.6 ± 1.1   
 Time 92.7 ± 17.7 88.9* ± 16.9         
Body Mass Index HP-LTG 36.2 ± 6.8 34.5g ± 6.6     T = 0.001 
(kg/m2) HP-HTG 35.5 ± 6.2 34.0g ± 6.0     D =0.001 
 HC-LTG 33.1 ± 5.5 32.0c,g ± 5.2     TG = 0.83 
 HC-HTG 33.6 ± 4.7 32.3d,g ± 4.4       D x TG = 0.29 
 HP 35.9 ± 6.6 34.3g ± 6.4 35.0† ± 0.3 T x D = 0.002 
 HC 33.3 ± 5.2 32.1a,g ± 5.0 32.8 ± 0.4 T x TG = 0.85 
 LTG 34.8 ± 6.4 33.4g ± 6.1 34.0 ± 0.3 T x D x TG = 0.24  
 HTG 34.7 ± 5.6 33.3g ± 5.4 33.8 ± 0.4   
 Time 34.8 ± 6.2 33.3* ± 5.9         
Waist HP-LTG 101.2 ± 13.8 97.5g ± 13.7     T = 0.001 
Circumference HP-HTG 101.6 ± 12.8 97.0g ± 12.1     D = 0.001 
(cm) HC-LTG 95.2 ± 11.8 91.7c,g ± 11.0     TG = 0.28 
 HC-HTG 96.9 ± 11.4 94.5g ± 11.4       D x TG = 0.26 
 HP 101.3 ± 13.5 97.3g ± 13.2 99.3† ± 0.7 T x D = 0.015 
 HC 95.8 ± 11.7 92.6a,g ± 11.2 94.6 ± 0.8 T x TG = 0.79 
 LTG 98.6 ± 13.3 94.9g ± 12.9 96.4 ± 0.6 T x D x TG =0.035  
 HTG 99.6 ± 12.4 95.9g ± 11.8 97.5 ± 0.8   
 Time 98.9 ± 13.0 95.2* ± 12.6         
Hip HP-LTG 123.1 ± 13.9 119.9g ± 13.6     T = 0.001 
Circumference HP-HTG 122.0 ± 13.8 118.9g ± 13.8     D = 0.001 
(cm) HC-LTG 117.8 ± 12.0 115.5c,g ± 10.9     TG = 0.97 
 HC-HTG 119.4 ± 10.5 115.9g ± 10.8       D x TG = 0.34 
 HP 122.7 ± 13.9 119.5g ± 13.6 121.0† ± 0.7 T x D = 0.48 
 HC 118.3 ± 11.5 115.6a,g ± 10.9 117.2 ± 0.8 T x TG = 0.22 
 LTG 120.8 ± 13.3 117.9g ± 12.7 119.1 ± 0.6 T x D x TG = 0.13  
 HTG 120.9 ± 12.5 117.6g ± 12.6 119.0 ± 0.8   
 Time 120.8 ± 13.1 117.8* ± 12.6         
HP = higher protein, HC = higher carbohydrate, LTG = low triglyceride, HTG = high triglyceride, T = time effect, D = diet effect, TG = triglyceride risk 
factor effect, D x TG = diet by triglyceride risk factor effect, T x D = time by diet effect, T x TG = time by triglyceride risk factor effect, T x D x TG = time 
by diet by triglyceride risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 247 participants in the HP-LTG group, 124 in the HP-HTG 
group, 196 in the HC-LTG group, 96 in the HC-TG group, 371 in the HP total group, 292 in the HC total group, 443 in the LTG group, 220 in the HTG 
group, and 663 participants total.  * Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant 
triglyceride effect, p < 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LTG group, p < 0.05 
(post hoc LSD).  c Significantly different than HP-LTG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HTG group, p < 0.05 (post hoc 
LSD).  f Significantly different than HC-LTG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table B.3: Resting Energy Expenditure After Ten Weeks of Exercise and Dietary 
Intervention Based on Triglyceride Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Resting Energy HP-LTG 1689.6 ± 294.2 1628.9g ± 291.9     T = 0.001 
Expenditure HP-HTG 1713.2 ± 266.7 1643.8g ± 294.6     D = 0.001 
(kcal/day) HC-LTG 1584.2 ± 241.0 1542.4c,g ± 247.9     TG = 0.13 
 HC-HTG 1635.8 ± 260.2 1583.5g ± 249.9       D x TG =0.53  
 HP 1697.4 ± 285.2 1633.8g ± 292.5 1668.9† ± 14.1 T x D = 0.32 
 HC 1600.7 ± 248.0 1555.5a,g ± 248.8 1586.5 ± 16.2 T x TG = 0.60 
 LTG 1643.2 ± 276.8 1590.8g ± 276.4 1611.2 ± 12.2 T x D x TG = 0.96 
 HTG 1680.2 ± 266.1 1618.1g ± 277.4 1644.1 ± 17.6   
 Time 1655.2 ± 273.7 1599.7* ± 276.8         
HP = higher protein, HC = higher carbohydrate, LTG = low triglyceride, HTG = high triglyceride, T = time effect, D = diet effect, TG = triglyceride risk 
factor effect, D x TG = diet by triglyceride risk factor effect, T x D = time by diet effect, T x TG = time by triglyceride risk factor effect, T x D x TG = time 
by diet by triglyceride risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 239 participants in the HP-LTG group, 118 in the HP-HTG 
group, 188 in the HC-LTG group, 88 in the HC-TG group, 357 in the HP total group, 276 in the HC total group, 427 in the LTG group, 206 in the HTG 
group, and 633 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant triglyceride effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LTG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LTG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HTG group, p < 0.05 (post hoc LSD).  f Significantly 
different than HC-LTG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table B.4: Resting Hemodynamic Measurements After Ten Weeks of Exercise and 
Dietary Intervention Based on Triglyceride Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Resting Heart HP-LTG 71.6 ± 10.0 68.6g ± 10.1     T = 0.001 
Rate (bpm) HP-HTG 72.8 ± 10.9 69.5g ± 8.8     D = 0.42 
 HC-LTG 70.4 ± 9.8 67.7g ± 10.2     TG = 0.035 
 HC-HTG 72.8 ± 11.8 69.3d,g ± 9.3       D x TG = 0.51 
 HP 72.0 ± 10.3 68.9g ± 9.7 70.6 ± 0.5 T x D = 0.95 
 HC 71.2 ± 10.5 68.2g ± 9.9 70.0 ± 0.5 T x TG = 0.53 
 LTG 71.1 ± 9.9 68.2g ± 10.2 69.6 ± 0.4 T x D x TG = 0.67  
 HTG 72.8 ± 11.3 69.4g ± 9.0 71.1‡ ± 0.6   
 Time 71.6 ± 10.4 68.6* ± 9.8         
Resting Systolic HP-LTG 68.6 ± 10.1 124.8g ± 14.6     T = 0.001 
Blood Pressure HP-HTG 69.5 ± 8.8 127.0g ± 14.9     D = 0.07 
(mmHg) HC-LTG 67.7 ± 10.2 123.8 ± 14.7     TG = 0.60 
 HC-HTG 69.3 ± 9.3 125.3d,g ± 13.8       D x TG = 0.35  
 HP 68.9 ± 9.7 125.6g ± 14.7 124.5† ± 0.7 T x D = 0.46 
 HC 68.2 ± 9.9 124.3a,g ± 14.4 122.7 ± 0.8 T x TG = 0.036 
 LTG 68.2 ± 10.2 124.4g ± 14.6 123.3 ± 0.6 T x D x TG = 0.35 
 HTG 69.4 ± 9.0 126.3g ± 14.4 123.9 ± 0.8   
 Time 68.6 ± 9.8 125.0* ± 14.6         
Resting Diastolic HP-LTG 124.8 ± 14.6 122.7g ± 14.3     T = 0.001 
Blood Pressure HP-HTG 127.0 ± 14.9 123.5 ± 12.5     D = 0.001 
(mmHg) HC-LTG 123.8 ± 14.7 121.9g ± 14.2     TG = 0.65 
 HC-HTG 125.3 ± 13.8 119.7d,g ± 14.0       D x TG = 0.96  
 HP 125.6 ± 14.7 123.0g ± 13.7 80.4† ± 0.4 T x D = 0.25 
 HC 124.3 ± 14.4 121.2a,g ± 14.1 78.1 ± 0.5 T x TG = 0.31 
 LTG 124.4 ± 14.6 122.4g ± 14.2 79.4 ± 0.4 T x D x TG =  0.27 
 HTG 126.3 ± 14.4 121.8g ± 13.3 79.1 ± 0.5   
 Time 125.0 ± 14.6 122.2* ± 13.9         
HP = higher protein, HC = higher carbohydrate, LTG = low triglyceride, HTG = high triglyceride, T = time effect, D = diet effect, TG = triglyceride risk 
factor effect, D x TG = diet by triglyceride risk factor effect, T x D = time by diet effect, T x TG = time by triglyceride risk factor effect, T x D x TG = time 
by diet by triglyceride risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 247 participants in the HP-LTG group, 124 in the HP-HTG 
group, 196 in the HC-LTG group, 96 in the HC-TG group, 371 in the HP total group, 292 in the HC total group, 443 in the LTG group, 220 in the HTG 
group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant triglyceride effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LTG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LTG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HTG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LTG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table B.5: Fasting Blood Lipid Values After Ten Weeks of Exercise  
and Dietary Intervention Based on Triglyceride Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Total Cholesterol HP-LTG 5.0 ± 0.8 4.9g ± 0.9     T = 0.001 
(mmol/L) HP-HTG 5.5 ± 1.1 5.2c,g ± 1.0     D = 0.61 
 HC-LTG 5.0 ± 1.0 4.9g ± 0.9     TG = 0.001 
 HC-HTG 5.5 ± 1.1 5.4f ± 1.0       D x TG = 0.76 
 HP 5.2 ± 1.0 5.0g ± 1.0 5.2 ± 0.05 T x D = 0.24 
 HC 5.2 ± 1.0 5.0g ± 1.0 5.2 ± 0.05 T x TG = 0.45 
 LTG 5.0 ± 0.9 4.9b,g ± 0.9 5.0 ± 0.04 T x D x TG = 0.19 
 HTG 5.5 ± 1.1 5.3g ± 1.0 5.4‡ ± 0.06   
 Time 5.2 ± 1.0 5.0* ± 1.0         
LDL (mmol/L) HP-LTG 3.0 ± 0.7 2.9g ± 0.7     T = 0.001 
 HP-HTG 3.3 ± 0.9 3.1c,g ± 0.8     D = 0.33 
 HC-LTG 3.0 ± 0.8 2.9g ± 0.8     TG = 0.001 
 HC-HTG 3.3 ± 0.9 3.3f ± 0.8       D x TG = 0.33 
 HP 3.1 ± 0.8 3.0g ± 0.8 3.1 ± 0.04 T x D = 0.31 
 HC 3.1 ± 0.8 3.0g ± 0.8 3.1 ± 0.04 T x TG = 0.68 
 LTG 3.0 ± 0.7 2.9b,g ± 0.7 3.0 ± 0.03 T x D x TG = 0.08 
 HTG 3.3 ± 0.9 3.2g ± 0.8 3.2‡ ± 0.05   
 Time 3.1 ± 0.8 3.0* ± 0.8         
HDL (mmol/L) HP-LTG 1.4 ± 0.3 1.4g ± 0.3     T = 0.001 
 HP-HTG 1.3 ± 0.3 1.2c,g ± 0.3     D = 0.83 
 HC-LTG 1.4 ± 0.3 1.4g ± 0.3     TG = 0.001 
 HC-HTG 1.3 ± 0.3 1.2f ± 0.3       D x TG = 0.81 
 HP 1.4 ± 0.3 1.3g ± 0.3 1.3 ± 0.02 T x D = 0.60 
 HC 1.4 ± 0.3 1.3g ± 0.3 1.3 ± 0.02 T x TG = 0.094 
 LTG 1.4 ± 0.3 1.4b,g ± 0.3 1.4 ± 0.01 T x D x TG = 0.52 
 HTG 1.3 ± 0.3 1.2g ± 0.3 1.3‡ ± 0.02   
 Time 1.4 ± 0.3 1.3* ± 0.3         
Triglycerides  HP-LTG 1.2 ± 0.4 1.2 ± 0.5     T = 0.001 
(mmol/L) HP-HTG 2.5 ± 0.9 2.1c,g ± 1.0     D = 0.28 
 HC-LTG 1.1 ± 0.4 1.2g ± 0.5     TG = 0.001 
 HC-HTG 2.3 ± 0.6 2.0f,g ± 0.8       D x TG = 0.35 
 HP 1.6 ± 0.8 1.5g ± 0.8 1.7 ± 0.03 T x D = 0.051 
 HC 1.5 ± 0.7 1.5g ± 0.7 1.7 ± 0.03 T x TG = 0.001 
 LTG 1.1 ± 0.4 1.2b ± 0.5 1.2 ± 0.03 T x D x TG = 0.90 
 HTG 2.4 ± 0.8 2.0g ± 0.9 2.2‡ ± 0.04   
 Time 1.6 ± 0.8 1.5* ± 0.8         
TC/HDL ratio HP-LTG 3.7 ± 0.8 3.8g ± 0.8     T = 0.11 
 HP-HTG 4.4 ± 0.9 4.3c ± 1.0     D = 0.78 
 HC-LTG 3.6 ± 0.9 3.7 ± 0.9     TG = 0.001 
 HC-HTG 4.4 ± 1.0 4.5f ± 1.1       D x TG = 0.47  
 HP 3.9 ± 0.9 3.9 ± 0.9 4.0 ± 0.05 T x D = 0.23 
 HC 3.9 ± 1.0 4.0 ± 1.1 4.1 ± 0.05 T x TG = 0.16 
 LTG 3.6 ± 0.8 3.7b,g ± 0.9 3.7 ± 0.04 T x D x TG = 0.12 
 HTG 4.4 ± 1.0 4.4 ± 1.0 4.4‡ ± 0.06   
 Time 3.9 ± 0.9 4.0 ± 1.0         
HP = higher protein, HC = higher carbohydrate, LTG = low triglyceride, HTG = high triglyceride, T = time effect, D = diet effect, TG = triglyceride risk 
factor effect, D x TG = diet by triglyceride risk factor effect, T x D = time by diet effect, T x TG = time by triglyceride risk factor effect, T x D x TG = 
time by diet by triglyceride risk factor effect.                                                                                                                                    Values are means ± 
standard deviations (except group means are means ± standard error) from 247 participants in the HP-LTG group, 124 in the HP-HTG group, 196 in the 
HC-LTG group, 96 in the HC-TG group, 371 in the HP total group, 292 in the HC total group, 443 in the LTG group, 220 in the HTG group, and 663 
participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant triglyceride effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LTG group, p < 0.05 (post hoc LSD).  c 
Significantly different than HP-LTG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HTG group, p < 0.05 (post hoc LSD).  f 
Significantly different than HC-LTG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table B.6: Fasting Glucose and Insulin Values After Ten Weeks of Exercise  
and Dietary Intervention Based on Triglyceride Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Glucose HP-LTG 99.6 ± 18.3 98.1 ± 16.7     T = 0.006 
(mmol/L) HP-HTG 109.4 ± 27.7 105.9c,g ± 28.0     D = 0.29 
 HC-LTG 98.3 ± 15.9 97.6 ± 13.6     TG = 0.001 
 HC-HTG 106.4 ± 33.7 104.0f ± 25.0       D x TG = 0.63  
 HP 102.9 ± 22.4 100.7g ± 21.4 103.3 ± 1.07 T x D = 0.50 
 HC 100.9 ± 23.6 99.7 ± 18.4 101.6 ± 1.21 T x TG = 0.21 
 LTG 99.0 ± 17.3 97.9b ± 15.4 98.4 ± 0.93 T x D x TG = 0.92 
 HTG 108.1 ± 30.4 105.1g ± 26.7 106.4‡ ± 1.32   
 Time 102.0 ± 22.9 100.3* ± 20.1         
Insulin HP-LTG 3.1 ± 8.3 3.5 ± 9.7     T = 0.66 
(uIU/mL) HP-HTG 5.8 ± 9.5 6.4 ± 10.7     D = 0.002 
 HC-LTG 6.9 ± 12.1 7.7c ± 11.5     TG = 0.031 
 HC-HTG 10.5 ± 13.9 9.8 ± 12.9       D x TG = 0.98 
 HP 4.0 ± 8.8 4.5 ± 10.1 4.7† ± 0.84 T x D = 0.67 
 HC 8.3 ± 12.8 8.4a ± 12.0 8.7 ± 0.99 T x TG = 0.62 
 LTG 4.6 ± 10.1 5.2 ± 10.6 5.3 ± 0.77 T x D x TG = 0.53 
 HTG 7.8 ± 11.7 7.9 ± 11.7 8.1‡ ± 1.04   
 Time 5.7 ± 10.8 6.1 ± 11.1         
Calculated  HP-LTG 0.8 ± 2.1 0.9 ± 2.4 
 
  
T = 0.98 
HOMA HP-HTG 1.6 ± 2.6 1.9 ± 3.6 D = 0.003 
 HC-LTG 1.8 ± 3.3 2.0c ± 3.5 TG = 0.010 
 HC-HTG 3.2 ± 6.2 2.6 ± 3.5 D x TG = 0.91 
 HP 1.0 ± 2.3 1.2 ± 2.9 1.3† ± 0.24 T x D = 0.42 
 HC 2.3 ± 4.6 2.2a ± 3.5 2.4 ± 0.29 T x TG = 0.40 
 LTG 1.2 ± 2.7 1.3 ± 3.0 1.4 ± 0.22 T x D x TG = 0.22 
 HTG 2.3 ± 4.6 2.2 ± 3.6 2.3‡ ± 0.30   
 Time 1.6 ± 3.5 1.6 ± 3.2         
HP = higher protein, HC = higher carbohydrate, LTG = low triglyceride, HTG = high triglyceride, T = time effect, D = diet effect, TG = triglyceride risk 
factor effect, D x TG = diet by triglyceride risk factor effect, T x D = time by diet effect, T x TG = time by triglyceride risk factor effect, T x D x TG = 
time by diet by triglyceride risk factor effect.                                                                                                                                     
Glucose values are means ± standard deviations (except group means are means ± standard error) from 247 participants in the HP-LTG group, 124 in the 
HP-HTG group, 196 in the HC-LTG group, 96 in the HC-TG group, 371 in the HP total group, 292 in the HC total group, 443 in the LTG group, 220 in 
the HTG group, and 663 participants total.  Insulin and HOMA values are means ± standard deviations (except group means are means ± standard error) 
from 99 participants in the HP-LTG group, 50 in the HP-HTG group, 65 in the HC-LWC group, 38 in the HC-HWC group, 149 in the HP total group, 
103 in the HC total group, 164 in the LWC group, 88 in the HWC group, and 252 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant triglyceride effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LTG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LTG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HTG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LTG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table B.7: Fitness Parameters After Ten Weeks of Exercise and Dietary Intervention 
Based on Triglyceride Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Bench Press  HP-LTG 31.5 ± 7.9 33.7g ± 7.6     T = 0.001 
Max Strength HP-HTG 29.7 ± 6.8 31.3c,g ± 6.7     D = 0.76 
(1 RM / kg body HC-LTG 29.3 ± 7.7 31.8c,g ± 8.0     TG = 0.69 
weight) HC-HTG 31.2 ± 8.0 33.1g ± 8.3       D x TG =0.004  
 HP 30.9 ± 7.6 32.9g ± 7.4 31.6 ± 0.4 T x D = 0.41 
 HC 29.9 ± 7.8 32.2g ± 8.1 31.4 ± 0.5 T x TG = 0.18 
 LTG 30.6 ± 7.9 32.9g ± 7.8 31.6 ± 0.4 T x D x TG = 0.96 
 HTG 30.3 ± 7.3 32.1g ± 7.4 31.3 ± 0.5   
 Time 30.5 ± 7.7 32.6* ± 7.7         
Bench Press HP-LTG 181.7 ± 76.3 186.2 ± 83.5     T = 0.89 
Lift Volume HP-HTG 177.3 ± 86.8 173.2 ± 74.1     D = 0.46 
(kg) HC-LTG 182.4 ± 83.3 174.7 ± 77.1     TG = 0.84 
 HC-HTG 187.0 ± 87.6 192.3 ± 85.1       D x TG = 0.10  
 HP 180.3 ± 79.7 182.0 ± 80.7 179.6 ± 3.9 T x D = 0.86 
 HC 183.8 ± 84.5 180.1 ± 79.9 184.1 ± 4.6 T x TG = 0.78 
 LTG 182.0 ± 79.3 181.2 ± 80.9 181.3 ± 3.4 T x D x TG = 0.17 
 HTG 181.4 ± 87.0 181.2 ± 79.2 182.5 ± 5.0   
 Time 181.8 ± 81.8 181.2 ± 80.3         
Leg Press  HP-LTG 166.4 ± 47.1 181.3g ± 50.1     T = 0.001 
Max Strength HP-HTG 159.3 ± 50.0 177.6g ± 56.7     D = 0.45 
(1 RM / kg body HC-LTG 155.1 ± 51.1 168.2c,g ± 55.5     TG = 0.43 
weight) HC-HTG 165.6 ± 49.8 182.3f,g ± 53.5       D x TG = 0.045  
 HP 164.1 ± 48.1 180.1g ± 52.3 171.2 ± 2.9 T x D = 0.51 
 HC 158.4 ± 50.8 172.5g ± 55.2 167.8 ± 3.3 T x TG = 0.17 
 LTG 161.5 ± 49.1 175.6g ± 52.9 167.8 ± 2.5 T x D x TG = 0.95 
 HTG 161.9 ± 49.8 179.6g ± 55.3 171.2 ± 3.6   
 Time 161.7 ± 49.3 176.8* ± 53.6         
Leg Press HP-LTG 1796.3 ± 899.7 1943.7g ± 918.4     T = 0.40 
Lift Volume HP-HTG 1874.9 ± 1100.6 1910.9 ± 1356.7     D = 0.016 
(kg) HC-LTG 1599.7 ± 877.6 1586.6c ± 837.1     TG = 0.13 
 HC-HTG 1818.7 ± 818.8 1783.6 ± 1024.7       D x TG = 0.23  
 HP 1821.8 ± 968.3 1933.1 ± 1077.9 1881.5† ± 49.6 T x D = 0.15 
 HC 1667.3 ± 864.3 1647.4a ± 901.7 1697.1 ± 57.9 T x TG = 0.40 
 LTG 1710.8 ± 894.4 1788.4 ± 900.5 1731.6 ± 42.8 T x D x TG = 0.58 
 HTG 1851.4 ± 990.6 1857.7 ± 1227.5 1847.0 ± 63.1   
 Time 1755.4 ± 927.5 1810.3 ± 1015.1         
Peak VO2 HP-LTG 20.2 ± 4.6 22.1g ± 4.6     T = 0.001 
(mL/kg/min) HP-HTG 19.7 ± 4.4 21.7g ± 4.4     D = 0.009 
 HC-LTG 20.5 ± 4.3 22.9c,g ± 4.6     TG = 0.85 
 HC-HTG 20.5 ± 4.0 23.4d,g ± 5.0       D x TG = 0.32  
 HP 20.0 ± 4.5 21.9g ± 4.5 20.9† ± 0.23 T x D = 0.012 
 HC 20.5 ± 4.2 23.1a,g ± 4.7 21.8 ± 0.26 T x TG = 0.30 
 LTG 20.3 ± 4.5 22.4g ± 4.6 21.4 ± 0.20 T x D x TG = 0.67 
 HTG 20.1 ± 4.2 22.5g ± 4.7 21.3 ± 0.28   
 Time 20.2 ± 4.4 22.4* ± 4.6         
HP = higher protein, HC = higher carbohydrate, LTG = low triglyceride, HTG = high triglyceride, T = time effect, D = diet effect, TG = triglyceride risk 
factor effect, D x TG = diet by triglyceride risk factor effect, T x D = time by diet effect, T x TG = time by triglyceride risk factor effect, T x D x TG = 
time by diet by triglyceride risk factor effect.                                                                                                                                     
Strength values are means ± standard deviations (except group means are means ± standard error) from 230 participants in the HP-LTG group, 110 in the 
HP-HTG group, 177 in the HC-LTG group, 79 in the HC-TG group, 340 in the HP total group, 256 in the HC total group, 407 in the LTG group, 189 in 
the HTG group, and 596 participants total.  Peak VO2 values are means ± standard deviations (except group means are means ± standard error) from 247 
participants in the HP-LTG group, 124 in the HP-HTG group, 196 in the HC-LTG group, 96 in the HC-TG group, 371 in the HP total group, 292 in the 
HC total group, 443 in the LTG group, 220 in the HTG group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant triglyceride effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LTG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LTG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HTG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LTG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table B.8: Changes in SF36 - Quality of Life Inventory Values After Ten Weeks of 
Exercise and Dietary Intervention Based on Triglyceride Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Physical  HP-LTG 77.1 ± 33.3 84.2g ± 27.0     T = 0.001 
Functioning HP-HTG 72.9 ± 21.4 75.8c ± 18.6     D = 0.43 
 HC-LTG 75.8 ± 24.5 83.3g ± 21.3     TG = 0.23 
 HC-HTG 77.2 ± 14.8 82.0 ± 18.5       D x TG = 0.24  
 HP 75.7 ± 29.7 81.3g ± 24.7 77.5 ± 1.85 T x D = 0.67 
 HC 76.4 ± 21.2 82.8g ± 20.2 79.6 ± 1.90 T x TG = 0.22 
 LTG 76.5 ± 29.5 83.8g ± 24.5 80.1 ± 1.60 T x D x TG = 0.79 
 HTG 75.1 ± 18.4 78.9 ± 18.7 76.9 ± 2.11   
 Time 76.0 ± 26.0 82.0* ± 22.7         
Role Physical HP-LTG 149.8 ± 140.4 158.5 ± 153.8     T = 0.52 
 HP-HTG 127.6 ± 132.0 123.3 ± 134.4     D = 0.001 
 HC-LTG 260.1 ± 138.9 265.4c ± 143.3     TG = 0.08 
 HC-HTG 230.4 ± 147.0 231.5d ± 152.0       D x TG = 0.93  
 HP 142.2 ± 137.5 146.4 ± 148.0 139.8† ± 11.91 T x D = 0.91 
 HC 248.6 ± 142.3 252.3a ± 147.1 246.9 ± 12.22 T x TG = 0.31 
 LTG 200.1 ± 149.8 207.3 ± 158.0 208.4 ± 10.31 T x D x TG = 0.60 
 HTG 179.5 ± 148.4 177.9 ± 152.9 178.2 ± 13.59   
 Time 192.6 ± 149.4 196.6 ± 156.5         
Bodily Pain HP-LTG 58.5 ± 18.9 63.2g ± 20.4     T = 0.039 
 HP-HTG 60.2 ± 19.2 62.9 ± 21.5     D = 0.42 
 HC-LTG 59.2 ± 21.9 63.0g ± 20.9     TG = 0.31 
 HC-HTG 66.4 ± 20.2 63.8 ± 22.9       D x TG =0.47  
 HP 59.1 ± 19.0 63.1g ± 20.7 61.2 ± 1.61 T x D = 0.13 
 HC 62.0 ± 21.4 63.3 ± 21.6 63.1 ± 1.65 T x TG = 0.047 
 LTG 58.8 ± 20.3 63.1g ± 20.6 61.0 ± 1.39 T x D x TG = 0.29 
 HTG 63.3 ± 19.9 63.4 ± 22.1 63.3 ± 1.84   
 Time 60.5 ± 20.2 63.2* ± 21.1         
General Health HP-LTG 49.5 ± 28.9 55.3g ± 28.8     T = 0.001 
 HP-HTG 51.9 ± 28.2 53.9 ± 28.5     D = 0.001 
 HC-LTG 66.4 ± 21.5 69.6c,g ± 21.7     TG = 0.66 
 HC-HTG 63.1 ± 23.6 66.4d,g ± 23.0       D x TG = 0.55  
 HP 50.4 ± 28.6 54.8g ± 28.6 52.6† ± 2.15 T x D = 0.72 
 HC 65.1 ± 22.3 68.4a,g ± 22.1 66.4 ± 2.21 T x TG = 0.21 
 LTG 57.2 ± 27.1 61.8g ± 26.7 60.2 ± 1.86 T x D x TG = 0.18 
 HTG 57.6 ± 26.5 60.2g ± 26.5 58.8 ± 2.46   
 Time 57.3 ± 26.8 61.2* ± 26.6         
Vital HP-LTG 37.2 ± 22.3 45.5g ± 27.8     T = 0.001 
 HP-HTG 49.0 ± 72.3 56.0g ± 71.5     D = 0.18 
 HC-LTG 50.7 ± 17.3 56.5c,g ± 17.1     TG = 0.28 
 HC-HTG 49.9 ± 20.4 54.0g ± 20.7       D x TG = 0.14  
 HP 41.3 ± 46.1 49.1g ± 47.5 46.9 ± 3.03 T x D = 0.13 
 HC 50.4 ± 18.5 55.5g ± 18.6 52.8 ± 3.11 T x TG = 0.41 
 LTG 43.4 ± 21.2 50.6g ± 24.1 47.5 ± 2.62 T x D x TG = 0.90 
 HTG 49.4 ± 52.7 55.0g ± 52.2 52.2 ± 3.46   
 Time 45.6 ± 36.0 52.2* ± 36.8         
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Table B.8: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Social 
Functioning 
HP-LTG 46.0 ± 25.7 49.9g ± 25.8 
 
  
T = 0.009 
HP-HTG 46.8 ± 26.1 52.3g ± 28.7 D = 0.001 
HC-LTG 61.4 ± 25.1 62.1c ± 24.1 TG = 0.52 
HC-HTG 55.8 ± 24.5 56.9 ± 25.0 D x TG = 0.23  
HP 46.2 ± 25.7 50.7g ± 26.7 48.7† ± 2.05 T x D = 0.07 
HC 59.3 ± 24.9 60.1a ± 24.5 59.1 ± 2.11 T x TG = 0.66 
LTG 53.0 ± 26.5 55.5 ± 25.7 54.8 ± 1.78 T x D x TG = 0.77 
HTG 51.4 ± 25.6 54.6g ± 26.9 52.9 ± 2.35   
  Time 52.4 ± 26.1 55.2* ± 26.1   
Role Emotional HP-LTG 224.3 ± 128.5 241.4 ± 140.6 
 
  
T = 0.33 
HP-HTG 206.6 ± 129.6 233.1 ± 141.8 D = 0.001 
HC-LTG 312.5 ± 219.9 290.2c ± 131.4 TG = 0.33 
HC-HTG 276.4 ± 129.5 288.0d ± 139.1 D x TG = 0.85  
HP 218.3 ± 128.7 238.6 ± 140.6 226.4† ± 11.38 T x D = 0.11 
HC 298.6 ± 190.3 289.4a ± 133.9 291.8 ± 11.68 T x TG = 0.20 
LTG 264.6 ± 181.1 263.7 ± 138.3 267.1 ± 9.85 T x D x TG = 0.47 
HTG 241.8 ± 133.6 260.9 ± 142.4 251.1 ± 13.00   
  Time 256.3 ± 165.6 262.7 ± 139.6   
Mental Health 
 
HP-LTG 56.9 ± 15.4 65.5g ± 15.6 
 
  
T = 0.001 
HP-HTG 55.9 ± 15.9 64.5g ± 14.9 D = 0.019 
HC-LTG 60.2 ± 14.2 65.6g ± 11.7 TG = 0.58 
HC-HTG 60.4 ± 14.7 70.8d,f,g ± 12.2 D x TG = 0.22  
HP 56.5 ± 15.5 65.1g ± 15.3 60.7† ± 1.06 T x D = 0.71 
HC 60.3 ± 14.4 67.6g ± 12.1 64.2 ± 1.08 T x TG = 0.17 
LTG 58.4 ± 14.9 65.5g ± 13.9 62.0 ± 0.92 T x D x TG = 0.18 
HTG 58.1 ± 15.4 67.7g ± 13.9 62.9 ± 1.21   
  Time 58.3 ± 15.1 66.3* ± 13.9   
HP = higher protein, HC = higher carbohydrate, LTG = low triglyceride, HTG = high triglyceride, T = time effect, D = diet effect, TG = triglyceride risk 
factor effect, D x TG = diet by triglyceride risk factor effect, T x D = time by diet effect, T x TG = time by triglyceride risk factor effect, T x D x TG = time 
by diet by triglyceride risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 100 participants in the HP-LTG group, 52 in the HP-HTG 
group, 84 in the HC-LTG group, 53 in the HC-TG group, 152 in the HP total group, 137 in the HC total group, 184 in the LTG group, 105 in the HTG 
group, and 289 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant triglyceride effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LTG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LTG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HTG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LTG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table B.9: Changes in Body Image Evaluation After Ten Weeks of Exercise  
and Dietary Intervention Based on Triglyceride Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Appearance 
Evaluation 
HP-LTG 2.4 ± 0.6 2.8g ± 0.7 
 
  
T = 0.001 
HP-HTG 2.4 ± 0.6 2.7g ± 0.6 D = 0.55 
HC-LTG 2.5 ± 0.6 2.8g ± 0.7 TG = 0.26 
HC-HTG 2.4 ± 0.6 2.8g ± 0.7 D x TG = 0.62  
HP 2.4 ± 0.6 2.7g ± 0.7 2.6 ± 0.04 T x D = 0.58 
HC 2.4 ± 0.6 2.8g ± 0.7 2.6 ± 0.04 T x TG = 0.71 
LTG 2.4 ± 0.6 2.8g ± 0.7 2.6 ± 0.03 T x D x TG = 0.96 
HTG 2.4 ± 0.6 2.7g ± 0.6 2.6 ± 0.05   
  Time 2.4 ± 0.6 2.8* ± 0.7   
Appearance 
Orientation 
HP-LTG 4.2 ± 0.8 4.1 ± 0.9 
 
  
T = 0.49 
HP-HTG 4.1 ± 0.9 4.1 ± 0.8 D =0.020 
HC-LTG 4.0 ± 0.8 3.9c ± 0.9 TG = 0.41 
HC-HTG 3.9 ± 0.8 3.9 ± 0.8 D x TG = 0.96  
HP 4.1 ± 0.9 4.1 ± 0.9 4.1† ± 0.06 T x D = 0.36 
HC 3.9 ± 0.8 3.9a ± 0.9 3.9 ± 0.06 T x TG = 0.23 
LTG 4.1 ± 0.8 4.0 ± 0.9 4.1 ± 0.05 T x D x TG = 0.77 
HTG 4.0 ± 0.8 4.0 ± 0.8 4.0 ± 0.07   
  Time 4.1 ± 0.8 4.0 ± 0.9   
Body Area HP-LTG 2.1 ± 0.8 2.3g ± 0.8     T = 0.001 
Satisfaction HP-HTG 2.0 ± 0.7 2.3g ± 0.8     D = 0.002 
 HC-LTG 2.2 ± 0.7 2.6c,g ± 0.8     TG = 0.74  
 HC-HTG 2.2 ± 0.7 2.5g ± 0.8       D x TG = 0.88  
 HP 2.0 ± 0.8 2.3g ± 0.8 2.2† ± 0.05 T x D = 0.64 
 HC 2.2 ± 0.7 2.5a,g ± 0.8 2.4 ± 0.06 T x TG = 0.20 
 LTG 2.1 ± 0.7 2.4g ± 0.8 2.3 ± 0.04 T x D x TG = 0.033 
 HTG 2.1 ± 0.7 2.4g ± 0.8 2.3 ± 0.06   
 Time 2.1 ± 0.7 2.4* ± 0.8         
Overweight HP-LTG 2.9 ± 0.7 3.4g ± 0.7     T = 0.001 
Preoccupation HP-HTG 2.9 ± 0.6 3.4g ± 0.7     D = 0.29 
 HC-LTG 2.9 ± 0.7 3.3g ± 0.7     TG = 0.74 
 HC-HTG 2.8 ± 0.7 3.2g ± 0.7       D x TG = 0.69 
 HP 2.9 ± 0.7 3.4g ± 0.7 3.1 ± 0.04 T x D = 0.12 
 HC 2.9 ± 0.7 3.3g ± 0.7 3.1 ± 0.05 T x TG = 0.98 
 LTG 2.9 ± 0.7 3.4g ± 0.7 3.1 ± 0.04 T x D x TG = 0.62  
 HTG 2.9 ± 0.7 3.3g ± 0.7 3.1 ± 0.05   
 Time 2.9 ± 0.7 3.3* ± 0.7         
Self-Classified HP-LTG 4.3 ± 0.7 4.2 ± 0.7     T = 0.024 
Weight HP-HTG 4.2 ± 0.8 4.2 ± 0.6     D = 0.14 
 HC-LTG 4.1 ± 0.7 4.0 ± 0.7     TG = 0.66 
 HC-HTG 4.2 ± 0.7 4.1 ± 0.8       D x TG = 0.39 
 HP 4.2 ± 0.7 4.2 ± 0.7 4.2 ± 0.04 T x D = 0.43 
 HC 4.2 ± 0.7 4.0 ± 0.7 4.1 ± 0.04 T x TG = 0.87 
 LTG 4.2 ± 0.7 4.1g ± 0.7 4.1 ± 0.03 T x D x TG = 0.48  
 HTG 4.2 ± 0.8 4.1g ± 0.7 4.2 ± 0.05   
 Time 4.2 ± 0.7 4.1* ± 0.7         
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Table B.9: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Rosenberg HP-LTG 26.0 ± 4.0 26.6g ± 4.0     T = 0.006 
Self Esteem HP-HTG 25.1 ± 3.7 25.7 ± 3.5     D = 0.94 
 HC-LTG 25.8 ± 4.0 25.8 ± 3.9     TG = 0.28 
 HC-HTG 25.5 ± 3.8 26.2 ± 4.1       D x TG = 0.20  
 HP 25.7 ± 3.9 26.3g ± 3.8 25.8 ± 0.24 T x D = 0.38 
 HC 25.7 ± 3.9 25.9 ± 4.0 25.8 ± 0.27 T x TG = 0.37 
 LTG 25.9 ± 4.0 26.3 ± 4.0 26.0 ± 0.21 T x D x TG = 0.32 
 HTG 25.3 ± 3.8 25.9g ± 3.8 25.6 ± 0.29   
 Time 25.7 ± 3.9 26.2* ± 3.9         
Social Physique HP-LTG 31.1 ± 6.4 31.2 ± 6.5     T = 0.56 
Anxiety HP-HTG 31.5 ± 6.0 31.8 ± 5.6     D = 0.74 
 HC-LTG 31.2 ± 6.1 31.0 ± 5.1     TG = 0.44 
 HC-HTG 31.0 ± 5.7 31.7 ± 7.6       D x TG = 0.85  
 HP 31.3 ± 6.3 31.4 ± 6.2 31.4 ± 0.35 T x D = 0.83 
 HC 31.1 ± 6.0 31.3 ± 6.1 31.2 ± 0.39 T x TG = 0.46 
 LTG 31.1 ± 6.3 31.1 ± 6.0 31.1 ± 0.30 T x D x TG = 0.59  
 HTG 31.3 ± 5.9 31.7 ± 6.6 31.5 ± 0.42   
 Time 31.2 ± 6.1 31.3 ± 6.2         
HP = higher protein, HC = higher carbohydrate, LTG = low triglyceride, HTG = high triglyceride, T = time effect, D = diet effect, TG = 
triglyceride risk factor effect, D x TG = diet by triglyceride risk factor effect, T x D = time by diet effect, T x TG = time by triglyceride risk 
factor effect, T x D x TG = time by diet by triglyceride risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 177 participants in the HP-LTG group, 79 in the 
HP-HTG group, 127 in the HC-LTG group, 68 in the HC-TG group, 256 in the HP total group, 195 in the HC total group, 304 in the LTG 
group, 147 in the HTG group, and 451 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant triglyceride effect, p 
< 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LTG group, p < 0.05 (post 
hoc LSD).  c Significantly different than HP-LTG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HTG group, p < 0.05 (post 
hoc LSD).  f Significantly different than HC-LTG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc 
LSD). 
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APPENDIX C 
HDL CHOLESTEROL RISK FACTOR TABLES 
Table C.1: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on HDL Status and Measured via DEXA Scan 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Scanned Mass  HP-HHDL 88.9 ± 18.4 85.1 ± 17.9     T = 0.001 
(kg) HP-LHDL 89.7 ± 17.7 85.7g ± 16.9     D = 0.001 
 HC-HHDL 81.2 ± 13.7 78.3c ± 13.1     HDL = 0.14 
 HC-LHDL 84.5 ± 15.2 81.3d ± 14.5       D x HDL = 0.37 
 HP 89.2 ± 18.1 85.3g ± 17.5 87.3† ± 0.85 T x D = 0.002 
 HC 82.5 ± 14.3 79.5a,g ± 13.7 81.3 ± 0.97 T x HDL = 0.35 
 HHDL 85.4 ± 16.9 82.0g ± 16.2 83.4 ± 0.81 T x D x HDL = 0.84  
 LHDL 87.5 ± 16.8 83.8g ± 16.0 85.3 ± 1.01   
 Time 86.2 ± 16.9 82.7* ± 16.2         
Fat Mass (kg) HP-HHDL 41.4 ± 11.6 38.3 ± 11.4     T = 0.001 
 HP-LHDL 40.7 ± 11.2 37.5g ± 10.9     D = 0.001 
 HC-HHDL 36.7 ± 9.0 34.4c ± 8.7     HDL = 0.93 
 HC-LHDL 37.8 ± 9.3 35.1 ± 8.7       D x HDL = 0.29 
 HP 41.1 ± 11.4 38.0g ± 11.2 39.5† ± 0.54 T x D = 0.003 
 HC 37.1 ± 9.1 34.7a,g ± 8.7 36.0 ± 0.62 T x HDL = 0.35 
 HHDL 39.3 ± 10.8 36.6b,c ± 10.5 37.7 ± 0.51 T x D x HDL = 0.47  
 LHDL 39.4 ± 10.5 36.5g ± 10.0 37.8 ± 0.64   
 Time 39.3 ± 10.7 36.5* ± 10.3         
Lean Mass (kg) HP-HHDL 45.6 ± 7.8 44.9 ± 7.5     T = 0.001 
 HP-LHDL 47.3 ± 7.5 46.4c,g ± 7.1     D = 0.001 
 HC-HHDL 42.8 ± 6.0 42.2c ± 5.6     HDL = 0.001 
 HC-LHDL 44.9 ± 6.9 44.3d,f ± 6.9       D x HDL = 0.61 
 HP 46.3 ± 7.7 45.5g ± 7.4 46.0† ± 0.37 T x D = 0.15 
 HC 43.6 ± 6.4 43.0a,g ± 6.2 43.6 ± 0.42 T x HDL = 0.80 
 HHDL 44.4 ± 7.2 43.7b,g ± 6.9 43.9 ± 0.35 T x D x HDL = 0.45  
 LHDL 46.2 ± 7.4 45.5g ± 7.1 45.7‡ ± 0.43   
 Time 45.1 ± 7.3 44.4* ± 7.0         
Body Fat (%) HP-HHDL 46.1 ± 4.3 44.5 ± 4.6     T = 0.001 
 HP-LHDL 44.7 ± 4.5 43.1c,g ± 4.7     D = 0.06 
 HC-HHDL 44.9 ± 4.3 43.7 ± 4.3     HDL = 0.003 
 HC-LHDL 44.3 ± 4.0 42.9 ± 4.2       D x HDL = 0.33 
 HP 45.5 ± 4.4 43.9g ± 4.7 44.6† ± 0.23 T x D = 0.21 
 HC 44.7 ± 4.2 43.4g ± 4.3 44.0 ± 0.26 T x HDL = 0.48 
 HHDL 45.6 ± 4.3 44.1g ± 4.5 44.8 ± 0.22 T x D x HDL = 0.46  
 LHDL 44.5 ± 4.3 43.0g ± 4.5 43.8‡ ± 0.27   
 Time 45.2 ± 4.3 43.7* ± 4.5         
HP = higher protein, HC = higher carbohydrate, HHDL = high HDL cholesterol, LHDL = low HDL cholesterol, T = time effect, D = diet effect, HDL = 
HDL risk factor effect, D x HDL = diet by HDL risk factor effect, T x D = time by diet effect, T x HDL = time by HDL risk factor effect, T x D x HDL = 
time by diet by HDL risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 220 participants in the HP-HHDL group, 151 in the HP-
LHDL group, 180 in the HC-HHDL group, 112 in the HC-LHDL group, 371 in the HP total group, 292 in the HC total group, 400 in the HHDL group, 
263 in the LHDL group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant HDL effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than HHDL group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-HHDL group, p < 0.05 (post hoc LSD).  d Significantly different than HP-LHDL group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-HHDL group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table C.2: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on HDL Status and Measured via Anthropometric Measurements 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Weight (kg) HP-HHDL 95.4 ± 19.4 91.2g ± 18.9     T = 0.001 
 HP-LHDL 96.3 ± 18.6 91.9g ± 17.6     D = 0.001 
 HC-HHDL 87.5 ± 14.2 84.4c,g ± 13.5     HDL = 0.15 
 HC-LHDL 90.8 ± 15.8 87.3d,g ± 15.2       D x HDL = 0.38 
 HP 95.8 ± 19.1 91.5g ± 18.3 93.7† ± 0.9 T x D = 0.001 
 HC 88.8 ± 14.9 85.5a,g ± 14.2 87.5 ± 1.0 T x HDL = 0.40 
 HHDL 91.9 ± 17.7 88.1g ± 17.0 89.6 ± 0.9 T x D x HDL = 0.77 
 LHDL 93.9 ± 17.6 90.0g ± 16.7 91.6‡ ± 1.1   
 Time 92.7 ± 17.7 88.9* ± 16.9         
Body Mass Index HP-HHDL 35.9 ± 6.7 34.3g ± 6.5     T = 0.001 
(kg/m2) HP-LHDL 36.0 ± 6.4 34.4g ± 6.1     D = 0.001 
 HC-HHDL 32.8 ± 5.1 31.6c,g ± 4.8     HDL = 0.16 
 HC-LHDL 34.1 ± 5.3 32.8d,g ± 5.1       D x HDL = 0.19  
 HP 35.9 ± 6.6 34.3g ± 6.4 35.1† ± 0.3 T x D = 0.001  
 HC 33.3 ± 5.2 32.1a,g ± 5.0 32.8 ± 0.4 T x HDL = 0.43 
 HHDL 34.5 ± 6.2 33.1g ± 6.0 33.7 ± 0.3 T x D x HDL = 0.67 
 LHDL 35.2 ± 6.0 33.7g ± 5.8 34.3 ± 0.4   
 Time 34.8 ± 6.2 33.3* ± 5.9         
Waist HP-HHDL 101.0 ± 14.0 97.0g ± 13.6     T = 0.001 
Circumference HP-LHDL 101.8 ± 12.7 97.7g ± 12.6     D = 0.001 
(cm) HC-HHDL 94.6 ± 11.3 91.4c,g ± 11.0     HDL = 0.055 
 HC-LHDL 97.6 ± 12.1 94.5d,f,g ± 11.3       D x HDL = 0.24 
 HP 101.3 ± 13.5 97.3g ± 13.2 99.4† ± 0.6 T x D = 0.07 
 HC 95.8 ± 11.7 92.6a,g ± 11.2 94.5 ± 0.7 T x HDL = 0.98 
 HHDL 98.2 ± 13.2 94.5g ± 12.8 96.0 ± 0.6 T x D x HDL = 0.87 
 LHDL 100.0 ± 12.6 96.3g ± 12.1 97.9 ± 0.8   
 Time 98.9 ± 13.0 95.2* ± 12.6         
Hip HP-HHDL 123.0 ± 14.1 119.9g ± 14.1     T = 0.001 
Circumference HP-LHDL 122.4 ± 13.6 119.0g ± 13.0     D = 0.001 
(cm) HC-HHDL 118.0 ± 11.4 115.2c,g ± 10.9     HDL = 0.88 
 HC-LHDL 118.9 ± 11.7 116.4g ± 10.8       D x HDL = 0.38  
 HP 122.7 ± 13.9 119.5g ± 13.6 121.1† ± 0.7 T x D = 0.15 
 HC 118.3 ± 11.5 115.6a,g ± 10.9 117.1 ± 0.7 T x HDL = 0.97 
 HHDL 120.7 ± 13.2 117.8g ± 13.0 119.0 ± 0.6 T x D x HDL = 0.42 
 LHDL 120.9 ± 12.9 117.9g ± 12.2 119.2 ± 0.8   
 Time 120.8 ± 13.1 117.8* ± 12.6         
HP = higher protein, HC = higher carbohydrate, HHDL = high HDL cholesterol, LHDL = low HDL cholesterol, T = time effect, D = diet effect, HDL = 
HDL risk factor effect, D x HDL = diet by HDL risk factor effect, T x D = time by diet effect, T x HDL = time by HDL risk factor effect, T x D x HDL = 
time by diet by HDL risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 220 participants in the HP-HHDL group, 151 in the HP-
LHDL group, 180 in the HC-HHDL group, 112 in the HC-LHDL group, 371 in the HP total group, 292 in the HC total group, 400 in the HHDL group, 263 
in the LHDL group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant HDL effect, p < 0.05 (univariate).  
a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than HHDL group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-HHDL group, p < 0.05 (post hoc LSD).  d Significantly different than HP-LHDL group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-HHDL group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table C.3: Resting Energy Expenditure After Ten Weeks of Exercise and Dietary 
Intervention Based on HDL Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Resting Energy HP-HHDL 1669.2 ± 284.7 1600.8g ± 269.3     T = 0.001 
Expenditure HP-LHDL 1737.7 ± 282.1 1681.0c,g ± 317.7     D = 0.001 
(kcal/day) HC-HHDL 1585.9 ± 242.9 1532.8c,g ± 245.2     HDL = 0.003 
 HC-LHDL 1624.4 ± 255.3 1591.8d ± 251.3       D x HDL = 0.53 
 HP 1697.4 ± 285.2 1633.8g ± 292.5 1672.2† ± 13.4 T x D = 0.26 
 HC 1600.7 ± 248.0 1555.5a,g ± 248.8 1583.7 ± 15.4 T x HDL = 0.36 
 HHDL 1631.9 ± 269.7 1570.4b,g ± 260.7 1597.2 ± 12.8 T x D x HDL = 0.80  
 LHDL 1690.2 ± 276.4 1643.6g ± 294.5 1658.7‡ ± 15.9   
 Time 1655.2 ± 273.7 1599.7* ± 276.8         
HP = higher protein, HC = higher carbohydrate, HHDL = high HDL cholesterol, LHDL = low HDL cholesterol, T = time effect, D = diet effect, HDL = HDL risk 
factor effect, D x HDL = diet by HDL risk factor effect, T x D = time by diet effect, T x HDL = time by HDL risk factor effect, T x D x HDL = time by diet by 
HDL risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 210 participants in the HP-HHDL group, 147 in the HP-LHDL 
group, 170 in the HC-HHDL group, 106 in the HC-LHDL group, 357 in the HP total group, 276 in the HC total group, 380 in the HHDL group, 253 in the LHDL 
group, and 633 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant HDL effect, p < 0.05 (univariate).   
a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than HHDL group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-HHDL group, p < 0.05 (post hoc LSD).  d Significantly different than HP-LHDL group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-HHDL group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table C.4: Resting Hemodynamic Measurements After Ten Weeks of Exercise and 
Dietary Intervention Based on HDL Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Resting Heart HP-HHDL 71.0 ± 10.2 68.5g ± 9.6     T = 0.001 
Rate (bpm) HP-LHDL 73.5 ± 10.4 69.6g ± 9.8     D = 0.23 
 HC-HHDL 70.6 ± 10.4 68.2g ± 10.7     HDL = 0.06 
 HC-LHDL 72.1 ± 10.7 68.2g ± 8.6       D x HDL = 0.47 
 HP 72.0 ± 10.3 68.9g ± 9.7 70.6 ± 0.5 T x D = 0.88 
 HC 71.2 ± 10.5 68.2g ± 9.9 69.8 ± 0.5 T x HDL = 0.07 
 HHDL 70.8 ± 10.3 68.4g ± 10.1 69.6 ± 0.4 T x D x HDL = 0.92 
 LHDL 72.9 ± 10.5 69.0g ± 9.3 70.9‡ ± 0.5   
 Time 71.6 ± 10.4 68.6* ± 9.8         
Resting Systolic HP-HHDL 126.0 ± 15.4 123.4g ± 13.8     T = 0.001 
Blood Pressure HP-LHDL 125.0 ± 13.7 122.4g ± 13.6     D = 0.09 
(mmHg) HC-HHDL 124.2 ± 13.9 122.8 ± 14.6     HDL = 0.12 
 HC-LHDL 124.4 ± 15.3 118.5d,f,g ± 13.0       D x HDL = 0.58 
 HP 125.6 ± 14.7 123.0g ± 13.7 124.2 ± 0.6 T x D = 0.39 
 HC 124.3 ± 14.4 121.2a,g ± 14.1 122.5 ± 0.7 T x HDL = 0.06 
 HHDL 125.2 ± 14.8 123.1b,g ± 14.1 124.1 ± 0.6 T x D x HDL =0.06  
 LHDL 124.7 ± 14.3 120.7g ± 13.5 122.6 ± 0.8   
 Time 125.0 ± 14.6 122.2* ± 13.9         
Resting Diastolic HP-HHDL 81.1 ± 9.0 80.1 ± 8.8     T = 0.001 
Blood Pressure HP-LHDL 81.5 ± 9.6 78.8g ± 8.8     D = 0.001 
(mmHg) HC-HHDL 79.7 ± 9.3 77.8c,g ± 8.8     HDL = 0.12 
 HC-LHDL 78.8 ± 9.5 75.7d,f,g ± 9.6       D x HDL = 0.35 
 HP 81.3 ± 9.3 79.6g ± 8.8 80.4† ± 0.4 T x D = 0.43 
 HC 79.3 ± 9.4 77.0a,g ± 9.2 78.0 ± 0.5 T x HDL = 0.06 
 HHDL 80.5 ± 9.2 79.1b,g ± 8.9 79.7 ± 0.4 T x D x HDL = 0.77  
 LHDL 80.3 ± 9.6 77.5g ± 9.3 78.7 ± 0.5   
 Time 80.4 ± 9.4 78.4* ± 9.1         
HP = higher protein, HC = higher carbohydrate, HHDL = high HDL cholesterol, LHDL = low HDL cholesterol, T = time effect, D = diet effect, HDL = HDL 
risk factor effect, D x HDL = diet by HDL risk factor effect, T x D = time by diet effect, T x HDL = time by HDL risk factor effect, T x D x HDL = time by 
diet by HDL risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 220 participants in the HP-HHDL group, 151 in the HP-LHDL 
group, 180 in the HC-HHDL group, 112 in the HC-LHDL group, 371 in the HP total group, 292 in the HC total group, 400 in the HHDL group, 263 in the 
LHDL group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant HDL effect, p < 0.05 (univariate).   
a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than HHDL group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-HHDL group, p < 0.05 (post hoc LSD).  d Significantly different than HP-LHDL group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-HHDL group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table C.5: Fasting Blood Lipid Values After Ten Weeks of Exercise  
and Dietary Intervention Based on HDL Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Total Cholesterol HP-HHDL 5.4 ± 0.9 5.1g ± 1.0     T = 0.001 
(mmol/L) HP-LHDL 4.9 ± 0.9 4.9c ± 1.0     D = 0.68 
 HC-HHDL 5.4 ± 1.0 5.1g ± 0.9     HDL = 0.001 
 HC-LHDL 4.9 ± 1.0 5.0 ± 1.0       D x HDL = 0.53 
 HP 5.2 ± 1.0 5.0g ± 1.0 5.1 ± 0.05 T x D = 0.37 
 HC 5.2 ± 1.0 5.0g ± 1.0 5.1 ± 0.05 T x HDL = 0.001 
 HHDL 5.4 ± 1.0 5.1b,g ± 0.9 5.2 ± 0.04 T x D x HDL = 0.96 
 LHDL 4.9 ± 0.9 4.9 ± 1.0 4.9‡ ± 0.06   
 Time 5.2 ± 1.0 5.0* ± 1.0         
LDL (mmol/L) HP-HHDL 3.2 ± 0.8 2.9g ± 0.8     T = 0.001 
 HP-LHDL 3.0 ± 0.7 3.0 ± 0.7     D = 0.42 
 HC-HHDL 3.1 ± 0.9 3.0g ± 0.8     HDL = 0.77 
 HC-LHDL 3.1 ± 0.8 3.1 ± 0.8       D x HDL = 0.39 
 HP 3.1 ± 0.8 3.0g ± 0.8 3.0 ± 0.04 T x D = 0.67 
 HC 3.1 ± 0.8 3.0g ± 0.8 3.1 ± 0.04 T x HDL = 0.001 
 HHDL 3.2 ± 0.8 2.9g ± 0.8 3.0 ± 0.04 T x D x HDL = 0.66 
 LHDL 3.1 ± 0.7 3.0 ± 0.8 3.1 ± 0.05   
 Time 3.1 ± 0.8 3.0* ± 0.8         
HDL (mmol/L) HP-HHDL 1.6 ± 0.3 1.4g ± 0.3     T = 0.001 
 HP-LHDL 1.1 ± 0.1 1.1c ± 0.2     D = 0.96 
 HC-HHDL 1.6 ± 0.3 1.4g ± 0.3     HDL = 0.001 
 HC-LHDL 1.1 ± 0.1 1.1f ± 0.2       D x HDL = 0.54 
 HP 1.4 ± 0.3 1.3g ± 0.3 1.3 ± 0.01 T x D = 0.60 
 HC 1.4 ± 0.3 1.3g ± 0.3 1.3 ± 0.01 T x HDL = 0.001 
 HHDL 1.6 ± 0.3 1.4b,g ± 0.3 1.5 ± 0.01 T x D x HDL = 0.88 
 LHDL 1.1 ± 0.1 1.1g ± 0.2 1.1‡ ± 0.01   
 Time 1.4 ± 0.3 1.3* ± 0.3         
Triglycerides  HP-HHDL 1.5 ± 0.7 1.3g ± 0.7     T = 0.001 
(mmol/L) HP-LHDL 1.8 ± 0.9 1.6c,g ± 0.9     D = 0.52 
 HC-HHDL 1.4 ± 0.7 1.4 ± 0.7     HDL = 0.001 
 HC-LHDL 1.7 ± 0.8 1.6f ± 0.8       D x HDL = 0.72 
 HP 1.6 ± 0.8 1.5g ± 0.8 1.6 ± 0.04 T x D = 0.047 
 HC 1.5 ± 0.7 1.5 ± 0.7 1.5 ± 0.04 T x HDL = 0.09 
 HHDL 1.4 ± 0.7 1.4b,g ± 0.7 1.4 ± 0.04 T x D x HDL = 0.94 
 LHDL 1.8 ± 0.9 1.6g ± 0.9 1.7‡ ± 0.05   
 Time 1.6 ± 0.8 1.5* ± 0.8         
TC/HDL ratio HP-HHDL 3.5 ± 0.7 3.6g ± 0.8     T = 0.18 
 HP-LHDL 4.5 ± 0.8 4.4c,g ± 0.9     D = 0.66 
 HC-HHDL 3.5 ± 0.8 3.6g ± 0.8     HDL = 0.001 
 HC-LHDL 4.5 ± 1.0 4.5f ± 1.1       D x HDL = 0.59 
 HP 3.9 ± 0.9 3.9 ± 0.9 4.0 ± 0.04 T x D = 0.42 
 HC 3.9 ± 1.0 4.0 ± 1.1 4.0 ± 0.05 T x HDL = 0.001 
 HHDL 3.5 ± 0.7 3.6b.g ± 0.8 3.6 ± 0.04 T x D x HDL = 0.42 
 LHDL 4.5 ± 0.9 4.4 ± 1.0 4.5‡ ± 0.05   
 Time 3.9 ± 0.9 4.0 ± 1.0         
HP = higher protein, HC = higher carbohydrate, HHDL = high HDL cholesterol, LHDL = low HDL cholesterol, T = time effect, D = diet effect, HDL = 
HDL risk factor effect, D x HDL = diet by HDL risk factor effect, T x D = time by diet effect, T x HDL = time by HDL risk factor effect, T x D x HDL 
= time by diet by HDL risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 220 participants in the HP-HHDL group, 151 in the HP-
LHDL group, 180 in the HC-HHDL group, 112 in the HC-LHDL group, 371 in the HP total group, 292 in the HC total group, 400 in the HHDL group, 
263 in the LHDL group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant HDL effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than HHDL group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-HHDL group, p < 0.05 (post hoc LSD).  d Significantly different than HP-LHDL group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-HHDL group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table C.6: Fasting Glucose and Insulin Values After Ten Weeks of Exercise  
and Dietary Intervention Based on HDL Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Glucose HP-HHDL 5.6 ± 1.1 5.5g ± 1.0     T = 0.032 
(mmol/L) HP-LHDL 5.8 ± 1.4 5.8c ± 1.4     D = 0.23 
 HC-HHDL 5.6 ± 1.3 5.5 ± 1.1     HDL = 0.18 
 HC-LHDL 5.6 ± 1.3 5.5 ± 0.8       D x HDL = 0.14 
 HP 5.7 ± 1.2 5.6g ± 1.2 5.7 ± 0.06 T x D = 0.50 
 HC 5.6 ± 1.3 5.5 ± 1.0 5.6 ± 0.07 T x HDL = 0.16 
 HHDL 5.6 ± 1.2 5.5b,g ± 1.1 5.6 ± 0.06 T x D x HDL = 0.39  
 LHDL 5.7 ± 1.4 5.7 ± 1.2 5.7 ± 0.07   
 Time 5.7 ± 1.3 5.6* ± 1.1         
Insulin HP-HHDL 3.4 ± 8.6 3.7 ± 9.3     T = 0.79 
(uIU/mL) HP-LHDL 4.7 ± 9.0 5.5 ± 11.0     D = 0.001 
 HC-HHDL 6.9 ± 9.1 8.7c ± 13.9     HDL = 0.25 
 HC-LHDL 10.3 ± 16.9 8.0 ± 8.3       D x HDL = 0.93 
 HP 4.0 ± 8.8 4.5 ± 10.1 4.3† ± 0.80 T x D = 0.52 
 HC 8.3 ± 12.8 8.4a ± 12.0 8.5 ± 0.98 T x HDL = 0.13 
 HHDL 4.9 ± 9.0 5.9 ± 11.7 5.7 ± 0.82 T x D x HDL = 0.06 
 LHDL 6.9 ± 12.9 6.5 ± 10.1 7.1 ± 0.97   
 Time 5.7 ± 10.8 6.1 ± 11.1         
Calculated  HP-HHDL 0.9 ± 2.2 0.9 ± 2.3 
 
  
T = 0.93 
HOMA HP-LHDL 1.3 ± 2.5 1.6 ± 3.5 D = 0.002 
 HC-HHDL 1.7 ± 2.3 2.3c ± 4.1 HDL = 0.12 
 HC-LHDL 3.1 ± 6.6 2.1g ± 2.4 D x HDL = 0.97 
 HP 1.0 ± 2.3 1.2 ± 2.9 1.2† ± 0.23 T x D = 0.37 
 HC 2.3 ± 4.6 2.2a ± 3.5 2.3 ± 0.28 T x HDL = 0.14 
 HHDL 1.2 ± 2.3 1.5 ± 3.3 1.5 ± 0.24 T x D x HDL = 0.030 
 LHDL 2.0 ± 4.6 1.8 ± 3.1 2.0 ± 0.28   
 Time 1.6 ± 3.5 1.6 ± 3.2         
HP = higher protein, HC = higher carbohydrate, HHDL = high HDL cholesterol, LHDL = low HDL cholesterol, T = time effect, D = diet effect, HDL = HDL 
risk factor effect, D x HDL = diet by HDL risk factor effect, T x D = time by diet effect, T x HDL = time by HDL risk factor effect, T x D x HDL = time by 
diet by HDL risk factor effect.                                                                                                                                     
Glucose values are means ± standard deviations (except group means are means ± standard error) from 220 participants in the HP-HHDL group, 151 in the 
HP-LHDL group, 180 in the HC-HHDL group, 112 in the HC-LHDL group, 371 in the HP total group, 292 in the HC total group, 400 in the HHDL group, 
263 in the LHDL group, and 663 participants total.  Insulin and HOMA values are means ± standard deviations (except group means are means ± standard 
error) from 83 participants in the HP-HHDL group, 66 in the HP-LHDL group, 62 in the HC-HHDL group, 41 in the HC-LHDL group, 149 in the HP total 
group, 103 in the HC total group, 145 in the HHDL group, 107 in the LHDL group, and 252 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant HDL effect, p < 0.05 (univariate).   
a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than HHDL group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-HHDL group, p < 0.05 (post hoc LSD).  d Significantly different than HP-LHDL group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-HHDL group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table C.7: Fitness Parameters After Ten Weeks of Exercise and Dietary Intervention 
Based on HDL Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Bench Press  HP-HHDL 30.3 ± 7.4 32.4g ± 7.2     T = 0.001 
Max Strength HP-LHDL 31.8 ± 7.8 33.7g ± 7.6     D = 0.39 
(1 RM / kg body HC-HHDL 28.5 ± 7.2 30.5c,g ± 7.2     HDL = 0.001 
weight) HC-LHDL 32.1 ± 8.3 35.0f,g ± 8.8       D x HDL = 0.031 
 HP 30.9 ± 7.6 32.9g ± 7.4 32.1 ± 0.4 T x D = 0.25 
 HC 29.9 ± 7.8 32.2c ± 8.1 31.5 ± 0.5 T x HDL = 0.38 
 HHDL 29.5 ± 7.4 31.6b,g ± 7.3 30.5 ± 0.4 T x D x HDL = 0.20  
 LHDL 31.9 ± 8.0 34.2g ± 8.2 33.1‡ ± 0.5   
 Time 30.5 ± 7.7 32.6* ± 7.7         
Bench Press HP-HHDL 173.9 ± 71.7 177.4 ± 74.0     T = 0.94 
Lift Volume HP-LHDL 189.6 ± 89.6 188.6 ± 89.3     D = 0.48 
(kg) HC-HHDL 172.3 ± 75.5 162.5 ± 67.2     HDL = 0.001  
 HC-LHDL 202.3 ± 94.8 208.5f ± 90.2       D x HDL = 0.031 
 HP 180.3 ± 79.7 182.0 ± 80.7 182.4 ± 3.7 T x D = 0.68 
 HC 183.8 ± 84.5 180.1 ± 79.9 186.4 ± 4.3 T x HDL = 0.44 
 HHDL 173.2 ± 73.3 170.9b ± 71.4 171.5 ± 3.6 T x D x HDL = 0.17 
 LHDL 194.9 ± 91.8 196.8 ± 90.1 197.3‡ ± 4.4   
 Time 181.8 ± 81.8 181.2 ± 80.3         
Leg Press  HP-HHDL 162.5 ± 48.6 178.0g ± 52.3     T = 0.001 
Max Strength HP-LHDL 166.4 ± 47.4 183.1g ± 52.3     D = 0.31 
(1 RM / kg body HC-HHDL 150.1 ± 49.7 162.1c,g ± 52.8     HDL = 0.001 
weight) HC-LHDL 171.7 ± 49.9 189.3f,g ± 55.1       D x HDL = 0.0.16 
 HP 164.1 ± 48.1 180.1g ± 52.3 172.5 ± 2.7 T x D = 0.61 
 HC 158.4 ± 50.8 172.5g ± 55.2 168.3 ± 3.1 T x HDL = 0.17 
 HHDL 157.1 ± 49.4 171.0b,d ± 53.0 163.2 ± 2.6 T x D x HDL = 0.36 
 LHDL 168.6 ± 48.4 185.6g ± 53.4 177.6‡ ± 3.2   
 Time 161.7 ± 49.3 176.8* ± 53.6         
Leg Press HP-HHDL 1866.9 ± 1045.3 1968.8 ± 1122.7     T = 0.13 
Lift Volume HP-LHDL 1756.5 ± 844.1 1881.4 ± 1011.4     D = 0.016 
(kg) HC-HHDL 1582.7 ± 842.0 1490.8c ± 791.3     HDL = 0.14 
 HC-LHDL 1803.6 ± 886.5 1899.8f ± 1009.8       D x HDL = 0.004 
 HP 1821.8 ± 968.3 1933.1g ± 1077.9 1868.4† ± 47.0 T x D = 0.14 
 HC 1667.3 ± 864.3 1647.4a ± 901.7 1694.2 ± 54.8 T x HDL = 0.16 
 HHDL 1741.8 ± 970.2 1758.4 ± 1017.5 1727.3 ± 45.3 T x D x HDL = 0.28 
 LHDL 1776.0 ± 860.4 1889.0 ± 1008.6 1835.3 ± 56.2   
 Time 1755.4 ± 927.5 1810.3 ± 1015.1         
Peak VO2 HP-HHDL 20.0 ± 4.5 21.7g ± 4.4     T = 0.002 
(mL/kg/min) HP-LHDL 20.0 ± 4.6 22.3g ± 4.6     D = 0.015 
 HC-HHDL 20.4 ± 4.4 22.8c,g ± 4.8     HDL = 0.30 
 HC-LHDL 20.6 ± 3.9 23.5d,g ± 4.6       D x HDL = 0.80 
 HP 20.0 ± 4.5 21.9g ± 4.5 21.0† ± 0.22 T x D = 0.012 
 HC 20.5 ± 4.2 23.1a,g ± 4.7 21.8 ± 0.25 T x HDL = 0.024 
 HHDL 20.2 ± 4.4 22.2g ± 4.6 21.2 ± 0.21 T x D x HDL = 0.98 
 LHDL 20.2 ± 4.3 22.8g ± 4.6 21.6 ± 0.26   
 Time 20.2 ± 4.4 22.4* ± 4.6         
HP = higher protein, HC = higher carbohydrate, HHDL = high HDL cholesterol, LHDL = low HDL cholesterol, T = time effect, D = diet effect, HDL = HDL 
risk factor effect, D x HDL = diet by HDL risk factor effect, T x D = time by diet effect, T x HDL = time by HDL risk factor effect, T x D x HDL = time by diet 
by HDL risk factor effect.                                                                                                                                     
Strength values are means ± standard deviations (except group means are means ± standard error) from 201 participants in the HP-HHDL group, 139 in the HP-
LHDL group, 158 in the HC-HHDL group, 98 in the HC-LHDL group, 340 in the HP total group, 256 in the HC total group, 359 in the HHDL group, 237 in the 
LHDL group, and 596 participants total.  Peak VO2 values are means ± standard deviations (except group means are means ± standard error) from 220 
participants in the HP-HHDL group, 151 in the HP-LHDL group, 180 in the HC-HHDL group, 112 in the HC-LHDL group, 371 in the HP total group, 292 in 
the HC total group, 400 in the HHDL group, 263 in the LHDL group, and 663 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant HDL effect, p < 0.05 (univariate).   
a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than HHDL group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-HHDL group, p < 0.05 (post hoc LSD).  d Significantly different than HP-LHDL group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-HHDL group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table C.8: Changes in SF36 - Quality of Life Inventory Values After Ten Weeks of 
Exercise and Dietary Intervention Based on HDL Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Physical  HP-HHDL 76.9 ± 27.6 81.8g ± 24.9     T = 0.001 
Functioning HP-LHDL 74.0 ± 32.7 80.5g ± 24.7     D = 0.61 
 HC-HHDL 77.5 ± 17.4 81.4 ± 18.0     HDL = 0.75 
 HC-LHDL 74.6 ± 26.1 85.0g ± 23.2       D x HDL = 0.64 
 HP 75.7 ± 29.7 81.3g ± 24.7 78.3 ± 1.79 T x D = 0.61 
 HC 76.4 ± 21.2 82.8g ± 20.2 79.6 ± 1.90 T x HDL = 0.14 
 HHDL 77.2 ± 23.2 81.6g ± 21.8 79.4 ± 1.66 T x D x HDL = 0.38  
 LHDL 74.3 ± 29.7 82.6g ± 24.0 78.5 ± 2.01   
 Time 76.0 ± 26.0 82.0* ± 22.7         
Role Physical HP-HHDL 147.5 ± 136.0 158.5 ± 151.9     T = 0.42 
 HP-LHDL 134.6 ± 140.4 129.4 ± 141.7     D = 0.001 
 HC-HHDL 265.5 ± 137.2 268.8c ± 138.6     HDL = 0.06 
 HC-LHDL 222.7 ± 147.4 227.0d ± 157.3       D x HDL = 0.53 
 HP 142.2 ± 137.5 146.4 ± 148.0 142.5† ± 11.45 T x D = 0.92 
 HC 248.6 ± 142.3 252.3a ± 147.1 246.0 ± 12.16 T x HDL = 0.36 
 HHDL 204.5 ± 148.5 211.7b ± 155.4 210.1 ± 10.61 T x D x HDL = 0.30 
 LHDL 175.3 ± 149.7 174.4 ± 156.3 178.4 ± 12.90   
 Time 192.6 ± 149.4 196.6 ± 156.5         
Bodily Pain HP-HHDL 58.8 ± 19.0 62.0 ± 20.5     T = 0.004 
 HP-LHDL 59.4 ± 19.1 64.8g ± 21.1     D = 0.35 
 HC-HHDL 60.2 ± 21.4 59.8 ± 21.2     HDL = 0.06 
 HC-LHDL 64.7 ± 21.4 68.7f ± 21.5       D x HDL = 0.26 
 HP 59.1 ± 19.0 63.1g ± 20.7 61.2 ± 1.54 T x D = 0.23 
 HC 62.0 ± 21.4 63.3 ± 21.6 63.4 ± 1.64 T x HDL = 0.11 
 HHDL 59.5 ± 20.1 60.9b ± 20.8 60.2 ± 1.43 T x D x HDL = 0.58 
 LHDL 61.9 ± 20.3 66.6g ± 21.2 64.4 ± 1.74   
 Time 60.5 ± 20.2 63.2* ± 21.1         
General Health HP-HHDL 51.0 ± 28.5 55.9g ± 29.2     T = 0.001 
 HP-LHDL 49.5 ± 28.9 53.2g ± 27.9     D = 0.001 
 HC-HHDL 68.1 ± 20.3 71.3c,g ± 20.0     HDL = 0.11 
 HC-LHDL 60.5 ± 24.6 63.8d,g ± 24.6       D x HDL = 0.37 
 HP 50.4 ± 28.6 54.8g ± 28.6 52.4† ± 2.06 T x D = 0.47 
 HC 65.1 ± 22.3 68.4a,g ± 22.1 65.9 ± 2.19 T x HDL = 0.66 
 HHDL 59.2 ± 26.3 63.4g ± 26.3 61.6 ± 1.91 T x D x HDL = 0.64 
 LHDL 54.6 ± 27.5 58.1g ± 26.8 56.8 ± 2.32   
 Time 57.3 ± 26.8 61.2* ± 26.6         
Vital HP-HHDL 37.4 ± 22.9 45.7g ± 28.0     T = 0.001 
 HP-LHDL 46.6 ± 66.2 54.0g ± 65.9     D = 0.12 
 HC-HHDL 51.0 ± 17.5 57.0c,g ± 15.8     HDL = 0.48  
 HC-LHDL 49.4 ± 20.0 53.3g ± 22.1       D x HDL = 0.18 
 HP 41.3 ± 46.1 49.1g ± 47.5 45.9 ± 2.92 T x D = 0.11 
 HC 50.4 ± 18.5 55.5g ± 18.6 52.7 ± 3.10 T x HDL = 0.40 
 HHDL 44.0 ± 21.5 51.2g ± 23.6 47.8 ± 2.71 T x D x HDL = 0.75 
 LHDL 47.9 ± 50.2 53.7g ± 50.5 50.8 ± 3.29   
 Time 45.6 ± 36.0 52.2* ± 36.8         
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Table C.8: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Social 
Functioning 
HP-HHDL 47.2 ± 26.7 53.3g ± 27.5 
 
  
T = 0.024 
HP-LHDL 44.9 ± 24.5 47.0 ± 25.4 D =0.001 
HC-HHDL 62.4 ± 24.0 64.2c ± 25.0 HDL = 0.11 
HC-LHDL 54.4 ± 25.7 53.8f ± 22.6 D x HDL = 0.39 
HP 46.2 ± 25.7 50.7g ± 26.7 48.1† ± 1.96 T x D = 0.09 
HC 59.3 ± 24.9 60.1a ± 24.5 58.7 ± 2.08 T x HDL = 0.11 
HHDL 54.5 ± 26.4 58.6b,g ± 26.8 56.8 ± 1.82 T x D x HDL = 0.69  
LHDL 49.3 ± 25.4 50.1 ± 24.3 50.0 ± 2.21   
  Time 52.4 ± 26.1 55.2* ± 26.1   
Role Emotional HP-HHDL 224.1 ± 123.1 249.1 ± 140.8 
 
  
T = 0.45 
HP-LHDL 210.1 ± 136.9 223.8 ± 140.1 D =0.001 
HC-HHDL 310.7 ± 220.7 292.6c ± 132.8 HDL = 0.22 
HC-LHDL 280.0 ± 130.5 284.4d ± 136.7 D x HDL = 1.00 
HP 218.3 ± 128.7 238.6 ± 140.6 226.7† ± 10.95 T x D = 0.12 
HC 298.6 ± 190.3 289.4a ± 133.9 291.9 ± 11.63 T x HDL = 0.73 
HHDL 265.9 ± 181.8 270.1 ± 138.3 269.1 ± 10.15 T x D x HDL = 0.31 
LHDL 242.3 ± 137.9 251.8 ± 141.2 249.6 ± 12.34   
  Time 256.3 ± 165.6 262.7 ± 139.6   
Mental Health 
 
HP-HHDL 55.9 ± 16.6 65.3g ± 15.0 
 
  
T = 0.001 
HP-LHDL 57.4 ± 14.0 64.9g ± 15.9 D = 0.035 
HC-HHDL 60.5 ± 14.9 66.7g ± 12.0 HDL = 0.65 
HC-LHDL 59.8 ± 13.7 69.0g ± 12.2 D x HDL = 0.93 
HP 56.5 ± 15.5 65.1g ± 15.3 60.9† ± 1.02 T x D = 0.67 
HC 60.3 ± 14.4 67.6g ± 12.1 64.0 ± 1.08 T x HDL = 0.75 
HHDL 58.2 ± 15.9 66.0g ± 13.6 62.1 ± 0.95 T x D x HDL = 0.17 
LHDL 58.5 ± 13.8 66.8g ± 14.4 62.8 ± 1.15   
  Time 58.3 ± 15.1 66.3* ± 13.9   
HP = higher protein, HC = higher carbohydrate, HHDL = high HDL cholesterol, LHDL = low HDL cholesterol, T = time effect, D = diet effect, HDL = HDL 
risk factor effect, D x HDL = diet by HDL risk factor effect, T x D = time by diet effect, T x HDL = time by HDL risk factor effect, T x D x HDL = time by diet 
by HDL risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 89 participants in the HP-HHDL group, 63 in the HP-LHDL 
group, 83 in the HC-HHDL group, 54 in the HC-LHDL group, 152 in the HP total group, 137 in the HC total group, 172 in the HHDL group, 117 in the LHDL 
group, and 289 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant HDL effect, p < 0.05 (univariate).   
a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than HHDL group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-HHDL group, p < 0.05 (post hoc LSD).  d Significantly different than HP-LHDL group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-HHDL group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table C.9: Changes in Body Image Evaluation After Ten Weeks of Exercise  
and Dietary Intervention Based on HDL Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Appearance 
Evaluation 
HP-HHDL 2.4 ± 0.6 2.7g ± 0.7 
 
  
T = 0.001 
HP-LHDL 2.5 ± 0.6 2.8g ± 0.6 D = 0.58 
HC-HHDL 2.5 ± 0.6 2.8g ± 0.7 HDL = 1.00 
HC-LHDL 2.4 ± 0.7 2.8g ± 0.8 D x HDL = 0.30 
HP 2.4 ± 0.6 2.7g ± 0.7 2.6 ± 0.04 T x D = 0.46 
HC 2.4 ± 0.6 2.8g ± 0.7 2.6 ± 0.04 T x HDL = 0.78 
HHDL 2.4 ± 0.6 2.8g ± 0.7 2.6 ± 0.04 T x D x HDL = 0.42  
LHDL 2.4 ± 0.7 2.8g ± 0.7 2.6 ± 0.04   
  Time 2.4 ± 0.6 2.8* ± 0.7   
Appearance 
Orientation 
HP-HHDL 4.1 ± 0.9 4.1 ± 0.9 
 
  
T = 0.20 
HP-LHDL 4.2 ± 0.8 4.1 ± 0.9 D = 0.010 
HC-HHDL 4.0 ± 0.8 3.9 ± 0.9 HDL = 0.83 
HC-LHDL 3.9 ± 0.8 3.8d ± 0.8 D x HDL = 0.48 
HP 4.1 ± 0.9 4.1 ± 0.9 4.1† ± 0.05 T x D = 0.35 
HC 3.9 ± 0.8 3.9a ± 0.9 3.9 ± 0.06 T x HDL = 0.59 
HHDL 4.0 ± 0.9 4.0 ± 0.9 4.0 ± 0.05 T x D x HDL = 0.52 
LHDL 4.1 ± 0.8 4.0 ± 0.9 4.0 ± 0.06   
  Time 4.1 ± 0.8 4.0 ± 0.9   
Body Area HP-HHDL 2.1 ± 0.7 2.3g ± 0.8     T = 0.001 
Satisfaction HP-LHDL 2.0 ± 0.8 2.2g ± 0.9     D = 0.001 
 HC-HHDL 2.2 ± 0.7 2.6c,g ± 0.8     HDL = 0.55 
 HC-LHDL 2.2 ± 0.7 2.5d,g ± 0.9       D x HDL = 0.62 
 HP 2.0 ± 0.8 2.3g ± 0.8 2.1† ± 0.05 T x D = 0.20 
 HC 2.2 ± 0.7 2.5a,g ± 0.8 2.4 ± 0.06 T x HDL = 0.75 
 HHDL 2.1 ± 0.7 2.4g ± 0.8 2.3 ± 0.05 T x D x HDL = 0.94 
 LHDL 2.1 ± 0.8 2.4g ± 0.9 2.2 ± 0.06   
 Time 2.1 ± 0.7 2.4* ± 0.8         
Overweight HP-HHDL 2.9 ± 0.7 3.4g ± 0.8     T = 0.001 
Preoccupation HP-LHDL 2.8 ± 0.7 3.4g ± 0.6     D = 0.30 
 HC-HHDL 2.9 ± 0.7 3.3g ± 0.7     HDL = 0.91 
 HC-LHDL 2.9 ± 0.8 3.3g ± 0.7       D x HDL = 0.76 
 HP 2.9 ± 0.7 3.4g ± 0.7 3.1 ± 0.04 T x D = 0.09 
 HC 2.9 ± 0.7 3.3g ± 0.7 3.1 ± 0.05 T x HDL = 0.29 
 HHDL 2.9 ± 0.7 3.3g ± 0.7 3.1 ± 0.04 T x D x HDL = 0.18 
 LHDL 2.8 ± 0.7 3.4g ± 0.7 3.1 ± 0.05   
 Time 2.9 ± 0.7 3.3* ± 0.7         
Self-Classified HP-HHDL 4.2 ± 0.8 4.2 ± 0.6     T = 0.007 
Weight HP-LHDL 4.3 ± 0.6 4.1 ± 0.7     D = 0.11 
 HC-HHDL 4.1 ± 0.7 4.0c ± 0.7     HDL = 0.53 
 HC-LHDL 4.2 ± 0.6 4.1 ± 0.7       D x HDL = 0.33 
 HP 4.2 ± 0.7 4.2 ± 0.7 4.2 ± 0.04 T x D = 0.57 
 HC 4.2 ± 0.7 4.0g ± 0.7 4.1 ± 0.04 T x HDL = 0.21 
 HHDL 4.2 ± 0.8 4.1 ± 0.7 4.1 ± 0.04 T x D x HDL = 0.92 
 LHDL 4.3 ± 0.6 4.1g ± 0.7 4.2 ± 0.04   
 Time 4.2 ± 0.7 4.1* ± 0.7         
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Table C.9: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Rosenberg HP-HHDL 25.4 ± 3.7 26.1g ± 3.6     T = 0.008 
Self Esteem HP-LHDL 26.1 ± 4.3 26.6 ± 4.2     D = 0.55 
 HC-HHDL 25.6 ± 3.7 25.7 ± 3.5     HDL = 0.16  
 HC-LHDL 25.8 ± 4.3 26.3 ± 4.6       D x HDL = 0.77 
 HP 25.7 ± 3.9 26.3g ± 3.8 26.1 ± 0.23 T x D = 0.29 
 HC 25.7 ± 3.9 25.9 ± 4.0 25.9 ± 0.26 T x HDL = 0.81 
 HHDL 25.5 ± 3.7 25.9g ± 3.6 25.7 ± 0.22 T x D x HDL = 0.42  
 LHDL 26.0 ± 4.3 26.5 ± 4.3 26.2 ± 0.27   
 Time 25.7 ± 3.9 26.2* ± 3.9         
Social Physique HP-HHDL 31.5 ± 6.0 31.5 ± 6.5     T = 0.58 
Anxiety HP-LHDL 30.8 ± 6.7 31.2 ± 5.8     D = 0.080 
 HC-HHDL 30.6 ± 5.8 30.5 ± 5.0     HDL = 0.19 
 HC-LHDL 32.0 ± 6.2 32.5f ± 7.4       D x HDL = 0.025 
 HP 31.3 ± 6.3 31.4 ± 6.2 31.3 ± 0.32 T x D = 0.91 
 HC 31.1 ± 6.0 31.3 ± 6.1 31.4 ± 0.38 T x HDL = 0.40 
 HHDL 31.1 ± 5.9 31.0 ± 5.9 31.0 ± 0.31 T x D x HDL = 0.90 
 LHDL 31.3 ± 6.5 31.8 ± 6.5 31.6 ± 0.38   
 Time 31.2 ± 6.1 31.3 ± 6.2         
HP = higher protein, HC = higher carbohydrate, HHDL = high HDL cholesterol, LHDL = low HDL cholesterol, T = time effect, D = diet effect, HDL = 
HDL risk factor effect, D x HDL = diet by HDL risk factor effect, T x D = time by diet effect, T x HDL = time by HDL risk factor effect, T x D x HDL 
= time by diet by HDL risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 150 participants in the HP-HHDL group, 106 in the HP-
LHDL group, 120 in the HC-HHDL group, 75 in the HC-LHDL group, 256 in the HP total group, 195 in the HC total group, 270 in the HHDL group, 
181 in the LHDL group, and 451 participants total.   
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant HDL effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than HHDL group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-HHDL group, p < 0.05 (post hoc LSD).  d Significantly different than HP-LHDL group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-HHDL group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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APPENDIX D 
BLOOD PRESSURE RISK FACTOR TABLES 
Table D.1: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Blood Pressure Status and Measured via DEXA Scan 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Scanned Mass  HP-LBP 87.5 ± 18.0 83.7g ± 17.7     T = 0.001 
(kg) HP-HBP 91.9 ± 18.0 87.7c,g ± 16.9     D = 0.001 
 HC-LBP 81.6 ± 13.7 78.8c,g ± 13.1     BP = 0.014 
 HC-HBP 84.1 ± 15.5 80.8d,g ± 14.8       D x BP = 0.47 
 HP 89.2 ± 18.1 85.3g ± 17.5 87.7† ± 0.85 T x D = 0.002 
 HC 82.5 ± 14.3 79.5a,g ± 13.7 81.4 ± 1.00 T x BP = 0.17 
 LBP 84.8 ± 16.4 81.4b,g ± 15.9 82.9 ± 0.79 T x D x BP = 0.94  
 HBP 88.8 ± 17.4 85.0g ± 16.4 86.1‡ ± 1.05   
 Time 86.2 ± 16.9 82.7* ± 16.2         
Fat Mass (kg) HP-LBP 40.2 ± 11.2 37.1g ± 11.2     T = 0.001 
 HP-HBP 42.5 ± 11.8 39.3c,g ± 11.1     D = 0.001 
 HC-LBP 36.4 ± 8.7 34.2c,g ± 8.3     BP = 0.018 
 HC-HBP 38.4 ± 9.8 35.6d,g ± 9.5       D x BP = 0.75 
 HP 41.1 ± 11.4 38.0g ± 11.2 39.8† ± 0.54 T x D = 0.007 
 HC 37.1 ± 9.1 34.7a,g ± 8.7 36.2 ± 0.64 T x BP = 0.13 
 LBP 38.4 ± 10.2 35.8b,g ± 10.0 37.0 ± 0.50 T x D x BP = 0.32 
 HBP 40.9 ± 11.2 37.9g ± 10.6 39.0‡ ± 0.67   
 Time 39.3 ± 10.7 36.5* ± 10.3         
Lean Mass (kg) HP-LBP 45.5 ± 7.8 44.8g ± 7.6     T = 0.001 
 HP-HBP 47.5 ± 7.5 46.6c,g ± 6.9     D = 0.001 
 HC-LBP 43.4 ± 6.3 42.8c,g ± 6.0     BP = 0.029 
 HC-HBP 44.0 ± 6.7 43.5d,g ± 6.5       D x BP = 0.26 
 HP 46.3 ± 7.7 45.5g ± 7.4 46.1† ± 0.37 T x D = 0.11 
 HC 43.6 ± 6.4 43.0a,g ± 6.2 43.4 ± 0.43 T x BP = 0.78 
 LBP 44.5 ± 7.2 43.9b,g ± 7.0 44.1 ± 0.34 T x D x BP = 0.22 
 HBP 46.1 ± 7.4 45.3g ± 6.9 45.4‡ ± 0.46   
 Time 45.1 ± 7.3 44.4* ± 7.0         
Body Fat (%) HP-LBP 45.5 ± 4.2 43.8g ± 4.7     T = 0.001 
 HP-HBP 45.6 ± 4.7 44.1g ± 4.8     D = 0.11 
 HC-LBP 44.4 ± 4.3 43.2g ± 4.3     BP = 0.15 
 HC-HBP 45.4 ± 3.8 43.7g ± 4.2       D x BP = 0.42 
 HP 45.5 ± 4.4 43.9g ± 4.7 44.7 ± 0.23 T x D = 0.41 
 HC 44.7 ± 4.2 43.4g ± 4.3 44.2 ± 0.27 T x BP = 0.52 
 LBP 45.0 ± 4.3 43.5g ± 4.5 44.2 ± 0.21 T x D x BP = 0.045 
 HBP 45.5 ± 4.4 44.0g ± 4.6 44.7 ± 0.28   
 Time 45.2 ± 4.3 43.7* ± 4.5         
HP = higher protein, HC = higher carbohydrate, LBP = low blood pressure, HBP = high blood pressure, T = time effect, D = diet effect, BP = blood 
pressure risk factor effect, D x BP = diet by blood pressure risk factor effect, T x D = time by diet effect, T x BP = time by blood pressure risk factor 
effect, T x D x BP = time by diet by blood pressure risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 223 participants in the HP-LBP group, 148 in the HP-
HBP group, 196 in the HC-LBP group, 96 in the HC-HBP group, 371 in the HP total group, 292 in the HC total group, 419 in the LBP group, 244 in the 
HBP group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant blood pressure effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LBP group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LBP group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HBP group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LBP group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD).  
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Table D.2: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Blood Pressure Status and Measured via Anthropometric 
Measurements 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Weight (kg) HP-LBP 94.0 ± 19.0 89.8g ± 18.6     T = 0.001 
 HP-HBP 98.5 ± 18.9 94.0c,g ± 17.7     D = 0.001 
 HC-LBP 87.9 ± 14.1 84.9c,g ± 13.5     BP = 0.016 
 HC-HBP 90.5 ± 16.3 86.8d,g ± 15.6       D x BP = 0.46 
 HP 95.8 ± 19.1 91.5g ± 18.3 94.1† ± 0.9 T x D = 0.001 
 HC 88.8 ± 14.9 85.5a,g ± 14.2 87.5 ± 1.0 T x BP = 0.07 
 LBP 91.1 ± 17.1 87.5b,g ± 16.6 89.1 ± 0.8 T x D x BP = 0.63 
 HBP 95.4 ± 18.3 91.2g ± 17.3 92.5‡ ± 1.1   
 Time 92.7 ± 17.7 88.9* ± 16.9         
Body Mass Index HP-LBP 35.3 ± 6.6 33.7g ± 6.5     T = 0.001 
(kg/m2) HP-HBP 36.9 ± 6.4 35.3c,g ± 6.1     D = 0.001 
 HC-LBP 33.0 ± 5.0 31.9c,g ± 4.7     BP = 0.013 
 HC-HBP 33.9 ± 5.7 32.5d,g ± 5.4       D x BP = 0.38 
 HP 35.9 ± 6.6 34.3g ± 6.4 35.3† ± 0.3 T x D = 0.001 
 HC 33.3 ± 5.2 32.1a,g ± 5.0 32.8 ± 0.4 T x BP = 0.085 
 LBP 34.2 ± 6.0 32.9b,g ± 5.8 33.5 ± 0.3 T x D x BP = 0.59 
 HBP 35.7 ± 6.3 34.2g ± 6.0 34.7‡ ± 0.4   
 Time 34.8 ± 6.2 33.3* ± 5.9         
Waist HP-LBP 99.5 ± 13.1 95.6g ± 13.0     T = 0.001 
Circumference HP-HBP 104.1 ± 13.5 99.9c,g ± 13.0     D = 0.001 
(cm) HC-LBP 94.7 ± 10.9 91.7c,g ± 10.1     BP = 0.001 
 HC-HBP 97.9 ± 12.9 94.5d,g ± 13.1       D x BP = 0.45 
 HP 101.3 ± 13.5 97.3g ± 13.2 99.8† ± 0.6 T x D = 0.10 
 HC 95.8 ± 11.7 92.6a,g ± 11.2 94.7 ± 0.8 T x BP = 0.48  
 LBP 97.3 ± 12.4 93.7b,g ± 11.9 95.4 ± 0.6 T x D x BP = 0.89 
 HBP 101.7 ± 13.6 97.8g ± 13.2 99.1‡ ± 0.8   
 Time 98.9 ± 13.0 95.2* ± 12.6         
Hip HP-LBP 121.6 ± 13.4 118.3g ± 13.5     T = 0.001 
Circumference HP-HBP 124.4 ± 14.5 121.4c,g ± 13.6     D = 0.001 
(cm) HC-LBP 117.3 ± 11.0 115.0c,g ± 10.5     BP = 0.005 
 HC-HBP 120.5 ± 12.3 117.0d,g ± 11.5       D x BP = 0.89 
 HP 122.7 ± 13.9 119.5g ± 13.6 121.4† ± 0.7 T x D = 0.51 
 HC 118.3 ± 11.5 115.6a,g ± 10.9 117.5 ± 0.8 T x BP = 0.29 
 LBP 119.6 ± 12.5 116.7b,g ± 12.3 118.0 ± 0.6 T x D x BP = 0.07 
 HBP 122.9 ± 13.8 119.7g ± 13.0 120.9‡ ± 0.8   
 Time 120.8 ± 13.1 117.8* ± 12.6         
HP = higher protein, HC = higher carbohydrate, LBP = low blood pressure, HBP = high blood pressure, T = time effect, D = diet effect, BP = blood 
pressure risk factor effect, D x BP = diet by blood pressure risk factor effect, T x D = time by diet effect, T x BP = time by blood pressure risk factor 
effect, T x D x BP = time by diet by blood pressure risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 223 participants in the HP-LBP group, 148 in the HP-HBP 
group, 196 in the HC-LBP group, 96 in the HC-HBP group, 371 in the HP total group, 292 in the HC total group, 419 in the LBP group, 244 in the HBP 
group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant blood pressure effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LBP group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LBP group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HBP group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LBP group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table D.3: Resting Energy Expenditure After Ten Weeks of Exercise and Dietary 
Intervention Based on Blood Pressure Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Resting Energy HP-LBP 1662.6 ± 272.3 1609.8g ± 274.9     T = 0.001 
Expenditure HP-HBP 1748.2 ± 296.9 1668.9c,g ± 314.1     D = 0.001 
(kcal/day) HC-LBP 1588.2 ± 245.1 1539.4c,g ± 245.8     BP = 0.005 
 HC-HBP 1627.3 ± 253.4 1589.8d ± 253.1       D x BP = 0.51 
 HP 1697.4 ± 285.2 1633.8g ± 292.5 1672.4† ± 13.4 T x D = 0.20 
 HC 1600.7 ± 248.0 1555.5a,g ± 248.8 1586.2 ± 16.1 T x BP = 0.67 
 LBP 1627.6 ± 262.2 1576.7b,g ± 263.6 1600.0 ± 12.5 T x D x BP = 0.29 
 HBP 1702.6 ± 286.8 1639.0g ± 294.5 1658.6‡ ± 16.8   
 Time 1655.2 ± 273.7 1599.7* ± 276.8         
HP = higher protein, HC = higher carbohydrate, LBP = low blood pressure, HBP = high blood pressure, T = time effect, D = diet effect, BP = blood pressure 
risk factor effect, D x BP = diet by blood pressure risk factor effect, T x D = time by diet effect, T x BP = time by blood pressure risk factor effect, T x D x 
BP = time by diet by blood pressure risk factor effect.                                                                                                                                    Values are means ± 
standard deviations (except group means are means ± standard error) from 212 participants in the HP-LBP group, 145 in the HP-HBP group, 188 in the HC-
LBP group, 88 in the HC-HBP group, 357 in the HP total group, 276 in the HC total group, 400 in the LBP group, 233 in the HBP group, and 633 
participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant blood pressure effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LBP group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LBP group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HBP group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LBP group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table D.4: Resting Hemodynamic Measurements After Ten Weeks of Exercise and 
Dietary Intervention Based on Blood Pressure Status 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Resting Heart HP-LBP 72.0 ± 9.6 69.0g ± 9.5     T = 0.001 
Rate (bpm) HP-HBP 72.1 ± 11.3 68.7g ± 10.0     D = 0.63 
 HC-LBP 70.3 ± 10.1 67.5g ± 10.1     BP = 0.11 
 HC-HBP 72.9 ± 11.2 69.7g ± 9.5       D x BP = 0.08 
 HP 72.0 ± 10.3 68.9g ± 9.7 70.4 ± 0.5 T x D = 0.87 
 HC 71.2 ± 10.5 68.2g ± 9.9 70.1 ± 0.5 T x BP = 0.61 
 LBP 71.2 ± 9.9 68.3g ± 9.8 69.7 ± 0.4 T x D x BP = 0.93 
 HBP 72.4 ± 11.2 69.1g ± 9.8 70.9 ± 0.6   
 Time 71.6 ± 10.4 68.6* ± 9.8         
Resting Systolic HP-LBP 117.5 ± 8.8 119.0 ± 11.3     T = 0.001 
Blood Pressure HP-HBP 137.7 ± 13.5 128.9c,g ± 14.9     D =0.54 
(mmHg) HC-LBP 117.6 ± 8.9 118.2 ± 12.8     BP = 0.001 
 HC-HBP 138.0 ± 13.7 127.3f,g ± 14.7       D x BP = 0.88 
 HP 125.6 ± 14.7 123.0g ± 13.7 125.8 ± 0.5 T x D = 0.22 
 HC 124.3 ± 14.4 121.2g ± 14.1 125.3 ± 0.6 T x BP = 0.001 
 LBP 117.5 ± 8.8 118.6b ± 12.0 118.1 ± 0.5 T x D x BP = 0.68 
 HBP 137.8 ± 13.6 128.3g ± 14.8 133.0‡ ± 0.6   
 Time 125.0 ± 14.6 122.2* ± 13.9         
Resting Diastolic HP-LBP 76.2 ± 6.4 77.6g ± 8.3     T = 0.001 
Blood Pressure HP-HBP 88.8 ± 7.7 82.6c,g ± 8.7     D = 0.004 
(mmHg) HC-LBP 75.1 ± 6.7 75.0c ± 8.8     BP = 0.001 
 HC-HBP 87.9 ± 8.1 81.1f,g ± 8.6       D x BP = 0.52 
 HP 81.3 ± 9.3 79.6g ± 8.8 81.3† ± 0.3 T x D = 0.17 
 HC 79.3 ± 9.4 77.0a,g ± 9.2 79.8 ± 0.4 T x BP = 0.001 
 LBP 75.7 ± 6.5 76.4b ± 8.6 76.0 ± 0.3 T x D x BP = 0.59 
 HBP 88.5 ± 7.9 82.0g ± 8.7 85.1‡ ± 0.4   
 Time 80.4 ± 9.4 78.4* ± 9.1         
HP = higher protein, HC = higher carbohydrate, LBP = low blood pressure, HBP = high blood pressure, T = time effect, D = diet effect, BP = blood 
pressure risk factor effect, D x BP = diet by blood pressure risk factor effect, T x D = time by diet effect, T x BP = time by blood pressure risk factor 
effect, T x D x BP = time by diet by blood pressure risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 223 participants in the HP-LBP group, 148 in the HP-HBP 
group, 196 in the HC-LBP group, 96 in the HC-HBP group, 371 in the HP total group, 292 in the HC total group, 419 in the LBP group, 244 in the HBP 
group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant blood pressure effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LBP group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LBP group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HBP group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LBP group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table D.5: Fasting Blood Lipid Values After Ten Weeks of Exercise and Dietary 
Intervention Based on Blood Pressure Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Total Cholesterol HP-LBP 5.1 ± 0.9 5.0g ± 0.9     T = 0.001 
(mmol/L) HP-HBP 5.3 ± 1.0 5.0g ± 1.0     D = 0.38 
 HC-LBP 5.1 ± 1.0 5.0g ± 0.9     BP = 0.003  
 HC-HBP 5.4 ± 1.1 5.2f,g ± 1.0       D x BP = 0.28 
 HP 5.2 ± 1.0 5.0g ± 1.0 5.1 ± 0.05 T x D = 0.53 
 HC 5.2 ± 1.0 5.0g ± 1.0 5.2 ± 0.06 T x BP = 0.085 
 LBP 5.1 ± 1.0 5.0b,g ± 0.9 5.0 ± 0.04 T x D x BP = 0.99 
 HBP 5.4 ± 1.0 5.1g ± 1.0 5.3‡ ± 0.06   
 Time 5.2 ± 1.0 5.0* ± 1.0         
LDL (mmol/L) HP-LBP 3.1 ± 0.7 2.9g ± 0.7     T =0 .001 
 HP-HBP 3.2 ± 0.8 3.0g ± 0.8     D = 0.32 
 HC-LBP 3.1 ± 0.8 3.0g ± 0.8     BP = 0.015 
 HC-HBP 3.3 ± 1.0 3.1g ± 0.8       D x BP = 0.44 
 HP 3.1 ± 0.8 3.0g ± 0.8 3.0 ± 0.04 T x D = 0.66 
 HC 3.1 ± 0.8 3.0g ± 0.8 3.1 ± 0.05 T x BP = 0.38 
 LBP 3.1 ± 0.7 2.9g ± 0.7 3.0 ± 0.04 T x D x BP = 0.76 
 HBP 3.2 ± 0.9 3.1g ± 0.8 3.1‡ ± 0.05   
 Time 3.1 ± 0.8 3.0* ± 0.8         
HDL (mmol/L) HP-LBP 1.4 ± 0.3 1.3g ± 0.3     T = 0.001 
 HP-HBP 1.4 ± 0.4 1.3g ± 0.3     D = 0.61 
 HC-LBP 1.4 ± 0.3 1.3g ± 0.3     BP = 0.27 
 HC-HBP 1.4 ± 0.3 1.3g ± 0.3       D x BP = 0.67  
 HP 1.4 ± 0.3 1.3g ± 0.3 1.4 ± 0.02 T x D = 0.85  
 HC 1.4 ± 0.3 1.3g ± 0.3 1.4 ± 0.02 T x BP = 0.045 
 LBP 1.4 ± 0.3 1.3g ± 0.3 1.3 ± 0.02 T x D x BP = 0.90 
 HBP 1.4 ± 0.3 1.3g ± 0.3 1.4 ± 0.02   
 Time 1.4 ± 0.3 1.3* ± 0.3         
Triglycerides  HP-LBP 1.5 ± 0.7 1.4g ± 0.8     T = 0.001 
(mmol/L) HP-HBP 1.7 ± 1.0 1.6c,g ± 0.8     D = 0.49 
 HC-LBP 1.5 ± 0.8 1.4 ± 0.7     BP = 0.019  
 HC-HBP 1.6 ± 0.7 1.5 ± 0.7       D x BP = 0.47 
 HP 1.6 ± 0.8 1.5g ± 0.8 1.5 ± 0.04 T x D = 0.06 
 HC 1.5 ± 0.7 1.5 ± 0.7 1.5 ± 0.05 T x BP = 0.92 
 LBP 1.5 ± 0.7 1.4b,g ± 0.8 1.5 ± 0.04 T x D x BP = 0.74 
 HBP 1.7 ± 0.9 1.6g ± 0.8 1.6‡ ± 0.05   
 Time 1.6 ± 0.8 1.5* ± 0.8         
TC/HDL ratio HP-LBP 3.9 ± 0.9 3.9 ± 0.9     T = 0.011 
 HP-HBP 3.9 ± 0.9 4.0 ± 1.0     D =0.81 
 HC-LBP 3.8 ± 1.0 3.9 ± 1.0     BP = 0.08 
 HC-HBP 4.0 ± 1.1 4.1g ± 1.2       D x BP =0.61  
 HP 3.9 ± 0.9 3.9 ± 0.9 3.9 ± 0.05 T x D = 0.39 
 HC 3.9 ± 1.0 4.0g ± 1.1 4.0 ± 0.06 T x BP = 0.12 
 LBP 3.9 ± 0.9 3.9b ± 0.9 3.9 ± 0.04 T x D x BP = 0.89 
 HBP 4.0 ± 1.0 4.1g ± 1.0 4.0 ± 0.06   
 Time 3.9 ± 0.9 4.0* ± 1.0         
HP = higher protein, HC = higher carbohydrate, LBP = low blood pressure, HBP = high blood pressure, T = time effect, D = diet effect, BP = blood 
pressure risk factor effect, D x BP = diet by blood pressure risk factor effect, T x D = time by diet effect, T x BP = time by blood pressure risk factor 
effect, T x D x BP = time by diet by blood pressure risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 223 participants in the HP-LBP group, 148 in the HP-
HBP group, 196 in the HC-LBP group, 96 in the HC-HBP group, 371 in the HP total group, 292 in the HC total group, 419 in the LBP group, 244 in the 
HBP group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant blood pressure effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LBP group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LBP group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HBP group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LBP group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table D.6: Fasting Glucose and Insulin Values After Ten Weeks of Exercise  
and Dietary Intervention Based on Blood Pressure Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Glucose HP-LBP 5.6 ± 1.1 5.4 ± 0.8     T = 0.014 
(mmol/L) HP-HBP 5.9 ± 1.4 5.8c ± 1.6     D = 0.15 
 HC-LBP 5.6 ± 1.5 5.6 ± 1.1     BP = 0.08 
 HC-HBP 5.6 ± 0.6 5.5d ± 0.7       D x BP = 0.014 
 HP 5.7 ± 1.2 5.6g ± 1.2 5.7 ± 0.06 T x D = 0.45 
 HC 5.6 ± 1.3 5.5 ± 1.0 5.6 ± 0.07 T x BP = 0.77 
 LBP 5.6 ± 1.3 5.5 ± 1.0 5.5 ± 0.05 T x D x BP = 0.92  
 HBP 5.8 ± 1.2 5.7 ± 1.3 5.7 ± 0.07   
 Time 5.7 ± 1.3 5.6* ± 1.1         
Insulin HP-LBP 5.0 ± 10.8 5.3 ± 11.7     T = 0.47 
(uIU/mL) HP-HBP 2.6 ± 4.0 3.3 ± 7.2     D =0.037 
 HC-LBP 9.8 ± 14.3 9.5c ± 11.7     BP = 0.019 
 HC-HBP 5.8 ± 9.8 6.8 ± 12.3       D x BP = 0.001 
 HP 4.0 ± 8.8 4.5 ± 10.1 4.0† ± 0.80 T x D = 0.87 
 HC 8.3 ± 12.8 8.4a ± 12.0 8.0 ± 0.98 T x BP = 0.52 
 LBP 7.0 ± 12.6 7.1 ± 11.8 7.4 ± 0.80 T x D x BP =0.68  
 HBP 3.9 ± 7.0 4.7 ± 9.7 4.6‡ ± 0.98   
 Time 5.7 ± 10.8 6.1 ± 11.1         
Calculated  HP-LBP 1.3 ± 2.8 1.4 ± 3.1 
 
  
T = 0.68 
HOMA HP-HBP 0.7 ± 1.2 0.9 ± 2.5 D = 0.034 
 HC-LBP 2.8 ± 5.4 2.5c ± 3.6 BP = 0.015 
 HC-HBP 1.6 ± 2.6 1.9 ± 3.4 D x BP = 0.001 
 HP 1.0 ± 2.3 1.2 ± 2.9 1.1† ± 0.23 T x D = 0.72 
 HC 2.3 ± 4.6 2.2a ± 3.5 2.2 ± 0.28 T x BP = 0.43 
 LBP 1.9 ± 4.2 1.8 ± 3.3 2.0 ± 0.23 T x D x BP = 0.60  
 HBP 1.0 ± 1.9 1.3 ± 3.0 1.3‡ ± 0.29   
 Time 1.6 ± 3.5 1.6 ± 3.2         
HP = higher protein, HC = higher carbohydrate, LBP = low blood pressure, HBP = high blood pressure, T = time effect, D = diet effect, BP = blood 
pressure risk factor effect, D x BP = diet by blood pressure risk factor effect, T x D = time by diet effect, T x BP = time by blood pressure risk factor 
effect, T x D x BP = time by diet by blood pressure risk factor effect.                                                                                                                                    
Glucose values are means ± standard deviations (except group means are means ± standard error) from 223 participants in the HP-LBP group, 148 in the 
HP-HBP group, 196 in the HC-LBP group, 96 in the HC-HBP group, 371 in the HP total group, 292 in the HC total group, 419 in the LBP group, 244 in 
the HBP group, and 663 participants total.  Insulin and HOMA values are means ± standard deviations (except group means are means ± standard error) 
from 88 participants in the HP-LBP group, 61 in the HP-HBP group, 63 in the HC-LBP group, 40 in the HC-HBP group, 149 in the HP total group, 103 
in the HC total group, 151 in the LBP group, 101 in the HBP group, and 252 participants total. 
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant blood pressure effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LBP group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LBP group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HBP group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LBP group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table D.7: Fitness Parameters After Ten Weeks of Exercise and Dietary Intervention 
Based on Blood Pressure Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Bench Press  HP-LBP 30.9 ± 7.6 33.0g ± 7.7     T = 0.001 
Max Strength HP-HBP 31.0 ± 7.7 32.9g ± 7.0     D = 0.07 
(1 RM / kg body HC-LBP 30.2 ± 8.2 33.0g ± 8.6     BP = 0.22 
weight) HC-HBP 29.2 ± 6.9 30.8d,f,g ± 6.7       D x BP = 0.19  
 HP 30.9 ± 7.6 32.9g ± 7.4 31.9† ± 0.4 T x D = 0.67 
 HC 29.9 ± 7.8 32.2g ± 8.1 30.8 ± 0.5 T x BP = 0.10 
 LBP 30.6 ± 7.9 33.0g ± 8.1 31.7 ± 0.4 T x D x BP = 0.27  
 HBP 30.4 ± 7.4 32.1g ± 7.0 31.0 ± 0.5   
 Time 30.5 ± 7.7 32.6* ± 7.7         
Bench Press HP-LBP 177.6 ± 75.7 177.9 ± 78.1     T = 0.96 
Lift Volume HP-HBP 184.2 ± 85.4 187.9 ± 84.1     D =0.60 
(kg) HC-LBP 191.8 ± 88.4 184.1 ± 82.8     BP = 0.39 
 HC-HBP 167.4 ± 73.6 171.9 ± 73.2       D x BP = 0.024 
 HP 180.3 ± 79.7 182.0 ± 80.7 181.9 ± 3.7 T x D = 0.64 
 HC 183.8 ± 84.5 180.1 ± 79.9 178.8 ± 4.5 T x BP = 0.30 
 LBP 184.2 ± 82.0 180.8 ± 80.3 182.9 ± 3.5 T x D x BP = 0.57  
 HBP 177.9 ± 81.4 181.9 ± 80.4 177.9 ± 4.7   
 Time 181.8 ± 81.8 181.2 ± 80.3         
Leg Press  HP-LBP 162.8 ± 47.1 179.0g ± 54.0     T = 0.001 
Max Strength HP-HBP 166.0 ± 49.5 181.6g ± 49.9     D = 0.047 
(1 RM / kg body HC-LBP 160.6 ± 51.2 176.4g ± 55.3     BP = 0.46 
weight) HC-HBP 153.8 ± 50.0 164.7d,g ± 54.4       D x BP = 0.16 
 HP 164.1 ± 48.1 180.1g ± 52.3 172.4† ± 2.7 T x D = 0.30 
 HC 158.4 ± 50.8 172.5a,g ± 55.2 163.9 ± 3.3 T x BP = 0.26 
 LBP 161.8 ± 49.0 177.8 ± 54.6 169.7 ± 2.6 T x D x BP = 0.40  
 HBP 161.4 ± 49.9 175.2 ± 52.2 166.5 ± 3.4   
 Time 161.7 ± 49.3 176.8* ± 53.6         
Leg Press HP-LBP 1773.0 ± 938.3 1870.5 ± 1021.5     T = 0.30 
Lift Volume HP-HBP 1891.4 ± 1008.9 2022.5 ± 1151.5     D = 0.001 
(kg) HC-LBP 1696.4 ± 903.1 1704.7 ± 885.6     BP = 0.98 
 HC-HBP 1607.6 ± 780.6 1530.0d ± 928.2       D x BP = 0.07 
 HP 1821.8 ± 968.3 1933.1g ± 1077.9 1889.3† ± 47.2 T x D = 0.054 
 HC 1667.3 ± 864.3 1647.4a ± 901.7 1634.7 ± 57.0 T x BP = 0.74 
 LBP 1737.6 ± 921.8 1793.8g ± 963.4 1761.2 ± 44.5 T x D x BP = 0.44  
 HBP 1785.0 ± 938.2 1837.8g ± 1097.4 1762.9 ± 59.1   
 Time 1755.4 ± 927.5 1810.3 ± 1015.1         
Peak VO2 HP-LBP 20.5 ± 4.6 22.4g ± 4.6     T = 0.001 
(mL/kg/min) HP-HBP 19.3 ± 4.3 21.3c,g ± 4.3     D = 0.043 
 HC-LBP 20.8 ± 4.4 23.6c,g ± 5.0     BP = 0.001 
 HC-HBP 19.8 ± 3.7 22.0f,g ± 4.0       D x BP = 0.85 
 HP 20.0 ± 4.5 21.9g ± 4.5 20.9† ± 0.22 T x D = 0.054 
 HC 20.5 ± 4.2 23.1a,g ± 4.7 21.6 ± 0.26 T x BP = 0.40 
 LBP 20.7 ± 4.5 22.9b,g ± 4.8 21.8 ± 0.20 T x D x BP = 0.13  
 HBP 19.5 ± 4.1 21.6g ± 4.2 20.6‡ ± 0.27   
 Time 20.2 ± 4.4 22.4* ± 4.6         
HP = higher protein, HC = higher carbohydrate, LBP = low blood pressure, HBP = high blood pressure, T = time effect, D = diet effect, BP = blood pressure 
risk factor effect, D x BP = diet by blood pressure risk factor effect, T x D = time by diet effect, T x BP = time by blood pressure risk factor effect, T x D x BP 
= time by diet by blood pressure risk factor effect.                                                                                                                                     
Strength values are means ± standard deviations (except group means are means ± standard error) from 200 participants in the HP-LBP group, 140 in the HP-
HBP group, 172 in the HC-LBP group, 84 in the HC-HBP group, 340 in the HP total group, 256 in the HC total group, 372 in the LBP group, 224 in the HBP 
group, and 596 participants total. Peak VO2 values are means ± standard deviations (except group means are means ± standard error) from 223 participants in 
the HP-LBP group, 148 in the HP-HBP group, 196 in the HC-LBP group, 96 in the HC-HBP group, 371 in the HP total group, 292 in the HC total group, 419 
in the LBP group, 244 in the HBP group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant blood pressure effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LBP group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LBP group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HBP group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LBP group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table D.8: Changes in SF36 - Quality of Life Inventory Values After Ten Weeks of 
Exercise and Dietary Intervention Based on Blood Pressure Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Physical  HP-LBP 77.8 ± 29.3 84.8g ± 25.8     T = 0.001 
Functioning HP-HBP 71.4 ± 30.4 74.1c ± 21.0     D = 0.60 
 HC-LBP 78.7 ± 21.6 84.1g ± 21.4     BP = 0.008 
 HC-HBP 71.0 ± 19.5 79.9g ± 17.1       D x BP = 0.64 
 HP 75.7 ± 29.7 81.3g ± 24.7 77.0 ± 1.85 T x D = 0.43 
 HC 76.4 ± 21.2 82.8g ± 20.2 78.4 ± 1.99 T x BP = 0.89 
 LBP 78.2 ± 25.8 84.5b,g ± 23.7 81.3 ± 1.53 T x D x BP = 0.17  
 HBP 71.2 ± 25.9 76.7g ± 19.4 74.1‡ ± 2.24   
 Time 76.0 ± 26.0 82.0* ± 22.7         
Role Physical HP-LBP 144.8 ± 137.2 151.6 ± 150.8     T = 0.89 
 HP-HBP 136.9 ± 139.4 136.0 ± 143.1     D = 0.001 
 HC-LBP 244.9 ± 145.5 257.2c ± 147.7     BP = 0.70 
 HC-HBP 257.0 ± 136.2 241.3d ± 146.8       D x BP = 0.78 
 HP 142.2 ± 137.5 146.4 ± 148.0 142.3† ± 12.09 T x D = 0.59 
 HC 248.6 ± 142.3 252.3a ± 147.1 250.1 ± 12.97 T x BP = 0.040 
 LBP 193.1 ± 149.6 202.5g ± 158.0 199.6 ± 9.98 T x D x BP = 0.24 
 HBP 191.7 ± 149.8 184.0 ± 153.4 192.8 ± 14.65   
 Time 192.6 ± 149.4 196.6 ± 156.5         
Bodily Pain HP-LBP 61.3 ± 18.5 65.2g ± 19.4     T = 0.014 
 HP-HBP 54.6 ± 19.2 58.9 ± 22.8     D = 0.94 
 HC-LBP 65.9 ± 20.9 67.2 ± 21.3     BP = 0.001 
 HC-HBP 53.2 ± 20.2 54.4f ± 20.0       D x BP = 0.18 
 HP 59.1 ± 19.0 63.1g ± 20.7 60.0 ± 1.58 T x D = 0.20 
 HC 62.0 ± 21.4 63.3 ± 21.6 60.2 ± 1.69 T x BP = 0.98 
 LBP 63.5 ± 19.8 66.2b,g ± 20.3 64.9 ± 1.30 T x D x BP = 0.93  
 HBP 54.0 ± 19.6 56.8 ± 21.5 55.3‡ ± 1.91   
 Time 60.5 ± 20.2 63.2* ± 21.1         
General Health HP-LBP 51.3 ± 28.6 55.8g ± 28.9     T = 0.001 
 HP-HBP 48.3 ± 28.7 52.6g ± 28.2     D = 0.001 
 HC-LBP 65.6 ± 22.1 68.5c,g ± 21.7     BP = 0.50 
 HC-HBP 63.9 ± 23.0 68.0d,g ± 23.3       D x BP = 0.76 
 HP 50.4 ± 28.6 54.8g ± 28.6 52.0† ± 2.17 T x D = 0.57 
 HC 65.1 ± 22.3 68.4a,g ± 22.1 66.5 ± 2.33 T x BP = 0.73 
 LBP 58.2 ± 26.6 62.0g ± 26.4 60.3 ± 1.79 T x D x BP = 0.62  
 HBP 55.4 ± 27.3 59.6g ± 27.0 58.2 ± 2.63   
 Time 57.3 ± 26.8 61.2* ± 26.6         
Vital HP-LBP 40.1 ± 41.2 49.8g ± 43.8     T = 0.001 
 HP-HBP 43.7 ± 55.1 47.7g ± 54.8     D = 0.10 
 HC-LBP 51.0 ± 18.5 55.8g ± 18.0     BP = 0.94 
 HC-HBP 49.0 ± 18.6 54.9g ± 20.0       D x BP = 0.81 
 HP 41.3 ± 46.1 49.1g ± 47.5 45.3 ± 3.08 T x D = 0.41 
 HC 50.4 ± 18.5 55.5g ± 18.6 52.7 ± 3.30 T x BP = 0.21 
 LBP 45.3 ± 32.7 52.7g ± 33.9 49.2 ± 2.54 T x D x BP = 0.07  
 HBP 46.1 ± 42.4 51.0g ± 42.6 48.8 ± 3.73   
 Time 45.6 ± 36.0 52.2* ± 36.8         
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Table D.8: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Social 
Functioning 
HP-LBP 45.1 ± 24.3 50.1g ± 25.2 
 
  
T = 0.06 
HP-HBP 48.6 ± 28.6 52.0 ± 29.8 D = 0.001 
HC-LBP 55.1 ± 22.6 57.3c ± 21.7 BP = 0.019  
HC-HBP 68.7 ± 27.3 66.5d,f ± 29.1 D x BP = 0.15 
HP 46.2 ± 25.7 50.7g ± 26.7 48.9† ± 2.06 T x D = 0.06 
HC 59.3 ± 24.9 60.1a ± 24.5 61.9 ± 2.21 T x BP = 0.17 
LBP 49.9 ± 24.0 53.5g ± 23.8 51.9 ± 1.70 T x D x BP = 0.51  
HBP 57.8 ± 29.7 58.6 ± 30.2 59.0‡ ± 2.49   Time 52.4 ± 26.1 55.2* ± 26.1  
Role Emotional HP-LBP 220.1 ± 130.2 240.4 ± 143.0 
 
  
T = 0.63 
HP-HBP 214.5 ± 127.0 235.0 ± 136.8 D = 0.001 
HC-LBP 297.6 ± 215.6 292.5c ± 134.4 BP = 0.79 
HC-HBP 300.8 ± 116.7 282.1 ± 134.2 D x BP = 0.96 
HP 218.3 ± 128.7 238.6 ± 140.6 227.5† ± 11.51 T x D = 0.07 
HC 298.6 ± 190.3 289.4a ± 133.9 293.3 ± 12.36 T x BP = 0.70 
LBP 257.5 ± 180.4 265.5 ± 141.0 262.6 ± 9.51 T x D x BP = 0.69  
HBP 253.9 ± 129.2 256.5 ± 136.9 258.1 ± 13.96   
  Time 256.3 ± 165.6 262.7 ± 139.6   
Mental Health 
 
HP-LBP 57.8 ± 15.4 66.8g ± 15.5 
 
  
T = 0.001 
HP-HBP 53.9 ± 15.6 61.7c,g ± 14.4 D = 0.008 
HC-LBP 59.8 ± 14.7 67.2g ± 12.7 BP = 0.33 
HC-HBP 61.3 ± 13.8 68.7d,g ± 10.8 D x BP = 0.06 
HP 56.5 ± 15.5 65.1g ± 15.3 60.1† ± 1.06 T x D = 0.60 
HC 60.3 ± 14.4 67.6a,g ± 12.1 64.2 ± 1.14 T x BP = 0.76 
LBP 58.8 ± 15.1 67.0g ± 14.2 62.9 ± 0.88 T x D x BP = 0.72  
HBP 57.3 ± 15.2 64.9g ± 13.3 61.4 ± 1.29   
  Time 58.3 ± 15.1 66.3* ± 13.9   
HP = higher protein, HC = higher carbohydrate, LBP = low blood pressure, HBP = high blood pressure, T = time effect, D = diet effect, BP = blood 
pressure risk factor effect, D x BP = diet by blood pressure risk factor effect, T x D = time by diet effect, T x BP = time by blood pressure risk factor effect, 
T x D x BP = time by diet by blood pressure risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 102 participants in the HP-LBP group, 50 in the HP-HBP 
group, 95 in the HC-LBP group, 42 in the HC-HBP group, 152 in the HP total group, 137 in the HC total group, 197 in the LBP group, 92 in the HBP 
group, and 289 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant blood pressure effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LBP group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LBP group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HBP group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LBP group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table D.9: Changes in Body Image Evaluation After Ten Weeks of Exercise  
and Dietary Intervention Based on Blood Pressure Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Appearance 
Evaluation 
HP-LBP 2.4 ± 0.7 2.8g ± 0.7 
 
  
T = 0.001 
HP-HBP 2.4 ± 0.6 2.7g ± 0.6 D = 0.58 
HC-LBP 2.5 ± 0.7 2.8g ± 0.7 BP = 0.80 
HC-HBP 2.4 ± 0.6 2.8g ± 0.7 D x BP = 0.49 
HP 2.4 ± 0.6 2.7g ± 0.7 2.6 ± 0.04 T x D = 0.48 
HC 2.4 ± 0.6 2.8g ± 0.7 2.6 ± 0.04 T x BP = 0.57 
LBP 2.4 ± 0.7 2.8g ± 0.7 2.6 ± 0.04 T x D x BP = 0.50  
HBP 2.4 ± 0.6 2.8g ± 0.6 2.6 ± 0.05   
  Time 2.4 ± 0.6 2.8* ± 0.7   
Appearance 
Orientation 
HP-LBP 4.1 ± 0.8 4.1 ± 0.9 
 
  
T = 0.32 
HP-HBP 4.2 ± 0.9 4.2 ± 1.0 D = 0.043 
HC-LBP 3.9 ± 0.7 3.8c ± 0.8 BP = 0.007 
HC-HBP 4.1 ± 0.9 4.1f ± 0.9 D x BP = 0.34 
HP 4.1 ± 0.9 4.1 ± 0.9 4.1† ± 0.05 T x D = 0.55 
HC 3.9 ± 0.8 3.9a ± 0.9 4.0 ± 0.06 T x BP = 0.68 
LBP 4.0 ± 0.8 3.9b ± 0.8 3.9 ± 0.05 T x D x BP = 0.53  
HBP 4.2 ± 0.9 4.2 ± 0.9 4.2‡ ± 0.07   
  Time 4.1 ± 0.8 4.0 ± 0.9   
Body Area HP-LBP 2.1 ± 0.7 2.3g ± 0.8     T = 0.001 
Satisfaction HP-HBP 1.9 ± 0.8 2.2g ± 0.9     D = 0.007 
 HC-LBP 2.3 ± 0.7 2.7c,g ± 0.8     BP = 0.001 
 HC-HBP 2.0 ± 0.7 2.3f,g ± 0.8       D x BP = 0.23 
 HP 2.0 ± 0.8 2.3g ± 0.8 2.1† ± 0.05 T x D = 0.31 
 HC 2.2 ± 0.7 2.5a,g ± 0.8 2.3 ± 0.06 T x BP = 0.52 
 LBP 2.2 ± 0.7 2.5b,g ± 0.8 2.4 ± 0.05 T x D x BP = 0.25  
 HBP 2.0 ± 0.7 2.3g ± 0.9 2.1‡ ± 0.06   
 Time 2.1 ± 0.7 2.4* ± 0.8         
Overweight HP-LBP 2.8 ± 0.7 3.4g ± 0.7     T = 0.001 
Preoccupation HP-HBP 2.9 ± 0.6 3.4g ± 0.8     D = 0.33 
 HC-LBP 2.8 ± 0.8 3.3g ± 0.7     BP = 0.51 
 HC-HBP 2.9 ± 0.7 3.3g ± 0.8       D x BP = 0.85 
 HP 2.9 ± 0.7 3.4g ± 0.7 3.1 ± 0.04 T x D = 0.11 
 HC 2.9 ± 0.7 3.3g ± 0.7 3.1 ± 0.05 T x BP = 0.49 
 LBP 2.8 ± 0.7 3.3g ± 0.7 3.1 ± 0.04 T x D x BP = 0.61  
 HBP 2.9 ± 0.7 3.4g ± 0.8 3.1 ± 0.05   
 Time 2.9 ± 0.7 3.3* ± 0.7         
Self-Classified HP-LBP 4.3 ± 0.7 4.2 ± 0.5     T = 0.013 
Weight HP-HBP 4.2 ± 0.8 4.1 ± 0.8     D = 0.12 
 HC-LBP 4.2 ± 0.7 4.0 ± 0.7     BP = 0.57 
 HC-HBP 4.2 ± 0.7 4.1 ± 0.7       D x BP = 0.29 
 HP 4.2 ± 0.7 4.2 ± 0.7 4.2 ± 0.04 T x D = 0.66 
 HC 4.2 ± 0.7 4.0 ± 0.7 4.1 ± 0.04 T x BP = 0.69 
 LBP 4.2 ± 0.7 4.1 ± 0.6 4.2 ± 0.03 T x D x BP = 0.61  
 HBP 4.2 ± 0.7 4.1 ± 0.8 4.1 ± 0.05   
 Time 4.2 ± 0.7 4.1* ± 0.7         
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Table D.9: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Rosenberg HP-LBP 25.6 ± 3.8 26.0 ± 3.6     T = 0.006 
Self Esteem HP-HBP 25.8 ± 4.2 26.8g ± 4.2     D = 0.54 
 HC-LBP 25.7 ± 3.6 25.9 ± 3.7     BP = 0.37 
 HC-HBP 25.8 ± 4.5 26.1 ± 4.6       D x BP = 0.70 
 HP 25.7 ± 3.9 26.3g ± 3.8 26.1 ± 0.23 T x D = 0.17 
 HC 25.7 ± 3.9 25.9 ± 4.0 25.8 ± 0.27 T x BP = 0.34 
 LBP 25.6 ± 3.7 26.0 ± 3.6 25.8 ± 0.21 T x D x BP = 0.42  
 HBP 25.8 ± 4.3 26.5g ± 4.3 26.1 ± 0.28   
 Time 25.7 ± 3.9 26.2* ± 3.9         
Social Physique HP-LBP 31.5 ± 6.8 31.5 ± 6.9     T = 0.61 
Anxiety HP-HBP 30.8 ± 5.4 31.1 ± 5.1     D = 0.95 
 HC-LBP 31.1 ± 6.1 31.1 ± 6.5     BP = 0.70 
 HC-HBP 31.1 ± 5.8 31.5 ± 5.3       D x BP = 0.45 
 HP 31.3 ± 6.3 31.4 ± 6.2 31.2 ± 0.33 T x D = 0.98 
 HC 31.1 ± 6.0 31.3 ± 6.1 31.2 ± 0.39 T x BP = 0.61 
 LBP 31.3 ± 6.5 31.3 ± 6.7 31.3 ± 0.31 T x D x BP = 0.84  
 HBP 30.9 ± 5.5 31.3 ± 5.2 31.1 ± 0.40   
 Time 31.2 ± 6.1 31.3 ± 6.2         
HP = higher protein, HC = higher carbohydrate, LBP = low blood pressure, HBP = high blood pressure, T = time effect, D = diet effect, BP = 
blood pressure risk factor effect, D x BP = diet by blood pressure risk factor effect, T x D = time by diet effect, T x BP = time by blood pressure 
risk factor effect, T x D x BP = time by diet by blood pressure risk factor effect.                                                                                                                                    
Values are means ± standard deviations (except group means are means ± standard error) from 154 participants in the HP-LBP group, 102 in 
the HP-HBP group, 128 in the HC-LBP group, 67 in the HC-HBP group, 256 in the HP total group, 195 in the HC total group, 282 in the LBP 
group, 169 in the HBP group, and 451 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant blood pressure effect, 
p < 0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LBP group, p < 0.05 (post 
hoc LSD).  c Significantly different than HP-LBP group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HBP group, p < 0.05 (post 
hoc LSD).  f Significantly different than HC-LBP group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc 
LSD). 
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APPENDIX E 
GLUCOSE RISK FACTOR TABLES 
Table E.1: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Glucose Status and Measured via DEXA Scan 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Scanned Mass  HP-LG 87.5 ± 17.6 83.7g ± 17.0     T = 0.001 
(kg) HP-HG 91.5 ± 18.5 87.5c,g ± 18.0     D = 0.001 
 HC-LG 80.8 ± 13.9 77.9c,g ± 13.1     G = 0.002 
 HC-HG 85.0 ± 14.7 81.9d,f,g ± 14.3       D x G = 0.99 
 HP 89.2 ± 18.1 85.3g ± 17.5 87.6† ± 0.84 T x D = 0.001 
 HC 82.5 ± 14.3 79.5a,g ± 13.7 81.4 ± 0.96 T x G = 0.47 
 LG 84.5 ± 16.4 81.1b,g ± 15.6 82.5 ± 0.82 T x D x G = 0.88  
 HG 88.8 ± 17.3 85.1g ± 16.7 86.5‡ ± 0.98   
 Time 86.2 ± 16.9 82.7* ± 16.2         
Fat Mass (kg) HP-LG 40.2 ± 10.9 37.1g ± 10.8     T = 0.001 
 HP-HG 42.4 ± 12.0 39.3c,g ± 11.6     D = 0.001 
 HC-LG 36.1 ± 8.7 33.9c,g ± 8.5     G = 0.006 
 HC-HG 38.6 ± 9.4 35.9d,g ± 8.9       D x G = 0.99 
 HP 41.1 ± 11.4 38.0g ± 11.2 39.7† ± 0.54 T x D = 0.004 
 HC 37.1 ± 9.1 34.7a,g ± 8.7 36.1 ± 0.61 T x G = 0.23 
 LG 38.3 ± 10.2 35.6b,g ± 9.9 36.8 ± 0.52 T x D x G =0.27  
 HG 40.8 ± 11.1 37.8g ± 10.7 39.0‡ ± 0.62   
 Time 39.3 ± 10.7 36.5* ± 10.3         
Lean Mass (kg) HP-LG 45.6 ± 7.8 44.8g ± 7.4     T = 0.001 
 HP-HG 47.3 ± 7.5 46.4c,g ± 7.3     D = 0.001 
 HC-LG 42.9 ± 6.4 42.2c,g ± 6.0     G = 0.002 
 HC-HG 44.7 ± 6.4 44.2d,f,g ± 6.4       D x G = 0.81 
 HP 46.3 ± 7.7 45.5g ± 7.4 46.0† ± 0.36 T x D = 0.12 
 HC 43.6 ± 6.4 43.0a,g ± 6.2 43.5 ± 0.41 T x G = 0.68 
 LG 44.4 ± 7.3 43.7b,g ± 6.9 43.9 ± 0.35 T x D x G = 0.23  
 HG 46.2 ± 7.2 45.5g ± 7.0 45.6‡ ± 0.42   
 Time 45.1 ± 7.3 44.4* ± 7.0         
Body Fat (%) HP-LG 45.3 ± 4.2 43.7g ± 4.6     T = 0.001 
 HP-HG 45.7 ± 4.7 44.2g ± 4.8     D = 0.06 
 HC-LG 44.4 ± 4.2 43.2g ± 4.4     G = 0.14 
 HC-HG 45.2 ± 4.1 43.5g ± 4.1       D x G = 0.84 
 HP 45.5 ± 4.4 43.9g ± 4.7 44.8 ± 0.23 T x D = 0.28 
 HC 44.7 ± 4.2 43.4g ± 4.3 44.1 ± 0.26 T x G = 0.18 
 LG 44.9 ± 4.2 43.5g ± 4.5 44.2 ± 0.22 T x D x G = 0.06  
 HG 45.5 ± 4.4 43.9g ± 4.5 44.7 ± 0.26   
 Time 45.2 ± 4.3 43.7* ± 4.5         
HP = higher protein, HC = higher carbohydrate, LG = low glucose, HG = high glucose, T = time effect, D = diet effect, G = glucose risk factor 
effect, D x G = diet by glucose risk factor effect, T x D = time by diet effect, T x G = time by glucose risk factor effect, T x D x G = time by diet 
by glucose risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 214 participants in the HP-LG group, 157 in the 
HP-HG group, 176 in the HC-LG group, 116 in the HC-HG group, 371 in the HP total group, 292 in the HC total group, 390 in the LG group, 273 
in the HG group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant glucose effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD).  
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Table E.2: Body Composition Before and After Ten Weeks of Exercise and Dietary 
Intervention Based on Glucose Status and Measured via Anthropometric Measurements 
 
Variable Grou
p 
Baseline 10 Weeks Group 
(SEM) 
P-level 
Weight (kg) HP-LG 94.0 ± 18.5 89.7g ± 17.8     T = 0.001 
 HP-HG 98.2 ± 19.6 93.9c,g ± 18.9     D = 0.001 
 HC-LG 86.7 ± 14.3 83.7c,g ± 13.4     G = 0.001 
 HC-HG 91.8 ± 15.4 88.3d,f,g ± 14.9       D x G = 0.82 
 HP 95.8 ± 19.1 91.5g ± 18.3 94.0† ± 0.9 T x D = 0.001 
 HC 88.8 ± 14.9 85.5a,g ± 14.2 87.6 ± 1.0 T x G = 0.32 
 LG 90.7 ± 17.1 87.0b,g ± 16.2 88.5 ± 0.9 T x D x G = 0.44 
 HG 95.5 ± 18.2 91.5g ± 17.5 93.1‡ ± 1.0   
 Time 92.7 ± 17.7 88.9* ± 16.9         
Body Mass Index HP-LG 35.1 ± 6.4 33.5g ± 6.2     T = 0.001 
(kg/m2) HP-HG 37.0 ± 6.7 35.4c,g ± 6.5     D = 0.001 
 HC-LG 32.7 ± 5.1 31.5c,g ± 4.8     G = 0.001 
 HC-HG 34.3 ± 5.3 32.9d,f,g ± 5.2       D x G = 0.68 
 HP 35.9 ± 6.6 34.3g ± 6.4 35.3† ± 0.3 T x D = 0.001 
 HC 33.3 ± 5.2 32.1a,g ± 5.0 32.8 ± 0.3 T x G = 0.32 
 LG 34.0 ± 6.0 32.6b,g ± 5.7 33.2 ± 0.3 T x D x G = 0.47 
 HG 35.9 ± 6.3 34.4g ± 6.1 34.9‡ ± 0.4   
 Time 34.8 ± 6.2 33.3* ± 5.9         
Waist HP-LG 99.4 ± 12.6 95.1g ± 12.5     T = 0.001 
Circumference HP-HG 104.0 ± 14.2 100.4c,g ± 13.5     D = 0.001 
(cm) HC-LG 93.7 ± 11.0 90.9c,g ± 10.5     G = 0.001 
 HC-HG 98.9 ± 12.0 95.2d,f,g ± 11.7       D x G = 0.92 
 HP 101.3 ± 13.5 97.3g ± 13.2 99.7† ± 0.6 T x D = 0.14 
 HC 95.8 ± 11.7 92.6a,g ± 11.2 94.7 ± 0.7 T x G = 0.90 
 LG 96.8 ± 12.2 93.2b,g ± 11.8 94.8 ± 0.6 T x D x G = 0.07 
 HG 101.8 ± 13.5 98.2g ± 13.0 99.6‡ ± 0.7   
 Time 98.9 ± 13.0 95.2* ± 12.6         
Hip HP-LG 121.7 ± 13.4 118.3g ± 12.8     T = 0.001 
Circumference HP-HG 124.1 ± 14.5 121.3c,g ± 14.5     D = 0.001 
(cm) HC-LG 116.7 ± 11.2 114.4c,g ± 10.6     G = 0.001 
 HC-HG 120.9 ± 11.6 117.5d,f,g ± 11.0       D x G = 0.62 
 HP 122.7 ± 13.9 119.5g ± 13.6 121.3† ± 0.6 T x D = 0.38 
 HC 118.3 ± 11.5 115.6a,g ± 10.9 117.4 ± 0.7 T x G = 0.63 
 LG 119.5 ± 12.7 116.5b,g ± 12.0 117.8 ± 0.6 T x D x G = 0.033 
 HG 122.7 ± 13.4 119.7a ± 13.3 120.9‡ ± 0.8   
 Time 120.8 ± 13.1 117.8* ± 12.6         
HP = higher protein, HC = higher carbohydrate, LG = low glucose, HG = high glucose, T = time effect, D = diet effect, G = glucose risk factor effect, D x 
G = diet by glucose risk factor effect, T x D = time by diet effect, T x G = time by glucose risk factor effect, T x D x G = time by diet by glucose risk 
factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 214 participants in the HP-LG group, 157 in the HP-HG 
group, 176 in the HC-LG group, 116 in the HC-HG group, 371 in the HP total group, 292 in the HC total group, 390 in the LG group, 273 in the HG 
group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant glucose effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table E.3: Resting Energy Expenditure After Ten Weeks of Exercise and Dietary 
Intervention Based on Glucose Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Resting Energy HP-LG 1657.6 ± 272.7 1602.8g ± 292.3     T = 0.001 
Expenditure HP-HG 1753.6 ± 294.0 1677.7a,g ± 288.0     D = 0.001 
(kcal/day) HC-LG 1565.6 ± 238.9 1538.5c ± 247.1     G = 0.001 
 HC-HG 1656.0 ± 253.1 1582.3d,g ± 250.2       D x G = 0.65 
 HP 1697.4 ± 285.2 1633.8g ± 292.5 1672.9† ± 13.3 T x D = 0.39 
 HC 1600.7 ± 248.0 1555.5a,g ± 248.8 1585.6 ± 15.3 T x G = 0.051 
 LG 1616.5 ± 261.8 1574.0b,g ± 274.5 1591.1 ± 12.8 T x D x G = 0.46 
 HG 1712.6 ± 281.2 1637.6a ± 276.3 1667.4‡ ± 15.7   
 Time 1655.2 ± 273.7 1599.7* ± 276.8         
HP = higher protein, HC = higher carbohydrate, LG = low glucose, HG = high glucose, T = time effect, D = diet effect, G = glucose risk factor effect, D x G 
= diet by glucose risk factor effect, T x D = time by diet effect, T x G = time by glucose risk factor effect, T x D x G = time by diet by glucose risk factor 
effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 209 participants in the HP-LG group, 148 in the HP-HG 
group, 169 in the HC-LG group, 107 in the HC-HG group, 357 in the HP total group, 276 in the HC total group, 378 in the LG group, 255 in the HG group, 
and 633 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant glucose effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table E.4: Resting Hemodynamic Measurements After Ten Weeks of Exercise and 
Dietary Intervention Based on Glucose Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Resting Heart HP-LG 70.9 ± 10.0 67.9g ± 10.0     T = 0.001 
Rate (bpm) HP-HG 73.5 ± 10.6 70.3c,g ± 9.2     D = 0.21 
 HC-LG 70.9 ± 10.2 67.9g ± 9.2     G = 0.019 
 HC-HG 71.5 ± 11.1 68.8g ± 11.0       D x G = 0.20 
 HP 72.0 ± 10.3 68.9g ± 9.7 70.6 ± 0.5 T x D = 0.79 
 HC 71.2 ± 10.5 68.2g ± 9.9 69.8 ± 0.5 T x G = 1.0 
 LG 70.9 ± 10.1 67.9b,g ± 9.6 69.4 ± 0.4 T x D x G = 0.78  
 HG 72.7 ± 10.8 69.6g ± 10.0 71.0‡ ± 0.5   
 Time 71.6 ± 10.4 68.6* ± 9.8         
Resting Systolic HP-LG 122.8 ± 12.8 122.0 ± 13.3     T = 0.001 
Blood Pressure HP-HG 129.3 ± 16.3 124.2g ± 14.2     D = 0.13 
(mmHg) HC-LG 123.3 ± 14.5 119.1c,g ± 12.6     G = 0.001 
 HC-HG 125.8 ± 14.2 124.3f ± 15.7       D x G = 0.77 
 HP 125.6 ± 14.7 123.0g ± 13.7 124.6 ± 0.6 T x D = 0.92 
 HC 124.3 ± 14.4 121.2g ± 14.1 123.1 ± 0.7 T x G = 0.49 
 LG 123.0 ± 13.6 120.7b,g ± 13.1 121.8 ± 0.6 T x D x G = 0.002 
 HG 127.8 ± 15.5 124.3g ± 14.8 125.9‡ ± 0.7   
 Time 125.0 ± 14.6 122.2* ± 13.9         
Resting Diastolic HP-LG 80.0 ± 8.3 79.3 ± 8.6     T = 0.001 
Blood Pressure HP-HG 83.0 ± 10.2 80.0g ± 9.1     D = 0.001 
(mmHg) HC-LG 78.4 ± 9.8 76.1c,g ± 9.1     G = 0.001 
 HC-HG 80.8 ± 8.6 78.4f,g ± 9.2       D x G = 0.74 
 HP 81.3 ± 9.3 79.6g ± 8.8 80.6† ± 0.4 T x D = 0.55 
 HC 79.3 ± 9.4 77.0a,g ± 9.2 78.4 ± 0.5 T x G = 0.11 
 LG 79.3 ± 9.0 77.9b,g ± 8.9 78.4 ± 0.4 T x D x G = 0.15 
 HG 82.1 ± 9.6 79.3g ± 9.2 80.5‡ ± 0.5   
 Time 80.4 ± 9.4 78.4* ± 9.1         
HP = higher protein, HC = higher carbohydrate, LG = low glucose, HG = high glucose, T = time effect, D = diet effect, G = glucose risk factor effect, D x 
G = diet by glucose risk factor effect, T x D = time by diet effect, T x G = time by glucose risk factor effect, T x D x G = time by diet by glucose risk 
factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 214 participants in the HP-LG group, 157 in the HP-HG 
group, 176 in the HC-LG group, 116 in the HC-HG group, 371 in the HP total group, 292 in the HC total group, 390 in the LG group, 273 in the HG 
group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant glucose effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table E.5: Fasting Blood Lipid Values After Ten Weeks of Exercise  
and Dietary Intervention Based on Glucose Status 
 
Variable Group Baseline 10 Weeks Group 
(SEM) 
P-level 
Total Cholesterol HP-LG 5.0 ± 0.9 4.9 ± 0.9     T = 0.001 
(mmol/L) HP-HG 5.4 ± 1.0 5.1g ± 1.0     D = 0.72 
 HC-LG 5.1 ± 1.0 5.0 ± 0.9     G = 0.001 
 HC-HG 5.4 ± 1.0 5.1g ± 1.0       D x G = 0.54 
 HP 5.2 ± 1.0 5.0g ± 1.0 5.1 ± 0.05 T x D = 0.47 
 HC 5.2 ± 1.0 5.0g ± 1.0 5.1 ± 0.05 T x G = 0.001 
 LG 5.1 ± 0.9 5.0g ± 0.9 5.0 ± 0.05 T x D x G = 0.77 
 HG 5.4 ± 1.0 5.1g ± 1.0 5.2‡ ± 0.05   
 Time 5.2 ± 1.0 5.0* ± 1.0         
LDL (mmol/L) HP-LG 2.9 ± 0.6 2.9 ± 0.7     T = 0.001 
 HP-HG 3.3 ± 0.8 3.1c,g ± 0.8     D = 0.55 
 HC-LG 3.0 ± 0.8 3.0 ± 0.8     G = 0.001 
 HC-HG 3.3 ± 0.9 3.1g ± 0.8       D x G = 0.41 
 HP 3.1 ± 0.8 3.0g ± 0.8 3.1 ± 0.04 T x D = 0.66 
 HC 3.1 ± 0.8 3.0g ± 0.8 3.1 ± 0.04 T x G = 0.001 
 LG 3.0 ± 0.7 2.9b,g ± 0.7 3.0 ± 0.04 T x D x G = 0.57 
 HG 3.3 ± 0.8 3.1g ± 0.8 3.2‡ ± 0.04   
 Time 3.1 ± 0.8 3.0* ± 0.8         
HDL (mmol/L) HP-LG 1.4 ± 0.4 1.4g ± 0.3     T = 0.001 
 HP-HG 1.3 ± 0.3 1.2c,g ± 0.3     D = 0.72 
 HC-LG 1.4 ± 0.3 1.4g ± 0.3     G = 0.001 
 HC-HG 1.4 ± 0.3 1.3f,g ± 0.3       D x G = 0.48 
 HP 1.4 ± 0.3 1.3g ± 0.3 1.3 ± 0.02 T x D = 0.96 
 HC 1.4 ± 0.3 1.3g ± 0.3 1.3 ± 0.02 T x G = 0.011 
 LG 1.4 ± 0.4 1.4b,g ± 0.3 1.4 ± 0.02 T x D x G = 0.27 
 HG 1.3 ± 0.3 1.2g ± 0.3 1.3‡ ± 0.02   
 Time 1.4 ± 0.3 1.3* ± 0.3         
Triglycerides  HP-LG 1.4 ± 0.8 1.3g ± 0.7     T = 0.001 
(mmol/L) HP-HG 1.8 ± 0.9 1.7c,g ± 0.9     D = 0.45 
 HC-LG 1.4 ± 0.6 1.4 ± 0.7     G = 0.001 
 HC-HG 1.7 ± 0.8 1.6f,g ± 0.8       D x G = 0.21 
 HP 1.6 ± 0.8 1.5g ± 0.8 1.6 ± 0.04 T x D = 0.09 
 HC 1.5 ± 0.7 1.5 ± 0.7 1.5 ± 0.04 T x G = 0.09 
 LG 1.4 ± 0.7 1.3b,g ± 0.7 1.4 ± 0.04 T x D x G = 0.14 
 HG 1.8 ± 0.9 1.7g ± 0.9 1.7‡ ± 0.04   
 Time 1.6 ± 0.8 1.5* ± 0.8         
TC/HDL ratio HP-LG 3.7 ± 0.8 3.7 ± 0.8     T = 0.025 
 HP-HG 4.2 ± 0.9 4.3c ± 1.0     D = 0.93 
 HC-LG 3.8 ± 1.0 3.8 ± 1.0     G = 0.001 
 HC-HG 4.1 ± 1.0 4.2f ± 1.1       D x G = 0.20 
 HP 3.9 ± 0.9 3.9 ± 0.9 4.0 ± 0.05 T x D = 0.42 
 HC 3.9 ± 1.0 4.0g ± 1.1 4.0 ± 0.05 T x G = 0.70 
 LG 3.7 ± 0.9 3.8b ± 0.9 3.7 ± 0.05 T x D x G = 0.68 
 HG 4.2 ± 1.0 4.2 ± 1.1 4.2‡ ± 0.05   
 Time 3.9 ± 0.9 4.0* ± 1.0         
HP = higher protein, HC = higher carbohydrate, LG = low glucose, HG = high glucose, T = time effect, D = diet effect, G = glucose risk 
factor effect, D x G = diet by glucose risk factor effect, T x D = time by diet effect, T x G = time by glucose risk factor effect, T x D x G = 
time by diet by glucose risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 214 participants in the HP-LG group, 157 in 
the HP-HG group, 176 in the HC-LG group, 116 in the HC-HG group, 371 in the HP total group, 292 in the HC total group, 390 in the LG 
group, 273 in the HG group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant glucose effect, p < 
0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LG group, p < 0.05 (post 
hoc LSD).  c Significantly different than HP-LG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HG group, p < 0.05 (post 
hoc LSD).  f Significantly different than HC-LG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc 
LSD). 
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Table E.6: Fasting Glucose and Insulin Values After Ten Weeks of Exercise  
and Dietary Intervention Based on Glucose Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Glucose HP-LG 5.1 ± 0.4 5.1 ± 0.5     T = 0.001 
(mmol/L) HP-HG 6.6 ± 1.5 6.2c,g ± 1.5     D = 0.32 
 HC-LG 5.1 ± 0.4 5.3g ± 0.5     G = 0.001 
 HC-HG 6.4 ± 1.7 5.9d,f,g ± 1.4       D x G = 0.07 
 HP 5.7 ± 1.2 5.6g ± 1.2 5.7 ± 0.05 T x D = 0.81 
 HC 5.6 ± 1.3 5.5g ± 1.0 5.7 ± 0.06 T x G = 0.001 
 LG 5.1 ± 0.4 5.2b,g ± 0.5 5.1 ± 0.05 T x D x G = 0.017 
 HG 6.5 ± 1.6 6.1b ± 1.5 6.3‡ ± 0.06   
 Time 5.7 ± 1.3 5.6* ± 1.1         
Insulin HP-LG 2.9 ± 7.7 3.4 ± 8.9     T = 0.74 
(uIU/mL) HP-HG 6.9 ± 10.8 7.6c ± 12.4     D =0.002 
 HC-LG 5.6 ± 6.8 6.6 ± 8.2     G = 0.001 
 HC-HG 13.1 ± 18.8 11.9f ± 16.5       D x G = 0.38 
 HP 4.0 ± 8.8 4.5 ± 10.1 5.2† ± 0.87 T x D = 0.59 
 HC 8.3 ± 12.8 8.4a ± 12.0 9.3 ± 0.97 T x G = 0.45 
 LG 3.9 ± 7.5 4.6b ± 8.7 4.6 ± 0.73 T x D x G = 0.36  
 HG 9.9 ± 15.4 9.7 ± 14.6 9.9‡ ± 1.08   
 Time 5.7 ± 10.8 6.1 ± 11.1         
Calculated  HP-LG 0.7 ± 1.9 0.8 ± 2.3 
 
  
T = 0.94 
HOMA HP-HG 2.0 ± 3.1 2.2c ± 3.9 D = 0.002 
 HC-LG 1.3 ± 1.6 1.6 ± 2.1 G = 0.001 
 HC-HG 4.2 ± 7.1 3.4f ± 5.1 D x G = 0.19 
 HP 1.0 ± 2.3 1.2 ± 2.9 1.4† ± 0.25 T x D = 0.38 
 HC 2.3 ± 4.6 2.2a ± 3.5 2.6 ± 0.28 T x G = 0.28 
 LG 0.9 ± 1.8 1.1b ± 2.3 1.1 ± 0.21 T x D x G = 0.19  
 HG 3.0 ± 5.5 2.8 ± 4.5 2.9‡ ± 0.31   
 Time 1.6 ± 3.5 1.6 ± 3.2         
HP = higher protein, HC = higher carbohydrate, LG = low glucose, HG = high glucose, T = time effect, D = diet effect, G = glucose risk factor effect, D 
x G = diet by glucose risk factor effect, T x D = time by diet effect, T x G = time by glucose risk factor effect, T x D x G = time by diet by glucose risk 
factor effect.                                                                                                                                     
Glucose values are means ± standard deviations (except group means are means ± standard error) from 214 participants in the HP-LG group, 157 in the 
HP-HG group, 176 in the HC-LG group, 116 in the HC-HG group, 371 in the HP total group, 292 in the HC total group, 390 in the LG group, 273 in the 
HG group, and 663 participants total.  Insulin and HOMA values are means ± standard deviations (except group means are means ± standard error) from 
109 participants in the HP-LG group, 40 in the HP-HG group, 67 in the HC-LG group, 36 in the HC-HG group, 149 in the HP total group, 103 in the HC 
total group, 176 in the LG group, 76 in the HG group, and 252 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant glucose effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table E.7: Fitness Parameters After Ten Weeks of Exercise and Dietary Intervention 
Based on Glucose Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Bench Press  HP-LG 31.3 ± 7.7 33.4g ± 7.6     T = 0.001 
Max Strength HP-HG 30.5 ± 7.4 32.3g ± 7.1     D = 0.15 
(1 RM / kg body HC-LG 30.1 ± 8.2 32.7g ± 8.4     G = 0.13 
weight) HC-HG 29.5 ± 7.2 31.6g ± 7.6       D x G = 0.96 
 HP 30.9 ± 7.6 32.9g ± 7.4 31.9 ± 0.4 T x D = 0.41 
 HC 29.9 ± 7.8 32.2g ± 8.1 31.0 ± 0.5 T x G = 0.34 
 LG 30.8 ± 8.0 33.1g ± 8.0 31.9 ± 0.4 T x D x G = 0.88  
 HG 30.1 ± 7.3 32.0g ± 7.3 30.9 ± 0.5   
 Time 30.5 ± 7.7 32.6* ± 7.7         
Bench Press HP-LG 177.4 ± 79.5 182.3 ± 81.0     T = 0.76 
Lift Volume HP-HG 184.3 ± 80.1 181.5 ± 80.5     D = 0.82 
(kg) HC-LG 181.7 ± 81.0 176.6 ± 87.4     G = 0.38 
 HC-HG 187.0 ± 89.9 185.4 ± 67.0       D x G = 0.73 
 HP 180.3 ± 79.7 182.0 ± 80.7 181.4 ± 3.7 T x D = 0.55 
 HC 183.8 ± 84.5 180.1 ± 79.9 182.7 ± 4.4 T x G = 0.78 
 LG 179.3 ± 80.1 179.8 ± 83.8 179.5 ± 3.7 T x D x G = 0.45  
 HG 185.4 ± 84.1 183.2 ± 75.1 184.6 ± 4.4   
 Time 181.8 ± 81.8 181.2 ± 80.3         
Leg Press  HP-LG 164.2 ± 45.8 179.0g ± 50.9     T = 0.001 
Max Strength HP-HG 164.1 ± 51.2 181.6g ± 54.2     D = 0.10 
(1 RM / kg body HC-LG 158.4 ± 53.5 174.3g ± 58.3     G = 0.90 
weight) HC-HG 158.2 ± 46.8 169.9g ± 50.3       D x G = 0.67 
 HP 164.1 ± 48.1 180.1g ± 52.3 172.2 ± 2.7 T x D = 0.32 
 HC 158.4 ± 50.8 172.5g ± 55.2 165.2 ± 3.2 T x G = 0.77 
 LG 161.7 ± 49.3 176.9g ± 54.3 169.0 ± 2.7 T x D x G = 0.15  
 HG 161.6 ± 49.4 176.8g ± 52.9 168.5 ± 3.2   
 Time 161.7 ± 49.3 176.8* ± 53.6         
Leg Press HP-LG 1815.4 ± 927.6 1908.1 ± 990.1     T = 0.15 
Lift Volume HP-HG 1830.4 ± 1024.4 1967.1 ± 1189.7     D = 0.003 
(kg) HC-LG 1658.1 ± 867.0 1580.0c ± 896.5     G = 0.36 
 HC-HG 1681.2 ± 864.3 1749.1 ± 904.4       D x G = 0.68 
 HP 1821.8 ± 968.3 1933.1g ± 1077.9 1880.2† ± 47.1 T x D = 0.11 
 HC 1667.3 ± 864.3 1647.4a ± 901.7 1667.1 ± 54.8 T x G = 0.21 
 LG 1746.2 ± 903.5 1763.7 ± 962.7 1740.4 ± 46.2 T x D x G = 0.50  
 HG 1768.5 ± 962.2 1876.7 ± 1083.9 1806.9 ± 55.5   
 Time 1755.4 ± 927.5 1810.3 ± 1015.1         
Peak VO2 HP-LG 20.7 ± 4.9 22.8g ± 4.7     T = 0.001 
(mL/kg/min) HP-HG 19.1 ± 3.7 20.8c,g ± 3.9     D = 0.020 
 HC-LG 20.9 ± 4.4 23.9c,g ± 4.9     G = 0.001 
 HC-HG 19.8 ± 3.8 21.8f,g ± 4.2       D x G = 0.85 
 HP 20.0 ± 4.5 21.9g ± 4.5 20.9† ± 0.22 T x D = 0.026 
 HC 20.5 ± 4.2 23.1a,g ± 4.7 21.6 ± 0.25 T x G = 0.014 
 LG 20.8 ± 4.7 23.3b,g ± 4.8 22.1 ± 0.21 T x D x G = 0.28 
 HG 19.4 ± 3.8 21.3g ± 4.1 20.4‡ ± 0.25   
 Time 20.2 ± 4.4 22.4* ± 4.6         
HP = higher protein, HC = higher carbohydrate, LG = low glucose, HG = high glucose, T = time effect, D = diet effect, G = glucose risk factor effect, D x 
G = diet by glucose risk factor effect, T x D = time by diet effect, T x G = time by glucose risk factor effect, T x D x G = time by diet by glucose risk 
factor effect.                                                                                                                                     
Strength values are means ± standard deviations (except group means are means ± standard error) from 196 participants in the HP-LG group, 144 in the 
HP-HG group, 154 in the HC-LG group, 102 in the HC-HG group, 340 in the HP total group, 256 in the HC total group, 350 in the LG group, 246 in the 
HG group, and 596 participants total.  Peak VO2 values are means ± standard deviations (except group means are means ± standard error) from 214 
participants in the HP-LG group, 157 in the HP-HG group, 176 in the HC-LG group, 116 in the HC-HG group, 371 in the HP total group, 292 in the HC 
total group, 390 in the LG group, 273 in the HG group, and 663 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant glucose effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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Table E.8: Changes in SF36 - Quality of Life Inventory Values After Ten Weeks of 
Exercise and Dietary Intervention Based on Glucose Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Physical  HP-LG 77.4 ± 32.7 84.6g ± 24.9     T = 0.001 
Functioning HP-HG 73.6 ± 25.8 77.2c ± 24.1     D = 0.62 
 HC-LG 77.2 ± 24.4 82.8g ± 21.5     G = 0.20 
 HC-HG 75.1 ± 15.5 82.8g ± 18.3       D x G = 0.38 
 HP 75.7 ± 29.7 81.3g ± 24.7 78.2 ± 1.76 T x D = 0.65 
 HC 76.4 ± 21.2 82.8g ± 20.2 79.5 ± 1.88 T x G = 0.79 
 LG 77.3 ± 28.8 83.7g ± 23.2 80.5 ± 1.68 T x D x G = 0.30  
 HG 74.2 ± 21.8 79.7g ± 21.8 77.2 ± 1.95   
 Time 76.0 ± 26.0 82.0* ± 22.7         
Role Physical HP-LG 152.6 ± 139.9 165.0 ± 154.3     T = 0.43 
 HP-HG 129.6 ± 134.5 124.1 ± 137.8     D = 0.001 
 HC-LG 253.2 ± 146.0 259.7c ± 146.1     G = 0.16 
 HC-HG 241.8 ± 137.6 241.2d ± 149.3       D x G = 0.61 
 HP 142.2 ± 137.5 146.4 ± 148.0 142.8† ± 11.36 T x D = 0.95 
 HC 248.6 ± 142.3 252.3a ± 147.1 249.0 ± 12.16 T x G = 0.13 
 LG 202.6 ± 151.2 212.1 ± 157.2 207.6 ± 10.86 T x D x G = 0.51  
 HG 179.4 ± 146.4 176.1 ± 153.9 184.2 ± 12.61   
 Time 192.6 ± 149.4 196.6 ± 156.5         
Bodily Pain HP-LG 60.8 ± 19.0 64.6g ± 20.2     T = 0.009 
 HP-HG 57.0 ± 18.9 61.4g ± 21.3     D = 0.50 
 HC-LG 62.7 ± 21.4 63.9 ± 21.4     G = 0.25 
 HC-HG 60.9 ± 21.6 62.4 ± 22.2       D x G = 0.69 
 HP 59.1 ± 19.0 63.1g ± 20.7 60.9 ± 1.53 T x D = 0.18 
 HC 62.0 ± 21.4 63.3 ± 21.6 62.5 ± 1.64 T x G = 0.81 
 LG 61.8 ± 20.2 64.3 ± 20.8 63.0 ± 1.47 T x D x G = 0.94  
 HG 58.7 ± 20.2 61.8 ± 21.6 60.4 ± 1.70   
 Time 60.5 ± 20.2 63.2* ± 21.1         
General Health HP-LG 52.8 ± 28.3 59.2g ± 28.6     T = 0.001 
 HP-HG 47.4 ± 28.8 49.5c ± 28.0     D = 0.001 
 HC-LG 67.6 ± 21.4 70.7c,g ± 20.9     G = 0.03 
 HC-HG 61.4 ± 23.4 65.0d,g ± 23.7       D x G = 0.79 
 HP 50.4 ± 28.6 54.8g ± 28.6 52.2† ± 2.03 T x D = 0.53 
 HC 65.1 ± 22.3 68.4a,g ± 22.1 66.2 ± 2.17 T x G = 0.19 
 LG 60.2 ± 26.1 64.9b,g ± 25.6 62.5 ± 1.94 T x D x G = 0.10  
 HG 53.6 ± 27.4 56.4b ± 27.2 55.8‡ ± 2.26   
 Time 57.3 ± 26.8 61.2* ± 26.6         
Vital HP-LG 38.7 ± 22.0 47.7g ± 23.9     T = 0.001 
 HP-HG 44.3 ± 64.1 50.8g ± 65.7     D = 0.09 
 HC-LG 53.1 ± 17.6 56.0 ± 17.5     G = 0.97 
 HC-HG 46.3 ± 19.1 54.9g ± 20.1       D x G = 0.33 
 HP 41.3 ± 46.1 49.1g ± 47.5 45.4 ± 2.90 T x D = 0.24 
 HC 50.4 ± 18.5 55.5g ± 18.6 52.6 ± 3.10 T x G = 0.37 
 LG 45.9 ± 21.2 51.8g ± 21.3 48.9 ± 2.77 T x D x G = 0.020  
 HG 45.2 ± 49.3 52.6g ± 50.7 49.1 ± 3.22   
 Time 45.6 ± 36.0 52.2* ± 36.8         
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Table E.8: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Social 
Functioning 
HP-LG 48.1 ± 24.8 54.7g ± 27.3 
 
  
T = 0.018 
HP-HG 44.0 ± 26.8 45.8c ± 25.4 D = 0.001 
HC-LG 58.8 ± 23.4 60.4 ± 23.4 G = 0.27 
HC-HG 60.0 ± 27.2 59.6d ± 26.3 D x G = 0.24 
HP 46.2 ± 25.7 50.7g ± 26.7 48.2† ± 1.95 T x D = 0.08 
HC 59.3 ± 24.9 60.1a ± 24.5 59.7 ± 2.09 T x G = 0.10 
LG 53.4 ± 24.6 57.6g ± 25.5 55.5 ± 1.87 T x D x G = 0.51  
HG 51.1 ± 28.1 51.9 ± 26.6 52.4 ± 2.17   
  Time 52.4 ± 26.1 55.2* ± 26.1   
Role Emotional HP-LG 213.2 ± 126.3 240.8 ± 143.7 
 
  
T = 0.64 
HP-HG 224.4 ± 132.2 236.0 ± 137.7 D = 0.001 
HC-LG 285.9 ± 130.3 287.5c ± 130.8 G = 0.50 
HC-HG 317.4 ± 255.3 292.1d ± 139.7 D x G = 0.64 
HP 218.3 ± 128.7 238.6 ± 140.6 228.6† ± 10.85 T x D = 0.06 
HC 298.6 ± 190.3 289.4a ± 133.9 295.7 ± 11.61 T x G = 0.19 
LG 249.3 ± 133.0 264.0 ± 139.0 256.8 ± 10.37 T x D x G = 0.74  
HG 265.7 ± 201.1 260.9 ± 140.8 267.5 ± 12.04   
  Time 256.3 ± 165.6 262.7 ± 139.6   
Mental Health 
 
HP-LG 56.7 ± 15.7 67.8g ± 14.7 
 
  
T = 0.001 
HP-HG 56.3 ± 15.4 61.9c,g ± 15.6 D = 0.036 
HC-LG 61.5 ± 14.0 67.6g ± 12.4 G = 0.12 
HC-HG 58.4 ± 14.8 67.7d,g ± 11.8 D x G = 0.57 
HP 56.5 ± 15.5 65.1g ± 15.3 60.7† ± 1.01 T x D = 0.71 
HC 60.3 ± 14.4 67.6g ± 12.1 63.8 ± 1.08 T x G = 0.54 
LG 59.1 ± 15.1 67.7g ± 13.6 63.4 ± 0.96 T x D x G = 0.014  
HG 57.2 ± 15.1 64.5g ± 14.3 61.1 ± 1.12   
  Time 58.3 ± 15.1 66.3* ± 13.9   
HP = higher protein, HC = higher carbohydrate, LG = low glucose, HG = high glucose, T = time effect, D = diet effect, G = glucose risk factor effect, D x 
G = diet by glucose risk factor effect, T x D = time by diet effect, T x G = time by glucose risk factor effect, T x D x G = time by diet by glucose risk factor 
effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 83 participants in the HP-LG group, 69 in the HP-HG group, 
82 in the HC-LG group, 55 in the HC-HG group, 152 in the HP total group, 137 in the HC total group, 165 in the LG group, 124 in the HG group, and 289 
participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant glucose effect, p < 0.05 
(univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LG group, p < 0.05 (post hoc LSD).   
c Significantly different than HP-LG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HG group, p < 0.05 (post hoc LSD).   
f Significantly different than HC-LG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
 
 
  
  
 
262 
Table E.9: Changes in Body Image Evaluation After Ten Weeks of Exercise  
and Dietary Intervention Based on Glucose Status 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Appearance 
Evaluation 
HP-LG 2.4 ± 0.7 2.8g ± 0.7 
 
  
T = 0.001 
HP-HG 2.4 ± 0.6 2.7g ± 0.7 D = 0.54 
HC-LG 2.4 ± 0.6 2.9g ± 0.7 G = 0.65 
HC-HG 2.4 ± 0.6 2.7g ± 0.7 D x G = 0.56 
HP 2.4 ± 0.6 2.7g ± 0.7 2.6 ± 0.04 T x D = 0.64 
HC 2.4 ± 0.6 2.8g ± 0.7 2.6 ± 0.04 T x G = 0.08 
LG 2.4 ± 0.7 2.8g ± 0.7 2.6 ± 0.04 T x D x G = 0.57  
HG 2.4 ± 0.6 2.7g ± 0.7 2.6 ± 0.05   
  Time 2.4 ± 0.6 2.8* ± 0.7   
Appearance 
Orientation 
HP-LG 4.3 ± 0.8 4.3 ± 0.9 
 
  
T = 0.31 
HP-HG 3.9 ± 0.9 3.9c ± 0.9 D = 0.032 
HC-LG 4.0 ± 0.8 4.0c ± 0.9 G = 0.002 
HC-HG 3.8 ± 0.7 3.8 ± 0.8 D x G = 0.28 
HP 4.1 ± 0.9 4.1 ± 0.9 4.1† ± 0.05 T x D = 0.66 
HC 3.9 ± 0.8 3.9a ± 0.9 3.9 ± 0.06 T x G = 0.52 
LG 4.2 ± 0.8 4.1b ± 0.9 4.1 ± 0.05 T x D x G = 0.15  
HG 3.9 ± 0.8 3.9 ± 0.8 3.9‡ ± 0.06   
  Time 4.1 ± 0.8 4.0 ± 0.9   
Body Area HP-LG 2.0 ± 0.8 2.2g ± 0.8     T = 0.001 
Satisfaction HP-HG 2.1 ± 0.7 2.4g ± 0.9     D = 0.002 
 HC-LG 2.2 ± 0.7 2.5c,g ± 0.9     G = 0.18 
 HC-HG 2.3 ± 0.7 2.6g ± 0.8       D x G = 0.69 
 HP 2.0 ± 0.8 2.3g ± 0.8 2.2† ± 0.05 T x D = 0.32 
 HC 2.2 ± 0.7 2.5a,g ± 0.8 2.4 ± 0.06 T x G = 0.56 
 LG 2.1 ± 0.8 2.4g ± 0.8 2.2 ± 0.05 T x D x G = 0.25  
 HG 2.2 ± 0.7 2.5g ± 0.8 2.3 ± 0.06   
 Time 2.1 ± 0.7 2.4* ± 0.8         
Overweight HP-LG 2.9 ± 0.7 3.4g ± 0.7     T = 0.001 
Preoccupation HP-HG 2.9 ± 0.6 3.4g ± 0.7     D = 0.22 
 HC-LG 2.9 ± 0.7 3.3g ± 0.7     G = 0.31 
 HC-HG 2.7 ± 0.7 3.2g ± 0.7       D x G = 0.29 
 HP 2.9 ± 0.7 3.4g ± 0.7 3.1 ± 0.04 T x D = 0.26 
 HC 2.9 ± 0.7 3.3g ± 0.7 3.1 ± 0.05 T x G = 0.72 
 LG 2.9 ± 0.7 3.4g ± 0.7 3.1 ± 0.04 T x D x G = 0.18  
 HG 2.8 ± 0.7 3.3g ± 0.7 3.1 ± 0.05   
 Time 2.9 ± 0.7 3.3* ± 0.7         
Self-Classified HP-LG 4.1 ± 0.8 4.1 ± 0.6     T = 0.008 
Weight HP-HG 4.5 ± 0.5 4.2g ± 0.7     D = 0.036 
 HC-LG 4.2 ± 0.7 4.0c,g ± 0.7     G = 0.009 
 HC-HG 4.2 ± 0.7 4.1 ± 0.7       D x G = 0.35 
 HP 4.2 ± 0.7 4.2g ± 0.7 4.2† ± 0.04 T x D = 0.93 
 HC 4.2 ± 0.7 4.0 ± 0.7 4.1 ± 0.04 T x G = 0.41 
 LG 4.1 ± 0.8 4.1 ± 0.7 4.1 ± 0.03 T x D x G = 0.010  
 HG 4.3 ± 0.6 4.2g ± 0.7 4.2‡ ± 0.04   
 Time 4.2 ± 0.7 4.1* ± 0.7         
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Table E.9: Continued 
 
Variable Group Baseline 10 Weeks Group (SEM) P-level 
Rosenberg HP-LG 26.2 ± 4.1 26.5 ± 3.8     T = 0.006 
Self Esteem HP-HG 25.0 ± 3.6 26.0g ± 3.8     D = 0.67 
 HC-LG 25.8 ± 4.1 26.2 ± 4.2     G = 0.06 
 HC-HG 25.5 ± 3.7 25.5 ± 3.7       D x G = 0.62 
 HP 25.7 ± 3.9 26.3g ± 3.8 25.9 ± 0.23 T x D = 0.10 
 HC 25.7 ± 3.9 25.9 ± 4.0 25.8 ± 0.26 T x G = 0.53 
 LG 26.0 ± 4.1 26.4 ± 4.0 26.2 ± 0.21 T x D x G = 0.11  
 HG 25.2 ± 3.7 25.8g ± 3.8 25.5 ± 0.27   
 Time 25.7 ± 3.9 26.2* ± 3.9         
Social Physique HP-LG 31.1 ± 6.4 31.6 ± 6.4     T = 0.74 
Anxiety HP-HG 31.4 ± 6.1 30.9 ± 5.9     D = 0.82 
 HC-LG 31.3 ± 6.1 31.2 ± 5.1     G = 0.72 
 HC-HG 30.7 ± 5.8 31.4 ± 7.4       D x G = 0.99 
 HP 31.3 ± 6.3 31.4 ± 6.2 31.3 ± 0.33 T x D = 0.70 
 HC 31.1 ± 6.0 31.3 ± 6.1 31.2 ± 0.38 T x G = 0.95 
 LG 31.2 ± 6.3 31.4 ± 5.9 31.3 ± 0.31 T x D x G = 0.18  
 HG 31.1 ± 5.9 31.2 ± 6.6 31.1 ± 0.40   
 Time 31.2 ± 6.1 31.3 ± 6.2         
HP = higher protein, HC = higher carbohydrate, LG = low glucose, HG = high glucose, T = time effect, D = diet effect, G = glucose risk factor 
effect, D x G = diet by glucose risk factor effect, T x D = time by diet effect, T x G = time by glucose risk factor effect, T x D x G = time by 
diet by glucose risk factor effect.                                                                                                                                     
Values are means ± standard deviations (except group means are means ± standard error) from 161 participants in the HP-LG group, 95 in the 
HP-HG group, 120 in the HC-LG group, 75 in the HC-HG group, 256 in the HP total group, 195 in the HC total group, 281 in the LG group, 
170 in the HG group, and 451 participants total.  
* Significantly different than baseline, p < 0.05 (univariate).  † Significant diet effect, p < 0.05 (univariate).  ‡ Significant glucose effect, p < 
0.05 (univariate).  a Significantly different than HP group, p < 0.05 (post hoc LSD).  b Significantly different than LG group, p < 0.05 (post hoc 
LSD).  c Significantly different than HP-LG group, p < 0.05 (post hoc LSD).  d Significantly different than HP-HG group, p < 0.05 (post hoc 
LSD).  f Significantly different than HC-LG group, p < 0.05 (post hoc LSD).  g Significantly different than baseline, p <0.05 (post hoc LSD). 
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APPENDIX F 
CARBOHYDRATE INTOLERANCE QUESTIONNAIRE 
 
